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ABSTRACT 
Microarray technology is continuously finding new applications in gene and protein 
profiling studies, and has huge potential for clinical and diagnostic applications. In 
this thesis multiple factors affecting probe - ligand interactions in a microarray 
format were investigated using blood group antigen and antibody sets for the 
development of a microarray based serology platform. Multiplexed microarray 
formats facilitate the complex analysis of structurally and functionally highly 
variable blood group antigens, which are classified into blood group systems. 
Epitopes often differ by a single sugar or amino acid substitution and the number of 
antigenic sites on red blood cells (RBC) and epitope accessibility vary significantly. 
Initial experiments focused on multiple parameters affecting immobilisation and 
functionality of monoclonal and polyclonal antibodies on various microarray 
surfaces. A range of critical parameters affecting protein - ligand interactions, such 
as efficient blocking of non-specific binding, detergent type, RBC concentration, 
reaction volume and mixing, were optimised in a series of experiments with labelled 
anti-species antibodies. Selected microarray surface and optimised spotting and 
reaction conditions were then used for studies of antibody - RBC antigen 
interactions in situ. 
Protein microarrays most frequently utilise classical antigen - antibody interactions 
where probe molecules are immobilised and target molecules are free in solution. A 
`dual' solid-phase approach was investigated for blood group serology reactions 
where probe antibodies were immobilised on the microarray and target antigens were 
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carried on the RBC surface, which can be considered as the second solid-phase. This 
multiplex approach contrasts with the majority of current blood testing, which is 
generally detected by haemagglutination. This thesis provides the first 
comprehensive study of non-agglutination blood group determination in an open- 
plan microarray format. Using direct or indirect fluorescent labelling, both 
carbohydrate (ABO) and protein blood group antigens (Rhesus D, c, E and K) were 
successfully typed. The use of further antibodies for Fya and Fyb typing, and the 
detection of RBCs sensitised with IgG have also been investigated using a 
microarray approach. 
In order to verify the performance of diagnostic antibodies and quantitatively 
characterise their interactions in a label-free detection system, we have exploited the 
Biacore system as a recognised platform for real-time interaction studies. Although 
this system is not designed for the high throughput applications needed in blood 
testing, in this study it provided detailed information on the interactions between 
blood group A antibody and RBCs of different specificity. In addition, 
immobilisation of synthetic carbohydrate antigen on a Biacore chip permitted the 
quantitative determination of the reactivity of monoclonal antibodies in a `reverse 
typing' system. 
Reverse typing for the detection of antibodies against blood group antigens is an 
integral part of blood group serology. Biacore experiments investigated direct 
attachment of synthetic RBC antigens onto the solid-phase, and subsequent detection 
using antibodies. However, native multi-transmembrane RBC antigens are not 
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optimal for microarray immobilisation. It is known that whole RBC ghosts can be 
immobilised in macroassays, but this approach was considered to be less suitable for 
miniaturised microarray probe spots due to cell size and stability. In this study an 
alternative method of RBC membrane fragment spotting was used for the first time 
for blood group serology by employing novel surfaces and defining parameters 
suitable for a reverse reaction system. 
In summary this investigation has 1) established a microarray format and the reaction 
conditions for antibody - antigen interaction studies in blood group serology; 2) for 
the first time successfully exploited microarray format for comprehensive blood 
typing; 3) examined the novel technique of membrane fragment microarray 
immobilisation for a reverse, antibody screen reaction; 4) verified the findings and 
quantitatively characterised the interactions on Biacore, a surface plasmon resonance 
real-time detection system. This provides a strong basis for the development of 
microarray based multi-parameter blood group serology diagnostic platforms. 
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The transfusion of blood and blood products can save lives or greatly improve the 
quality of life for recipients. Donor blood products must be compatible with the 
recipient's blood system or this life saving treatment can result in severe, if not fatal, 
consequences. The testing of samples for blood transfusion purposes is consequently 
a highly regulated area. 
The area of blood transfusion testing is covered by both United Kingdom (U. K. ) and 
European law in the U. K., and by other regional quality systems worldwide. Products 
for use in blood testing must be manufactured and standardised in accordance with 
the Guidelines for the Blood Transfusion Services in the United Kingdom (U. K. 
Blood Transfusion Services, 2002) and comply with the European Union in vitro 
Diagnostic Medical Devices Directive (IVD Directive (98/79/EC), (European 
Parliament website). Products for use in ABO, RhD typing and antibody screening 
are covered by Annex 2, List A and List B of the IVD Directive, which cover the 
most critical blood testing products. In the United States of America, blood testing 
products must comply with Food and Drug Administration (FDA) regulations. 
Testing procedures must comply with U. K. Blood Transfusion Service Guidelines 
and the Guidelines for compatibility procedures in blood transfusion laboratories 
(Working Party of the British Committee for Standards in Haematology Blood 
Transfusion Task Force, 2004). 
The purpose of blood testing of both donors and patients is to ensure as far as 
possible the provision of safe products for blood transfusion. A safe product is one 
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that is blood type compatible and that is free of known pathogenic organisms, to 
which there is a test available. 
In order to provide compatible blood, both donors and recipients are tested for their 
blood type and for the presence of blood group antibodies. These serological tests on 
blood samples are mandatory and involve the assay and interpretation of antibody- 
antigen interactions. This involves the complex analysis of structurally and 
functionally highly variable blood group antigens, which are classified into blood 
group systems. Epitopes often differ by a single sugar or amino acid substitution and 
the number of antigenic sites on erythrocytes (red blood cells) and epitope 
accessibility vary significantly. Blood group antigens are discussed in more detail in 
section 1.2. 
ABO is the most important of the blood group systems, due to the presence of 
alloantibodies to the antigens of the system that the individual lacks. For example, if 
a group A or 0 patient was given group B blood, then the anti-B in their plasma 
would react with the B antigen on the donor red cells and cause a severe or fatal 
transfusion reaction. The Rhesus blood group system is second in importance only to 
the ABO system. This system is clinically significant due to the high 
immunogenicity of the blood group antigens within this system. The transfusion of 
500 ml of Rhesus D (RhD) positive blood to an RhD negative individual is likely to 
result in the production of an anti-D in up to 81.8 % of cases (Pollack et al., 1971). 
The production and presence of alloantibodies has implications in subsequent 
transfusions. 
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Current testing methods will be described in this chapter, but it is hoped that a novel 
multiplexed microarray format would facilitate improvements to the existing 
technology. In this thesis multiple factors affecting probe-ligand interactions in a 
microarray format were investigated using blood group antigen and antibody sets for 
the development of a novel solid-phase non-agglutination based microarray serology 
platform. 
The primary aim of this project was to study the parameters important for protein- 
ligand interactions in a microarray format, and to apply the optimised parameters to 
develop blood typing and erythrocyte antibody screening in a solid-phase microarray 
format. 
1.1 Blood Grouping Related Protein and Ligands: Structures and 
Interactions 
In this project, the interaction of blood group related antigens and antibodies was 
studied using a microarray format. Antibodies are glycoproteins, and blood group 
related antigens are either proteins or carbohydrates. 
1.1.1 Protein Structure - General 
Proteins are made up of amino acids forming long polypeptide chains (see e. g. Berg 
et al., 2002). The carboxyl group of one amino acid joins to the amino group of 
another to form a peptide bond. The primary structure of proteins describes the linear 
sequence of amino acids. The secondary structure of peptides and proteins involves 
the organisation into structures such as a helix or ß pleated sheets, which are 
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stabilised by hydrogen bonds. The placement of the disulphide bonds determines the 
secondary structure. Disulphide bonds between cysteine amino acid residues on the 
chain stabilise the peptide chain. Tertiary structure describes the three-dimensional 
(3-D) structure of the complete protein where the relationship of amino acids to one 
another is very different than in the primary structure. Steric relationships can affect 
the structure. The tertiary structure can alter if subjected to small changes in the 
environment. The quaternary structure consists of the conformation of all subunits of 
a functional protein stabilised by electrostatic and hydrogen bonds. Proteins may also 
contain molecules of a non-amino acid source, such as vitamins, minerals, lipids and 
carbohydrates. Borrebaeck et al. (2001) found that proteins may denature and lose 
their tertiary and quaternary structure when attached to a solid surface such as those 
used in microarrays, and therefore care must be taken to retain their structure and 
function. 
1.1.2 The Immune Response - Antibody Production and Structure 
The transfusion of blood impacts on the immune response of recipients. To minimise 
the immunological complications of transfusion, a number of procedures are used in 
both the procurement and provision of blood and blood components (U. K. Blood 
Transfusion Services, 2002; Working Party of the British Committee for Standards in 
Haematology Blood Transfusion Task Force, 2004). Blood donor recruitment 
procedures, blood typing and blood processing such as leucocyte depletion, gamma 
irradiation or washing have been improved and refined to minimise these risks (see 
review by Brand, 2000). 
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The immune system has evolved to combat infectious and non-self agents, by 
distinguishing non-self molecules from self, which if left could potentially kill the 
host (see e. g. Roitt et al., 1996). There are two types of immune response, the 
difference being in whether the action is non-specific or specific. An innate (non- 
adaptive) immune response involves the non-specific interaction of phagocytic cells 
that bind, internalise and kill pathogens, or the action of lysozymes and natural killer 
cells (see e. g. Harlow and Lane, 1988). Innate immunity is a residual element of the 
primitive immune system, whereas the specific immune response system, or adaptive 
response, is more highly evolved. The adaptive immune response gives improved 
immunity on each encounter with a pathogen, or non-self antigen, as it remembers 
the immunogen and rapidly responds to another encounter with identical or closely 
related antigen. 
The immune system uses two systems in parallel; the humoral and cellular immune 
response systems. In the humoral system, antibodies function as recognition elements 
and bind to foreign molecules (see e. g. Berg et al., 2002). In the cellular system, 
killer T cells kill other cells that display foreign antigens. 
Helper T lymphocytes aid both systems by stimulating the differentiation and 
proliferation of B-lymphocytes (antibody producing cells) and killer T cells. Other 
molecules such as cytokines assist in the immune response by signalling between 
cells. Cytokines are proteins or peptides and can be further classified into interferons, 
interleukins and colony stimulating factors. 
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Antibody molecules are secreted by plasma cells, which are derived from B- 
lymphocytes, and are produced by an individual in response to the presence of a 
foreign `antigen' in the body (Roitt et al., 1996). An antigen may be any kind of 
molecule that is recognised as foreign to the body e. g. infectious agents or 
constituents of blood component transfusion. A specific area of the antigen known as 
the antigenic determinant, or epitope, determines the specificity of the antibody. 
There is great diversity in antibody generation to create a repertoire of specificities. 
This diversity is possible due to multiple variable region genes in germ lines, somatic 
mutation, random pairing of heavy and light chains and variation in gene 
recombination (review, Harlow and Lane, 1988). 
Antibodies (Ab), or immunoglobulins (Ig), may be divided into the following classes 
(or isotypes) depending on structure: IgA, IgD, IgE, IgG or IgM, and further details 
are shown in Table 1.1. In blood testing alloantibodies of type IgG and IgM are most 
commonly encountered. Structurally, antibody molecules are ß pleated sheets, with 
anti-parallel strands, linked by disulphide bonds. The structure of IgG and IgM 
molecules are discussed now in more detail. 
1.1.2.1 IgG Antibody Structure 
Most blood group alloantibodies are of the IgG isotype. An IgG molecule is made up 
of four polypeptide chains; two identical heavy chains and two identical light chains. 
The heavy chains are each of approximately 50 kDa and the light chains 25 kDa, 
therefore the entire IgG molecule is approximately 150 kDa, depending on subclass 
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Blood group alloantibodies are most frequently IgG, and usually IgGI or IgG3, or 
both in some cases. Each of the chains folds into structural domains of approximately 
110 amino acids in length. Each light chain consists of a variable domain (VL) and a 
constant domain (CL). Each heavy chain consists of one variable domain (VH) and 
three constant domains (CH1, CH2 and CH3). The variable domains of both heavy and 
light chains associate to form the antigen-binding site, of which the IgG molecule has 
two. Structural studies performed by Sarma et al. (1971) determined the maximum 
distance between the two antigen-binding sites is 14 nm. Disulphide bonds at the CL 
and the CHI domains link the heavy and light chains (early structural work 
performed by Feinstein et al., 1971; Sarma et al., 1971). There is a flexible region 
between the CHI and CH2 domains, which is known as the hinge, and here the two 
heavy chains are linked by disulphide bonds. The hinge region allows flexibility in 
the molecule, and thus allows the two antigen binding sites to operate independently. 
The CH3 domains link with each other by non-covalent interactions. The structure of 
an IgG molecule is shown schematically in Figure 1.1. 
Using appropriate concentrations and time, the enzyme papain can cleave an IgG 
molecule into three fragments (from which identifying nomenclature is derived): two 
identical Fab fragments (fragment antigen-binding) and one Fc fragment (fragment 
crystalline) because it can be crystallised (Porter, 1959). The Fc fragment has 
specific placental transmission sites and a site for binding complement (Berg et al., 
2002). 
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Figure 1.1. The structure of an IgG molecule, showing locations of domains, disulphide 
bonds and enzyme cleavage points (picture from Mollison et al., 1997). 
Within each of the variable domains of the heavy and light chain there are three 
hypervariable regions of approximately seven to twelve amino acids. The 
hypervariable regions lie within `framework' regions in which there is little 
variation. The hypervariable regions, also known as complementarity determining 
regions (CDRs), form loops at the tip of the Fab structure and make up the antigen- 
binding site. It is hypervariability at these regions that gives the diversity of the 
specificity of antibody molecules (see e. g. Harlow and Lane, 1988). 
1.1.2.2 IgM Antibody Structure 
Generally, the primary immune response initially produces IgM isotype antibodies, 
but over a period of time there is a transition to IgG antibodies. IgM molecules have 
a pentameric structure of the basic four-polypeptide chain described for IgG, 
therefore consisting of ten antigen-binding sites (Feinstein et al., 1971). The structure 
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of an IgM molecule is shown schematically in Figure 1.2. The diameter of an IgM 
molecule is on average 30-31 nm (Feinstein et al., 1971). 
Figure 1.2. The structure of an IgM molecule, showing locations of domains, carbohydrate 
units, J chain and disulphide bonds (picture from Mollison et a/., 1997). 
The type of heavy chain is described as u and it differs from the A. chain in that it has 
no hinge region but an extra constant domain CH4. The antibody heavy chains are 
held together by disulphide bonds between the CH3 domains. The IgM molecule also 
has a `J' chain; a polypeptide chain that helps in the assembly of the molecule. IgM 




1.1.3 Structure and Interaction of Antibodies and Antigens 
In every class of antibody, the VL and VH variable domains link at the ends of the 
arms of the antibody structure (Berg et al., 2002) and the three hypervariable regions 
of each chain come together to form the antigen-binding site. The antibody 
specificity varies with the sequence and structure of the hypervariable regions. 
Complementarity between antigen and antibody result in contacts between amino 
acids at the binding surfaces of each molecule and a combination of hydrogen 
bonding, electrostatic and van der Waals interactions result in specific binding (from 
Mollison et al., 1997). The antibody-antigen interaction is reversible. Antibody- 
antigen interactions can involve varying numbers of the amino acids at the 
hypervariable region depending on the size and structure of the antigen. Strong 
affinity (the binding strength of a single binding site) results from a high level of 
interaction and bonding. Avidity is the binding strength of multiple binding 
interactions between multivalent molecules. The structure of the antibody molecules 
used in haemagglutination assays determines how the interaction is detected. IgM 
molecules bind to form haemagglutination directly, while IgG molecules most often 
require the addition of a secondary antibody or other interaction to cause 
agglutination. IgG antibodies of some specificities can cause direct 
haemagglutination e. g. because of high antigen site density. 
When using a solid surface to perform antibody-antigen interaction studies, 
haemagglutination is inhibited as one component of the test is not free in solution, 
but is immobilised. Therefore interactions have to be detected in other ways. Also of 
consideration is the accessibility of the antigen-binding sites of the antibody to the 
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antigen. When molecules are immobilised on a solid support orientation may be 
random and some of the antigen or antigen-binding sites may be inaccessible. 
1.1.4 Antibody Production 
Antibodies are used throughout the field of immunoassays, including blood typing 
diagnostics. The isolation of polyclonal antibodies or the manufacture of monoclonal 
antibodies is of high importance to ensure continuity of supply. Both antibody types 
are used in this project. While polyclonal antibody preparations are specific towards 
multiple epitopes of the same antigen, monoclonal antibodies are specific to a single 
epitope. 
Polyclonal antibodies have been used in immunological testing for many years. 
These are alloantibodies produced in response to a foreign antigen and can be 
isolated for use in assays. Polyclonal antibodies can be produced in many animals 
but those used in blood grouping are usually of human source, or rabbit (e. g. current 
polyclonal anti-human IgG). Serum containing alloantibodies may have to be 
adsorbed to remove other unwanted antibodies, and because of this polyclonal 
antibodies are more time consuming and costly to produce than monoclonal derived 
antibodies. Batches of polyclonal antibodies can also be highly variable. 
In 1975, Köhler and Milstein defined methods to produce antibodies of a `predefined 
specificity'. These hybridoma cells can produce monoclonal antibodies (MAb) of 
single specificity in unlimited quantities. Fusing lymphocytes taken from an 
immunised donor species with myeloma cells produces hybridoma cell lines. A 
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myeloma cell has antibody-producing features but does not produce functional 
antibody (Harlow and Lane, 1988). It also undergoes continuous cell division 
providing the fused hybrid cell with immortality. Enhancement media are added to 
the lymphocytes and myeloma cells which allow and encourage the fusion of the 
cells. This can result in cells that express both the antibody of interest and the 
immortality of the myeloma cell. After fusion, cells are grown in selective media that 
eliminates growth of unfused cells (Köhler and Milstein, 1975). Fused cells are then 
assessed for specificity of antibody produced. Most ABO and Rhesus D antibodies 
used in blood typing are derived from monoclonal cell lines. There are some blood 
group antigen specificities, however, that have not been produced by hybridoma 
technology, despite several attempts. As the method is also fairly labour intensive, 
other methods have been developed. 
Antigen 
binding site 10' 
I Vi I Linker 
40 peptide 
Figure 1.3. Structure of a single-chain variable fragment (scFv) (original reference Bird et a/., 
1988, picture from Issitt and Anstee, 1998). 
An alternative to poly and monoclonal antibodies are in vitro produced fragments of 
antibody molecules containing the antigen-binding site. This can be used in the 
production of antibody Fab or single chain Fv fragments (see Figure 1.3). When 
filamentous bacteriophage are used to express the molecule on their surface, this is 
commonly referred to as ̀ antibody phage-display'. This method concentrates on the 
isolation of the genes for the variable regions of the antibody. These can be placed in 
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a constant region construct by recombinant DNA techniques. This area developed 
rapidly in the early 1990s, and Hoogenboom and Winter (1992) and Winter et al. 
(review, 1994) describe the advances in the technology. In 1994, Hughes-Jones et al. 
described the characterisation of scFv to blood group antigens B, RhD, RhE, Kpb and 
HI, prepared by use of phage-antibody libraries. In 1995, Griffin and Ouwehand 
demonstrated the production of a human monoclonal antibody to platelet 
glycoprotein lila from a V-gene phage-display library. Marks and Marks (1996) 
reviewed the strategy of the phage library method for the preparation of clinically 
useful antibodies. Miescher et al. (1998) described the use of phage-display to isolate 
human Fab fragments with specificity to Rhesus D blood group antigen. Chang and 
Siegel (2001) successfully isolated human IgG anti-B from a Fab phage-display 
library. Phage-display libraries could potentially be used to identify antibody 
fragments for difficult to source blood typing reagents. Another method for the 
display of functional proteins is ribosome display, where both the protein and its 
mRNA remain attached to the ribosome. This technique has been used to produce 
scFv fragments (Hanes and Plückthun, 1997; Schaffitzel et al, 1999), which can be 
enriched to enhance binding properties. 
1.1.5 Antigen Structure 
An antigen can be described as any substance which when introduced to a foreign 
immune system can elicit the production of an antibody against it. Antibodies are 
used throughout this work, and the ligands/antigens they are directed against include 
plasma/serum proteins, antibodies, blood group determinants on erythrocytes, 
synthetic peptides and synthetic blood group determinants. Blood groups are 
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determined by the antigens on the erythrocyte surface and these antigens are either 
protein or carbohydrate structures which are discussed now in more detail. 
1.2 Transfusion Related Antigens and Antibodies 
1.2.1 Blood Group Antigenic Determinants and Their Structure 
The primary focus of this work was to develop a novel system for the determination 
of blood type (ABO and RhD). The erythrocyte carries the blood group determinants, 
although for some groups these can be found in other secretions of the body. 
Erythrocytes are developed from an erythroid progenitor cell line, and during their 
maturation lose their nucleus and all other genetic material. Erythrocytes have 
developed the specialised function of carrying oxygen around the body. Normal 
erythrocytes are described as biconcave discs, 7.8-8.3 um in diameter and 1.7 pm 
thick (Lessin and Bessis, 1979). The membrane is made of proteins, lipids and 
carbohydrates (review, Schenkel-Brunner, 2000). The cell has great flexibility to 
enable it to pass through small capillaries of the body, and this property is due to the 
cell cytoskeleton -a network of proteins beneath the membrane and attached to the 
lipid bilayer (review, Gilligan and Bennett, 1993). The main component of the 
cytoskeleton is spectrin -a molecule of two subunits that combine to form 
heterodimers, which in turn form tetramers. These tetramers interact with the 
proteins actin and ankyrin to attach to the membrane through transmembrane 
proteins. A schematic of the erythrocyte membrane and associated proteins is shown 
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Figure 1.4. The erythrocyte membrane and associated proteins (picture from Mollison et al., 
1997). 
Blood group antigens are either carbohydrates, single-pass membrane proteins, 
multi-pass membrane or glycosylphosphatidylinositol linked proteins (review, Reid 
and Lomas-Francis, 1997). Transmembrane proteins attach themselves to a layer of 
phospholipids in the membrane, and they can traverse through the membrane many 
times (see e. g. Mollison et al., 1997). Figure 1.5 shows a schematic of the 
erythrocyte antigens and their attachment to the cell. 
A blood group consists of antigens produced by alleles at a single genetic locus 
(Issitt and Anstee, 1998). More than 270 blood group antigens (review, Daniels, 
2002) have been placed into at least 29 blood group systems (Reid, 2003). ABO is 
the most clinically significant blood group system, followed by the blood group 



























Figure 1.5. Model of the erythrocyte membrane showing antigen carrier proteins and antigen 
attachment (picture from Reid and Lomas-Francis, 1997). 
Antibodies to antigens of the ABO, Rhesus and Kell systems were studied in this 
project, and these systems are discussed below. The Rhesus, MNS and Kell blood 
group systems are considered the most complex. The molecular mechanisms that 
generate the great diversity that exists in blood group antigens include point 
mutation, deletion, insertion, altered splicing events, intra- and intergenic crossover 
and gene conversion (Reid and Rios, 1999). Most antithetic blood group antigens 
arise from missense mutations (where the change of one nucleotide results in a 
change in encoded amino acid). Other clinically significant blood group systems are 
referred to in Table 1.4. 
1.2.1.1 The ABO &H Blood Group Systems 
Discovered in 1900 by Karl Landsteiner (Landsteiner, 1900 and 1901), the ABO 
blood group system is based on the presence or absence of two carbohydrate 
antigens, A and B (Morgan, 1960). It is possible to classify individuals into four 
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main groups according to whether one, both or neither of these antigens is present. 
The H blood group system codes for only one antigen, and although genetically 
independent of the ABO system, represents the precursor substance on which the 
ABO structures are dependent. 
ABO is the most important of the blood group systems, due to the presence of 
`naturally occurring' alloantibodies to the antigens of the system which the 
individual lacks (see e. g. Mollison et al. 1997) as in Table 1.2. These antibodies are 
referred to as `naturally occurring' as they appear in normal healthy humans 
naturally within six months of birth. However, work performed by Springer et al. 
(1959) demonstrated that the production of these antibodies is in fact an immune 
response. Using chicks, they showed that germ-free chicks held in a sterile 
environment did not form anti-B, whereas conventional chicks produced anti-B 
within days of exposure to the normal environment. 
Table 1.2 Antigens and antibodies present in ABO blood groups. 
Blood group Antigens present on RBC Antibodies in plasma 
AA Anti-B 
BB Anti-A 
AB A and B None 
0 None Anti-A and Anti-B 
Therefore, it is thought that ABO system alloantibodies are raised to substances in 
nature, which have similar structure to A and B antigens e. g. microbial surface 
antigens. These alloantibodies are mostly IgM, and when tested against appropriate 
erythrocytes, react directly without the use of a secondary detection antibody. Due to 
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the presence of these antibodies, serum/plasma samples should be tested to aid 
confirmation of the ABO group by testing the sample against known group A and B 
erythrocytes. ABO system antibodies are efficient at complement activation, 
meaning that incompatible cells will be caused to lyse quickly and lead to severe 
transfusion reactions. 
The antigenic determinants of the ABO and H systems are carbohydrates and, 
therefore, are not direct gene products of the A, B and H genes (Morgan and Watkins, 
1959; Morgan, 1960; Rege et al., 1963). These genes code for glycosyltransferase 
enzymes (Watkins, 1966), which catalyse the transfer of individual sugar molecules 
(monosaccharides) from a donor substrate to a pre-determined precursor substance, 
to form oligosaccharides representing the A, B or H antigens. 
Structural studies have been performed on the oligosaccharides present in the ABO 
and H blood groups and have been used to determine the structure of A, B and H 
determinants. From these investigations six types of determinants have been 
identified (see e. g. Schenkel-Brunner, 2000). 
ABO and H carbohydrate chains are conjugated mostly to polypeptides to form 
glycoproteins (carbohydrate + protein) and attached to the anion exchange protein 
band 3 and the glucose transport protein band 4.5 (review, Daniels, 2002). There are 
approximately one million monomers of band 3 protein and 0.5 million monomers of 
band 4.5 protein per adult red cell. A smaller amount of chains are conjugated to 
ceramide to form glycolipids or glycosphingolipids (carbohydrate + lipid). The 
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average number of ABH sites on adult red cells is in the range of 1.5 - 2.0 x 106 
(Schenkel-Brunner, 2000). There are large differences in the density of antigen sites 
among different populations and blood groups of red cells. Economidou et al. (1967) 
gave results of an evaluation of the level of A and B antigens on different blood 
groups, and Cartron et al. (1974) reviewed group A subgroup antigen density. Voak 
and Lodge (1970) discussed the high number of A2B individuals found in certain 
populations and claim that this may be due to H substance deficiency which results 
in group A1B individuals appearing serologically as A2B. Antigen site density is 
important in blood grouping as low levels of antigen may result in mis-grouping. 
In Europe approximately 80 % of all group A individuals are Al and the remainder 
belong to subgroup A2. There are qualitative differences between group At and group 
A2 in the types of precursor chains used, but the main difference is a quantitative one 
(Greenbury et al., 1963). While group Al cells have an average of 0.81 - 1.17 x 106 
group A antigen determinants per erythrocyte, group A2 have an average of 0.24 - 
0.29 x 106 (Economidou et al., 1967), although different results can be found 
(Cartron et al., 1974) (refer to Table 1.4). 
Some A2 and A2B individuals can produce an antibody to A1. Although not clinically 
significant unless of high titre and reactive at 37 °C, it is considered important to 
detect anti-Al in pre-transfusion testing of both donors and patients. If A2 or A2B 
individuals with anti-A1 in their serum were grouped only as group A or AB, their 
blood donation would be available for transfusion to group Al or A1B individuals. 
The anti-A1 could react with the Al cells and cause a transfusion reaction, but only if 
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reactive at body temperature. It is important to detect specific weak subgroups in 
blood group testing. For example, the subgroup AX should be detected in blood 
donors as otherwise it may be grouped as an 0. Current guidelines state that this 
subgroup must be detected (Guidelines for the Blood Transfusion Services in the 
United Kingdom, U. K. Blood Transfusion Services, 2002), yet the subject has been 
much debated. The risk caused by misgrouping an AX as a group 0 is theoretical and 
there are few cases involving transfusion reactions caused by transfusion of such 
blood to a group 0 (review, Issitt and Anstee, 1998). 
Table 1.3 Expected reaction pattern of the main ABO blood types, where + is a positive 
reaction and - denotes a negative reaction. 
A, blood A2 blood B blood 0 blood AB blood 
Anti-B --+-+ 
Anti-A ++--+ 
Anti-A, B +++-+ 
A, cells --++- 
B cells +++- 
0 cells ----- 
Routine blood testing consists of testing erythrocytes with anti-A, anti-B and anti- 
A, B to determine presence or absence of the A and B antigens, and testing 
plasma/serum with known group Al, B and 0 erythrocytes for the presence of ABO 
antibodies (Guidelines for the Blood Transfusion Services in the United Kingdom, 
U. K. Blood Transfusion Services, 2002). Testing of erythrocytes is known as 
forward grouping, and testing of plasma/serum known as reverse grouping. Although 
reverse grouping is classified as part of routine ABO grouping, it is determining the 
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presence or absence of antibody and therefore in this work will be considered as 
antibody screening for anti-A and anti-B and described as ABO reverse grouping. 
Table 1.3 details the expected reaction patterns of the main ABO blood groups. 
Circumstances exist where the reaction patterns in Table 1.3 are weak or do not 
occur, such as in neonates, elderly people or individuals undergoing 
immunosuppressant therapy; these are cases where the immune system is not fully 
developed, in decline or suppressed. 
1.2.1.2 The Rhesus Blood Group System 
In 1939, Levine and Stetson discovered a case of haemolytic disease of the newborn 
caused by an antibody, which was later described as anti-D. In 1940, Landsteiner and 
Weiner made an antibody by injecting rhesus monkey erythrocytes into rabbits. The 
antibody agglutinated red cells from 85 % of samples, which were later described as 
RhD positive. There are now over 45 antigens in the Rhesus (Rh) system of which D, 
C, c, E and e are the most clinically significant (this system is reviewed in Daniels, 
2002). RhD is highly immunogenic (Pollack et al., 1971) and is therefore the most 
important Rhesus antigen in blood grouping. Rhesus antibodies tend to be IgG in 
class and generally do not activate complement. 
The antigens of the Rh system are encoded by variant forms of the highly 
homologous genes RHD and RHCE located on chromosome 1 (see e. g. Daniels, 
2002) and this theory was first forecast by Tippett (1986). The RHD gene encodes 
the RhD antigen and RHCE encodes the Cc and Ee antigens: two pairs of antithetical 
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antigens. Each gene encodes a polypeptide 417 amino acids in length which spans 
the red blood cell lipid bilayer 12 times, and functions as an ammonia transporter 
(Flegel and Wagner, 2002). 32 to 35 amino acid substitutions constitute the 
variations in the Rh phenotypes. 
The RhD antigen has no antithetical counterpart, but consists of a mosaic like 
structure with multiple epitopes (Avent et al., 2000). Individuals may lack one or 
more of these epitopes and produce an antibody to the part that they lack. Cases 
where RhD positive individuals have produced anti-D were investigated and in 1962, 
Tippett and Sanger reported six serologically different types of sample and described 
them as category I to VI. These individuals are now classed, as 'Partial RhD', of 
which there are currently more than'20 types with DVI being the most clinically 
significant (Flegel and Wagner, 2002). The DVI antigen has very few of the RhD 
epitopes and is highly immunogenic. The DVI phenotype results from different 
homologous exchanges of exons from RHCE into RHD. In the U. K., donor testing 
reagents must detect DVI; and an antibody that detects this type must be included in 
donor testing. Partial RhD types can cause production of anti-D in RhD negative 
individuals, and have been implicated in haemolytic disease of the newborn (Mayne 
et al., 1990). Also of concern in blood grouping are individuals classed as 'weak D'. 
These people have a complete RhD antigen but have fewer copies on the surface of 
the red cell, which can make detection more difficult. Weak D result from missense 
mutations in the RHD allele and are located in the transmembrane or intracellular 
segments of the protein (Flegel and Wagner, 2002). If weak D was undetected in 
donor blood and, therefore, classified as RhD negative, it could theoretically 
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stimulate anti-D production if given to RhD negative patients. Further details of the 
Rhesus antigens can be found in Table 1.4. 
1.2.1.3 The Kell Blood Group System 
There are 23 antigens in the Kell blood group system (Schenkel-Brunner, 2000), the 
most clinically significant antigen being K. The K antigen is clinically significant as 
it is highly immunogenic, second only to RhD in terms of immunogenicity 
(Schenkel-Brunner, 2000). The K antigen is a single-pass transmembrane 
glycoprotein that is highly folded via disulphide bonds (Reid and Lomas-Francis, 
1997), and considered to be a conformation-dependant antigen as it can be 
inactivated reaction with sulphydryl reagents (review, Schenkel-Brunner, 2000). 
Further details of the K and k antigens can be found in Table 1.4. 
1.2.1.4 The Duffy Blood Group System 
There are six antigens in the Duffy blood group system (review, Schenkel-Brunner, 
2000), Fya being the most clinically significant and fairly immunogenic. The Duffy 
glycoprotein is a multi-pass transmembrane structure (Reid and Lomas-Francis, 
1997). Further details of the F? and Fyb antigens can be found in Table 1.4. Other 
clinically significant blood group systems are described in Table 1.4. 
1.2.2 Irregular Blood Group Alloantibodies 
Testing for the presence of blood group alloantibodies in human plasma samples is 
mandatory in most countries worldwide. In the U. K. it is covered by the Guidelines 
for compatibility procedures in blood transfusion laboratories (Working Party of the 
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British Committee for Standards in Haematology Blood Transfusion Task Force, 
2004) for antenatal and pre-transfusion testing and the Guidelines for the Transfusion 
Services in the United Kingdom (U. K. Blood Transfusion Services, 2002). 
As such, the inclusion of this testing is critical in a new blood testing system. 
Irregular anti-erythrocytic antibodies are those produced to blood group antigens 
other than A or B, which do not occur naturally but are induced by immunisation 
with blood group antigen. An individual may produce an irregular erythrocytic 
antibody when they come into contact with blood that expresses an antigen `foreign' 
to their own. This usually occurs either during pregnancy or following blood 
transfusion. Antibodies of this kind are usually IgG and for sensitivity require the use 
of an anti-human IgG as a secondary reagent in order to visualise an agglutination 
reaction. Detection of irregular antibodies in antenatal testing is important to prevent 
haemolytic disease of the foetus and newborn. 
Regulations for irregular blood group alloantibody screening vary depending on 
whether testing donor or patient samples. The presence of such antibodies in a 
patient sample is of far greater clinical significance than if detected in a donor. This 
is because donor erythrocyte components have most of the plasma, and therefore 
antibody, removed and any residue is subject to dilution on transfusion. However, if 
antigen positive blood is introduced to an antibody producing patient it can lead to a 
severe transfusion reaction. 
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In the U. K. the technique used for irregular blood group antibody screening must be 
capable of detecting anti-D at 0.5 International Unit/ml or lower in donors, and 0.1 
International Units/ml in patients (Guidelines for the Blood Transfusion Services in 
the United Kingdom, U. K. Blood Transfusion Services, 2002). There are no limits 
for other antibody specificities. Samples found to be positive in an antibody screen 
must be further tested for specificity. 
Currently, erythrocytes from human blood are used in antibody screening tests and as 
blood typing controls, which means reliance on the constant despatch/receipt/change 
over of short shelf life products. The use of alternative source antigens or more stable 
erythrocyte antigens would both save precious donor blood as well as give a more 
consistent, reproducible and stable product. In Chapter 6, a solid-phase microarray 
method using various antigen-presenting formats will be explored for use as an 
antibody screening method. 
1.2.3 Blood Borne Pathogen Testing 
Mandatory blood donation testing includes testing samples for the presence of 
Hepatitis B Surface Antigen (HBsAg), Human Immunodeficiency Virus 1 and 2 
antibodies, Hepatitis C Virus antibodies and Syphilis antibodies. Microbiology 
testing was not a subject of this project, but is considered later for potential inclusion 
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1.3 Specifics of Blood Testing 
1.3.1 Mandatory Blood Testing 
The purpose of blood donation testing was discussed at the start of this chapter. The 
majority of current blood donation testing takes the form of either haemagglutination 
assays or enzyme-linked immunosorbant assays (ELISA). The tests described in 
Table 1.5 are mandatory in the UK and must be performed on every blood donation 
(Guidelines for the Blood Transfusion Services in the United Kingdom, U. K. Blood 
Transfusion Services, 2002). Additional testing may be performed on selected 
donations for specific purposes, i. e. testing for antibodies to cytomegalovirus or 
malaria, human leucocyte antigen typing, extended blood typing for C, E, C, e and K 
antigens. In Scotland, mandatory testing currently also includes nucleic acid 
amplification techniques (NAT) for Human Immunodeficiency Virus. Patient testing 
is somewhat different and routinely involves only blood typing and blood group 
alloantibody screening assays. 
1.3.2 Techniques Used in Blood Testing 
1.3.2.1 Haemagglutination Assays 
In blood group serology the interaction of antibody (Ab) on the erythrocytes (red 
blood cells) with the corresponding antigen (Ag) is routinely detected by 
haemagglutination assay. The technique of haemagglutination was discovered in 
1888 by Stillmark (reviewed in Plapp et al., 1984), who observed that extracts of 
Ricinus communis seeds strongly agglutinated erythrocytes. There are two stages to a 
haemagglutination reaction: sensitisation and agglutination. Sensitisation involves 
binding of antibody to antigen and is influenced by several factors. 
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Table 1.5. Mandatory blood donation testing in the United Kingdom, as of September 2005 
(Guidelines for the Blood Transfusion Services in the United Kingdom, U. K. Blood 
Transfusion Services, 2002). 
TEST PURPOSE FORMAT 
ABO Blood Typing Typing of donor red Haemagglutination 
blood cells for blood 
group antigens of the 
ABO blood group system 
ABO Reverse Typing Typing of donor plasma Haemagglutination 
(first time donors only) for blood group 
antibodies of the ABO 
blood group system 
Rhesus D Typing Typing of donor red Haemagglutination 
blood cells for the 
presence/absence of the 
Rhesus D blood group 
antigen 
Erythrocytic Alloantibody Testing of donor plasma Haemagglutination 
Screen for the presence of 
irregular antibodies to 
blood group antigens 
Hepatitis B Surface Testing of donor plasma ELISA 
Antigen (HBsAg) for the presence of 
Hepatitis B Surface 
Antigen 
Human Testing of donor plasma ELISA 
Immunodeficiency Virus for the presence of HIV 1 
Types 1 and 2 &2 antibodies 
(HIV 1& 2) 
Hepatitis C Virus Testing of donor plasma ELISA/HCV-NAT 
for the presence of HCV 
antibodies and RNA 
Syphilis Testing of donor plasma Agglutination 
for the presence of 
syphilis antibodies 
Agglutination may or may not happen after sensitisation, and is dependant on the 
type of antibody involved - an IgM molecule can cause direct agglutination while an 
IgG molecule usually requires a secondary antibody to cause indirect agglutination. 
Haemagglutination reactions are reversible, and can therefore be broken up and 
potentially lead to false negative reactions. Excessive agitation, whether by manual 
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or automated means, can give rise to this. Voak (1999b) explained that the major 
cause of false negative reactions in indirect haemagglutination assays was in fact 
attributed to excessive agitation. 
IgG molecules have two antigen-binding sites approximately 140 A apart, whereas 
an IgM molecule has ten antigen-binding sites approximately 300 A apart (review, 
Issitt and Anstee, 1998). IgM antibodies tend to agglutinate red cells in a one-stage 
test due to their size and number of antigen-binding sites; the molecule links between 
erythrocytes more easily than an IgG molecule and cross-links, forming agglutinates. 
The number and location of Ag sites can facilitate binding of Ab. For example, 
antigens of the ABO blood group system protrude from the erythrocyte membrane 
and are present in large numbers, whereas those of the Rh system are closer to the 
membrane and are present in lower numbers. Therefore, ABO sites are more readily 
accessible than Rhesus Ag sites. 
The concentration of Ag-Ab involved in the interaction can vary the sensitivity of the 
test. If the amount of Ab present is increased the Ab: Ag ratio increases and the 
stronger the observed reaction. If the concentration of Ag in a test is increased or 
decreased this too will influence the amount of Ab bound to each antigen. pH can 
affect the conformation of the protein molecule as well as its function, which is often 
pH dependent. Most antibodies are optimal between the pH value of 6.5 and 7.5 
(Issitt and Anstee, 1998), although there are exceptions. Most monoclonal anti-M, for 
example, react optimally at pH 8.5. 
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The ionic strength of the test environment influences the rate at which Ag-Ab 
complexes form. Erythrocytes are negatively charged and, therefore, repel each other 
due to the ionisation of carboxyl groups of N-acetyl neuraminic acid residues, or 
sialic acid. When suspended in an ionic solution, free cations are attracted to the 
negative charge on the cell surface, and this forms a repelling cloud around the cell. 
This electron repulsion is known as the zeta potential (Pollack and Reckel, 1970; 
1977). Adjusting the concentration of free cations in the environment alters the 
charge on the red cell, which alters the zeta potential. Reduction in zeta potential 
facilitates Ab agglutination as well as sensitisation. For example, when the ionic 
strength of the environment is decreased the zeta potential of red cells is increased 
and this leads to a greater attraction between the red cells and the usually oppositely 
charged Ab. The ionic strength of haemagglutination reactions is usually lowered by 
the use of low ionic strength saline (LISS) in which the red cells are suspended. 
Enzymes can also be used to lower cell repulsion by removing sialic acid and other 
proteins from the erythrocyte surface. 
Temperature can greatly influence the rate of Ag-Ab reaction. Lower temperatures 
can increase binding avidity but reactions happen more quickly at warmer 
temperatures (such as 37 °C). Temperature can also affect the conformation of the 
antigen (Kelton et al., 1984). 
As many factors can influence haemagglutination reactions, it could be advantageous 
to omit the agglutination stage, and detect the sensitisation interaction in alternative 
ways. Solid-phase formats rely only on sensitisation of antibody and antigen, and not 
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agglutination, and this will be further discussed. Blood group serological testing 
involving sensitisation and haemagglutination can be performed by a number of 
different techniques as follows and varies depending on the requirement of the 
laboratory. 
" Slide testing: This is the simplest form of test and tends to be the least 
sensitive. It involves mixing Ab with erythrocytes on a glass slide, and viewing 
over a light box to determine the presence or absence of Iiaemagglutination. This 
test can be very subjective and is not automated, and depending on operator 
experience, throughput can be limited. Like all manual techniques, slide testing 
requires good training on technique and the use of controls, and data recording 
has to be performed manually. 
Tube testing: The Ab and erythrocytes are added to a glass tube and mixed. 
Centrifugation must follow Guidelines for compatibility procedures in blood 
transfusion laboratories (Working Party. of the British Committee for Standards 
in Haematology Blood Transfusion Task Force, 2004) and usually follows an 
incubation period. Centrifugation pellets the cells at the bottom of the tube in a 
`cell button'. Centrifugation makes the test more sensitive than the slide 
technique, but this is not automated and depending on operator experience, 
throughput can be limited and errors more likely due to human error. 
" Microplate Testing: 96 well microplates are used in which the Ab and 
erythrocytes are mixed and incubated. The reagents are dispensed when required 
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by an automated system; the plates are not usually supplied with pre-dispensed 
reagents. This is usually automated and is, therefore, suited to high throughput 
testing as required in blood donation testing. Depending on the system used, 
centrifugation may or may not be used. Computer-driven spectrophotometry or 
digital photography are used to capture images and interpret the reaction. 
" Micro Column Technology A gel card usually consists of six microwells 
each containing a `gel' of either glass beads (Ortho BioVue system) or Sephadex 
(dextran derivative) (DiaMed ID System). The Ag-Ab reaction takes place above 
the gel during an incubation period, or the Ab can be suspended in the gel. The 
card is then centrifuged. A positive reaction, demonstrated by haemagglutination, 
cannot pass through the spaces in the gel and forms a line at the top of the gel, or 
partial movement through the gel. Non-agglutinated cells can easily pass through 
the spaces in the gel and the negative reaction demonstrated by erythrocytes at 
the bottom of the gel. The column technique was patented by DiaMed AG and 
described by Lapierre et al., (1990). This system is now available with varying 
degrees of automation. Although suitable for high-throughput testing, it is more 
often used for patient testing in lower throughput hospital laboratories or blood 
banks rather than for donor testing. An advantage of the micro column systems is 
that there is a reduced risk of infection of staff as the system allows enclosed 
testing and each card is pierced prior to use, although the costs of this system can 
be limiting to some laboratories. 
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" Solid Phase Antibody Screening: This differs from simple microplate 
testing as erythrocyte membranes are immobilised on microplate wells and used 
for the detection of erythrocytic alloantibodies in plasma or serum. Existing 
systems use `indicator' erythrocytes that demonstrate visible haemagglutination 
in positive tests. Currently, these systems (which can be automated) are only used 
for blood group alloantibody screening. Methods for solid-phase antibody 
screening will be discussed further in section 1.3.2.5. dealing with the technology 
available in solid-phase systems. 
" Flow cytometry: This method does not rely on agglutination, only 
sensitisation. It has been used to demonstrate the presence or absence of Ag-Ab 
reactions using fluorescently labelled antibodies. Although sophisticated and 
highly sensitive, the flow cytometer method is complex and not suitable for high- 
throughput testing. 
1.3.2.2 Enzyme-Linked Immunosorbant Assays (ELISA) 
Protein based testing for the presence or absence of pathogenic microorganisms, or 
antibodies to them, usually takes the form of an ELISA, which are mostly performed 
in microplates. This allows the testing of many blood donations at any one time. The 
ELISA method can be adapted to perform blood group serological assays (Scott, 
1991), but is not routinely used. 
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1.3.2.3 Nucleic Acid Amplification Testing (NAT) of Transfusion Related 
Antigens 
Recently NAT has been introduced for pathogen testing of donations. This type of 
testing gives increased sensitivity over ELISAs. NAT uses the polymerase chain 
reaction (PCR) to amplify viral RNA or DNA present in pooled samples. Pooled 
samples that give a positive reaction are cross-pooled and tested to determine 
positive donations, although there are now some automated systems available that 
can perform NAT testing on individual samples. 
While NAT techniques are used for pathogen testing of blood donations, it has not 
been fully adopted as a routine method for blood typing. Genes encoding most of the 
blood group systems have been cloned and sequenced and generally it has been 
found that blood group antigens arise from single-nucleotide polymorphisms (SNPs). 
The ABO and Rhesus systems pose more of a challenge; as the antigens do not arise 
from SNPs, their genetic basis is more complex and the current most reliable method 
of grouping remains agglutination (Anstee, 2005). 
For human platelet antigens much work has been done to prove that typing can be 
done by large-scale NAT methods, (Bugert et al., 2005) based on the use of SNP 
detection. 
Denomme and van Oene (2005) attempted blood group genotyping, but with a level 
of error - 98 % of samples were correctly typed, but with less success for Rhesus 
groups. Beiboer et al. (2005) also reported on rapid blood group genotyping. Hashmi 
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et al. (2005) performed DNA typing using bead array technology from Illumina, the 
BeadChipTM, discussed later, compared to manual PCR. In the bead array, SNPs 
were attached to the beads and then analysed after hybridisaton. They found 
comparable results by both methods and have developed a prototype chip, but the 
ABO and Rhesus systems were not tackled. The system seems more for screening 
purposes than an outright replacement for existing test procedures. Systems such as 
these may help with blood group antibody shortages to certain antigens, as only 
confirmatory testing is required. For purposes other than blood typing, Zhang et al. 
(1999) demonstrated that DNA genotyping could be performed directly from whole 
blood, without prior processing steps. This could potentially cut testing time if 
applied to blood group genotyping. 
While performing DNA based testing of genotypes it is important to remember that 
sometimes the genotype and phenotype do not correlate (Reid, 2003). This may be 
due to a number of circumstances. Certain medical practices can lead to the presence 
of non-self DNA i. e. transfusion/transplantation. Molecular events such as a point 
mutation in a regulatory element of a gene could impair transcription, or a mutation 
in splicing sites, a premature stop codon, the absence of an interacting protein or less 
protein in the membrane of the erythrocyte could all cause discrepancies. In some 
cases a PCR primer may not be able to bind efficiently to a target, yet a product is 
present on the erythrocyte membrane. For example hybrid genes, when part of the 
RHD gene is replaced with the RHCE gene, primers for the RHD gene will not 
amplify yet a partial RhD will be present on the surface of the red cell (Avent and 
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Reid, 2000). Anstee (2005) also reports that molecular methods are ̀ as yet' not error- 
free, and that mutations will continue to evolve. 
Although the technology of DNA based genotyping is unlikely to be employed for 
routine blood typing in the very near future, it has powerful potential for transfusion 
medicine through its accuracy and sensitivity (Reid and Rois, 1999; Petrik, 2001). 
Currently the two most valid uses for blood group genotyping are to determine the 
RhD type of foetuses of women with anti-D, and to predict phenotype of transfusion- 
dependent patients (Daniels et al., 2005). It is considered very important to continue 
serological testing and this will be explored within this work by looking at the 
evolving technology of microarrays, in which Ab-Ag interactions are interpreted 
without the use of haemagglutination. 
1.3.2.4 Automation in Blood Testing 
Levels of automation in blood testing are constantly increasing as automation gives 
more security in positive sample identification and can reduce overall costs. Tests 
can be performed simultaneously, yet these are still carried out as individual tests on 
multiple instrument platforms due to the different formats described above. This 
means that results from multiple testing platforms have to be reconciled at a 
computer interface, often leading to delays. Many different pieces of equipment 
mean that more than one blood sample is required for testing. If multiple tests were 
performed on one platform such as microarray it would mean fewer samples of 
reduced volume would be required, which is of particular benefit to patients, and 
results could be available more quickly. A microarray system would enable 
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multiplexing and full automation. This would aid the provision of donor blood and 
the selection of compatible blood for patients. A table comparing different 
techniques and throughputs is available in the paper Robb et al. (accepted 2005 for 
Transfusion Medicine) in Appendix 4. 
Currently most blood donation testing is carried out using the Olympus PK7200 or 
PK7300 systems, which carries out mandatory agglutination assays (blood typing 
and Syphilis). The cost and throughput of the Olympus system is too high for use in 
testing of patient samples (it can test 240 samples in one hour). It is also considered 
of lower sensitivity when testing for the presence of blood group alloantibodies, 
which is acceptable for the testing of donor blood. Using the Olympus system, the 
most commonly used high throughput method for blood group alloantibody 
screening of blood donations involves the use of group 0 erythrocytes that are papain 
treated (to detect IgG antibodies without the use of a secondary antibody). This 
testing uses a microplate format with stepped wells. The erythrocytes are prepared 
and dispensed into the microplate shortly before the addition of the donor serum. 
Incubation takes place and then the plate is read. Donation testing centres commonly 
use the Abbott Prism® (Wiesbaden, Germany) system for performing pathogen 
testing. 
Column agglutination testing is routinely used in patient testing blood banks 
throughout much of the developed world for antibody screening. Considering the 
sensitivity, throughput and automation available in parallel with costs, these systems 
are considered optimal for patient testing and mostly for lower throughput antibody 
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screening. The two most popular systems in use in the U. K. are those supplied by 
DiaMed AG (ID System) and Ortho Clinical Diagnostics (BioVue), although others 
are now available. The column agglutination methods are often referred to as solid- 
phase methods in the field of blood grouping. However, this does not comply with 
the definition that solid-phase means the immobilisation of a component of the test. 
The antibodies used in column agglutination methods are simply mixed into the 
matrix, not immobilised. The automated reading of this system uses a charge-coupled 
device camera. 
1.3.2.5 Solid Phase Methods for Use in Blood Testing 
There are existing techniques that use solid phase techniques rather than the 
traditional liquid phase methods. For this, solid phase refers to the immobilisation of 
the antigen or antibody to a surface before interaction with analyte/target solution. 
Advantages of solid-phase methods can include the pre-dispensing of reagents, 
which saves greatly on testing time, and the possibility of increased automation and 
reading. As microarrays are solid-phase platforms and will be used in this work, 
previous development work performed in microplates is very relevant. 
The immobilisation of antibodies to microplates for the purpose of blood typing is 
perhaps a more simple approach than that of antigen immobilisation for antibody 
screening. Fewer publications are available on microplate methods for antibody 
screening as the requirement for washing and the addition of a secondary detection 
antibody makes the microplate process more complicated. Complications also arise 
due to the complex nature of the antigens required for use in antibody screening, 
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which are immobilised on the erythrocyte, and can therefore also be considered in 
solid-phase. 
Investigations into non-haemagglutination based assays began in the 1950's. The 96- 
well format for microplates was first used in viral serological investigations, then in 
1966 it was described in serological tests for blood group serology (reviewed in 
Plapp et al., 1984). During the 1960s the idea of anti-globulin coated indicator cells 
was reported by Fagraeus and Espmark, and in the 1970s many groups were 
reporting variations of solid-phase assays involving erythrocytes and platelets in 
solid-phase (reviewed in Plapp et al., 1984). Solid-phase methods for blood typing 
and alloantibody screening are discussed below. 
1.3.5.2.1 Solid Phase Methods for Blood Typing 
To perform blood typing in solid-phase, blood typing antibodies must be 
immobilised onto a surface. This has been already been demonstrated in plastic 
microplates and, compared to antibody screening, is considered relatively simple. 
In 1985, Sinor et al. described a method for solid-phase ABO and RhD typing, and 
they also reported work on solid-phase antibody screening methods. They 
encountered problems with stability of both immobilised antibodies for ABO and 
RhD grouping and immobilised erythrocytes for reverse ABO grouping and antibody 
screening. For ABO and RhD grouping, Sinor et al. overcame problems by using 
immobilised Al RhD negative, B RhD negative and 0 RhD positive erythrocytes 
onto microplates. Once immobilised the cells were then sensitised with IgM 
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antibodies against blood group antigens A, B and RhD. The ABO and RhD type was 
determined when the patient/donor erythrocytes were added and bind to the 
appropriate immobilised antibodies, and a positive reaction was demonstrated by a 
layer of erythrocytes over the well. The same group (Beck et al., 1985) also reported 
the use of salivary substances to bind blood typing reagents to perform ABO 
grouping. 
A dipstick solid-phase method has been developed for use in bedside transfusion 
testing (Knight and de Silva, 1996). This consists of a stick onto which IgM blood 
typing antibodies were bound. This stick is dipped into a blood sample and then 
rinsed with saline. The results are visualised with the presence or absence of the red 
colour, and therefore haemagglutination, of bound erythrocytes. One disadvantage to 
this system would be the lack of ABO reverse typing and due to this its use is 
limited. 
Scott (1991) reported on the development of a solid-phase microplate system for 
blood typing. A direct correlation between the amount of antibody immobilised and 
the level of binding of erythrocytes to immobilised antibody was evident, yet too 
high a concentration resulted in less coating, which could possibly be attributed to 
the ̀ hook effect' (Fernando and Wilson, 1992). Critical factors were shown to be the 
type of microplate used, purity of antibody, concentration, pH and ionic strength of 
coating buffers. 
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Uthemann et al. (1999) developed a solid-phase method for ABO, Rhesus and K 
grouping using immobilised monoclonal IgM antibodies for forward grouping and 
erythrocyte membranes for reverse grouping. The main difference to previously 
described methods was due to the realisation that passive adsorption of the antibody 
occurred even if added immediately before the cells, therefore allowing erythrocyte 
adherence over the well. Other variations of blood typing in solid-phase are 
numerous. 
Diagast (Loos Cedex, France, Diagast. com) have developed a solid-phase blood 
typing system that does not rely on centrifugation. In this system they describe plates 
pre-coated with antibody to which test cells are added. These cells are diluted in a 
magnetising solution. Rather than centrifugation, the plates are held over a magnetic 
source, which pellets the magnetised cells. After this the plate is agitated and 
agglutination demonstrated by a pellet, whereas cells in solution demonstrate a 
negative reaction. To complement this system they have an antibody screen system 
where the reagent cells are pre-magnetised. 
In 2003, Hurt et al. reported on a compact disc system for ABO and RhD typing. 
They claimed that the system also had potential for pathogen testing, but no 
commercial progress has been reported. 
1.3.2.5.2 Solid Phase Methods for Alloantibody Screening 
The basic principles of solid-phase antibody screening are simple; a surface must be 
coated with blood group antigen, sample serum/plasma is added, unbound 
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serum/plasma proteins are washed away, antibody may or may not be detected to 
give a positive or negative result. As in ELISAs, the technique is more complicated 
in practice. Considerations include the optimal conditions/substrate for 
immobilisation of antigen, the format of the antigen itself, the blocking procedures 
and reduction of non-specific binding, incubation times and the detection antibody 
properties. Investigated methods for blood group antibody screening have included 
the immobilisation of the whole red cell. Methods based on other antigen types or 
cells have included the immobilisation of cell membranes, cell fragments, peptides, 
synthetic antigens and aptamers. These may be potential options if applied to blood 
testing microarrays. 
In 1985, Beck et al. reported the use of salivary ABO blood group substances in a 
microplate method for ABO grouping. Later they reported that these substances 
could be used for reverse grouping to detect anti-A and anti-B. Beck et al. found that 
the salivary substances bound readily to the plastic microplate. 
In 1986, a semi solid-phase microplate indirect antiglobulin test was reported (Ross 
and Gordon, 1986; review, Scott, 1991), and this technique was used routinely in 
some laboratories. However, this was not a total solid-phase method as only the 
incubation with the immobilised secondary antibody (anti-human globulin reagent) 
took place in the microplate environment. Incubation of serum and erythrocytes was 
performed by standard liquid phase techniques. To develop a totally solid-phase 
antibody screening method it is clear that the blood group antigen must be 
immobilised on a surface. Failure to do this means the test system would rely on 
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transfer from one reaction chamber to another and involve more time and 
manipulations. 
Erythrocytes or erythrocyte membranes do not bind to microplates as their surface is 
negatively charged, as is the microplate surface. This can be overcome by treatment 
of the surface to enhance binding conditions. Scott (1991) used poly-L-lysine-coated 
microplates, antibodies to erythrocytes and the use of castor bean lectin (a non- 
specific binder of all erythrocytes). The poly-L-lysine coated plates were positively 
charged and subsequently bound erythrocytes readily. Peroxidase substrate was 
added to lyse the cells before measuring the colour change in the well, and this 
indicated the level of erythrocyte binding. Poly-L-lysine gave the best results. These 
are used often in DNA microarrays and will be explored in this thesis for use in 
blood testing. 
Stocker and Heusser (1979) reported that cells (erythrocytes and lymphoid cells) 
could be bound to a microplate by the use of gluteraldehyde fixation or by antibodies 
bound to the plate. The resulting cell layers were used in a radio-immunoassay to 
screen monoclonal antibodies. Although the cell layers were stable for short periods, 
there were doubts over the stability of erythrocyte antigens following this treatment 
(Scott, 1991). 
Scott (1991) and Sinor (1992) found that erythrocyte ghosts were more stable in 
solid-phase than whole cells, and this fact may be used in the development of a 
microarray-based system. For quality control of bound ghosts, Scott used a positive 
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control antibody to determine the level of binding to the plate. The antibody 
screening system worked well when testing purified monoclonal antibodies. 
However, when human serum/plasma samples were tested, high non-specific binding 
was evident. For the testing described, an enzyme-linked antiglobulin reagent was 
used for detection. It appeared that high levels of immunoglobulin from the serum 
were binding to the immobilised ghosts. Blocking with casein, albumin or Tween did 
not alleviate the problem. Other groups were also working on the development of 
solid-phase antibody screening systems and finding similar problems. As described 
below, the problem was overcome using `indicator cells'. 
A group, which later became associated with the company Immucor (Norcross, GA, 
USA), began the development of solid-phase red cell adherence assays for routine 
blood transfusion testing during the 1980s. Sinor (1992) described the four main 
problems they encountered. Firstly they sought a method for immobilisation which 
did not rely on binding of erythrocytes to immobilised antibody, as they felt this 
would be unreliable due to problems in automated wash systems. They overcame this 
by using chemical coupling agents for immobilisation of erythrocytes, followed by 
the lysis of the erythrocytes in-situ to create membranes. The detail of the attachment 
chemistry was not published. To perform ABO reverse grouping and antibody 
screening, whole erythrocytes were immobilised and dried. Patient or donor 
serum/plasma would then be added. If antibodies were present they bound onto the 
immobilised erythrocytes. Binding of antibody was demonstrated by the addition of 
`indicator red cells'; erythrocytes coated with anti-IgG. These will bind to either anti- 
A or anti-B which has bound to the immobilised A or B erythrocytes, or to the 
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alloantibodies from serum/plasma bound to the antibody screening immobilised 
erythrocytes. The indicator cells are prepared by sensitising the erythrocytes with an 
IgG antibody, and then incubation with anti-IgG. The preparation process ensures 
this step does not result in haemagglutination. 
The final problem described by Sinor (1992) was that of non-specific binding of IgG 
in human serum/plasma samples, which can be common to microplate based assays. 
They discovered that this could be solved by centrifugation of the microplate at two 
different speeds, one low, and one high. The low centrifugation allows the indicator 
erythrocytes to bind specifically, while the higher centrifugation pellets the 
erythrocytes in a negative test without reducing the adherence of the indicator 
erythrocytes in a positive test. 
Immucor introduced this technology as the Capture RTM antibody screening system 
in 1989. This system is a total solid-phase system, i. e. all the testing is performed in 
one microplate well. Originally this system was supplied with activated microplates 
to which the user had to add reagent erythrocytes to immobilise them. Latterly the 
system was enhanced by the use of plates pre-coated with erythrocyte ghosts. 
Immucor also released similar technology for the testing of Cytomegalovirus and 
Lyme Disease antibodies. The Food & Drug Administration (FDA) in the United 
States of America, perhaps the most stringent regulatory system, has approved the 
Immucor testing systems. However, a limitation of this system is evident. Rolih et al. 
(1995) and Zeiler et al. (1996) both report on solid-phase systems, and when using 
IgG coated indicator cells, failed to detect IgM alloantibodies. 
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There have been other reports on the use of membranes to create solid-phase 
alloantibody screening methods (Million et al., 1998), which can also use different 
methods of detection such as antibody-coated beads. At this time, none are 
commercially available. 
Biotest (Dreieich, Germany) released an antibody screening system in the early 
nineties. The Biotest SolidScreen is now a commonly used technique throughout 
Europe. The microplates in this system are coated with an antibodies to anti-human 
globulin reagent. To this, reagent erythrocytes, test serum/plasma and antiglobulin 
reagent are added. If the cells are sensitised with antibody they will bind the anti- 
globulin reagent and then attach to the microplate. 
1.3.2.5.3 Biacore -A Solid Phase Platform for the Study of Biological 
Interactions 
One of the most sophisticated methods to study biological interactions in solid-phase 
is the Biacore platform using the detection method of surface plasmon resonance 
(SPR). SPR is a well-recognised method for the study of immobilised proteins, 
peptides, nucleic acids and other molecules for analysis. SPR systems are considered 
solid-phase and can be used to monitor real-time biological interactions without 
associated labelling of the samples (Yuk and Ha, 2005). The use of unlabelled 
biomolecules is advantageous as the sample preparation steps are reduced. Also, the 
labelling of some molecules can affect their function (Fagerstam et al., 1990). SPR is 
useful to provide more detailed analysis of interactions and specificities, and can be 
used for kinetic studies, but it is not a typical high throughput method. Currently, 
available SPR chips allow the study of one probe-ligand interaction at a time and is, 
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therefore, limited in its use and cannot be used in multiplex assays. However, there 
are groups working on the use of SPR in high-throughput systems (Yuk and Ha, 
2005) in combination with other technologies. 
SPR arises at the surface of a metal film when light is reflected onto it. Surface 
plasmons are free electrons on the surface of a film and are excited under specific 
conditions, therefore transferring energy. When energy transfer between the light and 
the metal match, this is known as resonance, and is seen as a dip in the reflected light 
intensity (Liebermann and Knoll, 2000). 
SPR relies on total internal reflection (TIR): when a light beam from a medium of 
high refractive index meets an interface of a lower refractive index, the light is 
reflected at the interface and propagates back into the higher refractive index 
medium. Although the light beam is reflected back into the higher refractive index 
medium, it does leak an electrical field into the lower refractive index medium, and 
this is known as an evanescent wave, which extends 100 nm above and below the 
metal surface. In SPR systems the interface is coated with a conducting metal, which 
is in contact with the lower refractive index medium. The presence of the metal 
enhances the evanescent wave effect due to its being penetrated by and propagating 
the wave. 
Any change in the electrical field results in a change in the wavelength of light that is 
absorbed rather than reflected. The magnitude of the change is quantitatively related 
to the magnitude of the chemical change, and therefore the bound mass. When 
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molecules bind to the sensor surface the mass increases, when they dissociate or are 
removed, it decreases. The amount of light reflected is measured by a reflectance 
spectrophotometer and the SPR angle is monitored by a change in the detector 
position (Filgerstam et al., 1990), demonstrated in Figure 1.6. SPR detects changes 
in mass in the aqueous layer close to the surface by measuring the change in 
refractive index (RI), which is the degree to which the light is bent. The actual 
response is measured in response units (RU) and is proportional to the mass on the 
sensor surface (one RU represents a change of 0.0001 in the angle of reflective light 
(Biacore. com). SPR systems output data as sensorgrams, which are computer- 
generated plots of response against time showing the interaction progress. 
SPR systems can be used to monitor interactions between molecules; one attached to 
the sensor surface and one in solution. However, the sensor chip detection method 
cannot differentiate between the binding of specific analyte and non-specific binding 
caused by binding of other molecules from the analyte solution (Brynda et al., 2002). 
The Biacore-XTM SPR system is used with Biacore Sensor ChipTM CM5 chips. In 
these chips a thin layer of gold (approximately 50 nm thick) covers the glass. Figure 
1.6 shows where the interaction takes place on the gold covered side of the sensor 






Figure 1.6. Diagram of an SPR flow cell (Biacore. com). The interaction takes place on the 
gold surface in contact with the flow cell. The analyte solution is passed through this flow cell 
under the control of a microfluidic system. The graphs show the effect of a change in the 
reflected light. 
The analyte solution is passed through the flow cell in a precisely controlled 
microfluidic system that allows it to interact with the ligand. The Biacore Sensor 
ChipTM CM5 gold layer is modified by the attachment of a hydrophobic alkanethiol 
layer. A layer of flexible unbranched carbohydrate polymer named 
carboxymethylated dextran covers the alkanethiol. 
This layer is hydrophilic, making it suitable for attachment of most biomolecules. At 
pH above 3.5, the 100 nm thick layer has many negatively charged carboxyl groups 
that are used for the covalent immobilisation of positively charged molecules. The 
flexible nature of the dextran allows free movement of attached ligands, and means 
they can be retained in a functional state and accessible in three dimensions. The 
Biacore Sensor ChipTM CM5 range can be used to covalently immobilise ligands 
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through -NH2, -SH, -CHO, -OH or -COOH groups, and can be used to study 
biomolecular interactions, kinetics and perform concentration analysis. 
Gomes et al., (2000) used SPR to analyse interactions between monoclonal antibody 
and peptides relevant to foot-and-mouth disease. The BiacoreTM SPR system was 
used by Quinn et al. (1997) for the detection of blood group antigen on erythrocytes 
using monoclonal antibodies. The antibodies used for immobilisation were dialysed 
in buffer to induce a net positive charge. A net positive charge may be achieved by 
lowering the pH of the Ab solution below its isoelectric point, which for IgM 
antibodies should be about pH 5.5 (Quinn et al., 1997). The positive charge allows 
the antibody to be covalently immobilised onto the negatively charged surface. 
The work performed by Quinn et al. (1997) was novel as it involved the detection of 
cells. The system demonstrated the specific reactivity of erythrocytes when passed 
over the sensor surface using SPR for the detection of the erythrocyte mass. Due to 
the size of an erythrocyte (7.8-8.3 am in diameter) the bulk of the bound erythrocyte 
may be situated outside the evanescent field of the chip and they may also be unable 
to penetrate the dextran layer. This will decrease sensitivity of the sensor chip, as not 
all immobilised ligand is available. The orientation of the bound erythrocyte is also 
unpredictable. Although the cell has a large diameter, it is only approximately 1.7 
pm thick. Therefore one cell may cover a large area if lying down on the chip, or a 
small area if bound on its side. 
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In addition, Quinn et al. (1997) described the used of Concanavalin A (ConA) as a 
lectin that binds to all erythrocytes irrespective of blood group. ConA binds to 
surface glycoproteins through mannose and glucose residues and is isolated from the 
Jack Bean (Kornfeld and Ferris, 1975). ConA has a molecular weight of 25,500 per 
protomer (Becker et al., 1975) although above pH 6.8 ConA exists as a tetramer with 
one binding site per monomer. Above pH 7.0 it forms larger aggregates. The 
molecule requires the presence of calcium and manganese ions for binding to 
glycoproteins (Becker et al., 1975). ConA is used for the development of SPR 
procedures in this work and is also considered as a secondary detection molecule 
when fluorescently labelled. 
1.3.2.6 Alternatives to Existing Solid-Phase Methods 
Diagnostic testing systems and products are constantly evolving and improving. Any 
new system must offer benefits over the existing technology to be accepted. Smaller, 
faster and cheaper methods are most likely to succeed if they also offer high 
throughput, specificity, sensitivity and positive sample identification. New 
technology may offer the next generation of diagnostic testing systems. It is probable 
that superior technology will replace existing technology, even if initial costs are 
higher, as increased uptake tends to lower costs (Petrik, 2001). 
In 1997, Quinn et al. demonstrated that the solid-phase method of SPR has the ability 
to determine blood groups. By the start of this work, data had also been published 
which stated that the microarray platform was suitable for protein applications. 
Therefore, there was potential that solid-phase assays such as microarrays could be 
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used for blood donation testing. Microarrays are already well established for DNA 
analysis. Microarray technology may potentially offer an alternative to the testing of 
one donation on many platforms where a donation could potentially be 
comprehensively characterised on one `chip'. The expansion of these chips to 
include further tests as they become available or required is also considered 
relatively straightforward provided the appropriate reagents are available. 
This attempt to develop this new technology is considered both timely and novel. 
Since the start of this work, the research in this field has advanced from limited 
published material to copious amounts available on many types of protein arrays. 
From literature searches performed thus far, this is the first and only work that looks 
into the possibility of comprehensive blood testing by protein microarray. 
1.4 Microarray Technology 
1.4.1 The Origins of Microarrays 
Watson and Crick published the double-helical structure of DNA in 1953. This was 
the origin of the scientific field of molecular biology. Many methods used in 
molecular biology exploit the fact that nucleic acid strands bind by base-pair 
complementarity, where bases adenine-thymine (A-T) and guanine-cytosine (G-C) 
pair in DNA and adenine-uracil (A-U) and G-C pair in RNA. Traditional methods in 
molecular biology worked on a one gene - one experiment basis, and this meant that 
experimental throughput was limited. However, the great advantage of microarrays is 
the potential for massive parallel analysis; the technology of DNA microarrays 
allows information on thousands of genes to be studied simultaneously on one 
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microarray `chip'. The term chip is used to describe microarrays, which are also 
referred to as slides or microchips, biochips, or more specifically as gene or protein 
chips. 
A biological array is described as an orderly arrangement or collection of molecules 
(Petrik, 2001). A traditional array experiment may use common assay equipment 
such as microplates or blotting membranes, and may be prepared manually or make 
use of robotics to deposit samples. Array assays may be described as either 
macroarrays or microarrays, the difference being in the size and density of the spots. 
The Southern blot, mentioned below, may contain spot sizes of 300 pm or above. 
Microarrays may have a far greater density - one array can potentially contain 
thousands of spots. 
It is generally accepted that the field of DNA microarray technology evolved from a 
discovery made in 1975 by Ed Southern (review, Lander, 1999). The Southern blot 
was one of the first kinds of arrays, where nucleic acid molecules are attached to a 
solid support and probed with labelled RNA/DNA molecules. In 1989, Ekins 
reported on the ambient analyte immunoassay and suggested the theory that a `large 
range of individual immunoassays on a small immunoprobe' could be used to 
measure analytes in small samples. Although the Ekins theory is based on 
immunoassay rather than DNA assay, the basic assay approach of microarrays had 
been in existence for quite some time. 
57 
In 1995, a group from Stanford University published work (Schena et al., 1995), 
which caused an explosion in the interest towards microarray technology (Lander, 
1999). Rather than using porous membranes, they described the use of solid supports 
such as glass microscope slides on which thousands of nucleic acid molecules could 
be `spotted' using pins. These spotted microarrays were then hybridised with a 
labelled probe, then scanned and analysed. Following this, high-density arrays soon 
became possible with advances in robotic printing technology. 
In 1991, Fodor et al. described a method to produce arrays of 400,000 distinct 
oligonucleotides each within its own 20 um area. This was achieved using 
photolithography-masking techniques that enabled the synthesis of the 
oligonucleotides at set positions. This innovation, along with that described by the 
Schena et al., (1995) led to the explosion of interest of microarrays. 
In the years between 1991 and 1995 other methods were being developed. Walt et al. 
(1993) were working with cDNA beads, which formed the basis of the Illumina 
system. Although beads offer advantages, the developments by Schena et al. made 
the most impact as it was more readily available technology. 
In the literature there is a conflict of opinion within publications on the historical 
developments in the microarray field. Ekins and Chu (1999) criticise the publication 
by Schena et al. (1998) for its descriptions of origins of the technology, which they 
believe had been originated with the ambient analyte theory (discussed later). 
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In array technology, there are two frequently used terms; probe and target. This 
manuscript follows the nomenclature that a `probe' is a molecule of known sequence 
or specificity (usually the immobilised molecule), and that a `target' is a sample of 
which the identity, presence or abundance is unknown. Figure 1.7 illustrates the 
simplest form of general microarray principles. A probe is first immobilised onto a 
solid surface. The surface is then blocked before incubation with a fluorescently 
labelled target. Options for each of these stages will be discussed later. 
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Figure 1.7. Schematic of simple microarray or solid-phase principles (not to scale). 
Since the invention of microarray technology the applications have been widely 
explored. It is now possible to analyse all the genes of certain organisms at once 
(Blohm and Guiseppe-Elie, 2001). In 1998, Ramsay reviewed the state-of-the-art, 
which gave an overview of the microarray technology at that time. This paper also 
clarifies the two variations in the use of DNA microarrays: one where sample (target) 
DNA is immobilised then exposed to labelled probes before complementary 
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sequences are analysed. This is the method initially developed by the Stanford 
University group (Schena et al., 1995). These microarrays have been used to monitor 
the expression levels of certain genes and for large-scale screening; secondly, 
oligonucleotide probes may be pre-synthesised and then immobilised or synthesised 
on the chip using light-directed synthesis (Fodor et al., 1991). The array is then 
exposed to labelled target DNA and complementary sequences analysed. The on-chip 
synthesis developed by Fodor et al. is the method employed by Affymetrix (Santa 
Clara, CA) in their product, the GeneChipTM. These chips have been used in the study 
of gene expression monitoring, mutations, the mapping of genomic libraries and gene 
discovery and sequencing. 
Usually, the preparation of microarrays requires specialised robotics and imaging 
equipment, which is generally not available as a complete system, although some 
manufacturers now supply all necessary components. Manual microarrayers are 
available. Blohm and Guiseppe-Elie (2001) describe how microarray work requires 
at least five components: a chip/slide on which to build a `microarray', a device to 
fabricate the microarrays, a system or method for hybridisation, a scanner to read the 
microarrays and software to process and analyse the results. This does not include 
equipment for the preparation of samples and probes. This paper also mentions the 
immense variability brought about by the various stages of the experimentation. 
Information on the building of a microarray system is available from the Stanford 
Microarray Database website and in Cheung et al. (1999). 
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1.4.2 Design Options for Microarray Experimentation 
This section outlines experimental design considerations in the development and 
optimisation of a microarray experiment, based on the existing work in this field. 
There are several steps involved in the design and use of a microarray system, and 
many different options available within each step. Figure 1.8 outlines the design 
considerations encountered in microarray development and can apply to both DNA 
based and protein based microarrays. These are discussed here and will be applied 
throughout this work. 
1.4.2.1 Options for Microarray Surfaces and Microfluidics 
Glass microscope slides, if chemically treated, can be used to prepare arrays 
containing thousands of spots (Cheung et al., 1999). Glass slides are ideal for the 
production of many types of arrays, especially DNA arrays, as they can withstand 
high temperatures, are relatively cheap and, as glass is non-porous, reaction volume 
may be kept to a minimum (Petrik, 2001). Glass slides are commonly coated with 
poly-L-lysine for the arraying of DNA as well as proteins (Haab et al., 2001), but 
other coatings have been explored. There are alternatives to glass slides such as 
silicone, plastic and beads, which could be selected if appropriate to the assay. 
Alternative slide coatings are discussed below, but the options available are always 
increasing as research laboratories seek optimal probe immobilisation and novel 
surfaces. 
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Figure 1.8. Design considerations in microarray development, experimentation and 
optimisation. 
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Recent advances in microarray technology have seen the development of 
`microfluidics' chips. These involve the flow of samples/targets through fine 
channels and in contact with a microarray environment. Examples of chips involving 
microfluidics include the Nanogen (San Diego, CA) NanoChipTM, where solutions 
are entered through ports on the chip and permitted to flow across the array. The 
Nanogen system uses microlithography techniques to prepare the semiconductor and 
microfluidics chip. The chip is coated with silicon dioxide and silicon nitrate layers 
between the electrodes and the silicon base. A streptavidin impregnated gel 
permeation layer covers the electrodes and provides an interface between the chip 
and the biological test environment, and provides an area for the attachment of 
biotinylated probes or target molecules. This technology currently has 400 electrodes 
for immobilisation, and Nanogen are currently developing this to give thousands of 
electrodes. Microfluidics can also be found in surface plasmon resonance biosensors. 
The use of miniaturised microfluidics chips may allow for the development of point 
of care diagnostics (Cahill, 2001). 
Other microfluidic methods involve the use of microbeads carrying millions of 
different cDNA clones, or indeed proteins, that are allowed to hybridise with targets. 
An array is assembled in a flow cell and analysed by a fluorescent based signature 
sequencing method (Blohm and Guiseppe-Elie, 2001). This method can be used for 
measuring gene expression and more recently has been developed for use in protein 
studies. Companies including Illumina have developed systems such as these for 
protein studies. Microbeads have also been used to attach molecular beacons that 
produce a fluorescence signal after binding of unlabelled target molecules. A 
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chemical change allows the beacon to give off a particular detectable fluorescence 
signal. 
Options for microarray surfaces, fabrication and immobilisation methods and 
detection methods are summarised in Table 1.6 with some examples of each. 
1.4.2.2 Selection of Probes for Spotting 
Probes selected for experimentation must be of suitable purity, specificity and 
concentration. High purity is optimal due to small spot sizes and, therefore, reaction 
area. Proteins can bind to surfaces non-specifically, and the presence of 
contaminating proteins means there will be competitive binding which should be 
avoided especially on small surface area (Beck et al., 1985). The reduction of 
unwanted substances may also reduce non-specific binding (NSB). The optimal 
concentration of the probes must be optimised, and it is important to use reasonably 
high concentrations with subsequent dilutions on the same chip until the optimal 
concentration is determined. At this point crucial control probes should also be 
considered. A microarray experiment without suitable positive and negative controls 
is statistically unsound. Negative controls are particularly important with regards to 
data analysis. In this work a data processing and analysis method was established 
which used the signal/noise ratio (S/N) to determine reactions. Negative controls are 






























Although proteins in this work are immobilised only in PBS, the use of preservatives 
to increase protein stability should be considered when evaluating the potential of 
products with a practical shelf-life. Glycerol can be added to minimise dehydration 
and sugars can be added to improve antibody stability (Lee and Kim, 2002). 
MacBeath and Schreiber (2000) describe the use of 40 % glycerol, which would 
obviously affect protein concentration, and Lee and Kim (2002) describe how PEG 
200 at concentrations of over 10 % can reduce evaporation and stabilise proteins. 
The different types of probes previously described or others with potential are 
discussed in section 1.4.3. 
1.4.2.3 Microarray Fabrication 
The density of a microarray depends on the spatial resolution of the robotics used 
(Sinclair, 1999). The value of the experiment depends critically on the quality of the 
printed array (Blohm and Guiseppe-Elie, 2001), which can be fabricated by a variety 
of methods. The most common method used is pin-transfer, although other methods 
include the in-situ synthesis method originally described by Fodor et al., (1991) and 
ink jet printing where there is no direct contact with the chip surface and has been 
used to reduce spot sizes to 25-30, um (Okamoto et al., 2000). Roda et al. (2000) 
describe the adaptation of a conventional ink jet printer for use in printing proteins 
onto various sheet surfaces. Non-contact methods may give better quality of array 
printing. In bead-based microarray systems the probe is attached by chemical means. 
Pin-transfer was developed by the Stanford group, and involves the use of a robotic 
arrayer to directly spot material onto the surface of a chip using metallic pins. 
66 
Various pin sizes may be used, with various spacing between the spots. The diameter 
and shape of the pins determines the volume spotted and the size of the spots. Solid 
pins, split pins or a `pin and ring' method may be used. The pin method can 
sometimes result in irregular printing and slide-to-slide variation (Petrik, 2001) and if 
using solid pins the print head must return to the stock plate prior to each contact, 
taking longer to print an array. Care must be taken when using pins to ensure 
wearing is minimal as this can affect printing. `Pin and ring' devices are available for 
sample spotting (Cortese, 2000a). The ring holds some of the arraying solution, the 
pin punches through this to deposit a small droplet onto the array surface. This 
system allows the deposition of many droplets without the print head having to return 
to the stock plate for array solution. 
For pin-transfer, most instruments use pins attached to a print head on a simple XYZ 
axis robot and transfer the sample from a microtitre plate to the microarray surface. 
The quality of a microarray can be seriously affected by the reproducibility and 
shape of the pins. Spot quality may also be affected by the solution composition, the 
slide surface and the environmental conditions (Bacarese-Hamilton and Crisanti, 
2002). Replicate spots must be considered, as this also is crucial in the soundness of 
statistical data. 
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Figure 1.9. The BioRobotics MicroGrid II Arrayer (biorobotics. com). 
In Figure 1.9 the BioRobotics MicroGrid II arrayer is pictured, which is capable of 
printing up to 120 K features per array. This arrayer uses typical XYZ robotics and 
was used extensively in the project presented in this thesis. Figure 1.10 shows steel 
pins for use in deposition, and the print heads in which they are held and positioned. 
The microarray spotting system must also provide a facility for washing and drying 
pins between samples to avoid sample cross-contamination. 
Washing of pins may be performed by shaking the pins in a cleaning solution 
(Lueking et al., 1999), or in a sonicator or flowing water bath. Pin drying may be 
performed by the use of a vacuum (Cheung et al., 1999). 
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Figure 1.10. Photographs showing steel pins for fabrication of microarrays. Figure 1.1 Oa 
shows 32 pins spring-loaded in a print head for robotic printing. Figure 1.1 Ob shows a split 
pin. In Figure 1.10c a 16-pin formation is seen printing onto microarray slides (photographs 
from combichemlab. com and microarray. uc. edu). 
Spotting should be performed in a clean but humid environment to prevent clogging 
of pins with dust and the evaporation of samples. After printing, the slides should be 
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left for sufficient time as to allow the spots to air dry. Cortese (2000a) reviews the 
`array of options' available within this field with regards to instrumentation. 
1.4.2.4 Blocking of Microarrays 
Blocking of microarrays must be performed to block sites where non-specific 
binding (NSB) may take place. In protein microarrays, blocking is usually performed 
using appropriate levels of milk protein or bovine serum albumin, in the presence of 
buffer and detergent. The introduction of non-target protein onto the assay surface 
prior to the addition of specific target molecules allows NSB of protein-protein to 
take place - the protein molecules effectively bind to and block any potential binding 
sites that may allow subsequent non-specific interactions. A detergent will compete 
with protein for hydrophobic sites on the surface, therefore reducing NSB (Matson, 
2000). Detergent should be at a low concentration as it may displace the desired 
protein probes from the surface (Matson, 2000). Therefore, an optimal blocking 
solution should minimise NSB, without reducing specific binding. To increase 
specificity and reduce NSB, it is of extreme importance to optimise the blocking of 
any assay. To reduce NSB further the blocking agent can also be included in the 
target solution. The use of different blockers and detergents will be explored in this 
thesis (see Chapter 3). 
1.4.2.5 Microarray Reaction Conditions 
The reaction conditions of the microarray have to be optimised throughout the 
development process. Considerations are: 
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" Target solution. The target must be of suitable concentration to be detected. It 
may or may not be diluted into blocking buffer. The volume of the target solution 
must be optimised considering concentration and likelihood of probe-ligand 
interaction. Particular thought is required when dealing with blood samples due 
the presence of plasma proteins. 
" Time of incubation. As with all biological assays, the time allowed for 
interaction can greatly influence the outcome of the assay. Here the optimal time 
period would be as short as possible while still allowing suitable sensitivity. 
" Temperature. Optimal temperature can affect results and the interaction of 
probe and target. Temperature is critical in the assay of clinically significant 
blood tests. 
Specific microarrays will require further optimisation e. g. blood typing microarrays 
could be affected by probe concentrations, ionic strength of solutions and pH. 
1.4.2.6 Washing and Processing of Microarrays 
Following incubation with target solution microarrays, like many other types of 
assay, require a washing step to remove unbound materials. An optimal processing 
method will remove unbound material whilst limiting removal of specifically bound 
targets. The procedure may also help in the reduction of NSB and, therefore, reduce 
background noise. Phosphate buffered saline is used commonly in protein assays and 
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in early examples of protein microarray publications. Detergents may also be 
included to optimise conditions. 
1.4.2.7 Microarray Interaction Detection Methods 
Existing microarrays commonly use `fluorophores' for detection of binding. The 
actual fluorescent label is not coloured, but when excited by a specific frequency of 
light by a laser, a detector measures the light emitted from the label. Only light of 
this specific wavelength will cause the fluorophore to emit a characteristic emission 
wavelength that is different from the excitation wavelength. The detector must filter 
out the excitation wavelength and measure only the emission. If using two 
fluorophores in an experiment, they must have distinct emission or excitation 
wavelengths. Two or more `fluorophores' may be used for simultaneous analysis of 
multiple test results or `multiplexing'. The detector resolution used must allow 
reading of fluorescence of the spot size used in the assay. 
Microarrays require fluorescence scanning to extract the results. Confocal laser 
scanning is used to provide high image and data quality. Confocal means that there 
are two places where light is in focus. Excitation light is focused at the microarray 
surface and emission light is focused at a pinhole. The use of the pinhole restricts the 
depth of focus therefore detecting fluorescence from a limited depth at the surface. 
This means that out of focus light from unwanted artefacts, such as dust on the 
microarray surface, is reduced. The microarray is `scanned' using mirrors that reflect 
the laser light across the slide. Light that gets through the pinhole is detected by a 
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photomultiplier tube (PMT), and the image is compiled from the scan. The voltage to 
the PMT can be altered to increase or decrease the image intensity. 
Cy3TM and Cy5TM are commonly used as the fluorophores in microarray experiments 
as they are intensely fluorescent. These are cyanine NHS-esters that bind to free 
amino groups. The emission wavelength of Cy3TM is 570 nm and Cy5TM is 670 nm. 
As an alternative it is possible to use Fluorescein Isothiocyanate (FITC) as a 
fluorophore, and generally this may be detected using the same scanning settings 
used for Cy3TM. 
In a protein microarray, ideally the target solution would be labelled. However, this 
may present problems in blood typing arrays where erythrocyte or antibody is the 
target. A sandwich type assay is one option where the fluorescent label is attached to 
another protein or antibody that will bind to all erythrocytes or human antibodies 
attached to the array. This could be a one or a two-step assay where the red blood 
cell is pre-labelled with the fluorescent protein. The compatibility of probe and 
detection methods must also be considered. For example, a human/mouse 
monoclonal antibody probe would be likely to bind an anti-human Ig antibody if 
used for detection and potentially give false positive results. 
Interactions on protein microarrays have been demonstrated by a variety of 
techniques already mentioned. In some assays it may be necessary to amplify the 
detection signal to allow more sensitivity in the detection of weak targets. Tyramide 
deposition and fluorophores such as cyanine dyes have been described to increase 
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sensitivity of detection in microarrays. Rolling circle DNA amplification (RCA) has 
been applied to improve sensitivity in immunoassays, including microarrays. In 
`immunoRCA' (Schweitzer et al., 2000) a primer is attached to the secondary 
antibody molecule by biotin-streptavidin interaction or covalent linkage. In the 
presence of DNA polymerase and nucleotides, and at isothermal temperature, 
circular DNA is allowed to hybridise to the primer and amplifies it by RCA. A label 
is added which hybridises with the tag resulting in a long DNA molecule with the 
detection label built in. This method is reported to increase signal greatly over non- 
amplified signals, and may be ideal for an open-plan microarray environment. 
1.4.2.8 Data Analysis 
Data from microarrays is quantified by measuring the fluorescence intensities of 
individual spots. Usually, computerised image analysis is performed by placing a 
grid over the array area and positioning imaging optics to the centre of the spot. A 
background signal for each spot is measured from around each spot on the chip 
surface. Several factors can give a poor signal to background noise ratio; fluctuations 
in light source, poor blocking and therefore NSB, scattering of fluorescence from 
other spots and other markings on the chips such as dirt or dust which must be 
avoided. The processing method is critical in the elimination of these factors. 
One of the greatest challenges encountered in microarrays is analysis of results. The 
sheer volume of data generated by a high-density microarray can be intimidating and 
requires much manipulation (Lander 1999), and methods of analysis have to be well 
developed to acquire meaningful data (Forster et al., 2003). Siedow (2001) reported 
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from a meeting devoted entirely to the evaluation of methods for analysing the large 
quantities of data generated from gene expression microarrays. Replication is 
valuable due to chip to chip variability and variability in sample preparation and 
gives a far better sense of data variability. 
Blohm and Guiseppe-Elie (2001) gives an overview, at that time, of the many uses of 
DNA microarrays. While the original microarrays were for DNA based analysis, the 
evolution of the technology to work with proteins and other biological molecules had 
been apparent. 
1.4.3 Protein Microarray Development 
1.4.3.1 The Requirement for Protein Microarrays 
While protein microarrays are built on the same principles as DNA microarrays, their 
use brings ' about new challenges in all aspects of the technology due to their 
structural and functional requirements. The number of publications on DNA 
microarrays far outweighs that of protein microarrays, although these have steadily 
increased in the course of this work. Siedow (2001) commented that the literature in 
DNA microarray field is so far ahead of the reality in 2001, yet this could not be said 
of protein microarrays when this work was initiated. The delay in protein 
microarrays compared to the advent of DNA microarrays may be partly due to 
problems with protein stability, immobilisation chemistries and weaker detection 
signals (due to lack of amplification) (Bacarese-Hamilton et al., 2002), and the range 
and complexity of protein targets. 
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The main driver for protein microarrays was to bridge the gap between genomics and 
proteomics and the study of protein function - not immediately for diagnostics, 
although this potential was realised once the technology began to evolve. Diagnostics 
could be the main area where protein microarrays are introduced in the near future 
(Cahill, 2001). Proteomics is the study of identification and characterisation of 
proteins in biological systems to assign function (McWhirter, 2001), the term 
proteome referring to all proteins expressed by a genome. Aspects such as 
expression, post-translational modifications and interactions with other substances 
can be studied. Nucleic acid based technologies such as PCR and microarrays 
provide important genomic results, yet there is a lack of correlation of gene 
expression and mRNA levels, with the amount of protein expressed in the cell 
(Dalmasso, 1999; Borrebaeck et al., 2001). This may be caused by different rates of 
translation from mRNA, post-translational changes that cannot be identified by DNA 
arrays, as well as protein degradation by proteolysis (de Wildt et al., 2000; 
Kusnezow and Hoheisel, 2002). Where DNA can be immobilised and denatured 
(Schena et al., 1995) proteins have secondary and tertiary structures that have to be 
maintained for functional analysis, and can be prone to denaturation if exposed to an 
unsuitable environment. 
Traditional techniques for the study of proteins include one and two-dimensional gel 
electrophoresis, sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS- 
PAGE), liquid chromatography, mass spectrometry, ELISAs and blotting. Where 
traditional methods meant limited amounts of assays could be run at any time, the 
microarray era has the potential to change this for protein arrays as it has for DNA 
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arrays (Borrebaeck, 2000). The use of DNA microarrays has demonstrated the ability 
to run thousands of assays in parallel. 
The development of protein microarrays has immense implications to the field of 
immunoassays, given that antibody-antigen interactions can be analysed in a similar 
format to microplate ELISAs but with far greater throughput, convenience and 
reduced costs (Bacarese-Hamilton and Crisanti, 2002). The technology was being 
explored as a potential replacement to ELISAs, such as the work performed by 
Bacarese-Hamilton et al. (2002). The first indication that miniaturised amounts of 
immobilised antibody could be used in a ligand binding assays may have come from 
Ekins (1989) who described the ambient analyte assay theory. Here, capture 
antibodies were immobilised as a microspot on a solid support and used to measure 
analyte concentration. Bound analyte could be measured using labelled molecules. 
However, it is probable that although the theory had been demonstrated, the potential 
for large-scale protein microarrays arose only as a result of genomic microarrays. 
Kusnezow and Hoheisel (2002) give a thorough overview of protein microarrays and 
discussed some of the promises and problems associated with the development of 
such arrays. 
1.4.3.2 The Development of Protein Microarray Technology 
Once the theory of microarrays was met by the potential to fabricate and process 
microarrays, publications on the use of protein microarrays began to emerge. Assay 
miniaturisations on microarray formats were being published by the late 1990s. 
Mendoza et al. (1999) attempted antibody arrays to replicate standard ELISAs. Filter 
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membranes were also being used as they were the standard for protein studies 
(Kusnezow and Hoheisel, 2002). Ge (2000) published work using nitrocellulose 
membranes and manual dot-blot apparatus to produce low-density protein arrays for 
quantitative detection of protein interactions with various ligands, using 
autoradiography for detection. Huang (2001) and Huang et al. (2001) described 
antibody based protein microarrays for detection of proteins, and specifically 
cytokines, in solutions and patient serum. de Wildt et al. (2000) used filter-based 
ELISAs to screen phage-antibody libraries, where clones were robotically picked and 
gridded onto an antigen coated filter in a mass array; protein L-horseradish 
peroxidase was used for detection of bound antibody fragments. Filter based arrays 
tend to be low resolution and have high background values (Kusnezow and Hoheisel, 
2002). The method described by de Wildt et al. can potentially be used for 
monitoring protein expression, using phage-displayed antibodies to proteins under 
study. Unlike conventional 2-D gel electrophoresis, the filter array method can be 
used to analyse the expression of more than one protein in a source material at one 
time. 
The move to glass slides for preparation of protein microarrays was demonstrated by 
Guschin et al. (1997) and Arenkov et al. (2000) who described methods for 
producing protein arrays using gel coated glass slides. Arenkov et al. (2000) 
accelerated their immunoassay using microelectrophoresis, during which the 
fluorescently labelled solution was added. The benefit of using the gel was that it 
gave low background, low non-specific binding and good support for immobilisation 
of proteins while retaining biological activity. These techniques have been 
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successfully employed in preparation of both antibody and antigen arrays. They 
immobilised recombinant hepatitis B virus antigen and showed detection of FITC 
labelled antibodies purified from hepatitis B positive human serum. The system they 
developed could accommodate proteins up to 400 kDa. This would be limiting in the 
field of blood typing diagnostics, as the standardised antibodies are IgM (970 kDa 
approximately). 
Much of the prior-art in protein microarrays uses solid pin printing as opposed to pin 
and ring or inkjet deposition. Solid pins may be preferable due to the viscosity of 
protein solutions, which may clog alternative systems (Bacarese-Hamilton and 
Crisanti, 2002). 
Lueking et al. (1999) described the use of polyvinylidene difluoride strips to 
immobilise proteins for the purpose of screening monoclonal antibodies against 
whole libraries of proteins. This technology could be adapted to be useful in the 
future development of monoclonal antibodies, to aid the isolation of antibodies with 
specificity of interest. Secondary antibodies could also be used to screen for 
antibodies of certain class or subclass depending on the requirement. 
1.4.3.3 Antibody Microarrays 
Antibodies are ideal for use in protein microarrays due to their specificity and 
structure, but they must be immobilised without affecting function. Globular proteins 
tend to unfold and lose activity when attached to a solid support (Borrebaeck et al., 
2001). The orientation of antibody molecules onto a solid surface has implications 
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with regards to the accessibility of the antigen binding sites. Malmsten (1995) reports 
that the Fc portion of an IgG molecule is more readily adsorbed onto a solid surface 
than the Fab portion. This may be because Fab is more structurally stable than the Fc 
portion (Hlady and Buijs, 1996) making the Fc more susceptible to adsorption to a 
surface. If the molecule binds via the Fc portion, it follows that the Fab region is 
more likely to be orientated in a favourable way to enable interaction with antigen. 
Using robotic instrumentation adapted from DNA microarrays, MacBeath and 
Schreiber (2000) developed high-density protein microarrays covalently attached to 
glass slides coated with aldehyde reagents. In parallel to the field of DNA 
microarrays, Haab et al. (2001) printed high-density protein microarrays onto poly- 
L-lysine slides (electrostatic adsorption) and used fluorescently labelled targets 
(antibodies or antigen) to detect antibody-antigen interactions. This meant that the 
equipment, software and experimental approaches were broadly similar to those used 
in DNA microarrays and opened the microarray field for high throughput protein 
microarrays. 
Belov et al. (2001) used an antibody microarray to investigate and characterise 
antigens on leucocytes and leukaemia cells and to determine antigenic expression, or 
immunophenotype of different malignancies. FITC conjugated secondary antibody 
was used for detection using a confocal microscope. This was the first publication in 
which antibody microarrays were shown to bind whole cells. 
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Li et al. (2003) used anti-cytokine arrays for the detection of cytokines, and 
performed a comparison of direct and indirect cytokine labelling. Their purpose is to 
develop anti-cytokine arrays for profiling cytokines in subcutaneous wound healing 
tissue. 
Where antibodies are not available or antigen not isolated, other probes can be used. 
Phage-antibody libraries can provide specificity to almost any antigen (de Wildt et 
al., 2000), where the phage expresses antibody Fab or single chain variable 
fragments (scFv) on its surface. Phage libraries use a genetic framework and attach 
various germ-line genes representing heavy and light chains. Some phage libraries 
can represent about 1011 to 1012 different antibodies. Zyomyx (Hayward, CA, USA) 
manufacture high-density microarrays of phage-display libraries. 
1.4.3.4 Antigen Microarrays 
Where antibody microarrays can be used to test for the presence of antigen, antigen 
arrays do the reverse. These can be used to check for presence of antibodies. Antigen 
microarrays may be used many purposes such as the determination of autoimmune 
disorders (Robinson et al., 2002) or for determination of serum antibody titres to 
pathogens (Ewart et al., 2001). Joos et al., (2000) demonstrated that high titres of 
antinuclear antibodies were detectable against nuclear proteins and nucleoprotein 
complexes in patients suffering from forms of rheumatic disease when analysed on 
an antigen microarray. The ability to diagnose disease has wide implications in 
immunodiagnostics, biotechnology, drug discovery and vaccine preparation (Cahill, 
2001). 
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Seong (2002) discusses the immobilisation of antigens for use in immunodiagnosis 
of infectious diseases and the paper reviews methods for optimisation of proteins for 
this purpose. The use of silylated, silanated and epoxy coated slides was explored to 
immobilise human IgM, human IgG and biotinylated Protein-L probes at different 
pH. A biotin-streptavidin detection method was employed. Seong (2002) reports that 
the use of a spotting buffer at a pH that induces an overall negative charge may help 
increase immobilisation of proteins to a positively charged surface. 
Any antigen which can be immobilised to the solid surface and retain its functional 
state can theoretically be used in an antigen microarray. Carbohydrate antigens can 
be immobilised, and as these are present on the surface of most cells they can be the 
target of molecular markers such as antibodies. This is true of the ABO blood group 
system antigens. Wang et al. (2002) demonstrated microarrays of carbohydrates, and 
their use in binding antibodies from serum. They immobilised several 
polysaccharides onto nitrocellulose coated slides and these were detectable by target 
IgG and IgM antibodies. As carbohydrate expression can also vary in disease states 
such as cancer, retroviral infection and in various stages of cell development, these 
could be useful microarray probes. Fukui et al. (2002) also demonstrated 
carbohydrate interaction studies on microarrays. This is of importance to proteomics 
due to protein glycosylation following translation. 
Angenendt et al. (2003) describe a multiple spotting technique (MIST) in which 
target samples are spotted directly onto probes already on the microarray. This relies 
on the same robotics used for spotting the original probes being precise, to spot again 
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onto the same co-ordinates. The use of this system allows much reduced sample 
consumption and allows multiple samples to be evaluated on one microarray surface. 
The same group (Angenendt et al., 2004) later used this format to evaluate and find 
specific recombinant antibody fragments. 
Aptamers are short sequences of DNA or RNA with protein binding properties and 
subsequently may be used to bind their targets in relevant assays. Their binding of 
proteins relies on the formation of unique arrangements of hydrogen bonding (Reddy 
and Perrotta, 2004) and they bind similarly to antigen-antibody interactions (Lee and 
Walt, 2000). Aptamers can be produced by a process called systemic evolution of 
ligands by exponential enrichment (SELEX) (Tuerk and Gold, 1990). The SELEX 
process involves alternate cycles of ligand selection and amplification, which results 
in the enrichment of the desired sequence. Stadtherr et al. (2005) described an 
aptamer-based protein biochip, capable of capturing analytes in solution at the same 
sensitivity as antibodies to the same specificity. The engineering of microbial 
proteins to obtain antibody-like properties has also been developed as another way of 
obtaining antibodies (Kusnezow and Hoheisel, 2002). Peptides representing epitopes 
of antigens can be used and have been shown to detect protein kinase activity by 
Houseman et al. (2002). 
Million et al. (1998) and Sinor et al. (1992) have demonstrated the immobilisation of 
erythrocyte membranes on microplates for antibody screening. Million et al. 
prepared membranes and then immobilised using paraformaldehyde. They used a 
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detection system of coloured antibody coated latex particles. This method could 
potentially be applied to microarray. 
Another approach closely related to this thesis is that membrane proteins of cells can 
be isolated and spotted to prepare membrane protein microarrays. Fang et al. (2002a) 
published the first work on fabricated membrane protein microarrays consisting of 
membrane bound G protein coupled receptors on aminopropylsilane coated slides. 
They found that the use of aminopropylsilane slides gave good retention of the 
probes. The ability to print cell membrane proteins means that drug screening can be 
performed, as many drug targets are membrane-bound. Cheng et al. (2000) report 
that membrane proteins can be studied by incorporation into artificial lipid bilayers 
attached to a solid support. Letarte et al. (2005) used leucocyte membrane proteins as 
probes on a microarray and used them to detect antibodies and ligands to the 
proteins. It is thought that erythrocyte membrane proteins or membrane fragment 
arrays will be more stable in a microarray format than whole cells, due to their 
limited lifespan. 
Very recently, Chan et al. (2004) demonstrated the preparation of whole cell lysate 
arrays. These were detected using specific primary antibodies followed by secondary 
antibodies conjugated to horseradish peroxidase. The signals were then amplified 
using tyramide-biotin conjugate, which is then reacted with fluorescently labelled 
streptavidin. 
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Tissue arrays have been prepared for molecular profiling of tumour specimens - 
samples from paraffin biopsies have been arrayed onto paraffin blocks and then 
analysed with appropriate reagents. This can be used to analyse tumours from 
different patients at different disease stages and for possible therapeutic use (Cahill, 
2001). 
1.4.3.5 Diagnostic and Commercial Protein Microarrays 
There is so much diversity and competition in the field of diagnostics that there are 
currently companies world-wide involved in research, development and 
implementation of microarray systems for very diverse applications (Blohm and 
Guiseppe-Elie, 2001). In order for the implementation and uptake of microarray 
technology outwith research laboratories, systems will have to prove themselves 
robust, specific and sensitive, competent, reproducible and cost effective in 
comparison to existing methods. The commercialisation of a blood typing microarray 
will form part of the discussion of this thesis. An overview of companies active in 
the protein microarray field is presented in Table 1.7. 
Ciphergen Biosystems Inc. (Palo Alto, CA) was one of the first companies to 
commercially enter into the protein array field (Cortese, 2000b) with its 
ProteinChipTM system. This system offers a range of surface chemistries for 
immobilisation and subsequent analysis. Interactions on the chip surface are read by 
surface enhanced laser desorption/ionisation time-of-flight mass spectrometry 
(SELDI-TOF-MS), so there is therefore no requirement to fluorescently label 
proteins. This approach determines the molecular weight or mass of the bound 
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material. This process can differentiate between expression of proteins in diseased 
and normal states (Dalmasso, 1999). The chips have been used in protein 
composition studies, target and marker protein discovery and identification, protein- 
Table 1.7. Companies actively involved in the protein microarray field. 
Company Website Information Product Description 
Affitech 
Affibody 
BD Biosciences (Clontech) 
Biacore 
Biosite 
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COVET functional protein 
arrays 
Aptamer arrays 
Planer wave guide 
technology 
Silicon based antibody 
arrays 
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DNA interactions, antibody capture, peptide mapping and sequencing. While it is 
similar to other solid-phase methods to study protein-protein interactions it cannot 
assess the interactions in real-time, in contrast to the technology of surface plasmon 
resonance. 
Illumina (San Diego, CA, USA) have developed BeadArrayTM technology for use in 
their Sentrix® system. They now sell the Whole Genome Genotyping BeadChip to 
analyse over 100K SNPs on one single microarray. The technology allows one 
million SNP assays per day (Oliphant et al., 2002). The system uses a fibre-optic 
bundle as a substrate for microarrays. The end of each fibre is etched to create a well 
that can hold a3 am bead, each bead coated in many copies of the probe of interest - 
a variety of surface chemistries are available for the attachment of DNA, RNA and 
proteins. 50,000 fibres are fused together to create an array 1.4 mm in diameter. Bead 
libraries can be prepared and then exposed to the fibre bundle onto which they are 
randomly ordered. The location of each bead is identified after assembly. The system 
detects the presence of fluorescent targets by the use of laser excitation beams being 
passed through the fibres and the detection of emitted fluorescence. This technology 
has been used to perform blood group genotyping (Hashmi et al., 2005) and has 
potential for a range of protein applications. 
Luminex market the Luminex 100TM System, which is a multi-analyte profiling assay 
known as xMAP® technology. This uses internally dyed polystyrene microspheres 
with two different fluorochromes mixed in ratios to give distinct spectral addresses 
for each set. Probes are attached to the outside of the microspheres and then 
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incubated with target solution. A third fluorochrome is coupled to a reporter 
molecule and is used to quantify the interaction at the microsphere surface. The 
microspheres then pass through in a rapid stream and are interrogated by two lasers 
(similar to flow cytometry), which classifies each microsphere and also quantitates 
the reaction. Many different probes can be attached to the microspheres using a 
variety of surface chemistries and the technology has been used to perform 
immunoassays. 100 different microspheres can be screened simultaneously against 
one sample. This system requires the addition of secondary biotinylated detection 
molecule (e. g. an antibody) and then streptavidin conjugated indicator molecule, 
therefore extra steps are involved and reagent quality is of high importance, although 
the technique does seem rapid (20 minute estimated, Luminex. com). 
Planar waveguide technology for microarray fluorescence imaging has been 
developed by Zeptosens. This utilises a special coating of Ta205 to induce an 
evanescence field for efficient fluorescence detection. This allows surface confined 
detection and dramatically cuts background noise interference, as only bound 
fluorescent molecules are measured (similar to SPR) and means that washing steps 
are not required (Pawlak et al., 2002). This technology is part of a fully automated 
high-throughput protein microarray system. Pawlak et al. (2002) used this system 
with a hydrophobic surface to immobilise antibodies to human cytokines using ink- 
jet technology. Target samples were preincubated with Cy5TM-streptavidin before 
incubation with the array, but no wash steps were required. This system offers 
advantages as there are fewer wash steps and the detection method is reported to be 
more sensitive than standard confocal scanning. Vörös et al. (2003) used the 
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Zeptosens detection system with PEG-Poly-L-lysine brushes to immobilise DNA, or 
if conjugated to biotin to attach streptavidin conjugated antibodies. 
Based on knowledge gained and reading undertaken, at the outset of this work there 
was no work published on microarrays for comprehensive blood testing by the 
methods reported herein. 
1.5 Project Aims 
" To investigate a variety of methods for the preparation of antibody and antigen 
microarrays and the parameters important to study protein-ligand interactions in a 
microarray format. 
. To establish optimal conditions for non-agglutination blood group determination 
on a microarray. 
" To evaluate suitable methods of data acquisition, processing and analysis. 
" To attempt to develop a reverse format assay for erythrocyte alloantibody 
screening. 




MATERIALS AND METHODS 
2. MATERIALS AND METHODS 
2.1 Sources 
The composition of all buffers and chemicals used are given in Table 2.1. All 
chemicals were obtained from Sigma-Aldrich (Poole, U. K. ) unless otherwise stated, 
and all were of reagent grade or higher. All water used was prepared by reverse 
osmosis unless stated otherwise. All probes and targets used are detailed in Table 
2.2. Contact information for all suppliers used is listed in Appendix 1. 
Table 2.1 Buffer and chemical preparations used, with details of final concentrations and pH 
(where appropriate). 
Buffer/chemical name Preparation 
Concentrated glacial acetic acid diluted to 0.3 % 
Acetic acid 0.3 % (52.2 mM) in purified water 
I% agarose diluted in 0.125 M Tris (hydroxymethyl) 
Agarose 1% methylamine (Tris)(BDH), 0.385 M NaCI, 2.2 mM 
polyethylene glycol, 38 mM sodium azide (NaN3). 
Array Buffer 2X (Schleicher & Schuell) diluted 1 in 2 in 
Array Buffer 1X 
PBS (pH 7.0) 
10 mM HEPES, 0.15 M NaCl, 0.005 % P20 (Biacore), pH 
Biacore running buffer 
adjusted to 7.4 using 1M NaOH 
Biacore running buffer-Mn/Ca 1 mM MnCl and 1 mM CaCI in Biacore running buffer. 
2.2 mM sodium bicarbonate (BDH), 2.2 mM sodium 
Bicarbonate buffer pH 9.0 
carbonate (BDH) 
Bicarbonate buffer pH 9.3 0.206 M sodium bicarbonate, 0.081 M sodium carbonate. 
One carbonate-bicarbonate buffer capsule diluted in 
Bicarbonate buffer pH 9.6 
water, to give 0.05 M buffer. 
0.87 M glacial acetic acid, 0.184 M trichloroacetic acid, 
Crowle's double stain 4.3 mM crocein scarlet, 0.18 mM brilliant blue R, filtered 
before use. 
10 % Marvel (Premier Brands Ltd, U. K. ) in ELISA wash 
ELISA blocking buffer 
buffer. 
ELISA coating buffer 0.02 M Tris pH adjusted to 9.0 using IM HCI. 
ELISA wash buffer ELISA coating buffer plus 0.05 % Tween 20. 
Ethanolamine 1M ethanolamine-HCI pH 8.5 (Biacore). 
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0.02 M ethanolamine, pH adjusted to 10.4 using 1M 
Ethanolamine pH 10.4 
NaOH. 
FITC ConA 0.1 mg/ml 0.1 mg/ml FITC Concanavalin A diluted in PBS. 
Fixing solution 50 % methanol, 7% concentrated acetic acid, 43 % water. 
Glycine-NaOH pH 9.8 25 mM glycine, 14 mM NaOH. 
HCI 1M 1M HCl. 
HCI pH 1.5 pH of purified water adjusted to 1.5 using 1M HCl. 
70 % (final concentration) methylated spirits in purified 
Methylated spirits 
water. 
5M stock solution prepared in water, from which dilutions NaOH 
were made. 
0.05 M N-hydroxysuccinimide, 0.2 M 1-ethyl-3-(3- 
NHS/EDC 
dimethylaminopropyl) carbodiimide. 
0.15 M sodium chloride, 2.632 M Phosphate Buffer Stock 
PBS 
Solution (Alba Bioscience), pH 7.0. 
0.137 M NaCl, 2.7 mM potassium chloride, 
PBS pH 7.4 1.5 mM potassium dihydrogen orthophosphate, 6.5 mM di- 
sodium hydrogen orthophosphate. 
PBS-azide 150 mM sodium azide in PBS pH 7.4. 
PBS-BSA 1% bovine serum albumin (BSA) (ID Bio, France) in PBS. 
PBS-BSA 2% 2% BSA in PBS. 
PBS-Ca/Mn 1 mM MnCl and 1 mM CaCI in PBS. 
PBS-milk 3% Marvel (Premier Brands Ltd, U. K. ) in PBS. 
PBST PBS, 0.1 % Tween 20. 
PBST-BSA PBS-BSA, 0.1 % Tween 20 
PBST-milk PBS-milk, 0.1 % Tween 20. 
ProSep elution buffer 0.1 M citric acid, pH adjusted to 3.0 using 5M NaOH. 
0.15 M sodium chloride, 1M glycine, pH adjusted to 8.6 
ProSep wash buffer 
using 1M NaOH. 
Erythrocytes suspended to haematocrit of 0.8 % in ID- RBC-ID Diluent 2 (0.8 %) 
Diluent 2 (DiaMed). 
Erythrocytes suspended to haematocrit of 5% in ID- RBC-ID Diluent 2 (5 %) 
Diluent 2 (DiaMed). 
RBC-PBS Erythrocytes suspended to haematocrit of 2% in PBS. 
NuPage MES SDS Running Buffer 20X (Invitrogen) 
SDS-PAGE running buffer diluted I in 20 in water. 
1M sodium acetate stock solution, pH adjusted using Sodium acetate 
acetic acid, dilutions made in purified water and degassed. 
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Wash/Block buffer 1X 
FAST PAK Protein Array Buffer 10X (Schleicher & 
Schuell) diluted 1 in 10 using purified water. 
Table 2.2 Details of all probes and targets used, including cell line if monoclonal. 
Probe/Target Protein Source 
Identification Description 
(cell line) 
Anti-A(B) (ES15) Mouse monoclonal IgM antibody against blood Alba Bioscience 
group antigens A and B (reacts weakly with B) 
Anti-A (ES9) Mouse monoclonal IgM antibody against blood Alba Bioscience 
group antigen A 
Anti-A (LA2) Mouse monoclonal IgM antibody against blood Alba Bioscience 
group antigen A 
Anti-B (LB2) Mouse monoclonal IgM antibody against blood Alba Bioscience 
group antigen B 
Anti-E (DEMI) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen E 
Anti-c (H48) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen c 
Anti-D (LDM1) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LDM2) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LDM3) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen D 
Anti-D (ESD1 M) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LDM77/64) Human monoclonal IgM antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM76/58) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM76/59) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM50/2B) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM169/81) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (ESD1) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM76/55) Human monoclonal IgG antibody against blood Alba Bioscience 
group antigen D 
Anti-D (LHM77/64) Human monoclonal IgG antibody against blood Alba Bioscience 
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group antigen D 
Anti-D (LHM70/45) Human monoclonal IgG antibody against blood 
group antigen D 
Alba Bioscience 
Anti-D (LHM59/19) Human monoclonal IgG antibody against blood 
group antigen D 
Alba Bioscience 
Anti-D (LHM169/80) Human monoclonal IgG antibody against blood 




Human monoclonal IgG antibody against blood 
group antigen D 
National Blood 
Service 
Anti-D Polyclonal Human polyclonal IgG antibody against blood 
group antigen D 
Alba Bioscience 
Anti-HIV (HIVG1) Mouse monoclonal IgG antibody against HIV 
gp140 
Alba Bioscience 
Anti-HIV (HIVG2) Mouse monoclonal IgG antibody against HIV 
gp140 
Alba Bioscience 
Anti-K (MS56) Human monoclonal IgM antibody against blood 
group antigen K 
Serologicals 
Anti-IgG3 (LG3A) Mouse monoclonal IgG antibody against human 
IgG3 
Alba Bioscience 
Anti-human IgG Rabbit polyclonal anti-human IgG Alba Bioscience 
BSA Bovine Serum Albumin ID Bio 
FCS Foetal Calf Serum Alba Bioscience 
Synthetic A antigen Blood group A trisaccharide conjugated to BSA Dextra Laboratories 
Synthetic B antigen Blood group B trisaccharide conjugated to BSA Dextra Laboratories 
Cy3 Anti-Human IgG Cy3 labelled goat antibody against human IgG Sigma-Aldrich 
Cy3 Anti-Human IgM Cy3 labelled goat antibody against human IgM Sigma-Aldrich 
FITC Anti-Mouse IgG FITC labelled goat antibody against mouse IgG Sigma-Aldrich 
FITC Anti-Mouse IgM FITC labelled goat antibody against mouse IgM Sigma-Aldrich 
FITC ConA FITC labelled Concanavalin A Sigma-Aldrich 
FITC Anti-Rh29 FITC labelled mouse monoclonal IgG antibody 
against blood group antigen Rh29 
Dr. D. Pepper 
FITC WGA FITC labelled wheat germ agglutinin 
(Tuiticum vulgaris) 
Sigma-Aldrich 
rProtein-L Recombinant protein-L from 
Peptostreptococcus magnus 
Actigen 
Sheep IgG Sheep IgG reagent grade Sigma-Aldrich 
Goat IgG Goat IgG reagent grade Sigma-Aldrich 
Rabbit IgG Rabbit IgG reagent grade Sigma-Aldrich 
Human Serum Human serum Alba Bioscience 
Bovine Serum Bovine serum Sigma-Aldrich 
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2.2 Antibody Purification Methods 
2.2.1 IgM Antibody Purification 
IgM antibody purification was carried out by either gel filtration or affinity 
chromatography. 
2.2.1.1 IgM Antibody Purification by Gel Filtration 
Culture supernatant to be purified was passed through a column that utilises size 
exclusion to separate the IgM molecule from unwanted molecules in the solution. 
Smaller molecules are retarded in the porous Sephadex beads and take longer to pass 
through the column, whereas the large IgM molecules pass directly through and are 
first to exit the column. 
30 g of Sephadex G200 (Amersham Pharmacia, U. K. ) was suspended in two litres of 
PBS pH 7.4 then placed at 4 °C overnight. The buffer was removed and replaced 
with fresh PBS pH 7.4 and left at 4 °C overnight. This was repeated three times and 
the supernatant removed. 
The suspension was de-gassed for 1.5 hours after then poured into a 2.5 cm x 100.0 
cm column. PBS pH 7.4 was pumped into the column at 20 rpm using a Watson 
Marlow 505S pump with 1 mm bore silicon tubing. This gave a flow rate of 3 ml per 
minute. As the Sephadex settled with gravity, the excess supernatant was removed 
and replaced with more suspension until the column was packed. 
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Column eluate was monitored using an ISCO UA-5 absorbance detector set to 280 
nm (OD280) with an ISCO T1197038 optical unit. PBS pH 7.4 was pumped through 
at 20 rpm to establish a baseline on chart recorder paper. The inlet line was placed 
into 30 ml 'of sample to be purified, and then this was loaded onto the column via the 
pump tubing. PBS pH 7.4 was used throughout as running buffer. 
When the chart recorder pen showed an increase in OD280 the output was collected 
until the baseline returned to zero. This breakthrough peak containing purified IgM 
was collected and then measured as in sections 2.3.1.2. and 2.3.2.3. PBS pH 7.4 was 
pumped through until the entire sample had passed through and the column was 
determined to be clean (one hour after the chart recorder had returned to baseline). 
2.2.1.2 IgM Antibody Purification by Affinity Chromatography 
Dr. N. O'Looney and C. McKee, of the Scottish National Blood Transfusion Service, 
carried out this purification and their provision of purified IgM antibodies is 
gratefully acknowledged. The columns used were 1 ml HiTrap IgM purification HP 
columns (Amersham Biosciences, U. K. ) and the method followed the manufacturers' 
instructions. 
2.2.2 IgG Antibody Purification 
Antibodies of the IgG class may be purified by the use of affinity chromatography 
columns. This method is based on the use of an insolubilised ligand 
(immunoadsorbent), which reacts with the antibody to form an antibody-ligand 
complex. The column is washed to remove any unbound proteins and other unwanted 
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components, then treated with a medium that dissociates the antibody-antigen 
complex and allows collection of the purified antibody. As the structure of IgGI and 
IgG3 are different, the immunosorbant is different for each. Some purifications were 
performed by E. Nelson of Alba Bioscience. 
2.2.2.1 IgG, Antibody Purification 
7 ml of ProSep Guard Column and 40 ml of ProSep A High Capacity (Millipore, 
U. K. ) were washed in PBS pH 7.4. Washed ProSep Guard Column was poured into a 
1.5 cm by 4.0 cm column and the washed ProSep A into a 1.5 cm by 23.0 cm 
column. 200 ml of ProSep wash buffer was pumped through the column at 60 rpm 
using a Watson Marlow 505S pump. One mm bore silicon tubing was used and ran at 
a flow rate of 20 ml/minute until a baseline was established on the chart recorder. 
The sample to be purified was loaded (volumes varied depending on quantity 
available) and the throughput collected. Once the entire sample was loaded 400 ml of 
ProSep wash buffer was pumped through. Bound antibody was eluted using ProSep 
elution buffer, and when the chart recorder showed an increase in OD280 the eluate 
was collected. The pH of this breakthrough peak containing purified IgG was 
adjusted to pH 9.0 using 1M NaOH before being dialysed into PBS pH 7.4 (see 
2.2.3). The column was cleaned by running through methylated spirits (70 %) then 
HCl pH 1.5. Once cleaned, PBS-azide was pumped through and the column was 
stored at 4 °C in this buffer until required. 
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2.2.2.2 IgG3 Antibody Purification 
5 ml of ProSep G High Capacity (Millipore, U. K. ) was washed in PBS pH 7.4. The 
washed ProSep G was then poured into a 1.5 cm by 3 cm column. The purification 
process was then continued as 2.2.2.1. 
2.2.3 Dialysis of Purified Antibodies 
Dialysis of purified antibodies was performed to transfer antibodies into a storage 
solution, buffers for use in microarrays, or for use in surface plasmon resonance 
analysis. This was performed using either dialysis tubing or cellulose membranes. 
Once dialysed, samples were either stored frozen until required, or used immediately. 
2.2.3.1 Dialysis of Purified Antibodies Using Dialysis Tubing 
Antibody samples purified using ProSep columns were dialysed from the elution 
buffer into PBS pH 7.4 for storage. 
A suitable length of cellulose dialysis tubing, MW cut-off 12,000 (Sigma-Aldrich, 
D9527) was cut and allowed to soften in PBS pH 7.4 for five minutes. The sample to 
be dialysed was poured in and both ends sealed. This was then placed into PBS pH 
7.4 that was 50 times the volume of the sample and was mixed using a magnetic 
stirrer and bar, at 4 °C overnight. The following day the sample was removed from 
the dialysis tubing. 
0 
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2.2.3.2 Dialysis of Purified Antibodies Using Cellulose Membranes 
Antibody probes for use in microarrays were dialysed into buffers at different pH. 
Antibodies for use in surface plasmon resonance analysis were dialysed into sodium 
acetate, at various pH. 
Buffer into which the antibody was to be dialysed was placed in an 85 mm diameter 
petri dish. The buffer was 100 times the volume of the sample. A cellulose filter 
membrane disc 0.025 µm (Millipore, U. K. ) was placed onto the buffer with the shiny 
side facing up. 50 or 100 µl of sample was pipetted onto the membrane. The sample 
was allowed to dialyse for one hour at room temperature. The sample was removed 
from the membrane using a pipette. 
2.2.4 Concentration of Purified Antibodies 
Samples were concentrated using a Filtron Stirred Cell System. A 30,000 molecular 
weight cut-off Filtron membrane was attached to the bottom of a Filtron vessel. A 
pressure of one bar was applied to the vessel using nitrogen, and this forced filtrate 
out the filtrate line while mixing was constant throughout. The process continued 
until the retentate reached the desired concentration factor. 
2.3 Quality Control of Antibody Probes and Target Samples 
Quality control of antibody probes included both quantitation and functional 
analysis. The functional analysis was performed by haemagglutination. Quality 
control of target samples (usually erythrocytes) involved haemagglutination testing, 
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and the appropriate methods are described here. A summary of all testing performed 
on the antibody probes used in this project is described in Table 2.4. 
2.3.1 Quantitation of Antibody Probes 
2.3.1.1 IgG Antibody Quantitation 
IgG antibodies were measured in a Cecil 1000 Series spectrophotometer at OD280.1 
ml of material was pipetted into a glass cuvette. The absorbance value was plotted on 
a standard curve that was prepared with standards at 0.1 mg/ml to 2.0 mg/ml. If the 
absorbance was above one then the sample was diluted in PBS pH 7.4 and measured. 
The result was then multiplied by the dilution factor. 
2.3.1.2 IgM Antibody Quantitation ELISA 
Linda Knowles of Alba Bioscience carried out the IgM antibody quantitation by 
ELISA. This work is gratefully acknowledged. The procedure involved the use of 
anti-IgM to the appropriate species being tested, and followed standard laboratory 
protocols. 
2.3.2 Haemagglutination Assays 
Haemagglutination assays were performed to determine functional pre- and post 
purification activity of antibodies and to confirm the blood type of samples for 
testing. Erythrocyte concentrations were all measured in a Sysmex KX-21 
Automated Haematology Analyser. Blood typing results were all confirmed using 
blood typing products from Alba Bioscience (Edinburgh, U. K. ), following the 
manufacturers recommended techniques. The system described in Table 2.3 was 
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used to grade haemagglutination reactions, performed in tube tests, according to the 
level of agglutination present. 
Table 2.3. Grading system used to determine level of agglutination present (U. K. Blood 
Transfusion Services, 2002). 
Reaction Description Titration 
Grade Score 
Grade 5 Cell button remains in one clump or dislodges into a few 12 






Cell button dislodges into numerous large clumps, 10 
macroscopically visible. 
Cell button dislodges into many small clumps, 8 
macroscopically visible. 
Cell button dislodges into finely granular but definite, small 5 
clumps, macroscopically visible. 
Cell button dislodges into fine granules, microscopically 3 
visible 
Negative result 0 
For potency determination, doubling dilutions were prepared in PBS-BSA 2 %, 
before testing the neat reagent and dilutions by the techniques described in 2.3.2.1 
and 2.3.2.3. Cells selected for testing were as described in Table 2.4. The titration 
end point, or potency, was the most dilute antibody dilution that gave a reaction 
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2.3.2.1 IgG Antibody Haemagglutination Assay 
80 µl of IgG antibody was added to a 12 x 75 mm glass tube, then 40 pl RBC-PBS 
was added. The tests were mixed thoroughly, then incubated at 37 °C in a water bath 
for one hour. The tests were washed four times using PBS, using a DiaCent 2 Cell 
Washing Centrifuge (DiaMed AG, Switzerland). On the last wash the program left a 
dry button of erythrocytes at the bottom of the tubes. 80µl of Anti-Human Globulin 
reagent (Alba Bioscience) was added to each tube. The tests were mixed thoroughly 
before being spun at 1000 relative centrifugal force (ref) for 10 seconds. The tests 
were read by tipping and rolling the tubes to dislodge the button of cells from the 
bottom of the tube and then observing for agglutination. Results were graded 
according to degree of agglutination as described in Table 2.3. 
2.3.2.2 IgM Antibody HaemaggIutination Assay 
40 pcl of IgM antibody was added to a 12 x 75 mm glass tube, then 40 p1 of RBC- 
PBS was added. The tubes were shaken and then incubated at room temperature for 
five minutes. The tests were then centrifuged at 1000 rcf for 10 seconds in a DiaCent 
2 Cell Washing Centrifuge (DiaMed AG, Switzerland) The tests were read by tipping 
and rolling the tubes to dislodge the button of cells from the bottom of the tube and 
then observing for. Results were graded according to degree of agglutination as 
described in Table 2.3. 
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2.3.2.3 Column Agglutination Testing 
2.3.2.3.1 ABO & RhD Blood Group Typing 
12.5 p1 of RBC-ID Diluent 2 (5 %) was added to a DiaClon ABO/D + Reverse 
Grouping card (DiaMed AG, Switzerland) and then spun immediately at 910 rpm for 
10 minutes in an ID-24S ID Centrifuge (DiaMed AG, Switzerland). The tests were 
then read by observing the cards for agglutination. 
2.3.2.3.2 IgG Antibody Testing 
50µl of RBC-ID Diluent 2 (0.8 %) was added to a LISS/Coombs Card (DiaMed AG, 
Switzerland). 25 µl of antibody to be tested was added and the card incubated at 37 
°C for 15 minutes. The card was spun at 910 rpm for 10 minutes in a 24S-ID 
Centrifuge (DiaMed AG, Switzerland). The tests were read by observing the cards 
for agglutination. 
2.3.3 Sodium Dodecyl Sulphate - Polyacrylamide Gel Electrophoresis 
Purified antibodies were run on sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE) gels to determine level of purification. Novex (U. S. A. ) 
supplied all reagents and equipment unless otherwise stated. 
A 4-12 % Bis-Tris Precast Gel Cassette was removed from its pouch and rinsed in 
water. The tape was removed from the bottom of the cassette and the comb gently 
removed. The cassette sample wells were rinsed with SDS-PAGE running buffer at 
least three times and excess was discarded. The cassette was placed in an Xcell II 
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Mini-Cell E19001 electrophoresis tank and fixed in place using wedges. The tank 
was filled with SDS-PAGE running buffer. 
The sample was diluted to 0.5-2 mg/ml. To 65 ul of sample, 25 p1 NuPage LDS 
Sample Buffer (Invitrogen, The Netherlands) and 10 µl of water were added. The 
sample was placed in boiling water for 10 minutes. 20, ul of this sample was added to 
a well in the gel cassette. 20 ul of Mark 12 Wide Range Protein Standard was added 
to one well. 
Electrodes were connected as appropriate and the gel was run at 200 V; 120 mA; 24 
W for at least 30 minutes or until visible blue lines were within one mm from the end 
of the gel. The gel was removed from the cassette and immersed in fixing solution 
(see Table 2.1) for 15 minutes with constant mixing. The fixing solution was 
discarded and replaced with 100 ml of water. This was mixed for 15 minutes and 
repeated a further three times. The water was discarded and replaced with 50 ml of 
Gel Code Blue Stain Reagent (Pierce, U. K. ) for one hour with constant mixing. 
The gel was then dried so it could be retained. The gel was washed twice with water 
for two minutes. The water was replaced with 35 ml of Gel-Dry Drying Solution 
(Invitrogen, The Netherlands) and this was mixed for 20 minutes. Two pieces of 
DryEase Mini Cellophane sheets were soaked in the Gel-Dry Drying Solution for 20 
seconds. One sheet was then placed on a DryEase Mini-Gel Dryer Frame and the gel 
placed in the centre of the sheet. The second sheet was placed on top of this and any 
wrinkles and bubbles smoothed out. The plastic clamps were pushed onto the four 
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edges of the frame and the assembly was placed upright on a benchtop. The gel was 
left for 24 hours until dry and the frame was removed. The gel was placed under light 
pressure for two days until flat. 
The molecular weight of proteins in the sample were assessed by comparing sample 
bands with bands obtained from the molecular weight markers. 
2.3.4 Immunodiffusion 
Agarose 1% was prepared and 10 ml poured into each of three petri dishes (85 mm 
diameter) to give a thin layer. This was allowed to set and using a gel punch, holes 
were made in the agarose - one large hole in the centre of the plate and six smaller 
holes near the edges of the plate. 80 µl of anti-mouse IgM (The Binding Site, U. K. ) 
was added to the centre of one plate, and to each of the other plates 80 µ1 of anti- 
human IgG and 80µl of anti-human IgG. 50 µl of test antibody solutions were added 
to the smaller surrounding holes on each plate. Six antibodies were tested at the same 
time. 
The plates were allowed to equilibrate for 10 minutes before being placed at 25 °C 
for 48 hours in a sealed box with an underlayer of wet paper towels. After this time 
the plates were viewed under a microscope for the presence of immune precipitates, 
seen as white lines. Where white lines were present the agarose was processed to 
develop them. 
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Excess solution was removed from the wells in the plates as necessary and then the 
agarose was removed from the plate onto a sheet of electrophoresis film (Sigma- 
Aldrich, U. K. ). This was flooded with PBS and then a piece of No. 3 Whatman 
chromatography paper (Sigma-Aldrich, U. K. ) was placed on top. On top of this 
paper was placed eight paper towels followed by a one kg weight. This was pressed 
for 30 minutes. The agarose plus electrophoresis film was placed into 600 ml of PBS 
and left overnight. The agarose was then placed on the benchtop and flooded with 
water and a piece of chromatography paper placed on top. Eight paper towels and a 
one-kg weight were placed on top of this and left for 30 minutes. 
The agarose was dried in an oven (Coming) for 30 minutes and immersed in 
Crowle's double stain for 30 minutes. The agarose was de-stained for 15 minutes 
against a 300 ml volume of acetic acid 0.3 % for a total of three washes. 
This process demonstrated the type and source of each of the purified antibodies 
used. If a positive reaction developed it was seen as a blue stained band between the 
centre well and the test well. 
2.4 Biotinylation of Antibody 
Antibody to be biotinylated was dialysed into bicarbonate buffer pH 9.3. The dialysis 
procedure described in 2.2.3.1 was followed, except the dialysis tubing was cut and 
allowed to soften in bicarbonate buffer pH 9.3 for five minutes rather than PBS pH 
7.4. 
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For IgG biotinylation, 10 mg of biotin was added to 0.3 ml of dimethyl sulphoxide 
(DMSO) and mixed well. For IgM biotinylation 50 mg of biotin was added to 0.3 ml 
of DMSO. 5 pi of the appropriate biotin/DMSO was added per one ml of antibody to 
be biotinylated and allowed to react at 25 °C for one hour. The reaction mixture was 
then dialysed against PBS pH 7.4. On recovery from dialysis, the mixture was made 
to final concentration of 5% glycerol, 1% Bovine Serum Albumin (ID Bio) and 0.1 
% Sodium Azide. 
2.5 Fluorescent Labelling Procedures 
2.5.1 Fluorescent Labelling of Antibody/Antigen/Lectin 
Fluorescent labelling of antibody, antigen or lectin was carried out using a Cy3 mAb 
Labelling Kit (Amersham Pharmacia, U. K. ). Except the protein to be labelled, all 
reagents required are included as part of this kit. 
Protein to be labelled was prepared to 1 mg/ml (in PBS if required) and 100, U1 was 
used (0.1 mg). 5 µl of coupling buffer was then added. The total volume was added 
to a vial of Cy3 monofunctional dye that was incubated at room temperature for 30 
minutes with occasional mixing. 
A D-Salt Dextran Desalting Column was prepared by the addition of 3 ml elution 
buffer, and this was allowed to drain. When the protein/dye mixture was ready it was 
added to the column. Once the mixture had entered the column, 1.1 ml of elution 
buffer was added. Another 1.1 ml of elution buffer was added after this. A faster 
moving pink coloured band developed and was collected when it reached the bottom 
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of the column. The collected one ml of dye-coupled protein contained 0.1 mg/ml in 
elution buffer. 
2.5.2 Fluorescent Labelling of Erythrocytes 
0.1 g of fluorescein isothiocyanate (FITC) was dissolved in 10 ml of DMSO in a 
glass vial, to give a 10 mg/ml FITC/DMSO solution. This was stored at -40 °C until 
required. 
10 ml of a RBC-PBS suspension was placed in a plastic universal containing a 
circular magnetic stirrer on a magnetic stirrer pad. A pH probe was placed into the 
solution and the pH was measured throughout. The pH of the solution was adjusted 
to between pH 8.5 and 9.0 using 1M NaOH. 100 µl of 10 mg/ml FITC/DMSO 
solution was added drop by drop into the erythrocyte suspension. The pH was 
maintained between 8.5 and 9.0. The universal was placed in a water bath at 37 °C 
for two hours. Cells were recovered by centrifugation at 1000 rpm for five minutes in 
a Jouan CR312 centrifuge, and the supernatant removed. 
Red Cell Wash Solution A 3.2 % (Baxter Healthcare Ltd., U. K. ) was diluted 1 in 2 in 
water to give a hypertonic saline solution at 1.6 % NaCl. 10 ml of this was added to 
the red cells. The solution was mixed and centrifuged and then the supernatant 
removed. 10 ml of PBS was added and this was repeated for a total of five washes. 
On the final wash the red cells were suspended to a haematocrit of 2% in PBS or 
Alsevers solution (Alba Bioscience) and BSA (ID Bio, France) added to 2% final 
concentration. 
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2.5.3 FACS Analysis of Fluorescently Labelled Erythrocytes 
A Becton Dickinson FACScan (fluorescence-activated cell sorter) was used to 
perform analysis of labelled erythrocyte suspensions. Samples were run through the 
machine under the supervision of Dr. Shirley Macdonald, SNBTS National Science 
Laboratory. Her assistance is gratefully acknowledged. Labelled cells were diluted to 
give approximately 2x 106 /ml. 10,000 events were counted in the FL1 channel 
(flow channel one). Events above 10 in this channel were counted as labelled. 
2.6 Microarray Methods 
2.6.1 Slide Printing 
Slides used to fabricate protein microarray chips were sourced as described in Table 
2.5. The poly-L-lysine slide preparation followed the method described by the 
Stanford Microarray Group (cmgm. stanford. edu/pbrownlprotocols/1 slides. html). 
Microarray fabrication was primarily performed with a robotic microarrayer. For 
some studies described in Chapter 6, a manual microarrayer was used and the 
methods are described here. 
2.6.1.1 Robotic Slide Printing 
Probe samples to be spotted onto FASTTM slides (Schleicher & Schuell, Germany) 
were prepared in Schleicher & Schuell 1X Array Buffer. 
Probe samples to be spotted onto all other slides were prepared in PBS. 15 p1 of each 
probe was pipetted into a 384 well microplate (Genetix Ltd., U. K. ). A map of the 
plate was prepared in Microsoft Excel (Microsoft, U. K. ) identifying the contents of 
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each well. The plate and plate map were passed to the Scottish Centre for Genomic 
Technology and Informatics, (SCGTD for printing. Alan Ross of the SCGTI is 
acknowledged for his expertise in printing microarrays, used in many of the 
experiments within this work. 
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Slides were printed using a BioRobotics MicroGrid II Arrayer. The following sizes 
of solid pins were used throughout as appropriate; 200 µm, 400 µm and 700 µm. 
Pins were all supplied by BioRobotics. A print head containing 16 pins, in a4x4 
formation, was used throughout. Replicates of each sample were printed on each 
slide, but this varied depending on the number of probe samples, and will be detailed 
where appropriate. 
Printed slides were allowed to air dry for at least one hour, before being sealed in a 
bag and placed at 4 °C until required. The MicroGrid II also generates a 
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QuantArray® (GSI Lumonics, Canada). input file, which was used in 
interpretation/processing steps. This file gives the location of each spot and the 
details of the probes printed at that location. 
2.6.1.2 Manual Slide Printing 
A manual microarrayer from V&P Scientific Inc. was used to manually prepare 
microarrays. One mm solid steel pins were used. Pins were rinsed in water then in 
absolute ethanol and dried completely before repeat immersion into probe solution. 
Probes were printed at least in duplicate. The spacing between spots was facilitated 
using the grid slots provided on the manual microarrayer. 
Printed slides were allowed to air dry for at least one hour, before placing at 4 °C 
until required. An array map of the slides was self-generated and used in analysis. 
Slides were subsequently processed using the methods described below. 
2.6.2 Slide Processing 
2.6.2.1 Slide Processing Method A 
This process was used for the first protein microarrays that were performed in this 
work and was based on the method by Haab et al. (2001); adjustments and 
improvements were made on this procedure in subsequent experiments. 
Protein microarrays were rinsed briefly in PBST-milk by submerging 10 times, then 
blocked by placing into a fresh container of PBS-milk. This was placed overnight at 
4 °C. 
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On removal from the blocking solution, the slides were rinsed briefly in PBS three 
times for at least one minute. The slides were shaken dry and, without allowing the 
slide to dry after the final wash, a Lifter S1ipTM (Erie Scientific) was placed over each 
array. The protein solution to be added was prepared in PBS-milk and 25 ul was 
pipetted under the Lifter S1ipTM. The slides were placed in a sealed box with an under 
layer of PBS then placed at 4 °C for two hours. 
The slides were briefly submerged into PBS to remove the cover slip and excess 
protein solution. They were transferred to PBST for 20 minutes with constant 
mixing. This was followed by two washes in PBS for 10 minutes and two washes in 
water for 10 minutes. After the final wash the slides were centrifuged to dryness and 
stored in a dust-free dark place until scanned. 
2.6.2.2 Slide Processing Method B 
This method was adapted from Slide Processing Method A with the following 
changes: 
Microarrays were rinsed briefly in PBST-BSA by submerging 10 times, then placed 
into a fresh container of PBS-BSA. The protein solution to be added was prepared in 
PBS-BSA. 
2.6.2.3 Slide Processing Method C 
Protein microarrays were placed in PBS in a glass slide dish at room temperature, 
and allowed to re-hydrate for 10 minutes. Where glass slide dishes were used the 
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volume in the dish was 200 ml. The slides were then rinsed briefly in PBST-milk 
before blocking in a container of PBS-milk. 
On removal from the blocking solution, the slides were rinsed briefly in PBS and 
centrifuged to dryness in an Eppendorf 5810R centrifuge at 1000 rpm for one 
minute. 
A Lifter S1ipTM (Erie Scientific) was placed over each array. The protein solution to 
be added was prepared in PBS-milk and 25 yl was pipetted under the Lifter S1ipTM. 
The slides were placed in a Hybe Chamber (Gene Machines) with a 300 µl under 
layer of PBS for each slide. The Hybe Chambers have positions for two slides, each 
with a reservoir for solution, and the chambers can be completely sealed to avoid 
evaporation. Once sealed the Hybe Chamber was placed at 4 °C for two hours, or 
covered with tin foil and left at room temperature if using erythrocytes. 
The slides were removed from the Hybe Chambers and briefly submerged into PBS 
to remove the cover slip and excess protein solution. They were transferred to PBST 
for 20 minutes with constant mixing. This was followed by two washes in PBS for 
10 minutes and two washes in water for 10 minutes. If using erythrocytes, the final 
washes in water were omitted. After the final wash the slides were centrifuged to 
dryness and stored in a dust-free dark place until scanning. 
When a secondary labelling procedure was required in the microarray experiment, 
the secondary protein solution was prepared in PBS-milk and 25 ul was pipetted 
115 
under the Lifter S1ipTM. The remainder of the procedure was as described above, 
except the incubation period was one hour. 
2.6.2.4 Slide Processing Method D 
Protein microarrays were placed in PBS in a glass slide dish at room temperature, 
and allowed to re-hydrate for 10 minutes. The slides were then rinsed briefly in a 
PBST-milk before being blocked in a container of PBS-milk for one hour at room 
temperature, with constant mixing. 
On removal from the blocking solution, the slides were rinsed briefly in PBS and 
centrifuged to dryness in an Eppendorf 5810R centrifuge at 1000 rpm for one 
minute. 
A Hybridisation ChamberTM (Schleicher & Schuell) was placed over each array. The 
protein solution to be added was prepared in the PBS-milk and 450 µl was pipetted 
through one of the portholes in the Hybridisation ChamberTM. The portholes were 
sealed with the provided port seals. The slides were placed in a slide box and mixed 
throughout the incubation period (two hours, reduced to one hour when optimised in 
Chapter 4) at room temperature. 
The Hybridisation Chambers were peeled off and the slides then briefly submerged 
into PBS to remove excess target solution. They were transferred to PBST for 20 
minutes with constant mixing. This was followed by two washes in PBS for 10 
minutes and two washes in water for 10 minutes. If using erythrocytes, the final 
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washes in water were omitted. After the final wash the slides were centrifuged to 
dryness and stored in a dust-free dark place until scanning. 
If a secondary labelling method was to be used, a new hybridisation chamber was 
used and the process above repeated. 
2.6.2.5 Slide Processing Method E 
This is the final fully optimised procedure and is derived from Slide Processing 
Method D, with the following adjustments. 
Slides were rinsed in PBST-BSA followed by blocking in PBS-BSA. However, no 
Tween was used at any stage if performing Rhesus grouping (D, c or E). The 
incubation times were one hour for both primary and secondary incubations (if 
performed). 
2.6.2.6 FASTTM Slide Method 
This method was adapted from the process specified by the slide manufacturer 
(Schleicher and Schuell, Germany). Printed protein microarrays were processed as 
follows. A Hybridisation Chamber (Schleicher and Schuell) was placed over the 
array and pressed down to form a seal. 500µl of 1X wash/block buffer was added 
through one of the access ports, which were all then sealed. The slides were 
incubated at room temperature for two hours, ensuring gentle agitation throughout. 
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The wash/block buffer was removed using a pipette, and was replaced with 500 µl 
target protein solution, which had been prepared in 1X wash/block buffer. The slides 
were then incubated at room temperature for one hour, ensuring gentle agitation 
throughout. 
The protein solution was removed from the slide and the Hybe Chambers were 
discarded. The slides were then placed in 1X wash/block solution for 10 minutes 
with constant mixing. This was repeated for a total of three washes. After the final 
wash the slides were allowed to air dry until the coating on the surface of the slides 
appeared white. They were then stored in a dust-free dark place until scanning. 
2.6.3 Slide Scanning 
2.6.3.1 Slide Scanning Method A 
Slides were scanned in an Affymetrix 428 Array Scanner. Cy3 or Cy5 settings were 
pre-set, and the Cy3 setting was used to scan FITC where appropriate. The 
appropriate slide setting was selected for the type of slide to be scanned i. e. glass or 
nitrocellulose. Photo-multiplier tube (PMT) settings were altered as appropriate. 
Each slide to be analysed was scanned with at least three different PMT settings, as 
multiple scanning is recommended by Forster et al. (2003). All slide scans were 
performed at 10 micron pixel size resolution and saved to compact disc as both a 
bitmap (bmp) and a tagged image file (tif) format. 
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2.6.3.2 Slide Scanning Method B 
Slides were scanned in a Packard BioScience (Billerica, MA, USA) ScanArray 5000. 
Cy3 or Cy5 settings were pre-set, and the Cy3 setting was used to scan FITC where 
appropriate. PMT and laser power settings were altered as appropriate. Each slide to 
be analysed was scanned with at least five different settings. Five scans were selected 
as optimum as described by Forster et al. (2003). All slide scans were performed at 
10 micron pixel size and saved to compact disc as both bmp and of formats. This 
scanner was used latterly as it was automated to batch scan slides. 
2.6.3.3 Slide Scanning Method C 
Slides were scanned in an Genepix Personal 4100A Scanner (Axon Instruments) 
Settings were pre-set, and the Cy3 setting was used to scan FITC where appropriate. 
The photo-multiplier tube (PMT) value was altered as appropriate. Each slide to be 
analysed was scanned at one setting, which was selected by a visual inspection of the 
scan. All slide scans were performed at 10 micron pixel size and saved to compact 
disc as both a bmp and a tif. 
2.6.4 Data Processing Methods 
Data was extracted from of files as described below. 
2.6.4.1 Data Processing Method A 
Numerical data was extracted from the microarray of files using QuantArray® 
Microarray Analysis Software (GSI Lumonics, Canada). A protocol for each 
experiment was prepared using the QuantArray® Protocol Wizard steps. These steps 
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included setting of the array pattern, grid and spot elasticity, quantitation method and 
the quantitation parameters. The array pattern was entered using the Pattern Wizard 
that was used to indicate the location and size of spots in the array. The grid and spot 
elasticity values were set at 50 throughout. At the quantitation step, the desired 
quantitation method for each array was selected (histogram, fixed-circle or adaptive) 
and the location and file name of the QuantArray® input file generated from the 
MicroGrid II print run was entered. This process gave an average fluorescence 
intensity value from the centre of each spot and an average background value from 
the area surrounding each spot. 
The QuantArray® program provided a text worksheet that was opened and saved as 
a Microsoft Excel worksheet. 
2.6.4.2 Data Processing Method B 
Numerical data was extracted from the microarrays using GenePix Pro 4.1 (Axon 
Instruments). The software controls the scanning, data input and date extraction from 
the microarray. A text input file was self-generated using microarray column and row 
positions to determine identity and location of each probe. This was used to generate 
an array list that was loaded once the microarray grid settings had been set up. Once 
the grid and the array list had been generated, the data was extracted to a text file. 
This process gave the median fluorescence intensity value from the centre of each 
spot and a median background value from the entire background area of the slide. 
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The program provided a text worksheet that was opened and saved as a Microsoft 
Excel worksheet. 
2.6.5 Data Analysis Methods 
2.6.5.1 Data Analysis Method 
To determine data quality, the data were sorted according to intensity value and a 
Microsoft Excel line graph was plotted using all intensity values versus all 
background values. The plotted graph showed if the intensity values for each spot 
were generally higher than the background values. Data that did not show this were 
disregarded, and no further analysis performed as the signal to noise ratio was too 
low. 
Data of suitable quality were processed using Microsoft Excel as follows. For each 
spot the background fluorescence value was subtracted from the fluorescence 
intensity value. For each slide the signal intensity values from each different scan 
setting were collated into one worksheet. A scatter plot was prepared using all values 
for each of the settings set against each other. The shape of the resulting data cloud 
gave an indication of the scan qualities, and can show if settings were too low, or if 
settings were too high giving saturated spots. The R2 value was applied to each graph 
and those that gave a value closest to one demonstrated the best data. One scan from 
each slide was selected for further data processing. 
Once the best data scan had been selected it was processed as follows. Unwanted 
data were removed from the worksheet to leave only one value per spot on the 
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microarray (the fluorescence intensity value minus the background fluorescence 
value for each spot). The negative control values were used to calculate a `noise' 
value - the mean plus two standard deviations of the negatives (mean + 2sd). This 
value represents non-specific binding (NSB). The value for each spot was divided by 
the mean + 2sd of the negative controls to give a signal-to-noise ratio (S/N). Values 
over one can be considered significant. The median of the S/N was calculated for the 
replicate spots of each sample. 
Using Microsoft Excel the processed data was analysed as appropriate. Bar charts 
were used throughout to analyse data. The Y-axis on the bar charts represents the 
S/N median for the sample. 
Where error bars were included, the standard error for each sample was calculated as 
follows. The standard deviation of the replicates of each sample was calculated (this 
was performed on S/N ratios or actual fluorescence values). The standard deviation 
was divided by the square root of the number of replicates of the sample to give the 
standard error. Error bars were appended using the Microsoft Excel `Format Data 
Series' function, or by importing the data into SigmaPlot version 9.0 (Systat 
Software, U. K. ) and indicating the standard error to be used for each sample to give 
Y error bars. Error bars were added either from replicates on a slide or from replicate 
slides, and show the level of variability between the data points. 
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2.6.5.2 Normalisation of Data for Slide Comparison 
Where comparisons were to be made between slides where a SIN ratio could not be 
used as a comparator, then the data was normalised. Normalisation helps neutralise 
non-biological effects (Forster et al., 2003) between microarrays, such as scanner 
settings and processing differences. 
For each signal intensity column, the Microsoft Excel percentile function was used to 
calculate the 75`' percentile value for the entire slide. For slides to be compared the 
`best' slide was selected and its percentile value divided by the percentile value of 
each of the other slides. The resulting ratio for each slide was used as a 
multiplication factor for all of the spots on the slide. 
2.7 Blood Typing in Enzyme-Linked Immunosorbent Assay (ELISA) 
Format 
This method was used to test blood typing antibodies with directly and indirectly 
FITC labelled erythrocytes, to establish if blood typing could be performed in solid- 
phase using the stated reagents. This uses ELISA principles but the detection was by 
eye or fluorescence. 
The pH of antibodies to be coated onto the ELISA plate was adjusted to 9.0 using 1 
M NaOH. 100 pl of each sample was added in triplicate to the wells of a MaxiSorp 
ELISA plate (NUNC). ELISA coating buffer was added to several wells to provide 
background values. The plate was wrapped in cling film and incubated at 37 °C for 
two hours. 
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Excess antibody solution was discarded and the plate was washed four times by 
adding 250 µl of ELISA wash buffer per well and discarding forcibly. On the last 
wash the plate was blotted onto paper towels to leave the plate as dry as possible. 250 
pl of ELISA blocking buffer was added per well and the plate was wrapped in cling 
film and placed at 37 °C for one hour. The plate was washed and dried as before. 100 
µl of a RBC-PBS suspension was added to the appropriate wells. The plate was 
wrapped in cling film and incubated at 4 °C for one hour. The plate was washed four 
times as before. 
Where directly FITC labelled erythrocytes had been used, the plate was viewed using 
an inverted microscope for the presence of erythrocytes and then read as below. If 
unlabelled erythrocytes had been used, 100µl of FITC ConA 0.1 mg/ml was added 
per well. The plate was wrapped in cling film and incubated at 4 °C for one hour. 
The plate was washed and dried as before and viewed under an inverted microscope 
before reading for fluorescence as described below. 
The plate was read in a Wallac Victor 2 1420 Multilabel Counter using the pre-set 
setting ̀ Fluorescein 1.0 seconds'. The results were printed out in a plate format. 
2.8 Antibody-Antigen Interaction Analysis Using Surface Plasmon 
Resonance 
The Biacore X, Biacore CM5 chip, Biacore X Control Software and BlAevaluation 
Software (Biacore AB) were used throughout. All data was saved onto compact disc 
before manipulation of data. The manuals supplied with the Biacore X gave detailed 
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information on the set up of the machine and experimental options. Where option 
choices were available in the manuals, these were the methods selected. 
A reference flow cell was set up when appropriate, which has been treated in the 
same way as the active flow cell but had no contact with ligand. Using this, the 
machine has the facility to perform reference subtraction, where the effects of bulk 
refractive index changes are corrected together with non-specific binding. Where 
appropriate, data presented in this work shall be reference subtracted using the 
reference flow cell values. 
2.8.1 Preparation of the Biacore. XTM 
The Biacore-XTM processing unit, PC and printer were switched on and allowed to 
stabilise for one hour. A Biacore CM5 Sensor Chip was removed from cold storage 
and the temperature equilibrated to room temperature for at least 30 minutes. The 
sensor chip was docked and the machine primed with Biacore running buffer. Data 
collection was initiated by commencing a sensorgram and setting the flow over flow 
cells 1 and 2 to 5 p1 per minute. This sensorgram was run for at least 30 minutes 
before any procedure was carried out to allow the sensorgram reading to stabilise. 
2.8.2 pH Scouting 
pH scouting is a procedure to find the pH at which optimal electrostatic binding of 
the ligand will occur. At this pH the ligand is more likely to be attracted to the sensor 
surface for covalent binding following chip surface activation. 
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The ligand (antibody, lectin or synthetic blood group antigen conjugate) was dialysed 
or diluted into sodium acetate 10 mM (at desired pH). The concentration of ligand 
was approximately 50 pg/ml. Dialysis was performed using the method described in 
2.2.3.2. pH scouting was performed on an unactivated chip. The sensorgram baseline 
was set before each injection of ligand. Starting with the highest pH, the ligand 
solutions were injected over the flow cell for a contact time of 2 minutes at a flow 
rate of 20 ul per minute. The pH at which the response was highest was the pH 
selected for amine coupling. 
2.8.3 Coupling of Ligand to the Sensor Chip Surface 
The coupling of a ligand to the sensor surface involved three main steps: activation 
of the surface, coupling of the ligand and then deactivation of the surface. This 
process was performed for each ligand immobilised. The surface of the CM5 chip 
must first be activated by passing a solution of 1-ethyl-3- (3-dimethylaminopropyl) 
carbodimide (EDC) and N-hydroxysuccinimide (NHS) over the surface, and a 
schematic is shown in Figure 2.1. The activation time affects the number of sites 




















Figure 2.1. Schematic showing activation of sensor chip surface by EDC/NHS (dextran 
chains omitted). (Modified from Biacore Sensor Surface Handbook, 2003). 
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Once activated, the ligand solution (at appropriate pH) is passed over the sensor 
surface and the reactive succinimide esters react spontaneously with the amine 
groups on the ligand, and the antibody or antigen is covalently linked to the chip. The 
coupling is demonstrated in Figure 2.2. It is important that the ligand has been 












Figure 2.2. Schematic showing amine coupling of ligand to the activated surface. (Modified 
from Biacore Sensor Surface Handbook, 2003). 
Ethanolamine is passed over the sensor surface to deactivate uncoupled active esters. 
This will bind to any remaining reactive groups on the sensor chip surface. This stage 
is vital to prevent non-specific binding of analyte to the sensor surface. 
Ligand was covalently immobilised on the sensor chip surface as follows. 100 p1 of 
ligand solution at concentration of approximately 50 pg/ml was dialysed into sodium 
acetate 10 mM at the pH determined in the pH scouting procedure. The flow rate was 
set at 5 p1 per minute throughout. The sensorgram baseline was set on the 
sensorgram before the activation procedure was performed. 
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The surface of the chip was activated by injection of NHS/EDC over flow cells 1 and 
2, for a contact time of 10 minutes. The coupling of ligand was performed by the 
injection of ligand solution (at desired pH) over flow cell 2 only, for a contact time of 
10 minutes. The surface of the chip was deactivated by the injection of ethanolamine 
over both flow cells 1 and 2 for a contact time of 7 minutes. 
The level of immobilisation of ligand was recorded as the response after 
deactivation, from the sensorgram of flow cell 2 minus flow cell 1. 
2.8.4 Interaction Analysis 
Binding to the sensor chip surface takes place during the injection of the analyte. The 
change in refractive index (RI) indicated on the sensorgram by a change in RU, 
demonstrates some change at the sensor chip surface. An increase in the RU means 
molecules are binding, a decrease means they are dissociating. The injection of 
sample environments that differ greatly from the running buffer will cause a bulk 
shift in the RI. An RI shift is demonstrated by a square pulse in the sensorgram and a 
shift in the RU. To prevent this the analyte is diluted in running buffer before 
injection. 
This procedure, and the initiation of a sensorgram, enables the monitoring of real- 
time molecular interactions of ligand and analyte on the chip sensor surface. To 
enable the re-use of the coupled sensor chip, the surface must be regenerated. This is 
the removal of analyte without the removal of ligand. Regeneration conditions were 
optimised during this study for each analyte. Regeneration can be achieved by 
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denaturing the analyte or disrupting the structure. When establishing regeneration 
conditions, the analyte must be injected over the sensor surface to ensure that the 
ligand activity has not been affected. If regeneration is not complete then this will 
affect the binding capacity of the chip. Regeneration is satisfactory if the sensorgram 
returns to within 5% of the baseline and when the repeat binding of analyte is within 
10% of the initial response (Biacore. com). 
The analyte (antibody, erythrocyte or synthetic blood group antigen conjugate) was 
prepared in Biacore running buffer or Biacore running buffer-Mn/Ca (if using 
Concanavalin A). The analyte was injected over flow cells 1 and 2 for a contact time 
of 10 minutes at a flow rate of 5 pl per minute. The baseline was set at the start of the 
injection. The Biacore normal wash procedure, as indicated in the operation manual, 
was carried out at the end of the injection. 
The surface was regenerated at the end of each injection of analyte and before the 
next injection. Regeneration was performed using one-minute pulses of 1 mM 
NaOH. This was injected over both flow cells until the response in sensorgram flow 
cell 2 minus 1 was within 5% of the baseline response. The level of binding was 
recorded as the response from flow cell 2 minus 1, at the end of the injection. 
In this work it was found that the bound ligands were not stable after storage 
following approximately seven day storage (data not shown), therefore any 
experimental work was performed within two days of the coupling of the ligand. 
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2.8.5 Evaluation of Biacore Data 
BlAevaluation software was used to manipulate the sensorgrams. Report point data 
from sensorgrams were interpreted in tabular form or using Microsoft Excel. 
2.9 Preparation of Erythrocyte Membrane Protein Fragments 
A ProteoExtractTM Native Membrane Protein Extraction Kit (CalbioChem) was used 
to prepare native membrane protein fragments from erythrocytes. All reagents used 
were supplied as part of the kit, except the PBS and cell samples. This kit extracts 
integral and membrane-associated proteins in a non-denatured state based on their 
association with cellular membranes. A bench top Eppendorf 5415R centrifuge was 
used throughout this process at the settings indicated. 
Erythrocytes were washed in PBS at least four times, then an aliquot containing 
approximately 1.25 x 107 erythrocytes was processed in an Eppendorf tube. The cells 
were spun down at 1000 g for one minute and excess supernatant removed. 7.5 pl of 
Protease Inhibitor Cocktail was added to the wall of the tube followed by 1.5 ml of 
ice cold Extraction Buffer I. The pellet was resuspended and mixed gently using a 
pipette. The tube was incubated at 4 °C for 10 minutes in a rotary shaker. The tube 
was then centrifuged at 16,000 g at 4 °C for 15 minutes. Following this the 
supernatant was removed using a pipette, and discarded. 
A further 5 p1 of Protease Inhibitor Cocktail was added to the side of the tube 
followed by 1.0 ml of ice-cold Extraction Buffer II. The pellet was resuspended and 
mixed gently using a pipette. The tube was incubated at 4 °C for 30 minutes in a 
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rotary shaker. The tube was then centrifuged at 16,000 g at 4 °C for 15 minutes. The 
supernatant containing the membrane proteins from the erythrocytes was then 
collected. 
The resultant aliquot contained the protein membranes from 1.25 x 107 erythrocytes, 
in a volume of approximately 0.9 ml. This was equivalent to protein membranes 
from 1.4 x 104 erythrocytes/pl. 
To prepare a more concentrated suspension of erythrocyte membrane protein 
fragments, less Protease Inhibitor Cocktail and Extraction Buffer II were added, in 
proportion. The volumes used were 1 pl of Protease Inhibitor Cocktail, followed by 
0.2 ml of ice-cold Extraction Buffer II. This contained the protein membranes from 
1.25 x 107 erythrocytes, in a volume of approximately 0.2 ml. This was equivalent to 
protein membranes from 6.25 x 104 erythrocytes/pl. Aliquots were frozen at -20 °C 
and thawed when required. 
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CHAPTER 3 
DEVELOPMENT AND EVALUATION 
OF PROTEIN MICROARRAYS 
FOR THE STUDY OF 
PROTEIN-LIGAND INTERACTIONS 
3. DEVELOPMENT AND EVALUATION OF PROTEIN MICROARRAYS 
FOR THE STUDY OF PROTEIN-LIGAND INTERACTIONS 
3.1 Introduction and Chapter Aims 
Various design options for microarray experimentation were described in Chapter 1 
(1.4.2), as was blood testing for transfusion purposes (1.3). In order to examine the 
interactions of blood group antigens and antibodies, it was necessary to first 
investigate the antibody-based protein microarray platform and then optimise for 
simple sets of related proteins and ligands. Protein microarrays for this purpose are 
not standardised systems available ready-for-use, but research and potentially 
diagnostic tools in development. 
The aims of this initial stage of the project were: 
" To determine the ability to fabricate protein microarrays using available 
equipment and using publications detailing similar type studies, then to probe the 
microarrays with anti-species detection/target solutions to determine if probes are 
retained on the slides. 
" To optimise protein microarray procedures such as blocking, washing, incubation 
conditions, detection methods, data extraction and data processing methods, to 
enable the study of probe-ligand interactions. 
" To evaluate different slide surface chemistries and select options for the next 
stage of the project (blood typing microarrays). 
" Amalgamate all findings and process optimisations to provide a basis for a multi- 
parameter blood typing microarray platform. 
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3.2 Determination of Conditions for Microarray Fabrication 
As mentioned in Chapter 1, MacBeath and Schreiber (2000) and Haab et al. (2001) 
had described the use of similar substrates and techniques used in DNA arrays for the 
preparation of protein microarrays. In order to apply and develop protein microarray 
procedures for the new application described in this thesis, experiments were devised 
to investigate if the work of Haab et al. could be repeated in our settings. For this 
purpose, a variety of protein-ligand sets were used, and processed using Haab et al. 
(2001) as a reference point. Probes were then detected using anti-species antibodies 
and the interactions studied. 
Serum proteins, polyclonal and monoclonal antibodies were used throughout this 
chapter as probes, and fluorescently labelled anti-species antibodies were used for 
detection (target antibodies). Serum proteins were purchased and used as supplied, or 
diluted. Antibodies of the IgG class were purified by the use of affinity 
chromatography columns. IgM antibodies were purified using the methods of gel 
filtration and affinity chromatography. Protein probes prepared in-house were 
assessed by various methods for activity, quantitation, and purity as described in 
Chapter 2. 
As discussed in Chapter 1 (1.4.2.2), the choice of probes for any microarray 
experiment must be considered carefully. Protein probes must include proteins of 
interest along with suitable controls for subsequent analysis. The proteins printed as 
probes in this protein microarray experiment are detailed in Table 3.1. Bovine serum 
albumin (BSA) and foetal calf serum (FCS) were included as negative controls. 
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Table 3.1. Protein probes spotted in protein microarray experiment in 3.2, and concentration 
(conc. ) in pg/ml. 
Protein Protein/Ab Conc. Conc. Conc. Conc. Conc. Conc. 
identification type DIL1 DIL2 DIL3 DIL4 DIL5 DIL6 
BSA neg. control 300 200 100 75 50 25 
ES15 mouse IgM 127 85 42 32 21 11 
ES9 mouse IgM 81 54 27 20 14 7 
ESD1 humanlgG 300 200 100 75 50 25 
FCS neg. control 300 200 100 75 50 25 
HIVG1 mouse IgG 300 200 100 75 50 25 
HIVG2 mouse IgG 300 200 100 75 50 25 
LA2 mouse IgM 55 37 18 14 95 
LB2 mouse IgM 108 72 36 27 18 9 
LDM3 human IgM 6.4 3.2 1.6 0.8 0.4 0.2 
LHM169/80 human IgG 300 200 100 75 50 25 
LHM59/19 human IgG 300 200 100 75 50 25 
LHM70/45 human IgG 300 200 100 75 50 25 
LHM76/55 human IgG 300 200 100 75 50 25 
LHM77/64 human IgG 300 200 100 75 50 25 
The target proteins, or those used for detection of bound probes, in this experiment 
were fluorescently labelled anti-species antibodies, and are described in Table 3.2. 
Table 3.2. Target proteins used in protein microarray experiment in 3.2, and concentration. 
Target protein identification Concentration used (pg/ml) 
Cy3 Anti-Human IgG 33.33 
Cy3 Anti-Human IgM 5.00 
FITC Anti-Mouse IgG 31.25 
FITC Anti-Mouse IgM 7.81 
Protein microarrays mainly follow the basic principles of standard immunoassays, as 
described in Chapter 1 (see Figure 1.8). In order to describe the process followed in 
this and subsequent experiments, and to facilitate the reading and interpretation of 
data, the basic parameters used for each experiment are described as follows: 
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slide type, number of replicate slides, pin size, probes, on-slide probe replicate 
spots, slide processing method (SPM), blocker used, target and label, target solution 
volume, incubation time, statictmixing, scanning method 
For instance, using this experiment as an example, the above parameters are 
summarised in figure legends as follows: 
Slide type poly-L-lysine, slide reps 1, pins 700 /an, probes Table 3.1, probe reps 2, SPM A; 
blocker PBS-milk, target/volume: Cy3 anti-hlgG/25 /l, incubation 120 min, static, scanning 
method A. 
Once processed the slides were scanned. Pseudo colour images from the scans are 
presented in Figure 3.1 and Figure 3.2. The colour spectrum used refers to the 
intensity of the signal, where black/blue are low fluorescence and red/orange/white 
are high. The figures show some artefacts on the microarrays, which can complicate 
analysis if not considered. Examples of `black holes' are shown in Figure 3.1a. 
Black holes can be a result of non-optimised blocking (u-vision-biotech. com) as the 
surrounding background to the spot has a higher fluorescence value than the actual 
spot. The fluorescence present may be autofluorescence from residual buffer, or dust 
due to poor processing procedures, or that the actual fluorescent antibody has bound 
non-specifically to the chip. 
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Figure 3.1. Pseudo-colour images (blue to white scale) from protein microarray experiment 
3.2. The PMT values used for these scans were different (3.1 a PMT was 35 and 3.1 b PMT 
was 25). Actual spot size is approximately one mm in diameter. 
Fig A. The boxed areas show examples of black holes. Slide type poly-L-lysine, slide reps 1, 
pins 700 In, probes Table 3.1, probe reps 2, SPM A; blocker PBS-milk, target/volume: Cy3 
anti-hlgM/25 pl, incubation 120 min, static, scanning method A. 
Fig B. The outlined area shows an example of 'comet-tailing'. Slide type poly-L-lysine, slide 
reps 1, pins 700 , um, probes Table 
3.1, probe reps 2, SPM A; blocker PBS-milk, 
target/volume: Cy3 anti-hlgG/25 4, incubation 120 min, static, scanning method A. 
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Figure 3.2. Pseudo-colour images (blue to white scale) from protein microarray experiment 
3.2. 
Fig A. Slide type poly-L-lysine, slide reps 1, pins 700 fpm, probes Table 3.1, probe reps 2, 
SPM A; blocker PBS-milk, target/volume: FITC anti-mlgM/25 pl, incubation 120 min, static, 
scanning method A. 
Fig B. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, probe reps 2, 
SPM A; blocker PBS-milk, target/volume: FITC anti-mlgG/25 »A, incubation 120 min, static, 
scanning method A. 
It is also considered that an increase in protein concentration of a target solution can 
result in an increase in non-specific background resulting from non-specific binding 
(NSB) of target proteins (Haab et al., 2001). The black hole effect can present itself 
in the data analysis as the subtraction of the background from the spot fluorescence 
can lead to a negative fluorescence value for the spot. An improvement to blocking 
procedures was later investigated (section 3.3) in an attempt to eliminate or reduce 
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this effect. In Figure 3.1b an improved image is seen as the level of fluorescence to 
background is much better than in Figure 3.1 a. Due to the highly specific nature and 
low non- specific binding, this image was acquired using lower photo-multiplier tube 
(PMT) settings, which can result in darker background. 
However, this image (Figure 3.1b) also demonstrates another area for improvement. 
The highlighted area gives an example of `comet-tailing'. A more extreme example 
of comet tailing can result in the lifting-off of the spot itself. This can arise from 
blocking and, it could be speculated, from overload of sample probes. This smearing 
effect was reported by Seong (2002) and was found when high probe protein 
concentrations were used. This phenomenon can also result in negative fluorescence 
values, as the* black hole area usually shows lower values than even negative 
controls. 
The effect of solution drying underneath the cover slip can be seen in Figure 3.2a (u- 
vision-biotech. com), demonstrated by the large amount of background shown in 
blue. Some spots also show the `doughnut' effect, where there is circular 
fluorescence with an area of lower fluorescence in the centre. This can be the result 
of the pin quality or from lack of humidity during slide drying (u-vision- 
biotech. com). There is also some variation in spot size. 
The effects of some of the phenomenon mentioned above can were overcome. Using 
statistics, the data can be handled to compensate for background and get the most 
from the data. Ideally the microarray should have clean and consistent spots and 
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background, and measures should be taken to minimise unwanted artefacts or 
unsuitable spots. 
The data from the scans shown in Figures 3.1 and 3.2 was extracted using Data 
Processing Method A and then manipulated using the Data Analysis Method. These 
methods will be used throughout this chapter. 
Values from the BSA and FCS spots were used as negative controls to calculate 
noise. The results are presented as bar graphs in Figures 3.3a-m. This standard 
format of data presentation is used throughout this thesis. The y-axis shows the 
signal to noise ratio (S/N) calculated from the fluorescence values from the probe 
antibody spot divided by the mean plus two standard deviations of the background 
noise probes. The x-axis will usually display the probe antibody identification 
details. Here, the interactions of all four target antibodies with one probe antibody 
are displayed in one figure. No error bars are used as samples were printed in 
duplicate. 
In order to show the reactivity of the probe mouse IgM antibodies with the 
fluorescently labelled target proteins the results are compiled in Figures 3.3a-d. 
While the anti-mouse IgM gives low SIN values, the anti-mouse IgG and anti-human 
IgM show cross-reactivity. Anti-A LA2 also shows reactivity with anti-human IgG. 
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DIL1 DIL2 DIL3 DIL4 DIL5 DIL6 
Anti-A(B) (ES15) dilution 
Figure 3.3a. Reactions of probe Anti-A(B) ESI5 mouse IgM, at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 /An, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pI, incubation 120 min, 
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DIL1 DIL2 DIL3 DIL4 DIL5 DIL6 
Anti-A (ES9) dilution 
Figure 3.3b. Reactions of probe Anti-A ES9 mouse IgM at various dilutions, with target anti- 
species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 »A, incubation 120 min, 
static, scanning method A. 
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Anti-A (LA2) dilution 
Figure 3.3c. Reactions of probe anti-A LA2 mouse IgM at various dilutions, with target anti- 
species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pl, incubation 120 min, 
static, scanning method A. 
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Anti-B (LB2) dilution 
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Figure 3.3d. Reactions of probe Anti-B (LB2) mouse IgM at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 In, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 t4, incubation 120 min, 
static, scanning method A. 










Figure 3.3e shows the specific interaction of probe antibody anti-D LDM3 with anti- 
human IgM, and cross-reactivity with other target antibodies. 











DILl DIL2 DIL3 DIL4 
Anti-D (LDM3) dilution 
DIL5 DIL6 
Figure 3.3e. Reactions of probe Anti-D LDM3 human IgM at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 prn, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pl, incubation 120 min, 
static, scanning method A. 
The reactions of the monoclonal mouse IgG probe antibodies are seen in Figures 
3.3f-g. Both show specific interaction with the anti-mouse IgG and cross-reactivity 
with the anti-human IgG. 
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DILl DIL2 DIL3 DIL4 DIL5 DIL6 
Anti-HIV (HIVG1) dilution 
Figure 3.3f. Reactions of probe Anti-HIV HIVG1 mouse IgG at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 Nm, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pl, incubation 120 min, 
static, scanning method A. 
















DIL2 DIL3 DIL4 DIL5 DIL6 
Anti-HIV (HIVG2) dilution 
Figure 3.3g. Reactions of probe anti-HIV HIVG2 mouse IgG at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pl, incubation 120 min, 
static, scanning method A. 
The results from all the human IgG probe antibodies are shown in Figures 3.3h-m. 
In all cases, specific reactions of probe antibody with the anti-human [gG are shown. 
The S/N ration reaches up to 25 in all but one graph, Figure 3.31, showing the results 
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from the probe antibody LHM76/55. In Figure 3.31 specific reactions with the anti- 
human IgG are seen, but the S/N ratios appear inverse to what would be expected, 
which would be a higher signal from the highest concentration of probe. This result 
may be due to the high concentration of the probe antibody. Alternatively, this could 
be contributed to the `hook' effect, which is further discussed at the end of this 
chapter. Generally, all results in Figures 3.3h-m show some cross-reactivity of either 
the mouse IgG or anti-human IgM which could be explained due to the similarity of 
the antibody structures, and that the antibodies were not anti-species adsorbed during 
manufacture (supplied by Sigma, U. K. ). Also, many of the cell lines (cell line 
identity prefix LHM, LDM or ESD) are human-mouse hybridomas and may give 
cross-reactivity with anti-mouse reagents. 








DILl DIL2 DIL3 DIL4 
Anti-D (ESD1) dilution 
DIL5 DIL6 
Figure 3.3h. Reactions of probe Anti-D ESD1 human IgG at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 , um, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/251A, incubation 120 min, 
static, scanning method A. 
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DILl DIL2 DIL3 DIL4 
Anti-D (LHM169/80) dilution 
DIL5 DIL6 
Figure 3.3i. Reactions of probe Anti-D LHM169/80 human IgG at various dilutions, with 
target anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 , urn, probes 
Table 3.1, probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pl, incubation 
120 min, static, scanning method A. 









DIL1 DIL2 DIL3 DIL4 
Anti-D (LHM59/19) dilution 
DIL5 DIL6 
Figure 3.3j. Reactions of probe Anti-D LHM59/19 human IgG at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 prn, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 1uI, incubation 120 min, 
static, scanning method A. 
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Anti-D (LHM70/45) dilution 
DIL5 DIL6 
Figure 3.3k. Reactions of probe Anti-D LHM70/45 human IgG at various dilutions, with 
target anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 , um, probes Table 3.1, probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 /A, incubation 
120 min, static, scanning method A. 
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Figure 3.31. Reactions of probe Anti-D LHM76/55 human IgG at various dilutions, with target 
anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, 
probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pA, incubation 120 min, 
static, scanning method A. 
147 








DILl DIL2 DIL3 DIL4 
Anti-D (LHM77/64) dilution 
DIL5 DIL6 
Figure 3.3m. Reactions of probe Anti-D LHM77/64 human IgG at various dilutions, with 
target anti-species antibodies. Slide type poly-L-lysine, slide reps 1, pins 700 »m, probes 
Table 3.1, probe reps 2, SPM A; blocker PBS-milk, target/volume: various/25 pi, incubation 
120 min, static, scanning method A. 
The aim of this experiment was to determine if the protein microarray procedures 
described by MacBeath and Schreiber (2000) and Haab et al. (2001) could be 
reproduced in our setting. From these results it was concluded that proteins could be 
printed onto a microarray format using the available equipment, and that the resultant 
microarrays can be processed and probed with target proteins to determine their 
presence. As the primary aim of the experiment, this was a successful outcome. 
However, to build on the success of this initial experiment, the scans and results 
pointed towards some areas for improvement of the procedure, prior to the use of the 
microarrays for the intended purpose of blood typing and antibody screening. 
The experiment showed the presence of the probe antibodies on the slides following 
blocking, sensitisation (interaction phase) and washing procedures. What was not 
shown by this experiment was whether the probes were still functional on the 
microarray solid-phase format. The target antigen-binding site of many of the anti- 
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species antibodies is on the Fc portion of the target antibody molecules, an area that 
may not be affected by immobilisation to a solid support. The functionality of the 
spotted antibodies would have to be determined, but prior to this the system would be 
optimised for the process. It was noted that the level of cross-reactivity of some 
target antibodies in this experiment was high. This could perhaps be improved using 
optimised reagents. The cross-reactivity can be partly explained by the high level of 
structural similarity of antibodies between classes and species, and also because the 
target reagents had not been anti-species adsorbed by the supplier. The concentration 
of target antibodies was not optimised prior to this experiment and it may be that 
adjusted levels would give more specific results. The specificity of the target 
antibodies was demonstrated clearly when graphs were plotted of each target against 
all the probes at similar concentrations (see Table 3.3), using the same data from that 
used above, as in Figures 3.4a-d. 
Table 3.3. Dilution of probe proteins used for analysis of target antibodies in Figures 3.4a-d. 
Protein ID Protein/Ab type Dilution Used Concentration (µg/ml) 
ES15 mouse IgM DIL3 42 
ES9 mouse IgM DIL2 54 
ESD1 human IgG DIL5 50 
HIVGI mouse IgG DIL5 50 
HIVG2 mouse IgG DIL5 50 
LA2 mouse IgM DILl 55 
LB2 mouse IgM DIL2 72 
LDM3 human IgM DIL1 6.4 
LHM169/80 human IgG DIL5 50 
LHM59119 human IgG DIL5 50 
LHM70/45 human IgG DIL5 50 
LHM76/55 human IgG DIL5 50 
LHM77/64 human IgG DIL5 50 
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The results show that concentration of the target reagents anti-mouse IgG and anti- 
mouse IgM would require adjustment to give enhanced reactions, but it is unlikely 
that a change in concentration would increase or decrease cross reactivity. This is 
analogous to results found in Haab et al. (2001). They reported that a variation in 
fluorescent target labelling/activity is a prominent source of variability in 
fluorescence measurements, and this will be further discussed at the end of this 
chapter. 
Figures 3.4a-d show the results from the separate slides from individual target 
antibodies. Although a very low level of LDM3 was spotted onto the microarray 
represented in Figure 3.4a, the target anti-human IgM still detects it and gives the 
highest level of S/N. Cross reactivity with a mouse IgM probe (ES9) is evident. 
  Cy3 Anti-hlgM 
Probe protein 
Figure 3.4a. Reactions of Cy3 anti-human IgM against spotted probe proteins. Slide type 
poly-L-lysine, slide reps 1, pins 700 In, probes Table 3.1, probe reps 2, SPM A; blocker 
PBS-milk, target/volume: Cy3 anti-hlgM/25 Nl, incubation 120 min, static, scanning 
method A. 
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In Figure 3.4b it is clear that the target anti-human IgG gives specific reactions from 
known human IgG probe antibodies. In Figure 3.4c the highest S/N values are seen 
with ES 15, ES9, LA2 and LB2, which are all mouse IgM antibodies. Figure 3.4d 
shows the reactions of the target anti-mouse IgG. Here, a very similar pattern to that 
found in Figure 3.4c is seen. The reactions with the mouse IgG antibody probes are 
lower than those of mouse IgM antibody probes. 
The presentation of the data in this alternative way demonstrated the specificity of 
the target antibodies. The graph shows that the Cy3 labelled anti-human IgG gives 
good S/N values with specific probes, and without an increase in NSB and is, 
therefore, near optimal concentration. 
  Cy3 Anti-hlgG 
Probe protein 
Figure 3.4b. Reactions of Cy3 anti-human IgG against spotted probe proteins. Slide type 
poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, probe reps 2, SPM A; blocker 
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Figure 3.4c. Reactions of FITC anti-mouse IgM against spotted probe proteins. Slide type 
poly-L-lysine, slide reps 1, pins 700 pm, probes Table 3.1, probe reps 2, SPM A; blocker 
PBS-milk, target/volume: FITC anti-mlgM/25 pl, incubation 120 min, static, scanning 
method A. 































Figure 3.4d. Reactions of FITC anti-mouse IgG against spotted probe proteins. Slide type 
poly-L-lysine, slide reps 1, pins 700 fin, probes Table 3.1, probe reps 2, SPM A; blocker 
PBS-milk, target/volume: FITC anti-mlgG/25, d, incubation 120 min, static, scanning 
method A. 
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Given the specificity of the reactions between the sets of human IgG antigens and 
antibodies, these were selected for subsequent experiments to optimise the protein 
microarray procedure. 
This experiment had demonstrated some problematic areas, which were indicated 
previously. Improvements were made to the slide processing methods and the 
analysis method developed to give meaningful results (see discussion). 
3.3 Optimisation of Protein Microarray Performance: Blocking 
Methods and Detergents 
3.3.1 Optimisation of the Microarray Blocking Procedure 
In this experiment, the protein microarray process was further optimised by 
investigating the blocking of the microarray slides. Blocking is performed to reduce 
NSB. For this purpose, the set of probe proteins detailed in Table 3.4 were selected. 
This probe set allows for far more varied interactions than those selected previously. 
The probes were printed and processed as described in the figure legends. 200 um 
pins were used in this experiment to allow many (21) replicate samples of the various 
probes. Two blockers were investigated, non-fat milk (Marvel) and BSA. 
Cy3 labelled anti-human IgG was selected as a target/detection reagent, as it was 
shown to have worked well in the previous experiment. Cy3 labelled rProtein-L was 
also used here for detection of probes. rProtein-L (recombinant) has been shown to 
bind strongly to kappa light chains on human antibodies as well as those from rat and 
mouse (actigen. com), but should not bind to bovine, sheep or goat antibodies. The 
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rProtein-L was labelled with Cy3 using the method for Fluorescent Labelling of 
Antibody/Antigen/Lectin. The target solutions were prepared in the blocking solution 
as used for each slide. 
Table 3.4 Probe proteins spotted in blocking protein microarray experiment, concentration in 
pg/ml. 
Protein ID Protein/Ab Conc. Conc. Conc. Conc. Conc. 
type DILl DIL2 DIL3 DIL4 DIL5 
mlgG mouse IgG 500 250 125 62.5 31.25 
mlgM mouse 1gM 500 250 125 62.5 31.25 
rIgG rabbit IgG 500 250 125 62.5 31.25 
sIgG sheep IgG 500 250 125 62.5 31.25 
gIgG goat IgG 500 250 125 62.5 31.25 
HS human serum 3000 1500 750 375 187.5 
BS bovine serum 3000 1500 750 375 187.5 
As this experiment aimed to evaluate the effect of blocking to improve specific 
reactions and reduce non-specific reactions, the values used to calculate noise were 
those from PBS spots. 
Microarrays processed using BSA blocking showed a high level of comet tailing. 
The scan images in Figure 3.5 show the difference in the level of comet tailing 
found in scans from BSA blocking compared to non-fat milk blocking, where no 
comet tailing was seen. The graphical results are presented in Figures 3.6a-b. Error 





Figure 3.5. Pseudo colour scan images to determine the blocking procedure for protein 
microarrays. Slide type poly-L-lysine, slide reps 1, pins 200 prn, probes Table 3.4, probe 
reps 21, Fig A, SPM A; blocker PBS-milk, Fig B, SPM B; blocker PBS-BSA, target/volume: 
Cy3 anti-hlgG/25 pl, incubation 120 min, static, scanning method A. 
Figure 3.6a demonstrates a higher binding (S/N) when using milk blocking. 
Although it also demonstrates higher cross reactivity with rabbit IgG, this method 
was selected for future processing. Only the data from human serum and rabbit IgG 
is presented as all other data gave very low S/N. The lack of results from HS DIL3 
was investigated and found to have resulted from insufficient reagent to deposit spots 
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Figure 3.6a. Comparison of BSA and Milk blocking using reactions of Cy3 anti-human IgG 
against spotted probe proteins. Slide type poly-L-lysine, slide reps 1, pins 200 pin, probes 
Table 3.4, probe reps 21, SPM A; blocker PBS-milk, SPM B; blocker PBS-BSA, 
target/volume: Cy3 anti-hlgG/25 pI, incubation 120 min, static, scanning method A. 
Figure 3.6b shows the results obtained from the milk-blocked slide to which Cy3 
rProtein-L was added as target. The results seen in the figure show low levels of 
binding, but also that higher S/N ratios are evident against human serum, which 
would be expected to bind the rProtein-L. This reagent had potential as a quality 
control reagent to determine antibody levels retained on the microarrays at various 
stages of processing but S/N values are low. This reagent may be giving low S/N 
values because of insufficient labelling as the labelling ratio was calculated as 1.45 
dye molecules per rProtein-L molecule. 
The reactions from the BSA blocked slide with target Cy3 rProtein-L gave such low 
quality data (when background values compared to signal intensity values as 
described in Chapter 2) that the data was not analysed. A colour image of the scan is 
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shown in Figure 3.6c. The entire reaction area is giving high fluorescence signals. 
The blue and green areas indicate where target came into contact with the surface. It 
was concluded that the BSA blocking and rProtein-L are incompatible for this 
purpose and the Ig in the BSA is binding the rProtein-L, contrary to the reactivity 
described by the manufacturer. 
From this experiment, the milk blocker was selected for subsequent experiments 
incorporated as Slide Processing Method A (SPM A). For this method, Tween 20 
was included as a detergent, following published methods. The next stage was to 
























































































Figure 3.6c. Scan image from Cy3 rProtein-L, BSA blocked chip. The black area at the top 
of the image shows an area of the slide not in contact with the target solution. The point of 
injection is indicated (green arrow). Slide type poly-L-lysine, slide reps 1, pins 200 fim, 
probes Table 3.4, probe reps 21, SPM B; blocker PBS-BSA, target/volume: Cy3 rProtein- 
L/25 pl, incubation 120 min, static, scanning method A. 
3.3.2 Further Optimisation of Blocking Procedure Using Detergents 
The action of detergents was described in Chapter 1 (1.4.2.4). For the purpose of 
optimisation of detergent in the blocking procedure, several different detergents were 
evaluated. The set of proteins detailed in Table 3.5 were printed as described in the 
figure legends. The slides were then processed using milk blocking as in Slide 
Processing Method A but with a variation in the detergent used. The detergents used 
were Tween 20, Tween 80, Triton-X-100 (t-octylphenoxypolyethoxyethanol) and 
CHAPS (3-[3-cholamidopropyl dimethylammonio]-1-propanesulfonate). Each was 
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used at concentrations of 0.1 and 0.5 % in solution. These replaced Tween 20 in 
Slide Processing Method A. The target solution was Cy3 anti-human IgG at 33.33 
pg/ml in the blocking solution without detergent. 
Table 3.5 Proteins spotted in protein microarray experiment to optimise detergent, 
concentration in deg/mi. 
Protein ID Protein/Ab type Conc. Conc. Conc. Conc. Conc. 
DILl DIL2 DIL3 DIL4 DIL5 
mIgG mouse IgG 500 250 125 62.5 - 
mIgM mouse IgM 500 250 125 62.5 - 
rlgG rabbit IgG 500 250 125 62.5 - 
slgG sheep IgG 500 250 125 62.5 - 
glgG goat IgG 500 250 125 62.5 - 
HS human serum 3000 1500 750 375 187.5 
BS bovine serum 3000 1500 750 375 187.5 
LDM3 human IgM 6.4 3.2 1.6 0.8 - 
ESD1 human IgG 500 250 125 62.5 - 
HIVG2 mouse IgG 500 250 125 62.5 - 
During development of this protein microarray process, the use of appropriate 
controls had become more apparent. For the previous experiment PBS spots were 
used to calculate the noise values as PBS represented the spotting buffer in which all 
probes were prepared. Further probes were included in this experiment to allow for 
more suitable biological controls. As shown in Figure 3.4b, the Cy3 anti-human IgG 
gave low S/N ratio with human IgM, mouse IgG and mouse IgM probes, but in 
Figure 3.6a is shown to cross-react with rabbit IgG. It has also been shown to cross 
react with sheep IgG (data not shown). An appropriate biological negative control is 
an antibody similar in structure and/or species to the expected positive probe, but 
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which is directed to an unrelated antigen that would not be present in the target 
solution. 
The large amount of data generated from this experiment was, therefore, analysed in 
two ways. All spots except those from human serum, human IgG (ESDI), rabbit IgG 
and sheep IgG were used to calculate the noise for the S/N ratios demonstrated in 
Figure 3.7a. For the data in Figure 3.7b, all data apart from human serum and 
human IgG (ESD1) were used to calculate S/N. 
The anti-human IgG reacted specifically with the monoclonal anti-D ESDI and the 
human serum (Figure 3.7a). Although while showing cross-reactivity with rabbit 
IgG, cross-reactivity with sheep IgG is not present. In Figure 3.7b, the data looks 
quite different and far lower S/N values are seen (error bars are not appended). This 
is because the expected negative probes have been used to calculate noise and this 
includes rabbit IgG. Therefore, the noise value is far higher and means resultant SIN 
values are far lower. 
Theoretically, a higher S/N ratio in this experiment could mean that noise had been 
reduced therefore resulting in a higher ratio, or that more specific binding had taken 
place. From this experiment it was decided that no alternative detergent gave 
improved results that justified a change from the use of Tween 20. 
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  Tween20 0.1 %  Tween20 0.5% p Tween80 0.1 %Q Tween80 0.5% 















HS DILl rIgG DILl 
Probe protein 
slgG DILl 
Figure 3.7a. Comparison of different detergents in the blocking solution using reactions of 
Cy3 anti-human IgG against spotted probe proteins, with all other probes used to calculate 
S/N values. Results are from Dilution 1 only. Slide type poly-L-lysine, slide reps 1, pins 200 
, um, probes 
Table 3.5, probe reps 8, SPM A; blocker PBS-milk, target/volume: Cy3 anti- 
hlgG/25 NI, incubation 120 min, static, scanning method A. 
  Tween20 0.1 %  Tween20 0.5 %Q Tween80 0.1 %Q Tween80 0.5 % 
  Triton-X 100 0.1 %  Triton-X 100 0.5 %  CHAPS 0.1 %Q CHAPS 0.5 % 
nI'H 
ESD1 ESD1 ESD1 ESD1 HS DILl HS DIL2 HS DIL3 HS DIL4 HS DIL5 
DILl DIL2 DIL3 DIL4 
Probe protein 
Figure 3.7b. Comparison of different detergents in the blocking solution using reactions of 
Cy3 anti-human IgG against spotted probe proteins. The figure shows the median of each 
sample S/N calculated from all other protein probes, against each detergent. Slide type poly- 
L-lysine, slide reps 1, pins 200 pm, probes Table 3.5, probe reps 8, SPM A; blocker PBS- 
milk, target/volume: Cy3 anti-hlgG/25 pI, incubation 120 min, static, scanning method A. 
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3.3.3 Improvements to Protein Microarray Procedures Following 
Blocking Optimisation 
The experiments described in sections 3.3.1 and 3.3.2 have resulted in the 
confirmation of the suitability and reproducibility of the procedure recommended by 
Haab et al. (2001). To summarise, this is the use of 3% non-fat milk blocking, using 
0.1 % Tween 20 where appropriate. 
However, several observations were made during these experiments that suggested 
improvements in the process. During the printing the humidity was set at 40 %, and 
is maintained by the microarrayer during the drying period. This can help reduce 
doughnut shaped spots. To avoid lifting off of the spots during processing, it was felt 
that a re-hydration step should be included prior to slide blocking. As mentioned 
previously, customised containers were included for the processing steps, which 
made processing easier. In addition to this the slides were centrifuged to dryness 
following blocking and before addition of target solution. This makes the addition of 
target solution more simple and the processing easier. Another area for improvement, 
noted as evident during the scanning of microarrays, was the apparent 
drying/evaporation of the target solution under the cover slip during incubation. 
Although the microarrays had been sealed in a box with an underlayer of PBS for 
humidity, this was inadequate therefore specialised Hybe Chambers (Gene 
Machines) were sourced and subsequently used. These chambers allow for improved 
sealing of the environment and therefore eliminate evaporation. It was also noted that 
the immersion of microarrays during washing must be quite rigorous to minimise 
residual unwanted solution on the slide surface. 
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All of the improvements summarised above were applied to the original method 
(Slide Processing Method A) and this is described in Chapter 2 as Slide Processing 
Method C (SPM Q. This new process was used in subsequent experiments. 
3.4 Confirmation of Optimised Protein Microarray Procedure 
Repeatability is of high importance in any assay procedure. Therefore, the following 
experiment was performed in order to repeat and confirm that the adjustments 
suggested to the process actually did improve the process developed so far. Some of 
the data would also be compared to the original process data. 
Table 3.6. Target proteins used in experiment detailed in section 3.5 and 3.6. 
Target Protein ID Concentration Used (Ng/ml) 
Cy3 Anti-Human IgG 33.33 
Cy3 Anti-Human 1gM 33.33 
FITC Anti-Mouse IgG 66.67 
FITC Anti-Mouse IgM 16.67 
Cy3 rProtein-L 10.00 
The probes described in Table 3.5 plus PBS were printed as described in the figure 
legends. The target solutions were as detailed in Table 3.6. In order to allow a 
comparison of procedures Slide Processing Method A to C, values from the PBS 
spots were used to calculate all the SIN values. 
To demonstrate that the new process (SPM C) gives the desired results and 
reproducibility, the data is presented in Figures 3.8a-e. The reactions of the probes 
with target anti-human IgG are shown in Figure 3.8a, which shows good S/N values 
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with specific probes and the previously experienced cross-reactivity with rabbit and 
sheep IgG. Figure 3.8b shows good SIN values and cross-reactivity, which is higher 
than S/N values from specific probes. This was seen before so was not introduced by 
the change in procedure. The reactions of both anti-mouse target reagents is quite 
similar to before (Figure 3.8c and Figure 3.8d), but with some increased S/N values. 
The anti-mouse reagents require optimisation in terms of concentration before they 
will give optimal reactions. 
Figure 3.8e shows the results obtained when Cy3 rProtein-L was added as target. 
This reagent had been used before and although it gave increased reactions with 
human serum, the S/N values were very low. Improved reactions are seen this in this 
experiment, with specific interactions demonstrated with monoclonal human IgG 
(ESD1), human serum and mouse IgG and the S/N values are also increased. With 
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To compare the original protein microarray processing procedure (SPM A) to the 
optimised process (SPM C), the data from two slides was compared. Those selected 
for comparison were one from the original experiment (section 3.2) and one from 
this experiment where the target solution was Cy3 anti-human IgG at 33 pg/ml. 
Probe proteins which were spotted onto both arrays at the same concentration were 
selected for further analysis. This data was processed using the Normalisation of 
































































Figure 3.9. Comparison of original protein microarray processing procedure to the optimised 
procedure. Fluorescence values are used here, not a S/N ratio (normalised between slides 
and medians calculated), and error bars appended. 
The improvements to the slide processing methods can be seen in several ways. 
Firstly, the images appeared visibly clearer (Figure 3.10 and Figure 3.11), with 
lower background, less dust or particles on the surface, fewer smears, doughnuts, 
171 
black holes and comet tailing. 
Secondly, once the data was analysed, increased fluorescence values were obtained. 
The error bars in Figure 3.9 demonstrate the variability between replicate spots on 
the same slide. When the new process was used the variability is also reduced, 
showing that more consistency is achieved. A suitable data processing and analysis 
method has also been established using recommended statistical methods and using 
the knowledge that suitable controls with characterised reactivity must be included. 
Much testing was performed to demonstrate the process repeatability. 
Reproducibility is critical to any assay, and the investigation of this is of high 
importance. In conclusion, the adjustments made to the processing methods led to 
overall improvements in the sensitivity of the microarray, and the quality and 














Figure 3.10. Pseudo colour images (blue to white scale) from slides scanned following 
optimisation. Slide type poly-L-lysine, slide reps 1, pins 200 fmm, probes Table 3.5, probe 
reps 8, SPM C; blocker PBS-milk, target/volume: A=Cy3 anti-hlgM, B= Cy3 anti-hlgG/25 NI, 





Figure 3.11. Pseudo colour images (blue to white scale) from slides scanned following 
optimisation. Slide type poly-L-lysine, slide reps 1, pins 200 fan, probes Table 3.5, probe 
reps 8, SPM C; blocker PBS-milk, target/volume: A=FITC anti-mlgG B= FITC anti-mlgM/25 
i4, incubation 120 min, static, scanning method A. 
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3.5 Comparison of Different Slide Surface Chemistries 
Poly-L-lysine coated slides were used in this work to establish protein microarray 
processing methods and capabilities. These slides were relatively cheap and easy to 
prepare and gave a platform, from which much useful data was obtained. Other slide 
types were available with varying surface chemistries, but when purchased 
commercially were prohibitively expensive. 
In an attempt to further optimise the protein microarray procedure, a range of slides 
with varying surface chemistries were assessed using the standardised processing 
methods (with one exception in which the manufacturers recommended procedures 
were supplied with specific reagents for use with the slides). The slide surfaces 
investigated are detailed in Table 3.7. Proteins may be affected by their method of 
attachment to a solid support, and may give higher or lower binding to ligand 
depending on the conditions. 
The probes described in Table 3.5 were printed onto poly-L-lysine, amino silane, 
polyacrylamide and nitrocellulose slides. Additional spots of the spotting buffer, 
either PBS or 1X Array Buffer, (spotting buffers as described in Chapter 2) were 
spotted onto these microarrays for use in data analysis. 
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Table 3.7 Slide substrates used in experiment in 3.5 and details of binding methods. 
Slide Surface Description Binding action 
Coating 
Poly-L-lysine High MW compound with free Positive charge at neutral pH. 
amino groups Binds negatively charged 
proteins through electrostatic 
forces 
Polyacrylamide Cross-linked matrix that holds Traps molecules in matrix 
molecules in 3-1) 
Amino Silane Two reactive groups bound to Binds negatively charged 
silicon atom in the molecule. proteins through electrostatic 
Hydroxy group at one end binds forces 
to glass, amino group at other 
end 
Nitrocellulose Nitrocellulose polymer. Positive charge binds negatively 
charged proteins by electrostatic 
forces 
Streptavidin Amine groups of proteins are Biotin has high affinity for the 
biotinylated using biotinyl-N- four tryptophan residues on 
hydroxysuccinimide ester each streptavidin unit 
Table 3.8. Biotinylated antibodies spotted on streptavidin coated slide, and concentration in 
µg/mI. 
Antibody Antibody type Conc. Conc. Conc. Conc. 
ID DIL1 DIL2 DIL3 DIL4 
LA2 mouse IgM 55 37 18 14 
ES9 mouse IgM 81 54 27 20 
L62 mouse IgM 108 72 36 27 
ES15 mouse IgM 127 85 42 32 
LDM3 human IgM 6.4 3.2 1.6 0.8 
ESDI human IgG 300 200 100 75 
HIVG2 mouse IgG 300 200 100 75 
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Streptavidin coated slides were printed and investigated independently, due to probe 
concentration differences to the non-biotinylated probes. The probes were 
biotinylated antibodies described in Table 3.8, which should bind to the streptavidin 
on the slide surface. 
Once processed, the values from the spotting buffers were used to calculate noise and 
the results are presented in Figures 3.12a-c. The data in Figure 3.12a showed that 
specific interactions between probe proteins and Cy3 anti-human IgG consistently 
gave higher S/N values on the polyacrylamide surface compared to all other surfaces. 
The good performance of the polyacrylamide surface may be due to several reasons, 
which are discussed at the end of the chapter. 
The data shown in Figure 3.12b shows the reactions of expected negative probes, 
showing a level of cross-reactivity with rabbit IgG that has been evident before. 
Although levels of positive S/N are higher on polyacrylamide, levels of NSB are not 
increased. The values of an expected positive probe (ESD1 DIL1) are divided by the 
negative probe values to give a ratio on the different slide surfaces. 
In Table 3.9 the positive/negative probe values are shown, the higher the value then 
the lower the NSB for each probe on each surface. This data shows that the 










Figure 3.12a. Reactions of Cy3 anti-human IgG against human IgG containing probe 
proteins on different surfaces. Slide type various, slide reps 1, pins 200 pin, probes Table 
3.5, probe reps 6, SPM A; blocker PBS-milk, target/volume: Cy3 anti-hlgG/25 pl, incubation 
120 min, static, scanning method A. 















& Ol M 
91 
BSDILI gIgG LDM3 LHIVG2 rlgG rIgG rlgG rIgG sIgG sIgG sIgG sIgG 
DIL1 DIL1 DIL1 DIL1 DIL2 DIL3 DIL4 DIL1 DIL2 DIL3 DIL4 
Robe protein 
Figure 3.12b. Reactions of Cy3 anti-human IgG against various probe proteins on different 
surfaces, showing cross-reactivity levels. Slide type various, slide reps 1, pins 200 jim, 
probes Table 3.5, probe reps 6, SPM A; blocker PBS-milk, target/volume: Cy3 anti-hlgG/25 
pl, incubation 120 min, static, scanning method A. 
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Table 3.9. Results of expected positive probe S/N value, from ESD1 DIL1, divided by 
expected negative probe S/N values. A higher value means lower NSB, the highest value for 
each probe is indicated in grey. 
Slide surface BS DIL1 gIgG LDM3 LHIVG2 rIgG slgG 
DIL1 DIL1 DIL1 DIL2 DIL1 
Poly-L-lysine 10.97 54.16 90.39 3.90 0.74 10.59 
Amino silane 23.04 75.10 105.59 10.57 0.38 8.49 
Polyacrylamide 43.30 45.32 277.64 115.76 1.54 1957.18 
Nitrocellulose 1.71 12.62 18.76 3.24 0.52 1.42 
The S/N values on the streptavidin slides, seen in Figure 3.12c, using biotinylatcd 
probes are substantially lower than those on the other surfaces evaluated. This may 
be due to either low biotinylation of the probes or a poor coating of streptavidin on 
the slides. As the biotinylation of probes is an extra step in the process, shown here 
not to improve results substantially, the streptavidin slides were not investigated 
further. 
Following this, the next stage of the project was to determine if blood typing could 
be performed on this established microarray format. For this purpose, the poly-l, - 
lysine slides were selected for further studies. The polyacrylamidc slides were also 





























































































































3.6 Chapter Discussion and Conclusions 
3.6.1 Chapter Discussion 
The first aim of this chapter was to determine if the protein microarray printing and 
processing of procedures described by MacBeath and Schreiber (2000) and Haab et 
al. (2001) could be used as a starting point for the preparation of protein microarrays 
and be reproduced in our setting. From the results it was concluded that proteins 
could be printed onto a microarray format using the available equipment, and that the 
resultant microarrays can be processed and probed with target proteins to determine 
probe presence. As the primary aim of the experiment, this was a successful 
outcome. However, to build on the success of the initial experiments, the results 
pointed towards some areas for improvement of the initial procedure. The process 
was subsequently optimised prior to the use of the microarrays for the intended 
purpose of blood typing and antibody screening. 
Blocking procedures and the use of detergents were investigated to determine 
optimal processing methods, using classical antibody-antigen sets of proteins and 
ligands. The resultant optimal procedure, confirmed the findings of Haab et al. 
(2001). However, it was necessary to make small adjustments to different stages of 
the process to give improved quality of results and reproducibility. Improvements 
included the use of glass containers and magnetic stirrers with customised racks for 
blocking and washing of the slides. 
Ideally, microarray spots of equal shape and size with immobilised material 
homogenously distributed throughout the spot are required. Conditions during 
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spotting may affect spot quality, producing imperfect spots including those described 
as doughnuts or small spots. Conditions during processing can influence the data 
quality and result in comet tailing, drying out or spot removal. 
Humidity during printing was introduced to reduce doughnut shaped spots. A re- 
hydration step prior to blocking was included to reduce the complete removal of 
probe spots during incubation with targets. Comet tailing was minimised with 
improvements to the processing and can be affected by blocking. To avoid drying of 
fluorescent target onto the slides, the incubation was performed in a purpose built 
chamber with an underlayer to reduce loss of moisture. All process improvements 
were included in the optimised procedure, referred to as Slide Processing Method C. 
When the improved process was compared to the original process, several 
improvements were seen. Even small improvements may mean the difference 
between detection of weak positive reactions and negatives. 
The use of target anti-human IgG was selected to perform most optimisation 
experiments, mainly due to the high level of specificity and reactivity shown with 
human serum and human IgG antibodies. Other detection/target antibodies used 
either gave lower S/N or showed greater cross-reactivity. The cross-reactivity found 
using certain reagents was to be expected as the antibodies were from polyclonal 
source and had not been adsorbed to remove unwanted antibodies. Cross reactivity 
may also be due to many of the antibody cell lines being human-mouse 
heterohybridomas. The experiments using various anti-species antibodies reinforced 
the importance of selecting the best reagents for the purpose, to achieve high 
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specificity and signal. If these reagents were to be used further, they would require 
anti-species adsorption. This would involve testing titre pre and post adsorption and 
tests by saline and papain spin tube with group A, B and 0 cells, as animal sera may 
also contain anti-A or anti-B. The results obtained using anti-species reagents 
showed that concentration of the anti-mouse IgG and anti-mouse IgM would require 
adjustment to give enhanced reactions, but it is unlikely that a change in 
concentration would increase or decrease cross reactivity; efforts can only be made 
to reduce NSB. This is similar to results found in Haab et al. (2001). They reported 
that a variation in fluorescent target labelling is a prominent source of variability in 
fluorescence measurements. As well as variability in the concentration of the target 
antibodies, there may also be variability in the number of fluorescent molecules 
attached to each antibody. If required, variability could be rectified for subsequent 
analysis by preparing titrations of target antibodies against probes to establish equal 
levels of antibody and fluorescence, or the labelling procedure could be modified to 
allow greater comparison between slides. This was not required for this work, as only 
a demonstration of presence of the probes was required. In some results (specifically 
in Figures 3.3a, e, f and 1) the unexpected reactions may be contributed to the 
`hook' effect (Fernando and Wilson, 1992). The hook effect occurs mostly in one 
step sandwich immunoassays, and is characterised as a decrease in assay response 
occurring at high analyte concentrations. This is one possible explanation for lower 
values at highest concentrations. 
During this stage of the project a procedure to analyse the data was developed 
(detailed in Chapter 2). To summarise the data processing method, it involves the 
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initial determination of data quality before further processing, then the subtraction of 
background for each spot and analysis to determine the `best' PMT scan. This is the 
scan that has used high enough excitation to allow the detection of low or weak 
signal, yet not too high to give saturated spots that in turn give unrepresentative 
values. Following this the selected negative control spots are used to calculate a 
mean plus two standard deviations, equal to the background noise, and this is used to 
calculate a signal to noise (S/N) ratio for each spot. Following this, a median of 
replicate spots was calculated. Error bars were included where appropriate and 
indicate the variability obtained from replicate probe spots on the array. The method 
of analysis was retrospectively applied to all data represented in this thesis. Initially, 
S/N ratio was performed using the actual mean of the negative control spots. 
Considerations in data analysis were reviewed with the assistance and direction of a 
statistician, Thorsten Forster of the SCGTI, who recommended the use of noise (or 
background) as the mean plus two standard deviations of the negative spots. This is a 
recognised statistical method used to provide signal ratios. 
An appropriate biological negative control is an antibody similar in structure and/or 
species to the expected positive probe, but which is directed to an unrelated or simply 
different antigen not present in the target solution. However, it is important that the 
selected control probes do not demonstrate a high level of non-specific binding or 
cross-reactivity. For example, if the control probe demonstrates a high level of non- 
specific binding then the test probes are likely to give reduced S/N values. This was 
demonstrated in section 3.3.2 (Further Optimisation of Blocking Procedure Using 
Detergents) where the data was Processed in two ways, using different probes as 
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negative controls to calculate noise. As some of the negative control probes actually 
showed cross-reactivity, it indicated that negative probes should be observed for 
expected reactions before using as background noise and that controls must be 
selected carefully. The reactivity of all probes and target materials should be well 
characterised or results may be lost or unrepresentative. 
When a comparison of four different slide surfaces was performed using the classical 
antibody-antigen type reaction, the polyacrylamide slides were superior to all other 
types (refer to Table 3.9). The matrix of the polyacrylamide gel coating gives a 3-D 
support for proteins, and due to its depth may allow for an increased capture of probe 
antibody, leading to the higher level of subsequent binding of the target protein. The 
nature of the matrix may mean that less probe and target are washed off the slide in 
the various stages of the process. The nitrocellulose surface was least suited to the 
interactions used for evaluation. While both poly-L-lysine and amino silane slides 
showed similar reactivity, the poly-L-lysine slides provided a satisfactory and cost 
efficient matrix for the antibody-antigen interactions, and can be prepared in-house. 
Therefore, polyacrylamide and poly-L-lysine slides were selected for further 
evaluation in Chapter 4, which uses the work in this chapter as a basis to develop a 
blood typing microarray platform. 
3.6.2 Chapter Conclusions 
The aims of this stage of the project have been met as follows: 
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" To determine the ability to fabricate protein microarrays using available 
equipment and using publications detailing similar type studies, probe the 
microarrays with anti-species detection/target solutions to determine if probes 
are retained on the slides. 
Protein microarrays have been printed and processed and subsequent experiments 
have shown that protein probe-ligand reactions can be reproducibly detected on 
the slides. 
" To optimise protein microarray procedures such as blocking, washing, 
incubation conditions, detection methods, data extraction and data processing 
methods, to enable the study ofprobe-ligand interactions. 
Processing procedures have been examined and optimised resulting in higher S/N 
ratios for probe - ligand interactions and less variance in replicates. Two types of 
fluorophores have been used with success, and data analysis methods have been 
adapted to suitably analyse each data set. 
" To evaluate different slide surface chemistries and select options for the next 
stage of the project, the development of blood typing microarrays. 
Various surfaces have been evaluated and two selected for further study in the 
investigation of probe-ligand interactions for the purpose of multi-parameter 
blood typing. 
" Amalgamate all findings and process optimisations to provide a basis for a multi- 
parameter blood typing microarrayplatform. 
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Protein microarray procedures have been optimised using sets of proteins and 
ligands, providing a solid basis for blood typing microarrays. 
The conclusions drawn from the work in this chapter will be applied in the next 





MULTI-PARAMETER BLOOD TYPING 
IN A MICROARRAY FORMAT 
4. NON-AGGLUTINATION MULTI-PARAMETER BLOOD TYPING IN A 
MICROARRAY FORMAT 
4.1 Introduction and Chapter Aims 
Chapter 3 gave the basis of a solid-phase microarray platform for the study of probe- 
ligand interactions and provided important information on aspects of fabrication, 
processing and detection of probe-ligand interactions using a microarray format. The 
next step was to determine whether the probes retained functionality. This chapter 
addresses this, and extends the work to develop a `dual' solid-phase system for the 
purpose of blood typing, where the immobilised probes are blood typing antibodies 
and the targets are blood group antigens carried on the surface of a larger particle, in 
this case erythrocytes. As the antigens are carried on the erythrocyte, they too can be 
considered in `solid-phase' as they are effectively immobilised to a solid support. 
Solid-phase blood typing interactions can be detected by methods other than 
haemagglutination. As the probes are not in liquid-phase, haemagglutination does not 
arise, and the interaction must be detected by an alternative method. For instance, if 
an antibody is immobilised and binds an erythrocyte, detection of the interaction can 
be through direct or indirect labelling as illustrated in Figure 4.1. This chapter looks 
at several techniques for detection of the antibody-erythrocyte interaction. If the 
membrane of the erythrocyte is labelled, then the detection is considered direct. If a 
label were attached via another molecule (e. g. an antibody or lectin) then this would 
be considered primary indirect labelling. If a labelled reagent is added once the cells 
are already bound to the array, then for the purpose of this thesis is considered 
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The selection of Ab probes for the purpose of routine blood typing is of critical 
importance. Legislation in blood typing states reagents must be well characterised 
and assessed in performance evaluation field trials and in rigourous stability testing. 
For this reason most antibody probes used in this work were obtained from Alba 
Bioscience, a division of the Scottish National Blood Transfusion Service (SNBTS). 
These antibodies were developed and manufactured by the SNBTS, have been 
evaluated in international monoclonal antibody workshops and several are used 
routinely throughout the world. 
The aims of this stage of the project were: 
" Evaluate whether blood typing can be performed in a microarray format, the 
basis of which was developed in Chapter 3, which will involve the use of 
erythrocytes of different blood groups, initially on mandatory RhD and ABO. 
" Establish detection methods for direct and indirect detection of erythrocytes 
bound to the blood typing microarray. 
" Optimise the blood typing microarray procedure to enhance reactions and 
improve the performance of the test platform. 
" Once ABO blood typing is achieved and optimised, extend the probe panel to 
include Rhesus c, E, and Kell antibodies to blood group antigens. 
" Determine the ability of microarray technology to perform detection of direct 
antiglobulin positive samples. 
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Details of all methods and reagents used can be found in Chapter 2. The information 
that defines the protein microarray printing, processing characteristics and describes 
target solutions for each experiment, will be detailed in the figure legends. However, 
where the target is not fluorescently labeled and a detection reagent is added, both 
target and detection solutions will be described. 
4.2 Blood Typing Interactions by Microarray 
This section looks at the interactions of ABO blood group antibodies with 
erythrocytes and whether a microarray format could accommodate a blood typing 
interaction. The optimal method for detection of bound erythrocytes had to be 
established. Throughout the early blood typing microarray work, many methods were 
investigated and are detailed in the following sections. 
4.2.1 Indirect Erythrocyte Detection Using Fluorescently Labelled 
ConA 
4.2.1.1 RhD Blood Grouping Using Indirect Detection 
For the detection of erythrocytes bound to a microarray, indirect labelling methods 
were first investigated. An ideal detection molecule should bind to all erythrocytes 
irrespective of blood group. As described in Chapter 1 (1.3.2.5.3), Concanavalin A 
(ConA) is a lectin that binds to glycoproteins through mannose and glucose residues, 
in the presence of calcium and manganese ions. Therefore, ConA was considered for 
detection of bound. erythrocytes in blood grouping microarrays in this thesis. For the 
purpose of erythrocyte detection, ConA could be either attached to the erythrocyte 
surface prior to addition to the array (indirect primary labelling), or added as a 
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secondary reagent (indirect secondary labelling) to attach to erythrocytes already 
bound to the microarray. 
ConA was first evaluated to confirm that it would bind to erythrocytes. 1 mg/ml 
ConA solution was titrated against erythrocytes of various blood groups using the 
IgM Antibody Haemagglutination Assay, with cells suspended in PBS-Ca/Mn. The 
titration end point averaged 256, equivalent to a ConA concentration of 3.9 pg/ml, 
and on the basis of calculations have between 100-200K molecules per erythrocyte 
(see calculations in Appendix 2). This testing demonstrated that ConA binds to 
erythrocytes, and also demonstrated the limits for occurrence of haemagglutination. 
Both FITC and Cy3 labelled ConA were used for detection. Fluorescence activated 
cell sorter (FACS) analysis was performed using the Analysis of Fluorescently 
Labelled Erythrocytes method. The results are presented in Appendix 2, Table A2. 
The results showed fluorescence is detected on erythrocytes only when the calculated 
level of ConA is above 100K molecules per erythrocyte when using FITC labelling, 
and at one million per cell if using the Cy3 labelled ConA. It may be that there are 
fewer Cy3 molecules per ConA incorporated during the labelling process and it was 
decided to only use the FITC ConA. When tested in a haemagglutination assays, 
100K ConA per erythrocyte was also the level at which visible haemagglutination 
ceases. A higher level of ConA may not be ideal for detection as clumps of 
agglutinates could form and obscure the array. 
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Many blood grouping microarrays were attempted at this point, but when scanned no 
fluorescence was evident and no erythrocytes were attached to any of the arrays 
when examined microscopically. It may be that the ConA bound to the erythrocyte 
masks the cells and consequently makes the blood group antigens inaccessible to the 
antibody probes on the microarray. To test this theory, a suspension of the ConA 
labelled cells (calculated at 100 molecules per cell, see Appendix 2) was tested 
against the antibody probes that had been used on the microarray, in liquid phase 
haemagglutination assay, as described in Chapter 2. There was no agglutination 
present, and this confirmed that the interaction of the cells with antibody is inhibited 
by the presence of ConA. 
To further determine if indirect primary labelling could be used, and to test the above 
theory, a blood typing microarray experiment using indirect primary and indirect 
secondary labelling was performed using ConA and anti-Rh29. Rh29 is present on all 
except Rh,,,, It phenotype erythrocytes (reviewed in Daniels, 2002). Several blood 
group antigen specific antibody probes and ConA and PBS were used. The 
erythrocytes used were group 0 R1r (CcDee). 
For the indirect primary labelling, cells were sensitised with FITC ConA (3.9 pg/ml 
in PBS-Mn/Ca) or Cy3 Anti-Rh29 (at 60 ug/ml in PBS) prior to addition to the 
microarray. For the indirect secondary labelling, erythrocytes were added to the 
microarray followed by the addition of either FITC ConA or Cy3 anti-Rh29, similar 
to a typical sandwich type assay. 
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The results of this work gave no clearly specific reactions or meaningful results. It 
was concluded that no erythrocytes were binding to the probe antibodies, and this 
was confirmed by microscopic examination. This experiment used cells of Rhesus 
phenotype Rlr, which is known to have a relatively weak expression of the D antigen 
at between 9,900-14,600 antigen sites per cell (Rochna and Hughes-Jones, 1965; 
Hughes-Jones et al, 1971). It was decided to test cells with a higher antigen density 
per cell. 
4.2.1.2 ABO Blood Grouping Using Indirect Detection 
In 4.2.1.1 two monoclonal antibodies against the blood group RhD antigen (one IgG 
and one IgM) failed to bind RhD positive erythrocytes. Therefore, erythrocytes 
expressing blood group B were selected. IgM mouse monoclonal antibody cell line 
LB2 is directed against blood group B antigen, and gives strong agglutination when 
tested in liquid phase haemagglutination assays. This antibody was spotted along 
with other probes as described in Table 4.1. The two target solutions were FITC 
ConA and Cy3 Anti-Rh29. 
This experiment gave no meaningful results from either the control slides or those to 
which erythrocytes and target solution were added. Both the probe antibodies and the 
detection molecules bind erythrocytes in liquid phase assays (data not shown). 
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Table 4.1. Probes spotted for experiment in 4.2.1.2, and concentration in ug/ml. 
Probe/ Protein/ Conc. Conc. Conc. Conc. 
Antibody ID Ab type DIL1 DIL2 DIL3 DIL4 
Anti-A (LA2) mouse IgM 55 37 18 14 
Anti-A (ES9) mouse IgM 81 54 27 20 
Anti-B (LB2) mouse IgM 108 72 36 27 
Anti-A, (B) ES15 mouse IgM 127 85 42 32 
Anti-D (LDM3) human IgM 34.8 17.4 8.7 4.35 
Anti- D (ESD1) human IgG 300 200 100 75 
Con A lectin 1000 500 250 125 
PBS neg. control n/a n/a n/a n/a 
4.2.1.3 ABO Typing Microplate Assay 
In order to assess the solid-phase suitability of the available ABO blood typing 
antibody probes, it was decided to use an ELISA type format. A polystyrene 
microplate has a highly hydrophobic surface and will therefore bind hydrophobic 
molecules, such as antibodies. Polystyrene microplates were used to immobilise 
various blood group antibodies using the Blood Typing ELISA method. Each probe 
(Table 4.1, `Dil 1' only) was immobilised in triplicate. Group B cells were added 
and incubated in appropriate wells, followed by FITC ConA in PBS-Mn/Ca. 
Table 4.2. Identity of plates used in experiment detailed in 4.2.1.3, with description of cells 
added and labelling method. 
Target description Plate identity 
Group A cells prelabelled with FITC ConA (indirect primary labelling) Plate 1 
Group B cells prelabelled with FITC ConA (indirect primary labelling) Plate 2 
Group A cells added, followed by FITC ConA (indirect secondary labelling) Plate 3 
Group B cells added, followed by FITC ConA (indirect secondary labelling) Plate 4 
PBS only used followed by FITC ConA (to determine NSB) Plate 5 
FITC anti-mouse IgM added (to determine if probes are present) Plate 6 
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No specific binding of erythrocytes was apparent by either fluorescence or 
microscopic examination. One possible reason for negative results was that antibody 
probes were not immobilised on the microplate. Therefore, the following experiment 
was performed to investigate whether antibodies were attached to the plate using this 
method. The same probe antibodies as before were used (Table 4.1), but the target 
solutions were as described in Table 4.2, which also details the plate identities for 
analysis purposes. 
In plates 1 and 2, clumps of cells could be seen macroscopically. Plates 3 and 4 were 
examined prior to the addition of the secondary labelling solution. In plate 3, to 
which group A cells had been added, wells containing Anti-A LA2, Anti-A ES9 and 
Anti-A, (B) ES 15 contained bound erythrocytes when examined macroscopically. In 
plate 4 containing group B cells, wells containing Anti-B (LB2) and Anti-A, (B) also 
contained bound cells. When plates 3&4 were re-examined after incubation with 
FITC ConA, no cells were evident even microscopically. When examined in a 
fluorescence reader, the plates gave no distinct readings for wells in plates 1 to 5. In 
plate 6, where FITC anti-mouse IgM was added, low-level reactions were found 
(data not shown). As specific binding of erythrocytes to the plate was seen, it was 
concluded that antibody was being immobilised to the microplates. 
In summary, this experiment established; that antibody had been coated onto the 
microplates, erythrocytes can bind to antibodies immobilised to a solid support, and 
that indirect secondary labelling somehow interferes with binding to antibody. Due 
to problems with labeling methods, another suitable method of detection was critical 
to the development of a blood typing microarray. 
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4.3 Direct Detection Using FITC Labelled Erythrocytes 
4.3.1 Evaluation of Directly FITC Labelled Erythrocytes 
A method to directly FITC label erythrocyte membranes, developed by Dr. D. 
Pepper, was adopted. Several methods were used to assess the FITC labelling of the 
erythrocytes. Cells were analysed by FACS analysis to determine the labelling 
efficiency. The results detailed in Table 4.3 show that, regardless of blood group, the 
FITC labelling is over 99 % efficient. 
Table 4.3. FACS analysis of directly FITC labelled erythrocytes. 
Label & quantity % of total labelled 
Unlabelled group A cells 0.02 
FITC labelled group A cells 99.92 
FITC labelled group B cells 99.95 
FITC labelled group 0 cells 99.92 
The cells described in the above table were also smeared onto glass slides, dried and 
then scanned. High levels of fluorescence were seen from labelled cells, and a low 
level of autofluorescence was evident with unlabelled cells. 
As the previous experiment had shown that erythrocytes had bound specifically in a 
blood typing microplate assay, a microplate blood typing assay was performed using 
FITC labelled erythrocytes. This would determine if the labelled cells could bind to 
immobilised antibody and if the FITC labelling method could be used for detection. 
While erythrocyte binding was visible, no fluorescent signals were found. It was 
concluded that the plate reader was not optimal for FITC detection in this format. 
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The microplate assay also demonstrated that, unlike the FITC ConA, direct FITC 
labelling does not block binding of cells to immobilised antibody, as cells could be 
seen bound to the plate both macro- and microscopically. It was decided to use the 
direct FITC labelling of erythrocytes in a blood typing microarray, as the equipment 
available was specifically designed to detect and read fluorescent signals from 
microarray slides. 
4.3.2 Blood Typing Microarray Using Directly FITC Labelled 
Erythrocytes 
Prior to this stage, blood typing microarrays had been unsuccessful. As directly 
labelled erythrocytes had bound to the blood typing microplate, it was decided to use 
the cells in a blood typing microarray. Due to a lack of erythrocyte binding in 
previous microarray experiments, it was felt that allowing the cells to be mixed over 
the microarray surface in solution might increase the opportunity for interaction and 
binding. 
Table 4.4. Probes spotted for blood typing microarray using different reaction volumes, 
concentration in ig/ml. 
Protein/ Protein Conc. Conc. Conc. Conc. 
Antibody ID /Ab type DIL1 DIL2 DIL3 DIL4 
Anti-A (LA2) mouse IgM 55 37 18 14 
Anti-A (ES9) mouse IgM 81 54 27 20 
Anti-B (LB2) mouse IgM 108 72 36 27 
Anti-A, (B) ES15 mouse IgM 127 85 42 32 
Anti-D (LDM3) human IgM 34.8 17.4 8.7 4.35 
Anti-D (ESDI) human IgG 300 200 100 75 
In all previous microarray experiments detailed in this thesis, a 25 pl volume of 
target solution has been used. This was added under cover slip on which the edges 
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are `lifted' (i. e. heightened) allow a volume to be pulled under. These are called 
Lifter SlipsTM (Erie Scientific, U. S. A. ) and they allow limited mixing of the solution 
on the solid surface. The use of a larger target solution volume may increase both the 
movement and allow greater mixing, and therefore more efficient binding. For this 
purpose Hybridisation Chambers from Schleicher & Schuell (Germany) were used 
which can hold a 500 pl volume. To allow mixing in this experiment, a 450 ul 
volume was used, and the slides were rotated throughout the incubation period. The 
use of both reaction volumes was compared to determine if a reaction between cells 
and specific antibody is facilitated by this method. Antibody probes printed for this 
experiment are detailed in Table 4.4. 
The target erythrocyte solutions were FITC labelled group Al, B and 0 erythrocytes, 
and unlabelled group Al was also used as a control, and all were RhD negative. The 
values from LDM3 and ESDI spots (anti-D antibodies) were used to calculate noise 
for the S/N ratio. The results are presented in Figures 4.2a-c. 
Group Al and group B cells have bound specifically to the microarrays when using 
both the 25 , ul and 450 p1 volumes. However, Figures 4.2a and 4.2b clearly 
demonstrate that the larger volume and mixing substantially increase the S/N values 
both from group Al and group B cells, over that obtained using the 25 µl volume. 
Figure 4.2a also demonstrates the level of autofluorescence present when unlabelled 
cells are used, and is presented against the S/N values achieved using the FITC 
labelling. Here, specific reactions are also increased when using a larger volume and 
mixing. Figure 4.2c demonstrates the reactions using two group 0 labelled cells 
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(volume 450 u1) where no binding is expected, and consequently reactions are low. 
The results demonstrate the first successful blood typing microarray performed in 
this work, and it was apparent that blood typing could be successfully performed 
using microarrays. This was a defining moment, proving the principle and potential 
for blood typing microarrays. 
The larger reaction volume, along with mixing, had allowed increased Ab-Ag 
interactions and subsequently increased the S/N values through enhanced binding to 
the array. 
Although the smaller 25 µl volume had also allowed specific interaction to take 
place, the Hybridisation Chambers were used in subsequent experiments where 
appropriate (Slide Processing Method D) as these provided better results. 
As the data shows, the scan results gave detectable fluorescence values, which could 
be used to give S/N ratios demonstrating specific blood typing reactions. As the spot 
sizes were one mm in diameter, the binding of the cells could be checked visually. 
When examined microscopically differential cell binding to various spots could be 
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In Figure 4.3, A shows a spot where the capture of erythrocytes is almost saturated, 
the antibody is spotted neat. By calculation of area, it is estimated that a one mm spot 
(area of 0.785 mm2) could theoretically bind 15,700 cells (if approximate area of cell 
is 5x 10"5 mm2, and all lay `flat' on the surface). Figure 4.3B shows a spot where the 
antibody was diluted 1 in 2 and subsequently fewer cells are bound. This figure has a 
highlighted area of approximately 1/16th of the whole spot, in which it is estimated 
are 250 erythrocytes bound. This would equate to a total of 4,000 cells bound to the 
one mm spot. Figure 4.3C shows a more dilute antibody spot and Figure 4.3D a1 in 
4 antibody dilution where very few cells are bound. Figure 4.3E shows a pseudo 
colour image from a scan representing the scan image from the photographed spots 
(dilution same as each photograph above the spots). 
4.3.3 Optimisation of Erythrocyte Concentration 
In 4.3.2, a2% haematocrit suspension (estimated to contain 2x 105 cells per pi) of 
erythrocytes was used, adopted from a concentration used in routine blood typing 
assays. This experiment was performed to determine the optimal concentration of 
erythrocytes for the further development of the microarray method detailed in Table 
4.5. Group B RhD negative cell suspensions were prepared in blocking buffer at the 
different haematocrits. 
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Table 4.5. Haematocrit and estimated number of cells present in reaction volume of 450 pl. 
Erythrocyte Number of cells in 450 µl volume 
haematocrit (%) (estimated) 




10.0 4.50 x 108 
The results from this experiment are presented in Figure 4.4a and Figure 4.4b. 
When a suspension of erythrocytes containing 0.5 or 1.0 % cells was used, the SIN 
was greatly increased, without an increase in NSB, demonstrated by minimal 
reactions of the cells with Anti-A and Anti-A(B) on the array. Lower concentrations 
of erythrocytes increases the SIN value by up to 900 % on reactions compared with a 
2% suspension (in Figure 4.4a). As there was such a variance between 1.0 and 2.0 
% the experiment was repeated. Again, group B erythrocytes were used, but from a 
different individual. As demonstrated in Figure 4.4b, a1% suspension again gives 
the highest level of binding, where 1% S/N is 130 and 2% is 102. The haematocrit 
value of 1% had repeatedly given the highest S/N values and was, therefore, selected 
for all subsequent experiments. 
4.3.4 Comparison of Poly-L-lysine and Polyacrylamide Slides For Use 
in Blood Typing Microarrays 
It has been demonstrated in Chapter 3 that both poly-L-lysine and polyacrylamide 
slides gave good results in model microarray antibody-antigen experiments. This 
looked at the interaction of various probes and ligands, and the level of interaction on 
the various surfaces, by using anti-species antibodies. Polyacrylamide slides 
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demonstrated a superior SIN ratio to others tested. The polyacrylamide is a gel 
matrix that supplies a three dimensional scaffold to help maintain structural integrity, 
holding the large antibody molecules in their quaternary structure and consequently 
is likely to retain proteins after washing and blocking procedures. In contrast, poly- 
L-lysine slides bind proteins by electrostatic forces on a two-dimensional surface but 
were also shown to give suitable results 
Here, the two slide surfaces were evaluated for their use in blood typing, antibody- 
cell microarrays. It was expected that the cells would be too large to penetrate the 
polyacrylamide matrix to interact with probe antibodies, but it was important to 
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Antibodies (described in Table 4.4) were printed onto poly-L-lysine and 
polyacrylamide slides (Hydrogel slides, Packard BioScience). FITC labelled 
erythrocytes were used, and also Cy3 labelled erythrocytes, which were prepared by 
Dr. D. Pepper. Labelled erythrocytes were prepared from the same sample of group 
Al cells, and used at the same concentration (1 %), thus allowing a comparison of the 
two labelling methods. 
Figure 4.5a shows results from the use of the FITC labelled cells, and Figure 4.5b 
from Cy3 labelled cells. It is evident that when using both FITC and Cy3 labelled 
cells, S/N values are consistently higher on the poly-L-lysine, with the exception of 
the highest concentration of antibody when using Cy3 labelled cells. The poly-L- 
lysine surface gives a greater level of binding than the polyacrylamide matrix. 
The use of Cy3 gives a small increase in the SIN ratios when compared to FITC 
labelled cells. Although other fluorophores are available, FITC provides satisfactory 
results from direct labeling, and at the same time FITC labeling is substantially 
cheaper. Due to this, FITC labelling was selected as the method in subsequent blood 
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4.3.5 Investigation of Optimal Incubation Time for Blood Typing 
Microarrays 
In Ab-Ag interactions, time of incubation can greatly influence the specificity and 
sensitivity of the test. So far in this work, a two-hour incubation time has been used 
when performing blood typing microarrays. The antibodies used in this work are 
routinely (in blood typing reagents) used with reduced incubation times, some in 
immediate spin techniques. Part of the process optimisation was an evaluation of 
various testing times. Incubation times of 120,60,30 and 15 minutes were selected. 
As no centrifugation step is included during the Ab-Ag interaction in microarrays to 
speed up the reaction, it was considered unlikely that times shorter than 15 minutes 
would be possible. Another consideration is that other tests would be included 
(antibody screening, see Chapter 6) which are likely to require at least a 15-minute 
incubation period. 
Directly FITC labelled erythrocytes of group Al were used in the study of a range of 
incubation times and were added to the slides at appropriate intervals so all slides 
were washed at the same time. 
In Figure 4.6 no distinct or consistent pattern of improved binding is evident at any 
incubation time. However, no time period used demonstrated a significant increase in 
NSB, as reactions of the cells with anti-B did not increase. S/N ratios appeared 
slightly reduced to those presented previously, therefore this experiment was 
repeated using further cells. Also, a comparison of erythrocytes suspended in normal 
ionic strength saline (NIS) and low ionic strength saline (LIS) was included. The 
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results of this experiment are Figure 4.7a and Figure 4.7b. The results from 120- 
minute incubations are not included. 
In Figure 4.7a an incubation time of 60 minutes is clearly optimal, giving S/N ratios 
of over 10. In Figure 4.7b it appears that there is less differentiation between 
incubation times, with the 15 minute incubation time performing as well as 60 
minutes. 
Using the same batch of slides, this experiment was repeated using another batch of 
FITC labelled group Al cells, performed at all four incubation times using NIS and 
LIS (data not shown). The NIS results showed that a reduction from 120 minutes to 
either 60 or 30 minutes gives an increased level of binding. An incubation time of 60 
minutes was selected as a suitable incubation time if using cells suspended in PBS. In 
blood grouping serological techniques, it is common that a time period of 45-60 
minutes is optimal when using normal ionic strength saline. 
When using low ionic strength saline, a time period of 15-20 minutes is usually 
recommended. Using LIS at 15 minutes in Figure 4.7b, the 15-minute incubation 
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4.3.6 Interaction of Probe and Erythrocytes Expressing Reduced 
Levels of Antigen 
While previous experiments have shown that the developed microarray method can 
be used to perform blood typing in a microarray format, the erythrocytes tested so far 
had expressed high levels of antigenic determinant (group At or B). These highly 
expressed antigens are, most probably, easier to detect. To further evaluate the test 
method, cells expressing lower levels of clinically significant blood group antigens 
were investigated. This would give an indication of the sensitivity of the test method, 
as well as the potential use in a clinical environment for routine detection of 
clinically significant antigens. As described in Table 4.6, different blood types 
express a variable number of antigenic determinants on the surface of the 
erythrocyte. 
Table 4.6. Estimation of number of blood group antigenic determinants per erythrocyte of 
various ABO blood groups (Econimidou et al, 1967; Cartron et al., 1974). 
Erythrocyte Average number of antigenic determinant 
Antigenic Determinant sites per erythrocyte (x 106) 
A, 0.81-1.17 
A2 0.24-0.29 
AlB 0.46-0.85 (A), 0.31-0.56 (B) 





As discussed in Chapter 1 (1.3.1), it is mandatory to detect certain blood group 
antigens; therefore a new testing system must be sensitive enough to detect low 
levels of antigen. Erythrocyte types selected for analysis were B, A2, A1B and A,,. 
The data from the experiment is in Figure 4.8. All probe antibodies were spotted at 
different concentrations. Consequently, the data here is presented in two alternative 
ways: the complete data in one graph (Figure 4.8), and then each cell against each 
antibody at one concentration (Figure 4.9). The concentration selected for 
presentation is where the antibody probes are at the concentration detailed in yellow 
Table 4.7. These were selected as most comparable concentrations. 
Table 4.7. Probes selected for presentation in data in Figures 4.13 and 4.14. Those selected 
at most similar ug/ml are highlighted in yellow. Anti-D were used to calculate noise. 
Probe/ Protein/ Conc. Conc. Conc. Conc. 
antibody ID Ab type DILl DIL2 DIL3 DIL4 
Anti-A (LA2) mouse IgM 55 37 18 14 
Anti-A (ES9) mouse IgM 81 40.5 20.25 10.13 
Anti-B (LB2) mouse IgM 108 54 36 27 
Anti-A, (B) ES15 mouse IgM 127 63.5 31.75 15.9 
Anti-D (LDM3) human IgM 34.8 17.4 8.7 4.35 
Anti- D (ESD1) human IgG 300 200 100 75 
Figure 4.9a demonstrates specific binding of group B erythrocytes to anti-B LB2 
with a S/N ratio of 12. Figure 4.9b gives the result from the A1B cells. A1B 
erythrocytes, on average, have fewer A and B antigen sites than a normal group A, or 
group B (see Table 4.6). However, the antigen density is still high enough to give 
strong binding (S/N values of 15 to 20) to the microarray. Differences in either the 
antibody concentration or affinity to antigen can be seen in this data. 
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Figure 4.9c shows the results from the group A2 cell. Although specific reactions are 
present with both anti-A on the microarray, the S/N ratios are low at around 2. The 
cells give only <1 S/N with the anti-A(B) ES 15. This antibody reacts more weakly 
with cells of the A2 subgroup (Moore et al., 1984). Cells of type Ax have 
comparatively low numbers of antigen sites on the cell surface (see Table 4.6). 
Figure 4.9d shows that the only result above a S/N ratio of 1 is that with anti-A(B) 
ES15, which is described by Moore et al. (1984) as an antibody that reacts well with 
Ax cells. This cell line is used in many commercially available products as it is 
known to be excellent for the detection of Ax cells. It is usually blended with anti-A 
and anti-B cell lines to give a product that detects Al and B cells equally. In Figure 
4.8, the reaction with Ax cells gives a higher S/N value with the same antibody at its 
highest concentration. 
To develop this platform further, the next section investigates alternative detection 
methods. Alternative detection may be more compatible with routine testing, and 
with other tests to be performed on the microarray once a comprehensive blood 
testing microarray is investigated. For example it may be unpractical to label all 
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Figure 4.9. Detection of reduced expression blood group antigenic determinants by 
microarray, displaying similar antibody probe concentrations only. Fig A. acts as the control 
group B. Fig. B shows group A1B, Fig. C group A2, and Fig. D group A. Note that the scales 
differ in figures A to D. Slide type poly-L-lysine, slide reps 1, pins 700 pm, probes Table 4.7 
(highlighted in yellow), probe reps 3, SPM D; blocker PBS-milk, target/volume: various FITC 
labeled RBC/450p1, incubation time 60min, mixing, scanning method B. 
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4.4 Alternative Detection Methods for Erythrocyte Binding 
The addition of ConA lectin to erythrocytes as a labelling method led to masking of 
the antigen sites, and resulted in inhibition of Ab-Ag interactions. This was found in 
both liquid and solid-phase tests. Secondary reagents were investigated which could 
be added after the incubation of erythrocytes with microarray, making them 
secondary target reagents (indirect secondary labelling). An ideal reagent would be 
capable of binding to all erythrocytes attached to the microarray, with minimal non- 
specific binding to the probes. The principle of a secondary labelling assay is to bind 
a detection molecule to all specifically bound targets bound to the platform. 
Two detection reagents were selected for the secondary labelling experiment. These 
were FITC labelled wheat germ agglutinin and FITC labelled anti-Rh29. Both are 
known to bind erythrocytes. As the FITC anti-Rh29 was prepared (by Dr. D. Pepper) 
at a concentration of 0.3 mg/ml, it was decided to use both reagents at concentrations 
of 0.3 and 0.03 mg/ml. Group Al cells were used, and were also tested with no 
labelling to assess NSB. The antibody probes are detailed in Table 4.8. Slide 
Processing Method E, using secondary labelling steps, was used to process the slides. 
This processing method involves the use of BSA blocking and allows secondary 
labelling. The change to BSA blocking is explained in Appendix 3. 
The results are presented in Figure 4.10. Although the signal is lower than that with 
directly FITC labelled cells, it is still sufficient for specific blood group typing. The 
effect of autofluorescence of the erythrocytes is seen in Figure 4.10. In this slide, the 
secondary reagent was omitted. 
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Anti-A (LA2) mouse IgM 205 50 
Anti-B (LB2) mouse IgM 484 50 
Anti-A, (B) ES15 mouse IgM 425 50 
Anti-D (LDM3) human IgM 35 n/a 
Anti- D (LHM59/19) human IgG 1000 n/a 
PBS n/a 
For some results, the S/N is higher using autofluorescence than from those obtained 
with the anti-Rh29. The wheat germ agglutinin gives the optimal results in this 
experiment, and reacts with higher SIN values when more dilute (at 30 pg/ml rather 
than at 300 pg/ml). Although this area requires further investigation, it shows that 
there are alternatives to direct labelling. For the purpose of this thesis, work 
continued using directly labelled erythrocytes. 
4.5 Alternative Slide Surfaces for Blood Typing Microarrays 
As part of the wider group project (Proof of Concept (PoC), see discussion), it was 
discovered that epoxy silane coated slides gave improved S/N ratios over the poly-L- 
lysine slides (data not shown). The process had been shown capable of ABO blood 
grouping, but had not been optimised. Therefore, the blocking was examined in an 
attempt to improve the SIN values and reduce NSB. 
The blocking optimisation was performed as part of this work, and is presented in 
Appendix 3. The selection of BSA blocking was subsequently applied to gold slides 
225 
and was found to give excellent results. This resulted in the fully optimised 
procedure for processing of slides, which is described as Slide Processing Method E. 
4.6 Rhesus Typing by Microarray 
Mandatory testing of donors and patients includes the determination of RhD blood 
group status. In the U. K. it is recommended that this testing be carried out using at 
least two different monoclonal antibodies. If testing donors, partial RhD type VI 
(DVI) must be detected. Patient testing does not require the detection of DVI (Jones 
et al., 1995; UK Blood Transfusion Services, 2002). Consequently, antibodies for 
this purpose must be selected appropriately. It would also be advantageous for a new 
testing system to incorporate tests for other relevant blood group antigens in addition 
to mandatory probes. For this reason, available antibodies to Rhesus antigens E and c 
were also tested. 
Monoclonal antibodies for use in the following section were purified by the methods 
detailed in Chapter 2, where information on all cell lines is presented. All antibodies 
had been shown to work in haemagglutination assays and the titration end point is 
also presented in Chapter 2. The identification and concentrations of the extensive 
range of antibodies used in this section are detailed in Table 4.9. All were printed at 
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Table 4.9. Probes used in Rhesus blood typing experiments. 
Specificity and Cell line (if MAb) or Antibody Concentration 
identity in results protein identity class (mg/ml) 
Anti-D A LHM76/58 IgG 1.00 
Anti-D B LHM76/59 IgG 1.60 
Anti-D D LHM50/2B IgG 1.56 
Anti-D E LHM169/81 IgG 1.28 
Anti-D F ESDI IgG 1.02 
Anti-D Fsf ESD1 serum free IgG 0.29 
Anti-D G LHM76/55 IgG 1.78 
Anti-D H LHM77/64 IgG 1.07 
Anti-D I LHM70/45 IgG 1.38 
Anti-D J LHM59/19 IgG 1.07 
Anti-D K LHM169/80 IgG 1.09 
Anti-D M Polyclonal IgG 2.61 
Anti-D N BRAD-3 IgG 1.00 
Anti-D 0 LDMI IgM 0 
Anti-D P LDM2 IgM 0.0087 
Anti-D Q LDM3 IgM 0.0348 
Anti-D R LDM77/64 IgM 0 
Anti-D S ESD1 M IgM 0 
Anti-E DEM1 IgM 0.437 
Anti-c H48 IgM 0.0075 
HS Human serum n/a 3 
M IgG LHIVG2 IgG 0.3 
R IgG Rabbit IgG IgG 0.5 
S IgG Sheep IgG IgG 0.5 
G IgG Goat IgG IgG 0.5 
Anti-B (control Ab) LB2 IgM 0.484 
Anti-A (control Ab) LA2 IgM 0.205 
Anti-A(B) (control Ab) ES15 IgM 0.425 
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4.6.1 Rhesus D, E and c Grouping by Microarray 
Antibodies to Rhesus D, E and c were selected as antibody probes for printing onto 
gold-coated slides. Gold-coated slides have superior properties that could be 
potentially advantageous for Rhesus grouping. It is probable that gold binds 
antibodies via thiol groups. The cells selected for use in this experiment showed 
either homozygous or heterozygous expression of the antigens of interest. The 
nomenclature used in Rhesus grouping is described in Table 4.10 and the cells 
selected are described in Table 4.11. 
Table 4.10. Rhesus nomenclature used in this work, 'antigens present' represents antigens 
inherited from one parent (review, Daniels, 2002). 
Antigens present Fisher Weiner 
CDe CDe R, 
cDE cDE R2 
CDE CDE RZ 
cDe cDe Ro 
cde cde r 
Cde Cde r' 
cdE cdE r" 
CdE CdE ry 
The cells were selected to demonstrate different antigen site densities of the relevant 
antigens. For example, a homozygous R1R1 cell carries two copies of the RHD gene 
and, therefore, expresses a higher amount of RhD antigen, whereas a heterozygous 
R1r has only one copy and would be expected to express fewer RhD antigen sites. 
Homozygous expression was beneficial in this experiment, as antigen site density is 
higher and should be more easily detected. 
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Human serum, mouse IgG, rabbit IgG, sheep IgG and goat IgG spots on the 
microarrays were considered negative controls and were used to calculate noise for 
the S/N ratios. The results are presented in Figures 4.11 a-f. 
Table 4.11. Rhesus phenotypes of erythrocyte samples selected for experiment 4.6.1. 
Rhesus phenotype Rhesus phenotype 





r"r" cd E/cd E 
rr cdelcde 
Results from R1R1 are presented in Figure 4.11 a. Of the three antigens being tested 
this cell has only D, and as it presents homozygous expression the antigen density is 
estimated to be between 14,500 - 19,300 per cell (Rochna and Hughes-Jones, 1965; 
Hughes-Jones et al., 1971). However, the presence of the C antigen can affect the 
expression of the D antigen. For example, the R2R2 phenotype expresses between 
15,800-33,300 RhD antigens per cell. The R1R1 cell reacts clearly with anti-Ds J, K 
and N with S/N values of up to 28. The highest concentration of antibody does not 
consistently give the highest S/N value. There is a lower reaction present with anti-D 
B (S/N 2.3) and reactions with anti-E and anti-c are negative as expected. None of 
the IgM anti-D react, but this is possibly due to the concentration of antibody or 
accessibility of antibody to antigen. 
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Figure 4.11b shows the results from the R2R2 cell. This cell has homozygous 
expression of D, E and c antigens. According to Hughes-Jones et al., (1971) the cell 
will express between 15,800-33,300 D sites and 78,000-80,000 c sites. The cell 
reacts with several of the IgG anti-D and one of the IgM's, as well as a S/N value of 
5.3 with the anti-c. No reaction is evident with the anti-E. 
The Rlr cell results are shown in Figure 4.11c. This cell phenotype has heterozygous 
expression of D, and therefore has weaker expression than other Rhesus phenotypes 
at 9,900-14,600 antigen sites per cell (Rochna and Hughes-Jones, 1965; Hughes- 
Jones et al., 1971). The weaker expression is reflected in the results where the S/N 
ratios are below eight with the anti-Ds and at a S/N ratio of two with the anti-c. 
Expression of c is also heterozygous with around half the c antigen sites of a R2R2 
cell (37,000-42,000). 
Cells of phenotype r'r' do not express D, E or c antigens on the erythrocyte surface. 
This cell is effectively a negative control for all three specificities and as seen in 
Figure 4.11 d, all S/N values are below 1.2. 
Neither r"r" nor rr phenotypes express the D antigen. r"r" cells express both the E 
and c antigens and in Figure 4. l1e there are evident interactions with specific 
antibodies. With the anti-E the reaction is weak at S/N of 3.5, whereas the anti-c 
reaction is very strong at over 30 S/N. The results of the rr cell are presented in 
Figure 4.11f. This cell should only be positive with anti-c as it has homozygous 
expression of the c antigen and the results agree with this, giving a S/N ratio of 22. 
231 



















O LO O U) 
04 r. r. 
F-W 
'Cl /1411 










6ý -Y pO 
















/cl, 01 yT4b r6wS 
"yp,, Tý /w/6i,. Oyn_b 






, w"wsýDyIUý 'ý" ý0'ýlU 
















































































yJV U b 
U- 
b äi 







p7JVb, ö 0) co r6t4, 
ý 
Al O-! 1v U) m /ýi6 9Z as 
wo " 
AY 
a) ä /ýi6w y Ov 
Jvb 
cýE /4, sb Jvb o rn ° rn ý6w0 pYJ 
/(1/8, bL>, Wc 





6ý8d' p'ýJVb ýýý .ý 
/ 
i6iv0 
L/ p. ýJV co (3) a) .ý 
°ö 









a) v °. ý 
/ýýr. g0y0/JVb o 
.0 
v 
/wý8zi ! JVb a. c ý6ý0't ý ý! JV U) N 
04 
iý. 
/4, w9S ý vyýýb ýý iGi,, n_ýý 00--(7- qi 
OL 
141i6w 0p0 ýýý4b ý vý 
9 Jvb 
LL. ýwi6wo ý eo_I rv 32 ý 
AO'4vb 
ý ýýýS 0 

















i&,.,. ý4b Em L (3) 
ýýUia0 0 '1 Ai CU 














/to 0 -1 
07/4 výwc 
-7U,  -1 (7_.. - ; ý, U) y 
ýý 
ý1 
/(7, bö cl. E 
öE 
0L 
ý 0ilv cß 3 :a wi6 Jdý oý o ýS' 01! 




.E ... _ 
S i, 0'4c. l -0 CL 
m 
R4 9s+"ý vy/vb ý ýQ 
00'l OO'ijvb ý 
/4,0 p 
Oyýýb °_' m w 9.0,1 EL ý 
p, ý /wi6ýZ 90,4b N 





































oý! vb /t rý60 
ý/6wSbN'4(, b, 
w o-i ws ZW 1Ob 

























ýSb ý! lOb 
/tu 
%8Z1 ý Wvb 









o GP,! 14 




4,0 .18 owUb 


















m o_? ýo 
c a) 2) 
















































o. /j, b 
b 
0! /c, b 
Oy/ýb 
Oy/4b 












ýý6ýS pý/0i1ýb c 
/4' 
w0 







/ý ý lrub ý 
/4 
ýS 















6t' 0 00-1 0'4v 



































































































r64i ýy O, ý 
b 
R46ýS0ýpý'l4b' 






, l4 >, ýýr6Z4S0/ 
p 
. /lob 0 
%0ai 
r6wS 
"N OYl4 0 
ý 
4i8! y pw4 Ö 
/ 0. 
ý) 0'ýl4 -0 
ýr6wS 0 Oyl4b cýa 
/wi 





ý9S ý Oý'l4b 
0° ý 
00ý44b 
/wr6 S00 p`ý14b 
/t4 




r6w0 8 0, I14 /u, rý4S0 



























































4.6.2 The Effect of pH on Probe Immobilisation and Performance 
Rhesus blood typing by microarray was performed with successful results in the 
previous section. However, although some antibodies bound cells to give high SIN 
values, many of the antibodies either did not react or reacted weakly. It is known that 
different antibodies require different environments to react optimally. Scott (1991) 
reported that anti-D antibodies at increased pH gave increased immobilisation to 
plastic microplates. Therefore, a pH 9.6 buffer was selected as spotting buffer to 
determine its effect on antibody immobilisation and hopefully increase reactivity on 
the microarray. Also, this work was further extended to compare reactions on gold 
and poly-L-lysine slides and then a wider range of spotting buffer pH. 
4.6.2.1 Comparison of Spotting Buffers pH 7.0 and pH 9.6 on Poly-L- 
lysine and Gold Slides 
This experiment was performed on both gold and poly-L-lysine slides. Poly-L-lysine 
slides had not yet been used successfully for Rhesus grouping, but were used as they 
had previously demonstrated successful ABO grouping. All antibodies were dialysed 
into pH 9.6 bicarbonate buffer as described in Chapter 2. Cells of phenotypes RJR,, 
R2R2 and r"r" were used and slides were performed in triplicate. The aims of this 
particular experiment were, therefore, three-fold: to improve reactions of weak or 
negative antibodies from previous experiment in 4.6.1; compare gold to poly-L- 
lysine slides; and demonstrate Rhesus typing using slide replicates. Antibodies 
spotted were those described in Table 4.9. 
238 
The R1R1 reactivity in Figure 4.12a is improved from that in Figure 4.11 a. The S/N 
values in general are far higher on gold slides, most likely as background noise 
values were lower. This may also be due to a different R1R1 cell being used, and the 
variance that can be apparent from expression levels in different individuals. The 
error bars show the variability between the three slide replicates. It is very clear that 
the gold slides give far higher S/N values than the poly-L-lysine slides. In the 
previous experiment, R1R1 cells reacted with anti-Ds B, J, K and N. In this 
experiment an increased number of anti-D are reacting. Anti-Ds A, B and D are 
giving low reactivity at pH 9.6. Anti-D F and G, which did not react before, are 
giving S/N values of 41 and 14 respectively at pH 7.0. As before, anti-Ds J, K and N 
are all reacting well at pH 7.0. 
Figure 4.12b shows the results of the R2R2 testing. Again S/N values are generally 
higher than those found in the previous experiment. The S/N values are far higher on 
the gold slides. However, the anti-E and anti-c do not react at all. In Figure 4.12b in 
the previous experiment only the anti-c reacted weakly. 
In Figure 4.12c, the r"r" cell is showing some false positive results with some of the 
anti-Ds, especially those at pH 9.6. However, it is encouraging that the three `best' 
performing anti-D, J, K and N, are not giving high value non-specific reactions. The 
anti-E and anti-c look specific but the S/N values are far lower than some of those 
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This experiment has demonstrated that gold slides give greater S/N values than the 
poly-L-lysine slides, that some anti-D react better at higher pH, and that there is a 
level of variability of antibody reactions between experiments. Antibody stability 
may be a factor here, and will be discussed later. Given that some antibodies give 
enhanced reactions at pH 9.6, while some at pH 7.0, it is clear that each antibody 
requires optimisation of the spotting buffer characteristics. For this reason the pH 
range and buffers were extended to explore this further. 
4.6.2.2 Determination of Optimal Spotting Buffers for Rhesus 
Antibodies 
The last experiment showed that pH could affect the reactivity of various blood 
grouping antibodies. As it is clear each antibody will react differently, the following 
experiment was performed to determine the optimal pH for the available Rhesus 
antibodies. 
The antibodies were all stored in PBS at pH 7.0, and an aliquot of each was dialysed 
into the following buffers; bicarbonate buffer pH 9.0, glycine NaOH pH 9.8 and 
ethanolamine buffer pH 10.4. Scott (1991) described how pH buffers were useful 
when immobilising anti-D onto microplates. Here, however, the antibodies are being 
adapted to use in microarrays. 
The identity and pH of the antibodies is referred to in the result figures. All were 
used at the most concentrated level available as described in Table 4.9. ABO 
antibodies were also included to demonstrate the multiplexing capability of the 
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microarray, but these were used only at pH 7.0. Samples were printed in duplicate 
onto gold-coated slides. FITC labelled erythrocyte samples were selected which 
express various ABO and Rhesus groups, details of which are in the figures. The 
results of this experiment are presented in Figures 4.13a-g. Due to the large amount 
of data generated in this experiment, the results presented are from those probe 
antibodies which gave S/N values of greater than one, and are arranged in 
descending order. With results presented in this format, the optimal antibody and pH 
can be seen more clearly. 
A group B R2r erythrocyte sample was evaluated on the microarray. The results in 
Figure 4.13a confirm that this cell is a group B as it reacts strongly with anti-B LB2, 
and RhD positive due to its reactions with several anti-D. 
Figure 4.13b shows the results from a group 0 R1R2 cell, which gives excellent S/N 
ratios with anti-D probes. Anti-Ds K and N react well at pH 7.0 while anti-D J gives 
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Probe antibody specificity and pH 
Figure 4.13a. Optimal spotting buffer pH determination, using group B R2r cell. 
Slide type gold, slide reps 3, pins 700 µum, probes Table 4.9, probe reps 2, SPM E; blocker 
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Figure 4.13b. Optimal spotting buffer pH determination, using group 0 R, R2cell. 
Slide type gold, slide reps 3, pins 700 , um, probes Table 4.9, probe reps 2, SPM E; blocker 





Figure 4.13c confirms the group of the A1B RhD positive cell tested, again with 
anti-Ds J, K and N all reacting with high levels of S/N (>200). Figure 4.13d shows 
that the Rlr phenotype, again, gives lower S/N than other Rhesus phenotypes. Figure 
4.13e agrees with the group A, RhD positive cell type. Figure 4.13f shows the 
results from another group 0 R1r cell and the results are very similar to those of the 
other example of the same phenotype. Figure 4.13g shows the results from the 
negative control cell, which is group 0 and RhD negative, therefore all values are 
low as expected. The results from the anti-c and anti-E are low throughout, which 
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Probe antibody specificity and pH 
Figure 4.13c. Optimal spotting buffer pH determination, using group A, B R, R, cell. There 
are no error bars as only one slide performed for this cell. Slide type gold, slide reps 1, pins 
700 pm, probes Table 4.9, probe reps 2, SPM E; blocker PBS-BSA, target/volume: FITC 
























ä Probe antibody specificity and pH 
Figure 4.13d. Optimal spotting buffer pH determination, using group 0 R1r cell. Slide type gold, slide 
reps 1, pins 700 ern, probes Table 4.9, probe reps 2, SPM E; blocker PBS-BSA, target/volume: FITC 
group 0 R1r/450p1, incubation time 60min, mixing, scanning method B. 
Probe antibody specificity and pH 
Figure 4.13e. Optimal spotting buffer pH determination, using group A, R2R2 cell. Slide type gold, slide 
reps 3, pins 700 gym, probes Table 4.9, probe reps 2, SPM E; blocker PBS-BSA, target/volume: FITC 















Group 0 R1r (D+ E- c+) 
=ýTýýý --------------- 
oCD vaoCD o 
r. - ooir-.: vi 
=2ý222 
aa= c)- n. a 
Zý CL --3 d -> 
ääääQ 
00 0't 0 Co vo ao 0 ao ao vo0 ao CD ao 
ai o ti rn or-- ai ai ai ai o ai oi oi rý o ai 
II Iý I Iý 2I2I Iý III Iý I 
aa aI a a2 aaaa a2 aaa a2 a 
'7 ln m Q. S 






- (n 2 wm C lL LL 0 C? I? 
ý 




Probe antibody specificity and pH 
Figure 4.13f. Optimal spotting buffer pH determination, using second group 0 R1r cell. 
Slide type gold, slide reps 3, pins 700 gym, probes Table 4.9, probe reps 2, SPM E; blocker 
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Probe antibody specificity and pH 
Figure 4.13g. Optimal spotting buffer pH determination, using group 0 r"r cell. Slide type 
gold, slide reps 3, pins 700 pm, probes Table 4.9, probe reps 2, SPM E; blocker PBS-BSA, 
target/volume: FITC group 0 r"r/450, u1, incubation time 60min, mixing, scanning method B. 
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This section concluded that ABO and Rhesus typing can be performed 
simultaneously in microarray format. This project continued to develop typing for 
the Kell blood group system antigen, K. 
4.7 Kell Typing by Microarray 
As mentioned in Chapter 1 (1.3.1), it could be valuable to include tests for the 
determination of Kell blood group system antigen status on a blood typing 
microarray. The K antigen of the Kell system is of particular importance in blood 
transfusion, as it is highly immunogenic and can initiate the production of anti-K in a 
K negative recipient. To extend the microarray to this specificity, a monoclonal anti- 
K antibody was evaluated. 
The probe antibody was monoclonal IgM anti-K cell line MS56, which had been 
purified. This was used at 1.0 and 0.5 mg/ml in PBS pH 7.0. FITC labelled 
erythrocyte samples were selected which expressed either homozygous K (KK), 
heterozygous K (Kk) or were negative for K (kk) and these are detailed in the results 
figure. 
Figure 4.14 shows the result of the K grouping by microarray. Two of the test 
erythrocyte samples were positive for the K antigen, one homozygous and one 
heterozygous. The results of the homozygous cell (in red) demonstrate the expected 
results i. e. higher with the more concentrated probe antibody spots. The 
heterozygous cell fails to react with the 1.0 mg/ml spot of antibody. The 1.0 mg/ml 
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spots also give a false positive reaction with aK negative cell (in green). It was 
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Probe antibody specificity and concentration 
Figure 4.14. K grouping by microarray, using cells of varying K antigen status. 
Slide type gold, slide reps 3, pins 700 gym, probes anti-K only, probe reps 2, SPM E; blocker 
PBS-BSA, target/volume: FITC labelled various RBC/450NI, incubation time 60min, mixing, 
scanning method B. 
The experiments in this and the previous section were performed as one experiment, 
with the results presented separately for clarification. This experiment demonstrates 
for the first time that ABO, Rhesus and K grouping can all be performed 
simultaneously in an open-plan blood typing microarray. This also demonstrates the 
capability and potential for multiplex analysis, as different types of antigen can be 
detected in one experiment i. e. carbohydrate (ABO) and protein (Rhesus, K). 
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4.8 Direct Antiglobulin Test by Microarray 
This project has shown successfully that the mandatory blood typing can be 
performed on a blood typing microarray platform. The inclusion of a test for in vivo 
bound IgG or C3 complement components on the same platform could be beneficial. 
Therefore, this section aims to determine if anti-IgG probe antibody can detect IgG 
sensitised cells. This test is useful in donor testing to prevent the transfusion of blood 
with in vivo bound IgG, and in patient testing to detect those with possible 
autoimmune disorders. 
The probe antibodies are detailed in Table 4.12. The IgG sensitised cells were 
incubated with three replicate slides. To prepare the IgG sensitised cells, group 0 Rlr 
cells were selected (presented in Figure 4.13f) and these were sensitised with anti-D 
`K' (LHM169/80) following the method used for IgG antibody serological testing in 
Chapter 2. This antibody is of isotype IgG3. Un-sensitised cells (native) were also 
tested. 
Table 4.12. Probe antibodies for use in direct antiglobutin testing by microarray. 
Specificity and Cell line/ Antibody Concentration 
identity in results Identity Class (mg/ml) 
Anti-D'K' LHM169/80 IgG3 1.09 
Monoclonal Anti-IgG3 LG3A IgG 1.20 
Rabbit Anti-IgG Rabbit polyclonal IgG 0.39 
Monoclonal Anti-C3 3G8 IgG 1.00 
The results are presented in Figure 4.15. The dark blue bars show how the native 









































































































with anti-D `K' (pale blue), the cells do not react with the anti-D `K' probe, but give 
very high S/N against the anti-IgG probes. The anti-C3 gives no cross-reactivity. 
This experiment proves the principle that the direct antiglobulin test (DAT) can be 
performed in a microarray format. To determine if the sensitisation by the sensitising 
antibody inhibited the reaction of the cells with other antibodies, the other probes on 
the array were analysed. These probes were as in Table 4.9. No S/N value was over 
one, and it was concluded that all antigen sites were blocked due to the presence of 
high levels of IgG antibody. 
4.9 Chapter Discussion and Conclusions 
4.9.1 Chapter Discussion 
As mentioned in Chapter 1 (1.3.1), mandatory blood testing includes testing of ABO 
and Rhesus D blood group status (U. K. Blood Transfusion Services, 2002). Blood 
testing systems must be able to determine these blood groups. However, it could be 
advantageous to facilitate further blood group typing on a single microarray format, 
and this `multiplexing' feature is an important advantage of microarrays. Many blood 
testing centres routinely type a percentage of blood donations for further Rhesus 
antigens (C, c, E, e), as well as Kell antigens (K). Some test centres also perform a 
direct antiglobulin test (DAT) to determine if erythrocytes are sensitised with IgG in- 
vivo (indicative of some infections and autoimmune disorders, and therefore not 
desirable for transfusion to a patient). New probes can be added to a microarray with 
relative ease to exploit the multiplexing power of the microarray format. 
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However, probes must be well characterised with known and established levels of 
specificity and activity to meet the industry standards. 
A new solid-phase test format must also be able to compete with existing systems in 
specificity, sensitivity, economy and speed. In terms of sensitivity, weak but 
clinically significant groups must be detectable without the introduction of false 
positive reactions. As described in Chapter 1 (1.2.1.1 and 1.2.1.2), rarer blood groups 
such as AX and weak D need not be detected in recipients but must be detected in 
blood donations. Reagents used must not detect the acquired B antigen, which is not 
a true B antigen and, if detected, can lead to the transfusion of incompatible blood. 
Scott and Voak (1997) discuss the implications of the use of anti-B reagents that 
detect acquired B. It is noted that antigenic expression varies between individuals, 
and that many different examples require evaluation on this system. However, the 
work presented has shown that ABO, Rhesus, K typing and, in principle, direct 
antiglobulin testing can be performed using the developed non-agglutination based 
microarray platform. It was demonstrated that different antibodies were better at the 
detection of certain antigens e. g. ES9 was good for detection of A2 and ES 15 for the 
detection of A,, and many antibodies require optimisation to improve S/N values. 
In this project, the first attempts of blood typing microarrays gave little success. The 
failure of the early stage approach led to doubt as to whether the antibody- 
erythrocyte interaction was possible in a microarray solid-phase format. However, 
there have been several successful attempts of ABO typing in solid-phase systems 
such as microplates (see Chapter 1,1.3.5.2.1). It was decided to use microplates as a 
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solid-phase to evaluate whether another similar solid-phase format might facilitate 
the reaction. In Chapter 5, the technology of surface plasmon resonance was also 
used to demonstrate that the solid-phase interaction of probe and erythrocyte could 
be detected. To develop the blood typing microarray, blood typing was performed in 
a microplate format. Direct and indirect erythrocyte binding detection methods were 
both investigated, which do not rely on the occurrence of haemagglutination. 
In the blood typing ELISAs performed, it was found that erythrocytes could bind 
specifically to the antibody coated plates, but that indirect fluorescent labelling 
methods either prevented binding or caused detachment of the cells. It was apparent 
that labelling the erythrocytes with fluorescently labelled molecules, such as ConA, 
inhibited the probe Ab-Ag interaction. It was felt that directly labelling the 
erythrocyte with a fluorophore, rather than indirectly via another molecule, may 
improve the retention of the erythrocytes and give a detectable signal. Therefore, 
direct fluorescent labelling of the erythrocytes was investigated, as it would be a 
useful tool in the analysis of microarray interactions. The direct labelling concept 
was used with success in subsequent microarrays. This technique proved very useful 
in the development stage of the microarrays and led to the successful blood typing of 
many samples. 
Non-agglutination blood typing on a solid-phase has been reported previously by 
Quinn et al. (1997). The authors used the Biacore platform to differentiate between 
blood types. In this thesis, non-agglutination based blood typing was performed 
using an open plane, multi-parameter microarray and a fluorescence readout. 
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However, direct labelling of every blood sample would be impractical for routine 
high-throughput use, mainly due to timescales, but it would also be an extra step that 
would require automation. The optimal detection method for high-throughput testing 
may be a secondary detection molecule added along with other detection molecules. 
Compatibility with other detection molecules and probes should be considered. This 
will be of particular importance when amalgamating antibody screening with blood 
typing, and extending to pathogen testing. This will be discussed further in Chapter 
7. For this purpose, other methods to indirectly detect bound erythrocytes were 
attempted, with some success. 
To improve the indirect fluorescent labelling method, the number of fluorophore 
molecules attached to the detection molecule could possibly be increased. Other 
detection molecules could also be investigated. The anti-Rh29 binds to an integral 
membrane protein and it may be more beneficial to select a molecule specific for a 
peripheral antigen, such as H or glycophorin. If considering a final blood typing 
microarray system, anti-H is available, but would not detect the rare Bombay 
phenotype (frequency 1 in 7600 in India, lower elsewhere (review, Daniels, 2002)), 
which has no H on the cell surface. To address this problem, the anti-H could be used 
as a probe antibody. In this case, the Bombay phenotype would be demonstrated by 
the absence of binding to the anti-H control probe. The inclusion of this extra probe 
would be beneficial, and incremental costs are small. The use of an antibody to 
glycophorin was used during this development work (data not shown), but gave no 
meaningful results. 
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Scanning of unlabelled cells gave an indication that autofluorescence may be a 
possible form of detection of cell binding if it were optimised. However, the high 
level of fluorescence seen with directly FITC labelled cells would indicate that the 
test system might be more sensitive, as many fluorescent molecules may be attached 
to each cell making it more easily detectable. Nevertheless, autofluorescence may 
have advantages in certain situations, and this phenomenon was pursued as part of 
the Proof of Concept project and an Intellectual Property application submitted. 
For a probe-ligand interaction to occur, the two active sites must come within close 
proximity to each other. It is likely that interaction may be increased when 
movement is facilitated. Because of this, two different incubation methods were 
investigated. It was found that using Hybridisation Chambers, which allow a larger 
volume of target solution and mixing, greater S/N ratios were obtained when 
compared to a smaller incubation volume with minimal mixing. Mixing is difficult 
when using a small 25 Pl volume, such as that used with Lifter SlipsTM. A general 
observation from use of the Hybridisation Chambers is that `comet tailing' 
(described in Chapter 3) is less frequent than when using the Lifter SlipsTM. This may 
be due to the Lifter SlipsTM sliding off the array when washed following incubation, 
and causing drag of materials over the array. The concentration of erythrocytes in 
suspension was also investigated to determine if this would affect binding to the 
array. It was found that a1% erythrocyte suspension was optimal, and that more 
highly concentrated suspensions had a detrimental effect. Incubation time was also 
investigated as the interaction of solid-phase probe antibodies and targets is different 
to solution-based agglutination, and required evaluation. 
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In Chapter 3, polyacrylamide coated slides had shown a superior level of probe 
protein retention and these, along with poly-L-lysine slides, were selected for 
investigation in blood typing microarrays. In contrast to the results found in Chapter 
3, the poly-L-lysine slides gave far higher S/N levels than the polyacrylamide, when 
using whole erythrocytes. This is most likely due to the erythrocytes being unable to 
penetrate the small gaps in the gel (Robb et al., accepted to Transfusion Medicine, 
2005, Appendix 4). 
Using the optimised procedure, erythrocytes carrying a low number of blood group 
antigen sites were evaluated on a blood typing microarray. The experiment showed 
that the microarray blood typing format is capable of detecting clinically significant 
ABO blood groups. The experiment also demonstrated that the antibodies require 
optimisation of concentration, especially to detect weak blood groups. In future 
work, it will be important to use weak antigen cell types to ensure the sensitivity of 
the antibodies and test system used. This was a crucial development as the potential 
of the testing platform as a routine test system could be seen. Further development of 
the system demonstrated it capable of both Rhesus and K typing erythrocytes. The 
experiments produced some very good results, demonstrating that D, E and c typing 
can be performed in a microarray format. The only anomaly was the anti-E, which 
did not detect the R2R2 cells. It was expected that not all antibodies would show 
reactivity in solid phase, which was the main reason for using an extensive panel. 
However, most monoclonal antibodies require extensive testing to determine the 
optimum reaction conditions (e. g. pH, ionic strength, concentration and possible 
potentiation), and may or may not benefit from manipulation. The inclusion of higher 
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avidity reagents may be required to achieve reliable stronger results with weak cell 
types. 
A summary of the observed and expected reactions of the panel of anti-Rhesus 
antibodies was prepared (Table 4.13). In this table, if an antibody has only shown the 
expected reactivity at one pH, then this was input as the observed reactivity 
alongside the expected reactivity. Most of the unexpected reactions (shown in white) 
are unwanted negative reactions, and these antibodies require further development 
and optimisation. While some probe anti-Rhesus antibodies have shown consistently 
good results, others have been variable. Although this may be due to optimisation 
issues, the subject of stability must also be considered. The purification of probe 
material is important to fabricate spots with specific probes and to minimise NSB. 
However, it may be that the probe antibodies require the addition of chemical factors 
to ensure stability. Purification can remove almost all other proteins in the sample as 
well as salts and sugars, which can provide stability to reagents. Investigation of 
stability is not covered in this thesis but is considered further in Chapter 7. One 
antibody that performed well overall (anti-D `N') was supplied as a freeze-dried 
material and this may contribute to the overall stability and performance of the 
antibody. While anti-Ds can vary in their RhD epitope specificity, it is unlikely that 
this is a factor in the experiments presented as all RhD positive cell samples used 
were most likely `normal' RhD positive i. e. positive for all RhD epitopes. Anti-D `N' 
is specific for RhD epitope 6/7, as are Anti-D `D' and `K', while all other anti-D are 
specific to a variety of epitopes. In fact, many of these anti-D are part of a kit to 
determine partial RhD types due to their epitope specificity. 
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The direct antiglobulin test was performed by microarray in this chapter. The 
sensitising antibody used was of high potency and therefore, the sensitised cells 
completely inhibited the reaction with the same probe antibody. The level of IgG 
sensitisation was perhaps far higher than would be expected in a naturally DAT 
positive sample, so it is unknown whether this test format would detect real or 
weakly sensitised samples. It would be expected that a potent antibody might bind to 
all RhD antigen sites on the cell surface, therefore blocking these sites to any other 
antibody to the same epitope. Reduced level sensitisation using antibody dilutions 
would require investigation, to determine if this still affects the typing of other blood 
groups. 
It would be advantageous if the microarray format could correctly group DAT 
positive samples. In liquid phase testing, the presence of IgG means that all tests give 
positive reactions when tested with anti-IgG, meaning that IgG blood grouping 
reagents cannot give accurate results. DAT positive samples are usually tested with 
IgM typing antibodies. The detection system would be critical when testing DAT 
positives, especially if blood typing was performed alongside antibody screening. It 
is likely that the detection system for antibody screening would include anti-human 
IgG, and this would bind to any DAT positive cells on the array. This would require 
clarification when comprehensive testing was amalgamated on one microarray. 
About midway through this stage of the project, some of the data presented in this 
thesis, along with the whole concept of blood typing microarrays, was used by the 
Scottish National Blood Transfusion Service in collaboration with the Scottish 
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Centre for Genomic Technology and Informatics (University of Edinburgh) to apply 
for Proof of Concept (PoC) funding from Scottish Enterprise. Based on the work 
presented in this application, funding was successfully gained and amounted to 
£200K over a period of two years. This led to the appointment of others to work on 
the project. With more personnel involved in the work, new developments were 
made and at times affected the work presented in this thesis. This was mentioned 
where appropriate. Two major developments were the preparation of new antibody 
probes by a different method to that used previously, and the use of further slide 
types for the immobilisation of probes. This input helps demonstrate the huge 
potential which is recognised in microarray technology. 
4.9.2 Chapter Conclusions 
The work of this chapter has demonstrated the following in response to the chapter 
aims: 
" Evaluate whether blood typing can be performed in a microarray format, the 
basis of which was developed in Chapter 3, which will involve the use of 
erythrocytes of different blood groups, initially Rh and ABO. 
Using the selected antibody probes, Rhesus D typing was first attempted with no 
success. This was followed by ABO grouping of both high and low antigen 
density expression samples performed successfully in a microarray format. 
. Establish detection methods for direct and indirect detection of erythrocytes 
bound to the blood typing microarray. 
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Both direct and indirect methods for the detection of erythrocytes bound to a 
blood typing microarray were evaluated. Indirect methods using fluorescently 
labelled lectin were shown to inhibit subsequent blood typing interactions. 
However, those using direct labelling of the erythrocyte with fluorophore proved 
highly successful although perhaps impractical for scale-up. Indirect methods 
using fluorescently labelled secondary reagents were successful, but resulted in 
lower S/N values which were still suitable for blood typing purposes. 
" Optimise the blood typing microarray procedure to enhance reactions and 
improve the performance of the test platform. 
Several parameters, including reaction volume, mixing, incubation time were 
optimised for successful blood typing using the microarray platform. 
" Once ABO blood typing is achieved and optimised, extend the probe panel to 
include Rhesus and Kell antibodies to blood group antigens. 
Rhesus D, E and c typing was performed using a blood typing microarray format. 
Some probe antibodies gave inconsistent reactions (anti-E and anti-c). Anti-D 
antibodies showed good correlation with the level of antigen expression. The 
effect of pH on antibody immobilisation and reactions were investigated and 
demonstrated individual requirements for different antibodies. 
9 Determine the ability of microarray technology to perform detection of direct 
antiglobulin positive samples. 
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Erythrocytes sensitised with IgG antibody were detected by both monoclonal and 
polyclonal anti-IgG, with no cross reactivity with anti-C3. 
In summary, this chapter has demonstrated that ABO, Rhesus D, c and E, K blood 
typing and direct antiglobulin tests can be performed in a microarray format. The 
multiplexing ability of the microarray format has been demonstrated, by typing 
erythrocytes against a multi-parameter panel of immobilised probe antibodies. The 
potential for comprehensive blood testing by protein microarray technology is clear. 
Chapter 5 looks at the use of many of the probe antibodies used in this chapter in a 
complementary solid-phase system, using surface plasmon resonance. 
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CHAPTER 5 
ANTIBODY ANTIGEN INTERACTION 
ANALYSIS USING 
SURFACE PLASMON RESONANCE 
5. ANTIBODY ANTIGEN INTERACTION ANALYSIS USING SURFACE 
PLASMON RESONANCE 
5.1 Introduction and Chapter Aims 
This chapter utilises the Biacore platform as an alternative solid-phase method for 
the study of protein-ligand interactions. The principles of surface plasmon resonance 
(SPR) technology were described in Chapter 1 (1.3.2.5.3). The work detailed herein 
focuses on the examination of real-time interactions between molecules of interest, 
and therefore imparts another perspective on these reactions. For work involving 
SPR, the immobilised substance is referred to as ligand, and the target as analyte. 
Before SPR interaction analysis could commence, preparatory work was performed 
to enable the optimal conditions for immobilisation of ligand to be established and to 
determine protocols before interaction with analyte. The work of Quinn et al. (1997) 
was used as an initial reference point and procedures were optimised from this. 
The performance of probe ligands can be evaluated using SPR, and this knowledge 
may be used for the selection of reagents. Chapters 3 and 4 have described the use of 
microarrays for the immobilisation of proteins (mainly antibodies), and an 
examination of the interactions with target ligands or cells. In most cases the 
detection of target binding has been by the use of fluorescently labelled reagents. As 
SPR detects changes in mass on the sensor surface, the use of labelling is not 
required for detection. 
266 
This chapter also demonstrates the use of synthetic carbohydrate probe molecules for 
capture of specific antibodies. These synthetic antigens are used in two ways; to rank 
antibodies on performance and to evaluate their potential for use in antibody 
screening (see Chapter 6). 
The aims of this stage of the project were; 
" Use SPR as an established solid-phase reference technology and as a control for 
the new solid-phase microarray technologies presented in earlier chapters. 
" Measure the reactivity of antibody immobilised on a solid surface, supplementary 
to protein microarrays. 
" Compare antibodies using SPR and indicate their suitability for use on a solid- 
phase. 
" Compare the interaction of different erythrocyte types and conditions with 
immobilised antibody. 
5.2 SPR Process Optimisation 
Similar to the preparation of protein microarrays, SPR assays involve the deposition 
of probe ligands on the surface of the chip before an interaction assay can be 
performed. However, in contrast to microarrays, SPR chips allow the regeneration 
and re-use of the surface for further analysis. 
There are four main stages involved that are common to SPR assays. These stages 
are: 
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Immobilisation. A molecule is linked to the sensor chip. For attachment of 
proteins amine coupling is the immobilisation method used. The attached or coupled 
molecule is referred to as the ligand. Prior to this stage, optimisation of pH, flow 
rates, timescales and buffers must be performed. 
Binding. The target (referred to as analyte) solution is injected to allow interaction 
with the probe ligand. 
Regeneration. Bound analyte must be removed from the ligand surface before the 
chip may be used for another analysis 
Controls. Controls are included to determine if observed binding is specific by 
checking for non-specific binding 
This section details the procedures that were necessary to optimise and use the chip 
for interaction analysis. The process flow of SPR experimentation is detailed in 
Figure 5.1. All methods used in this chapter are detailed in Chapter 2. 
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Selection of appropriate sensor chip 
1 pH scouting - see Figure 5.2 
(Section 5.2.1) 
1 Activation of sensor surface- see Figures 2.1 & 5.4 
(Refer to 2.8.3) 
1 Coupling/immobilisation of ligand - see Figures 2.2 & 5.4 
(Refer to 2.8.3) 
Deactivation of sensor surface - see Figure 5.4 





(Refer to 2.8.4) 
Regeneration of surface 
(Refer to 2.8.4) 
1 Data evaluation 
(Refer to chapter 2.8.5) 
Figure 5.1. Surface plasmon resonance process flow diagram. This describes the various 
stages required to optimise and perform SPR analysis. References are made to the main 
text. 
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5.2.1 pH Scouting 
pH scouting was used to determine the pH at which optimal binding of the ligand to 
the sensor chip surface will occur. Throughout this project the ligands used are IgG 
or IgM antibody, lectin or synthetic blood group antigen conjugated to bovine serum 
albumin. It is recommend by Biacore (Biacore. com) that the pH that has the highest 
level of electrostatic attraction of the ligand to the chip surface is the pH at which the 
ligand should prepared for covalent binding. Electrostatic binding of ligand cannot 
be used for immobilisation since it can be easily dissociated from the sensor chip 
during the analysis or regeneration steps. The Biacore CM5 chip has an overall 
negative charge at pH >3.5 and the buffer in which the ligand is delivered should 
ensure a net positive charge, depending on the isoelectric point of the ligand (the pH 
at which the charge on the protein is zero). The effect of overall ligand charge is 
demonstrated in Figure 5.2. If the pH of ligand solution is lower than the isoelectric 
point of the ligand then the ligand will have overall positive charge and, therefore, be 






pH of solution less than isoelectric point of 
ligand 
pH of solution higher than isoelectric point 
of ligand 
Figure 5.2. Schematic of surface plasmon resonance pH scouting principle. 
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10 mM sodium acetate is recommended as the ligand buffer for most proteins as it 
has low ionic strength and lacks components that compete with the ligand for active 
esters on the sensor surface. pH scouting was performed for each ligand to be 
coupled to a chip, and one example of this process is shown below. The monoclonal 
mouse IgM anti-A antibody ES9 was used in this example. The concentration of 
antibody ligand used was approximately 50 , ug/ml. 
The antibody was dialysed into 
10 mM sodium acetate buffer at various pH as indicated in Figure 5.3, and then 
injected over sensor chip surface. 
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Figure 5.3. Sensorgram showing pH scouting of monoclonal mouse IgM antibody ES9 
The sensorgram in Figure 5.3 shows the SPR responses from the antibody ES9 at 
different pH and Table 5.1 summarises the response at each pH. Actual response is 
the difference between the response at the start of each injection (baseline) to the top 
of the response curve at that pH. The electrostatic attraction to the CM5 chip for this 
ligand is highest at pH 5.0. This can be determined from both the sensorgram and the 
pH 4.5 
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table showing actual response values. A high level of electrostatic binding is also 
evident at pH 4.5 and 4.0. It is likely that the antibody was more positively charged 
at the lower pH i. e. at points below the isoelectric point, which will be pH 6.0 or 
above where no binding is seen. 
Table 5.1. Summary of pH scouting responses from monoclonal mouse IgM antibody ES9. 






When choosing the immobilisation pH, it should be taken into account that amine 
coupling may be less efficient at lower pH as this method requires uncharged amine 
groups and low pH may also result in protein precipitation. 
5.2.2 Amine Coupling of Ligand to SPR Sensor Surface 
Once the optimal immobilisation pH was determined, the ligands were coupled to the 
sensor chip for use in analysis. A description of the coupling process is given in 
Chapter 2. The Biacore-XTM uses a reference flow cell, a flow cell that has been 
treated in the same way as the active flow cell, but has had no contact with ligand. 
The reference flow cell allows the user to perform reference subtraction of binding 
curves, where the effects of bulk refractive index changes are removed, as well as 
non-specific binding, from the response in the active flow cell. Reference subtraction 
can sometimes lead to irregular sensorgrams due to the short time delay in the 
sample reaching both flow cells. This is depicted in pale blue in Figure 5.4, which 
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shows the `reference subtraction' response (FC2-1). As any binding of analyte to the 
reference flow cell is due to non-specific binding, reference subtraction was 
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Figure 5.4. Sensorgram of amine coupling of IgM antibody, LA2. The level of antibody 
bound is shown by the red arrow - the response after deactivation, taken from the response 
in FC2-1, which was 33,368 RU. FC1, FC2 and FC2-1 indicate the responses from flow cell 
1, flow cell 2 and flow cell 2 minus 1 respectively. 
Figure 5.4 shows a sensorgram resulting from a typical amine coupling procedure. 
The mouse monoclonal antibody LA2 was coupled in this example, and it was used 
later in erythrocyte binding experiments. 
5.2.3 Immobilisation Level of the SPR Sensor Chip Surface 
When coupling a ligand to the SPR sensor chip surface, the potential maximum level 
of immobilisation can be calculated using the following equation: 
Ligand MW/15 = maximum ligand immobilisation RU 
deactivation 
e. g. for an IgM antibody molecule: 950kDa/15 = 63,333 RU 
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For the example in Figure 5.4 the amount of antibody bound was 33,368.3 RU. It is 
unlikely that the maximum level of binding would ever be reached due to the size of 
the IgM molecule, the presence of non-activated esters, or the removal of some 
ligand at the deactivation stage. 
In the Biacore-XTM, a response of 1,000 RU corresponds to a 0.1° shift in the SPR 
angle and equates to a surface concentration of 1 ng/mm2 for an average ligand on 
the CM5 chip (Fägerstam et al., 1990). So for the LA2,33.3683 ng/mm2 was bound. 
For an IgM molecule of size 950 kDa, this means that there are approximately 2.1 x 
1010 IgM bound per mm 2. 
5.3 Effect of Erythrocyte Concentration on Binding Response 
As erythrocytes were to be used in analysis, the optimal concentration was 
determined using ConA as a model ligand. This experiment would also determine if 
the assay microfluidic system would allow the flow of erythrocytes, and if the ConA 
could bind them to show a response. As ConA is a lectin with an affinity for 
mannose groups it is an ideal reagent for use in optimisation experiments involving 
erythrocytes, as it will bind irrespective of blood group. The optimal concentration 
for binding to ConA was to be used in subsequent experiment with antibodies. ConA 
requires the presence of Mn2+ and Ca2+ ions to bind to mannose, so this was included 
in the running buffer solution. Erythrocytes were suspended in Biacore running 
buffer-Mn/Ca, which was used as the running buffer in this experiment. Erythrocyte 
concentrations and results from this experiment are detailed in Table 5.2. 
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Table 5.2. Effect of erythrocyte concentration on binding to coupled ConA. 





The response increases with an increase in erythrocyte concentration. However due 
to the large difference in binding from 1.0 to 1.5 x 106 erythrocytes/ , ul, this 
experiment was repeated with a larger range of erythrocyte concentrations, and using 
immobilised anti-A LA2. 
In the repeat experiment, the buffer used was Biacore running buffer, and the cells 
were of blood group Al. The results are presented in Table 5.3, and the effect of 
concentration demonstrated in Figure 5.5. Here, the variability between 
concentrations is less variable. It was noted that there was a high level of variability 
between runs, but the mean value was used in the figure. The concentration of 1.76 x 
106 erythrocytes/pt showed the optimal results, although within the range of 1.51-2.4 
x 106, results are very similar. Higher concentrations were not analysed due to 
difficulties in injection over the flowcell caused by packed erythrocytes increasing 
the viscosity of the solution. All erythrocyte suspensions used in subsequent 
experiments were at a concentration of 1.76 +/- 0.2 x 106 //l. 
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Table 5.3. Effect of group A, erythrocyte concentration on binding to coupled anti-A LA2. 
Erythrocyte Concentration Response Response Mean 
(x 106 µL) (Run 1) (Run 2) Response (RU) 
0.95 5014.4 2442.9 3728.7 
1.36 5593.4 2033.2 3813.3 
1.51 10301.7 13028.7 9133.7 
1.76 15210 5977.3 10593.7 
2.05 6823.1 14724.3 9124.1 
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Figure 5.5. Line graph showing the effect of erythrocyte concentration on binding to anti-A 
LA2, using SPR. 
5.4 Effect of Erythrocyte Antigen Expression Level on Binding to 
Sensor Chip 
In Chapter 4 it was shown that different blood group erythrocytes show varying 
levels of binding to a blood typing microarray. Different erythrocyte phenotypes 
have different levels of blood group antigen expression on their surface. This can 
affect the detection of antigen. Table 4.6 (Chapter 4) details the average numbers of 
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blood group A antigen sites per erythrocyte from different phenotypes. If the average 
number of blood group A antigen sites per Al erythrocyte is 990,000, then a 50 p1 
suspension at 1.5 x 106 erythrocytes/ml will contain approximately 7.425 x 1013 
group A antigen sites. 
It would be expected that binding of different blood group erythrocyte types to an 
anti-A antibody would show a reduction in response as follows (group 0 and group 
B erythrocytes are suitable negative controls as there are no group A antigens 
present): 
A1 - A1B - A2 - A2B - A,, - A3 - O/B 
To investigate the binding of different erythrocyte phenotypes to an anti-A blood 
group antibody in the SPR solid-phase platform, monoclonal mouse IgM anti-A LA2 
was coupled to a chip and erythrocytes of different phenotypes were passed over the 
sensor chip surface. The resulting sensorgram can be seen in Figure 5.8 and the 
response levels in Table 5.4. The experiment was performed twice (runs I and 2). 
The level of repeatability of this analysis is evident when the results are displayed in 
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Figure 5.8. Sensorgram showing binding of different erythrocyte phenotypes to Anti-A (LA2), 
run 1 only. 
Table 5.4. Reactions of different erythrocyte phenotypes with Anti-A (LA2) antibody, results 
from runs 1 and 2, and serological haemagglutination potency results for comparison. 
Erythrocyte Response Response Potency by 
Phenotype (run 1) (run 2) haemagglutination 
A, 5351.5 5316.1 1024 
A2 3751.0 3874.6 512 
Al B 1558.3 702.5 512 
A2B 1126.5 1123.9 256 
B 384.8 452.6 negative 
0 387.0 308.5 negative 
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Figure 5.9. Line graph showing the repeatability in the reactions of different erythrocyte 
phenotypes with anti-A (LA2) antibody by SPR. 
Variation in the level of binding of different erythrocyte groups is evident and will be 
discussed at the end of this chapter. This experiment was repeated with further 
examples of A2 and A1B cells (identified as X, Y and Z) to determine if the LA2 
repeatedly binds A2 better than A1B. The repeat analysis was performed on a new 
chip over two days. The results are detailed in Table 5.5, and the repeatability 
demonstrated in a line graph, Figure 5.10. 
Table 5.5. Reactions of different erythrocyte phenotypes with Anti-A (LA2), results from 
repeat experiment. 
Erythrocyte Identification Response (Day One) Response (Day Two) 
A2 X 4,583.2 5,785.8 
A2 Y 2,762.2 2,525.0 
A2 Z 2,799.3 3,503.0 
A, B X 18,722.8 19,292.7 
AlB Y 7,900.4 10,108.4 
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Figure 5.10. Reactions of different erythrocyte phenotypes with anti-A (LA2), results from 
repeat experiment. 
On repeat the results are very different to the first experiment. The second 
experiment was performed with three examples of each type of erythrocyte, from 
three different donors so is, therefore, a fairer representation of the variety that exists. 
These results were repeatable over the two days. The haemagglutination results from 
the repeat experiment are shown in Table 5.6, and discussed at the end of this 
chapter. 
Table 5.6. Haemagglutination titration assay of A2 and A, B erythrocytes. 
Erythrocyte Titration End Point Titration Score 
A2 (first experiment) 512 109 
A2X 1024 122 
A2 Y 256 105 
A2 Z 512 107 
A1B (first experiment) 512 107 
A1B X 2048 136 
A1B Y 1024 115 
A1B Z 1024 115 
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5.5 Effect of FITC Labelling of Erythrocytes 
Fluorescent labelling of erythrocytes was used in Chapter 4 as a method to detect 
erythrocyte binding to a blood typing microarray. It is possible that the attachment of 
a fluorescent molecule may affect the structure of the erythrocyte surface, and 
therefore possibly affect antibody binding to blood group antigen. To determine if 
FITC labelling of erythrocytes affects their binding to antibody, both in liquid phase 
(haemagglutination assay) and solid phase (when antibody is coupled to a sensor 
chip) this experiment was performed. 
Erythrocytes of group Al and B were used. The group B cells were used to determine 
the effect of labelling on non-specific interactions. An aliquot of the erythrocytes 
remained unlabelled and another was FITC labelled. All cell samples were prepared 
to the same concentration as appropriate for the assay, therefore the same number of 
labelled and unlabelled cells was present in each sample. 
For the SPR assay the monoclonal mouse IgM anti-A LA2 was coupled to a chip and 
the erythrocytes were passed over the sensor chip surface. The potency determination 
was carried out using haemagglutination assay. 
Table 5.7. Effect of FITC labelling of erythrocytes on binding to LA2. 
Erythrocyte Response (run 1) Response (run 2) Potency by 
haemagglutination 
A, unlabelled 5351.5 5316.1 1024 
A, FITC labelled 1214.0 667.0 1024 
B unlabelled 384.8 452.6 0 
B FITC labelled 35.5 123.5 0 
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This shows that the FITC labelling results in an average of 82.37% reduction in 
specific binding to the LA2, and an 81.01% reduction in non-specific binding in the 
SPR assay. This is a large amount, and from this it was deduced that the labelling 
procedure was affecting the antibody-antigen reaction on this analysis platform. 
However, as the FITC labelling did not appear to restrict binding of cells to the blood 
typing microarray, this was later repeated using more examples of labelled and 
unlabelled cells. Table 5.8 details the results from the repeat experiment using two 
examples of group Al cells and a group B negative control. All conditions were the 
same as before. 
Table 5.8. Effect of FITC labelling of erythrocytes on binding to LA2, repeated. 
Erythrocyte Response (run 1) Response (run 2) Mean response (RU) 
A, unlabelled (1) 10301.7 13028.7 9133.7 
A, FITC labelled (1) 11261.2 5912.2 6376.0 
A, unlabelled (2) 8772 15268.2 12020.1 
A, FITC labelled (2) 15485.1 8728.4 12106.8 
B unlabelled -10.1 16 3.0 
In the repeat experiment, the FITC labelling did not appear to affect the binding of 
erythrocytes to the chip to the same level as in Table 5.8. 
5.6 Synthetic Antigen Binding 
Isolation of blood group antigens from the erythrocyte membrane can be 
problematic, especially when trying to retain the antigen in its functional state. 
Isolated and functional blood group antigen could potentially be used to evaluate the 
binding of different blood group antibodies, or could be used in the antibody 
screening of human serum samples. The blood group A and B antigenic determinants 
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are carbohydrate and can therefore be synthesised and conjugated to BSA. To 
determine if an immobilised antibody would specifically bind to synthetic 
carbohydrate antigen, an interaction analysis was performed using synthetic A and B 
antigens. The resulting sensorgram can be seen in Figure 5.11. The response from 
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Figure 5.11. Sensorgram of synthetic group A and B antigen binding to Anti-A LA2. 
Table 5.9. Synthetic A and B antigen binding to Anti-A LA2 on an SPR chip. 
Synthetic Antigen Response (first) Response (repeat) 
A 736.9 615.0 
B -43.0 0.7 
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The results show that the LA2 antibody specifically binds the synthetic group A 
antigen. Therefore, it was concluded from this experiment that the synthetic antigens 
could be useful in an experiment to `rank' the blood typing antibodies that are 
available and determine which may be suited for use in another solid phase system 
for blood typing. Also, the synthetic antigens were to be investigated for suitability 
for use in microarray-based blood group antibody screening methods (Chapter 6). 
5.7 Ranking of Antibodies Using Synthetic Blood Group A Antigen 
Synthetic group A antigen may be used to compare or rank several anti-A blood 
typing antibodies in terms of binding to that particular antigen. For the purpose of 
ranking, the antigen would be immobilised and the antibody becomes the target. This 
may be useful when selecting antibodies for use in microarrays. As some of the 
antibodies used in this project had also been purified by a different method, it could 
serve as a comparison of functionality when the antibodies have been processed 
differently. 
Synthetic blood group A antigen conjugated to BSA was coupled to a CM5 chip. A 
selection of available IgM anti-A blood group antibodies was prepared to a 
concentration of 50 pg/mL, before injection over the sensor chip surface. The 
antibodies had been purified by different methods; gel filtration denoted as (*) and 
by affinity column denoted as (**). The responses are presented in Table 5.10, and 
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Table 5.10. Responses in ranking of antibodies against synthetic group A antigen. 
Antibody Antibody Response Response Mean Rank 
Identification Specificity (first) (repeat) Response 
LA2 (**) Anti-A 9267.8 8431.1 8849.45 2 
LA2 (*) Anti-A 8114.3 7573.9 7844.1 4 
ES9 (*) Anti-A 12393.5 12503.1 12448.3 1 
DAM 1 (**) Anti-A 8112.7 7816.3 7964.5 3 
ES15 (**) Anti-A(B) 4605.1 4158.6 4381.7 5 
ES15 (*) Anti-A(B) 4369.0 3795.6 4082.3 6 
LB2 (**) Anti-B 83.1 39.7 61.4 7 
LB2(*) Anti-B -103.5 -177.8 -140.65 8 
The antibody ES9 gives the best response against the synthetic blood group A 
antigen, and therefore would theoretically perform better than the other antibodies in 
another solid phase system such as microarrays. This is a potential method for 
screening reagents for use in microarrays. 
5.8 Binding of Erythrocytes to Immobilised Anti-D Blood Typing 
Antibody 
The detection of the RhD antigen on donor and patient erythrocytes is vital for safe 
blood transfusion. The structure and location of the RhD antigen means that the 
isolation of a structural and functional antigen for evaluation is very difficult. 
Isolation may result in a linear polypeptide chain that is unrepresentative of the 
antigen epitopes and therefore is unlikely to be recognised by anti-D. It is possible to 
synthesise peptides that represent RhD antigen epitopes but these are outwith the 
detection levels of the SPR system (approximately 1,500 Da), but could possibly be 
used if conjugated to a larger molecule for immobilisation e. g. BSA. 
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Blood typing microarrays using anti-D of both immunoglobulin class IgG and IgM 
had been attempted in Chapter 4, but were unsuccessful in the early stage 
development. The interaction analysis provided by SPR was used to determine if 
specific binding could be detected. Experiments included immobilisation of both IgG 
(ESD1) and IgM (LDM3) purified antibodies but no binding was detected. 
Erythrocytes of different Rhesus phenotypes were used in the study. Those of types 
R1R1, R1r and rr were selected and the number of RhD antigens present on each is on 
average 22,900,14,600 and zero respectively (reviewed in Daniels, 2002). No 
binding was evident with any sample during SPR analysis. Papainised erythrocytes 
were also passed over the flow cell and again no reactions were detected. 
All antibody ligands used in this experiment were tested in liquid phase 
haemagglutination techniques and found to react strongly with the RhD positive cells 
used in the SPR assay. During the development of the blood typing microarray in 
Chapter 4, several anti-D were found to react with RhD positive erythrocytes only 
once procedures had been optimised. This subject is discussed in more detail at the 
end of this chapter. 
5.9 Chapter Discussion and Conclusions 
5.9.1 Chapter Discussion 
The Biacore-XTM is a useful tool for the real-time analysis of antibody-antigen 
interactions, although there are other SPR systems available (Gizeli & Lowe, 1996). 
Biacore SPR gives reproducibility and sensitivity in experiments. However, one 
major disadvantage of the Biacore-XTM is the low throughput. 
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Initially in this chapter, the Biacore platform was optimised for use in the subsequent 
experiments. The first step was to determine the optimal pH of each ligand prior to 
immobilisation. However, the pH scouting exercise is only an indication of the 
optimal binding pH. The accurate optimal binding pH is determined by the amine 
coupling procedure. Using amine coupling for this purpose would mean the use of 
multiple chips and large quantities of ligand, which is impractical. Following 
recommendations by an expert in the field (Dr. P. Brown, Medical Research 
Council), the pH identified as optimal during pH scouting was used in the coupling. 
Another consideration is the possible change to the ligand function when 
immobilised at low pH. The buffer used during interaction analysis is optimal for the 
interactions and therefore, the specific binding of ligand would not be expected to 
change, unless it has been denatured by the low pH. 
Following pH scouting, immobilisation procedures by amine coupling were 
evaluated and suitable conditions established for the procedure. IgM and IgG 
antibodies, lectin and synthetic blood group antigen were all coupled for use in SPR 
analysis. The maximum immobilisation for each ligand was calculated, and routinely 
the actual level immobilised was around 50 % of the calculated maximum. The use 
of amine coupling means that ligands are attached via free amino groups on the 
molecule. An IgM antibody is a large molecule (approximately 950 kDa) that may 
bind more than once to the sensor chip surface. The antigen binding sites of antibody 
molecules could be coupled to the sensor chip surface, making the antibody/antigen 
reaction more unlikely. Therefore, using amine coupling with antibody molecules 
means that the orientation of the antibody is random. 
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The analyte binding capacity of the chip surface is highly dependent on the quantity 
of ligand bound, as well as the integrity and activity of the ligand. At saturation 
(when all activated sites are coupled with ligand) this is known as the maximum 
response (Rmax) and can be calculated as follows: 
(Rma,, ) = analyte MW/ ligand MW x immobilised amount x stoichiometric ratio 
For example, the R.,, if using synthetic group A antigen as analyte and monoclonal 
mouse anti-A (LA2) as ligand, may be calculated as follows: 
82,563/950,000 x 33,368.3 x 10 = 28,999.863 maximum response 
This experiment was performed in 5.6, where the response found was only 2.5 % of 
this R,,, a,,, demonstrating that the theoretical value is not met. This may be due to the 
presence of non-activated sites, inactive ligand/analyte, or removal of ligand at 
deactivation stage. It may be possible to increase the response by activating the 
surface for longer time periods or running the interaction analysis for longer. 
However, when using relatively large molecules as analyte the importance of 
saturation of the surface is debatable. For example, an erythrocyte (7.8-8.3 '"m 
in 
diameter) may give the same response on binding to one IgM molecule as it would if 
it were to bind to 10 due to saturation of the surface with the large erythrocytes. The 
actual value obtained may be sufficient to perform analysis. Therefore, saturation of 
all possible ligand immobilisation sites may not be required to produce a measurable 
response. 
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Following process optimisation procedures, erythrocytes were used in the Biacore. 
Using immobilised ConA and anti-A LA2, the optimal erythrocyte concentration for 
use in SPR was determined. This work also allowed the optimisation of conditions 
for erythrocyte-antibody analysis. The SPR platform was used to analyse interactions 
between antibody and erythrocytes. It was found that the binding response of 
different blood group erythrocytes to immobilised antibody varied depending on 
blood group and antigen expression. This phenomenon is expected and has been 
reported in other solid-phase methods such as those on microplates (Scott, 1991) and 
was observed in experiments in Chapter 4 (Figure 4.14). 
A2 erythrocytes bound to anti-A LA2 to a higher level than AIB. This may be 
indicative of the fit of this antibody-antigen interaction i. e. the LA2 antibody may 
find the group A antigen site less accessible if the B antigen is present. It may be that 
the group A2 cells selected had an exceptionally high level of antigen expression, or 
that the AIB sample selected had less AI antigen than average i. e. much of the 
available H sites (refer to Chapter 1,1.2.1.1) have been converted to group B rather 
than AI. This cell line has always shown similar reactivity with AI, A2 and AIB 
erythrocytes when tested in haemagglutination assays (personal communication, 
Professor R. Fraser, SNBTS R&D). However, in this SPR assay it showed a marked 
difference in reactivity between A2 and AIB. 
This experiment was repeated with blood samples from three different donors. It 
could be assumed that the A2 erythrocytes used in the first experiment were unusual 
in their expression of blood group antigen A i. e. they had an unusually high level of 
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A antigen for a group A2. To investigate this, potency determination by 
haemagglutination assay was performed (Table 5.7). From the serological 
haemagglutination assay carried out it appears more likely that the A1B had a lower 
than average level of antigen, therefore it reacted similarly to the A2. 
Although the levels of binding were marginally lower in the second round of the 
experiments the trend was the same. The drop in response levels may be due to some 
loss of ligand during the regeneration phases, or from the incomplete removal of 
erythrocytes, or erythrocyte fragments. Data from this experiment demonstrated that 
SPR offers a repeatable test platform for antibody-erythrocyte assay, and that the 
response is sensitive enough to demonstrate antigen level variation. This also 
confirms the trend found when using the blood typing microarray as another solid- 
phase format. When reactions of the probe antibody LA2 were compared between 
SPR and microarray platforms, the results both demonstrated the same drop in 
response/reactivity as was expected from a reduction in antigen site density of the 
erythrocytes used (i. e. Al to A1B to A2). 
Analysis of FITC labelled cells showed that the labelling procedure was affecting the 
antibody-antigen reaction on this analysis platform, and indicated that perhaps the 
erythrocytes should be unlabelled for optimal detection. Due to this discovery and 
the fact that FITC labelling is unlikely to be compatible with routine blood testing, 
methods for the detection of unlabelled erythrocytes were investigated (detailed in 
Chapter 4). As FITC labelling did not appear to affect erythrocyte binding to a blood 
typing microarray the experiment was repeated. On repeat the FITC labelling did not 
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affect the binding of the cells to the sensor chip. This inconsistency may have been 
due to age of the cells at the time of labelling, those that are older being more 
affected by the FITC treatment involving increase of the pH of the sample. Due to 
the nature of these results, it was concluded that it would be worthwhile investigating 
alternative forms of detection. 
Using immobilised anti-A LA2, specific binding of synthetic blood group A antigen 
was demonstrated. Due to this result, it was decided to use this antibody-antigen 
pairing in reverse, where the synthetic antigen was immobilised and used to analyse 
antibody. This was used to compare, or rank, several blood group antibodies in an 
effort to determine suitability for use in solid-phase testing. The SPR analysis 
showed that the antibodies performed in the order ES9-LA2/DAM1-ES15 where ES9 
was the best reactor. Data from blood typing microarrays has shown that the 
antibodies ES9 and LA2 perform very similarly. Figure 4.14 (Chapter 4) showed the 
binding of different blood group erythrocytes to these antibodies at similar 
concentration (ES9 at 40.5 and LA2 at 55.0 pg/ml). In microarrays against group 
A1B cells, the ES9 performed better than the LA2, but against A2 and A. cells they 
were very similar. When looking only at reactions with cells of group A1B, the 
reactions followed that described in the SPR experiments i. e. ES9 was best followed 
by LA2 and ES 15. The experiment also showed that the antibodies purified by the 
different methods gave very similar results when tested, and the high level of 
repeatability of SPR. The method developed here could potentially be used to screen 
potential antibody probes and be useful for their selection for use in solid-phase 
systems, such as microarrays. 
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In the early stage development, anti-D blood typing by microarray had shown no 
success. SPR was used as an alternative solid-phase system to determine if the anti-D 
antibodies would bind RhD positive erythrocytes. Erythrocytes of varying RhD 
antigen expression were used and no SPR response was recorded. 
Enzymes such as papain are often used in blood typing serological methods to 
enhance the agglutination reactions between certain antibodies and antigens. Papain 
treatment of erythrocytes removes some blood group antigens from the surface of the 
cell and lowers the sialic acid level, and therefore the overall charge on the cell. This 
can enhance the antibody and antigen interaction since they are more accessible to 
each other, and a reaction may take place which otherwise may not. The use of 
papainised cells is known to enhance detection of anti-Rhesus antibodies, but did not 
give a binding response in SPR analysis. 
It has been reported (John Allan, Director Alba Bioscience, personal communication) 
that the presence of surfactant agents such as Tween can affect the antigen binding 
capacity of some anti-D reagents. The level of surfactant in the running buffer used 
in the SPR is necessary for injection of the viscous erythrocyte suspension, and is 
also at such a low level that it is unlikely to interfere with an antibody-antigen 
interaction. 
Rhesus grouping by microarray became successful during the development of the 
blood typing microarray (Chapter 4), where reactivity of a large panel of anti-D 
antibodies was evaluated. Anti-D which showed microarray reactivity included 
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ESD1 (IgG) but not LDM3, in fact no IgM anti-D was reactive. Therefore, it was 
concluded that the use of a solid phase format for attachment of anti-D antibodies 
must somehow interfere with the function of some anti-D antibodies. As they are all 
reactive in liquid phase, it may be that the attachment restricts conformational change 
of the antibody and does not allow the antigen-binding site to manoeuvre to fit the 
antigen. The problem may lie with the accessibility of the antigen site on the 
erythrocyte. As the antigens are integral to the membrane the antibody may not come 
within the proximity required to interact with the antigen and the erythrocytes 
bounce off the surface of the chip due to the flow. The flow may cause reduced 
interaction, as cells only cross the surface in one direction and are not mixed like in 
microarray. 
SPR technology can use a variety of immobilisation methods to capture ligand on the 
sensor surface. Given the problems associated with RhD antigens, especially their 
requirement to be inserted into the membrane, then the technology of liposomes 
could be used to immobilise membrane proteins. Liposomes are fluid filled pouches 
made up of phospholipids resembling cell membranes and work by accommodating 
proteins and allowing them to take on their natural state. If isolated RhD proteins 
were available this may be one system that could be used to study the interactions 
with antibodies. Another option is the use of peptides that represent the antigen 
epitopes. However, the peptides may require conjugation to larger molecules for 
immobilisation due to their size, which could be below the detection limits of SPR. 
Were either of these methods successful, they could potentially be used in a 
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microarray system for antibody screening purposes. These are areas of further 
research identified from this work. 
This SPR work has provided much useful information that can be applied when using 
the same reagents in blood typing microarrays. It has provided a more detailed 
interaction analysis than can be obtained in microarray. The use of microarray gives 
a yes or no answer, which is what is required in diagnostics. SPR has demonstrated 
the effect of solid phase immobilisation on the reactivity of antibodies, the effect of 
fluorescent labelling and concentration of erythrocytes, has differentiated the 
reactivity of several antibodies of same specificity, and has shown the ability of 
antibodies to bind erythrocytes expressing different levels of antigen. 
It is doubtful whether this platform could be suitable for high throughput testing 
which is required for routine blood donation diagnostics. In Scotland alone, over 
1000 blood donations are tested every 24 hours. Sensor chips would have to be 
developed onto which many different ligands could be immobilised and then the 
technology to be able to evaluate the reactions of one analyte sample with every 
ligand. The system would also have cost implications as it would possibly be 
prohibitively expensive. Any new method for blood donation diagnostics would have 
to compete with the existing costs and timescales of current testing. The fact that the 
SPR response does not differentiate between specific binding of analyte and non- 
specific binding from the analyte solution also questions the systems use in medical 
diagnostics. In this study washed erythrocytes were used. The use of whole blood, 
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which may be required for full donation testing, may lead to high levels of non- 
specific binding caused by high protein levels. 
5.9.2 Chapter Conclusion 
" Use SPR as an established solid phase reference technology and as a control for 
the new solid phase microarray technologies presented in earlier chapters. 
SPR was used as a long established platform for the study of protein interactions, 
and therefore enabled a comparison with data gained in microarrays. The ABO 
blood group antibodies all reacted with antigen using SPR and microarray, but 
Rhesus D typing was not facilitated by the SPR format. 
" Measure the reactivity of antibody immobilised on a solid surface, supplementary 
to protein microarrays. 
SPR in the form of Biacore has been used to demonstrate specific binding of 
erythrocytes to immobilised antibodies, and thus has confirmed the findings of 
the blood typing microarray work carried out in Chapter 4. This stage has shown 
that immobilised antibodies are reactive in solid-phase and can show differential 
binding of different blood group antigens on erythrocytes. 
" Compare antibodies using SPR and indicate their suitabilityfor use on a solid- 
phase. 
Using a reverse arrangement with immobilised antigen (synthetic), the SPR 
system was used to rank antibodies to allow an insight into which perform well in 
a solid-phase system. 
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" Compare the interaction of different erythrocyte types and conditions with 
immobilised antibody. 
As SPR does not rely on labelling of analyte for detection, and therefore allowed 
a study of the effect of erythrocyte binding to the array when fluorescently 




ANTIBODY SCREENING BY MICROARRAY 
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6. BLOOD GROUP ANTIBODY SCREENING BY MICROARRAY 
6.1 Introduction and Chapter Aims 
As described in Chapter 1 (1.3.1), erythrocyte antibody screening and reverse 
antibody screening are mandatory components of blood donation testing. This 
chapter looks at the development of a novel microarray-based technique for blood 
group antibody screening, which involves the immobilisation of antigens for 
detection of antibodies. 
The result of reverse antibody screening is used to confirm the forward ABO blood 
typing performed. To perform reverse ABO grouping of donors and patients, the 
current guidelines (U. K. Blood Transfusion Services, 2002) state that, as a minimum, 
plasma/serum should be tested against cells of type Al, B and O. Cells used for this 
purpose may be pooled donations from individuals of identical ABO group. 
Guidelines for testing of blood donors and recipients varies with respect to 
erythrocyte alloantibody screening, and the minimum blood group antigens required 
for each use are: 
Donor testing: D, C, c, E, e, K 
Patient testing: D, C, c, E, e, K, k, Fya, Fyb, Jka, Jkb, S, s, M, N, P1, Lea, Leb 
(For full characterisation of antigens see Table 1.4). 
Cells for patient testing must be from a minimum of two individuals, should not be 
pooled and at least one cell phenotype should be Rhesus R2R2 and another RIRI 
299 
(Guidelines for the Blood Transfusion Services in the United Kingdom, U. K. Blood 
Transfusion Services, 2002) (for descriptions of Rhesus phenotypes see Table 4.10). 
Homozygous Fya, Fyb, Jka, Jkb, S, and s expression of antigens is also recommended. 
All reagent erythrocytes for this purpose must be group 0, should not express blood 
group antigens present in less than 1% of the population, and should not be used if 
shown to cause reactions with Human Leucocyte Antigen (HLA) specific antibodies. 
HLA antigens, if present, can cause unwanted clinically insignificant reactions with 
certain HLA antibodies. 
The principles of solid-phase testing are outlined in Figure 6.1. Existing solid-phase 
methods use either immobilised erythrocyte membranes or anti-human globulin 
reagents. Erythrocyte antibody screening by microarray has not been described yet in 
the available literature. 
For comprehensive blood testing, the inclusion of an antibody screen is mandatory. 
As the use of the microarray format for blood typing has already been demonstrated 
in this thesis, this chapter will look at the use of this format for erythrocyte antibody 
screening. For this purpose, different forms of antigen presentation will be used: 
whole erythrocytes which retain the antigens in their native environment, erythrocyte 
membrane (protein) fragments which contain integral and membrane-associated 
proteins in a non-denatured state based on their association with cellular membranes, 
and synthetic carbohydrate antigens conjugated to BSA. 
Therefore, the aims of this final stage of the project were: 
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" Investigation of different slide surface chemistries for the immobilisation of 
novel blood group antigens. 
" Evaluation of blood group antigens in a variety of forms for their use in antibody 
screening - whole erythrocytes, erythrocyte membrane (protein) fragments and 
synthetic antigens. 
Preparation of solid substrate 
1 
Solid substrate coated with blood group antigen 
Blocking vPP 
Test plasma/serum added 
incubation period 
Wash to eliminate unbound serum/proteins 
1 Secondary antibody added (to detect bound IgG/IgM) 
I 
Read test 
Figure 6.1. Basic principles of solid phase antibody screening. 
Details of all methods and reagents used can be found in Chapter 2. The information 
that defines the protein microarray printing, processing characteristics and target 
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solutions for each experiment will be detailed in the figure legends, and as used in 
Chapters 3 and 4. 
6.2 Evaluation of Erythrocytes and Membrane Protein Fragments for 
Antibody Screening 
This experiment was performed to determine whether whole erythrocytes and 
erythrocyte membrane (protein) fragments could be immobilised on microarrays. For 
this, manual microarraying was employed for quick preliminary analysis. 
Manual spotting has advantages for an early stage experimental design, when only a 
few slides of a particular kind need to be printed, but under a variety of conditions. 
The microarray work performed previously has been prepared using robotic arrayers 
and standardised equipment. There is no difference in principle between manual and 
programmed robotic printing. A large pin size of 900 pm was used throughout this 
chapter, chosen so that the spots could be seen macroscopically, and large amounts 
of probe could be deposited. 
As it had been shown previously in this work that poly-L-lysine slides could be used 
for immobilisation of antibodies, it was decided to use these initially to determine if 
whole erythrocytes and erythrocyte membrane (protein) fragments could be 
deposited and retained. As the poly-L-lysine coating gives the slide surface an 
overall positive charge, this surface should retain the negatively charged cells. Scott 
(1991) had previously shown that poly-L-lysine coated microplates could be used to 
immobilise erythrocytes. 
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The probes printed for this experiment are described in Table 6.1. Whole 
erythrocytes were washed in PBS, and then re-suspended to represent the 
haematocrit of whole blood plus doubling dilutions in PBS (starting at 1 in 4). One 
dilution was used to represent the same number of cells as there was used to prepare 
the erythrocyte membrane (protein) fragments, which were spotted neat and at one 
dilution in PBS. 
Table 6.1. Identity and concentration of probes used in experiment in 6.2. 
Probe identity Concentration (no. of cells//A) 
Erythrocyte membrane protein fragments (membranes) 0.14 x 10 
Erythrocyte membrane protein fragments (membranes) 0.07 x 105 
Whole erythrocytes (Whole RBC) 0.14 x 105 
Whole erythrocytes (Whole RBC) 0.28 x 106 
Whole erythrocytes (Whole RBC) 0.56 x 106 
Whole erythrocytes (Whole RBC) 1.13 x106 
Whole erythrocytes (Whole RBC) 4.5 x 106 
Erythrocyte membrane (protein) fragments were extracted from erythrocytes as 
described in Chapter 2. FITC labelled wheat germ agglutinin (FITC-WGA) (Triticum 
vulgaris lectin) was diluted in PBS-BSA and added as target solution. WGA 
recognises N-acetyl-D-glucosamine (G1cNAc) and N-acetyl-D-neuraminic acid 
(NeuAc) residues (Krotkiewska et al., 2002), which are attached to the erythrocyte 
via glycophorins (reviewed in Schenkel-Brunner, 2000). Values from PBS spots 
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Figure 6.2. Results from spotting of whole erythrocytes and membrane protein fragments 
onto poly-L-lysine slides with FITC WGA 33.3, ug/mi added as target. Slide type poly-L- 
lysine, slide reps 1, pins 900 pm, probes Table 6.1, probe reps 3, SPM E; blocker PBS-BSA, 
target/volume: FITC WGA/450, u1, incubation time 60min, mixing, scanning method C, data 
processing method B. 
The results (Figure 6.2. ) show that whole erythrocytes, at the highest concentration, 
give the strongest S/N value of over 115. The values from the erythrocyte membrane 
(protein) fragments are very low. Whole erythrocytes spotted at the same 
concentration used to prepare the membrane (protein) fragments (0.14 x 105) gave a 
low S/N value of 2.49, and the membrane (protein) fragments were lower. This could 
be due to the concentration of membrane (protein) fragments being too low, or that 
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FITC WGA does not interact with the membrane proteins and the procedure has 
removed the glycophorins and/or the carbohydrate residues, or that the poly-L-lysine 
surface does not retain them. It was decided to prepare the membrane fragments at a 
higher concentration. As expected, the poly-L-lysine surface retained the whole 
erythrocytes due to the positive charge on the slide and the negative charge on the 
cells. 
6.3 Whole Erythrocyte Antibody Screening 
As the experiment in 6.2 demonstrated that the poly-L-lysine surface was able to 
immobilise and retain whole erythrocytes, further experiments involving whole cells 
were attempted. For this purpose, other surfaces were explored. The slide types used 
were GAPS (prepared by Dr. D. Pepper), BioGold (Erie Scientific), ZetaGrip and 
SuperProtein (Arrayit). For details of suppliers refer to Appendix 1. The slide 
surfaces used here are discussed later in further detail. All were used for their protein 
binding properties. The probes printed for this experiment are described in Table 6.2 
and were prepared in PBS. 
Table 6.2. Identity of probes printed in experiment detailed in 6.3. 
Probe 
Group A RhD positive 
Group A RhD negative 
Group B RhD positive 
Group B RhD negative 
Group 0 RhD positive 
Group 0 RhD negative 
Synthetic group B antigen 
Probe ID in figures Concentration 
A RhD pos 4.5 x 108/µI 
A RhD neg 4.5 x 108/µl 
B RhD pos 4.5 x 108/µl 
B RhD neg 4.5 x 108/µI 
O RhD pos 4.5 x 108/µl 
O RhD neg 4.5 x 108/µI 
Synthetic B Ag I mg/ml 
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Once printed and processed, the target and detection antibodies were used as detailed 
in Table 6.3. Concentration of the monoclonal antibodies prior to dilution is detailed 
in Chapter 2 (affinity purified antibodies). Prior to the experiment, the ABO group of 
the human anti-D serum was not known, but it had a potency of 1/256 against group 
O Rlr cells. The human group 0 serum contained both anti-A and anti-B at a potency 
of 1/32 against group Al and B cells. 
Table 6.3. Identity of target and detection antibodies used in experiment in 6.3. 
Target Antibody (dilution) Detection Antibody (concentration) 
Monoclonal Anti-A LA2 (1/50) FITC anti-mouse IgM (33.3 pg/ml) 
Monoclonal Anti-B LB2 (1/50) FITC anti-mouse IgM (33.3 pg/ml) 
Monoclonal Anti-D LHM169/80 (1/50) Cy3 anti-human IgG (33.3 pg/ml) 
Human anti-D serum (1/10) Cy3 anti-human IgG (33.3 pg/ml) 
Human group 0 serum (1/10) Cy3 anti-human IgG (33.3 pg/ml) 
The results are compiled so that the reactions of all five different target antibodies 
evaluated on the same slide type are displayed together in Figures 6.3a-d. The error 
bars show the standard error from the replicate spots. Figure 6.5 shows the results 
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The GAPS (y-aminopropylsilane) surface has positively charged amino groups 
(NH3) as demonstrated in Figure 6.4, which will bind negatively charged molecules 
electrostatically. 
++ -+- NHs NH3 NH3 
Figure 6.4. Schematic of GAPS slide surface (arrayit. com). 
High levels of S/N are evident both with monoclonal anti-A and anti-B against the 
group A and group B whole erythrocytes respectively using the GAPS slides (Figure 
6.3a), also the anti-B reacts specifically with the synthetic B antigen. The dilution 
factor of both the target and the detection antibodies requires optimisation to reduce 
the NSB of these antibodies to other cells, which although present are much reduced 
than those expected positive results. 
The method of binding of proteins to gold surfaces may be via thiol groups of 
proteins (the -SH groups of cysteine). The reactions on the gold slides (Figure 6.3b) 
show high S/N values. Again, monoclonal anti-A and anti-B give good results, with a 
level of NSB. While the reactions with monoclonal anti-D are examined again later, 
the reactions of the group 0 serum are clearly non-specific and reasons for this are 
reviewed in the chapter discussion. 
The ZetaGrip coating is a micro porous polymer that binds proteins via hydrophobic 
interactions (arrayit. com). The results from these slides (Figure 6.3c) do not show 
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the expected pattern. Both monoclonal anti-A and anti-B react with only one of two 
cells, which should be positive. 
The SuperProtein surface also binds proteins via hydrophobic interactions. There are 
specific reactions (Figure 6.3d) with the monoclonal anti-A and anti-B, with the 
anti-B also interacting with the synthetic B antigen. 
When each specificity was examined separately, it was noted that the monoclonal 
anti-D gave weak but specific reactions on the BioGold surface. The bar chart in 
Figure 6.5 shows that although giving a low SIN value, it is clear the reactions of the 
monoclonal anti-D are specific on the gold surface, but not on any other surface. 
6.4 Retention of Erythrocyte Membrane Protein Fragments on Various 
Surfaces 
In the experiment in 6.2, an erythrocyte membrane (protein) fragment preparation 
was spotted, but possibly at too low a concentration for detection. It was also not 
determined if the fragments were actually retained on the surface. This experiment 
was performed to examine the extent to which different surfaces could retain 
membrane (protein) fragments, using fragments prepared from FITC labelled 
erythrocytes. The probe erythrocyte fragments were prepared at two concentrations 
(Table 6.4). 
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Using these preparations, the slides were processed routinely but with no detection 
solution added, as the fragments were FITC labelled and would be detectable 
directly. The slides were scanned at three stages in the process, each slide always at 
the same PMT value. Various slides were used in this experiment in an attempt to 
find a surface that could retain the membrane (protein) fragments effectively. Table 
6.5 describes the slide surface coatings used in this experiment. 
Table 6.4. Probes used to demonstrate retention of membrane protein fragments on various 
microarray surfaces. 
Probe Identity Concentration (cells per MI) 
FITC labelled erythrocyte membrane protein fragments 0.14 x 105 
FITC labelled erythrocyte membrane protein fragments 0.625 x 105 
The data presented shows the actual fluorescent values from each slide type at the 
stages; spotting, blocking and processing for the higher membrane fragment 
concentration only (0.625 x 1051 Al) and is shown in Figure 6.6. 
The actual fluorescent values between different slide surface coatings cannot be 
compared directly, due to slide-to-slide variation. From Figure 6.6 it is clear that 
most slides followed the same pattern; a high fluorescence value which drops after 
blocking and even more so after full processing. There are two exceptions to this and 
they are the ZetaGrip and SuperProtein slides. The results for these two slide types 
increase after blocking, which cannot be explained unless a component of the 
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The BioGold slides showed good results when using whole erythrocytes, but when 
using erythrocyte membrane (protein) fragments the effect is opposite. It is clear that 
different surfaces are more suited to certain purposes. This has been demonstrated 
before in Chapters 3 and 4. In the processing of this experiment (after incubation 
with mock target solution) the surfactant Tween was used to wash the slides. Tween 
is incompatible with the ZetaGrip slides and with membranes. Therefore, the actual 
fluorescence results were used to calculate percentage retention following blocking 
only, and are in Table 6.6. 
Table 6.6. Comparison of erythrocyte membrane protein fragment retention on different slide 










































The results highlighted in grey (Table 6.6) show that FITC labelled erythrocyte 
membrane (protein) fragments were bound more to those slide coatings. These slides 
were selected for further experiments. The BioGold slides were also selected as they 
had previously shown to retain whole erythrocytes on their surface. 
6.5 Antibody Screening Using Whole Erythrocytes and Membrane 
Protein Fragments on Selected Slide Surface Coatings 
Experiments performed thus far have shown that gold coated slides can bind whole 
erythrocytes to successfully perform antibody screening, and that P4VP, ZetaGrip 
and SuperProtein coated slides can retain erythrocyte membrane (protein) fragments. 
The following experiment was performed to determine if antibody screening could 
be performed on these slide types. 
Erythrocyte membrane fragments were prepared at the highest concentration (as 
described in Chapter 2 and in previous experiment) and spotted onto the various slide 
types. Also spotted were the whole erythrocytes used to prepare the membrane 
fragments, where available, and the antibodies that were later used as targets. The 
target antibodies were printed to give a positive control for the detection antibody. 
Target and detection antibodies are described in Table 6.7. The anti-A and anti-B 
had previously been shown to detect whole erythrocytes in a microarray format. The 
antigens to which they are directed are carbohydrates. The anti-K is directed to the K 
antigen, a glycoprotein molecule (see Table 1.4), which is close to the erythrocyte 
membrane and, therefore, may be less accessible for detection. 
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Table 6.7. Identity of target and detection antibodies used in experiment in 6.5. 
Target antibody (dilution) Detection antibody (concentration) 
Monoclonal anti-A LA2 (1/50) FITC anti-mouse IgM (33.3 pg/ml) 
Monoclonal anti-D LHM169/80 (1/50) Cy3 anti-human IgG (33.3 pg/ml) 
Monoclonal anti-K (MS56)(1/50) Cy3 anti-human IgM (33.3 pg/ml) 
The results from this experiment are presented in Figures 6.7a-d. The fluorescence 
values are used as data points in these figures, and are arranged in a descending 
numerical order to aid the interpretation of the results. The values given are the 
average of the duplicate spots for each sample (no error bars). 
When scanning the slides in this experiment it was noticed that there were many 
black holes on the scan images. These can arise where blocking is inadequate and 
leads to NSB around the spot, or perhaps where there is free fluorescent label in the 
detection solution (i. e. the post-labelling washing was not sufficient). As some of 
these were present, the actual fluorescence value is used rather than a S/N ratio. In 
the charts, MP is the erythrocyte membrane (protein) fragments and WC refers to the 
whole cells. 
Figure 6.7a shows the results from the P4VP slides. Where anti-A was used, the 
reactions are greater with the control anti-A, the Al and A2B membrane protein 
fragments, but not largely greater than the other fragments present. The anti-D results 


































































































































































































Figure 6.7a. Results from P4VP slides with target antibodies anti-A, anti-D and anti-K. Slide 
type P4VP, slide reps 1, pins 900 pm, probes detailed on x-axis, probe reps 2, SPM E; 
blocker PBS-BSA, target/detection Table 6.7, incubation time 60min, mixing, scanning 




The anti-K gives stronger reactions with some of the membrane (protein) fragments 
that are K positive on the P4VP slides (Figure 6.7a), but gives non-specific reactions 
with other fragments and whole cells. In general, the fragments are giving the greater 
fluorescence values. This could be showing that they are retained on the surfaces, 
that they are presenting antigen to be able to detect target, or that they are more likely 
to give false positive results. 
The gold-coated slides had been shown to retain whole erythrocytes on the surface 
and were shown to give specific antibody screening for monoclonal anti-A, anti-B 
and anti-D. In this experiment the results (Figure 6.7b) are encouraging but not as 
clear. When anti-A was the target the highest fluorescence values are from the anti- 
A, the MP A1, the WC A2B, anti-D and WC A1. The reaction with anti-D may result 
from cross reactivity of the anti-mouse IgM. The anti-D target gives strongest 
reactions with the WC and MP OR1R2 but does not react consistently with the other 
probes. Where anti-K was the target the strongest reaction results are with the anti-A 
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Figure 6.7b. Results from BioGold slides with target antibodies anti-A, anti-D and anti-K. 
Slide type BioGold, slide reps 1, pins 900 »m, probes detailed on x-axis, probe reps 2, SPM 
E; blocker PBS-BSA, target/detection Table 6.7, incubation time 60min, mixing, scanning 
method C, data processing method B. 
322 
Results from the ZetaGrip slides had shown that the surface retained membrane 
(protein) fragments. The reactions with the anti-A target are highest with the 
expected positives (Figure 6.7c) apart from with the MP OR1R1. The reactions of the 
target anti-D on the ZetaGrip is encouraging as the MP results are higher for all the 
RhD positives, but the reaction from the MP A1rr results are showing some cross- 
reactivity. In the anti-K target slide the same cross-reactivity of the detection 
antibody with the anti-A is evident. Otherwise the results look promising with the 
MP K positives giving greater values. 
The SuperProtein slides had also shown they retained membrane fragments, and 
when target anti-A was used, the highest values are given from MP and WC of group 
Al erythrocytes (Figure 6.7d). The anti-D slide gives strongest reactions with all the 
MP probes, and therefore looks non-specific. On the SuperProtein slides the anti-K 
does react most strongly with one of the K positive MP probes, but is not consistent 
with other K positive probes. 
In conclusion, this experiment has given variable results with some encouraging high 
fluorescence values with specific probes, and some non-specific reactions. When 
using monoclonals of three different sources (mouse IgM, human IgG and human 
IgM) the detection antibodies are also of importance and it is noted that the detection 
antibodies used have given cross reactivity previously (Chapter 3). This may give 
rise to some of the unwanted results here if they cross-react with molecules of the 
MP and WC probes. 
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Figure 6.7c. Results from ZetaGrip slides with target antibodies anti-A, anti-D and anti-K. 
Slide type ZetaGrip, slide reps 1, pins 900 »rtn, probes detailed on x-axis, probe reps 2, SPM 
E; blocker PBS-BSA, target/detection Table 6.7, incubation time 60min, mixing, scanning 
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Figure 6.7d. Results of SuperProtein slides with target antibodies anti-A, anti-D and anti-K. 
Slide type SuperProtein, slide reps 1, pins 900 »m, probes detailed on x-axis, probe reps 2, 
SPM E; blocker PBS-BSA, target/detection Table 6.7, incubation time 60min, mixing, 
scanning method C, data processing method B. 
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6.6 Antibody Screening Using Whole Erythrocytes, Membrane Protein 
Fragments and Synthetic Antigens on Selected Slide Surfaces 
As both BioGold and SuperProtein slides have shown some success for the purpose 
of retaining whole cells, cell fragments and synthetic antigens, these were used here 
to perform further experiments. 
BioGold and SuperProtein slides were used and probes are detailed on the results 
figures. These included erythrocyte membrane (protein) fragments (MP) and whole 
erythrocytes (WC), plus synthetic A and B blood group antigens conjugated to BSA. 
The synthetic antigens were spotted at 1 mg/ml. The target and detection antibodies 
are detailed in Table 6.8. 
Table 6.8. Identity of target and detection antibodies used in experiment in 6.6. 
Target antibody (dilution) Detection antibody (concentration) 
Monoclonal anti-A LA2 (1/50) FITC anti-mouse IgM (33.3 pg/ml) 
Monoclonal anti-B LB2 (1/50) FITC anti-mouse IgM (33.3 /Q/ml) 
Monoclonal anti-D LHM169/80 (1/50) Cy3 anti-human IgG (33.3 IQ/ml) 
Polyclonal human anti-D Serum Cy3 anti-human IgG (33.3 /Q/ml) 
The fluorescence values are used as data points in the results figures, and are 
arranged in descending numerical order to aid the interpretation of the results. As in 
the previous experiment, there were black holes on the scan images. As the PBS spot 
values were unaffected, the S/N ratios were calculated and are presented, with error 
bars showing the variability by standard error of triplicate spots. Results from the 
BioGold and SuperProtein slides against the same target antibody are presented in 
the same figure. 
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The results from the anti-A target when evaluated on both BioGold and SuperProtein 
slides are shown in Figure 6.8a. The BioGold slide gives the highest SIN ratio 
against both the WC and MP group Al, but the ratio is less than that demonstrated in 
Figure 6.3b. In Figure 6.3b there also was some cross-reactivity. The SuperProtein 
slide shows the highest SIN with MP Al but the next in descending order is an MP 
group 0. 
The results from the anti-B target when evaluated on both BioGold and SuperProtein 
slides are shown in Figure 6.8b. The gold surface shows again that it retains whole 
erythrocytes, as there are specific reactions with both group B WC probes and the 
anti-B reacts with the synthetic B antigen. 
The monoclonal anti-D (LHM169/80) reacts specifically with the RhD positive 
whole cells on the gold surface, although S/N levels are low (3-6) (Figure 6.8c). The 
monoclonal anti-D on the SuperProtein surface shows quite different results (Figure 
6.8c) where all membrane (protein) fragments give similar results and reactions are, 
therefore non-specific. 
Again on the gold slides, the polyclonal anti-D reacts with highest SIN with RhD 
positive whole cells (Figure 6.8d), however values from group Al and B RhD 
negative whole cells are giving a notable level of S/N (positives 16-22, while 
negatives 7-10). In the same figure the SuperProtein slides are showing highest S/N 
values with RhD positive membrane (protein) fragments, although group Al MP are 
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Figure 6.8a. Results of BioGold and SuperProtein slides against target anti-A. Slide type 
detailed in figure, slide reps 1, pins 900 Ion, probes detailed on x-axis, probe reps 3, SPM E; 
blocker PBS-BSA, target/detection Table 6.8, incubation time 60min, mixing, scanning 
method C, data processing method B. 
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Figure 6.8b. Results of BioGold and SuperProtein slides against target anti-B. Slide type 
detailed in figure, slide reps 1, pins 900 »m, probes detailed on x-axis, probe reps 3, SPM E; 
blocker PBS-BSA, target/detection Table 6.8, incubation time 60min, mixing, scanning 
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Figure 6.8c. Results of BioGold and SuperProtein slides against target anti-D LHM169/80. 
Slide type detailed in figure, slide reps 1, pins 900 pmrn, probes detailed on x-axis, probe reps 
3, SPM E; blocker PBS-BSA, target/detection Table 6.8, incubation time 60min, mixing, 






































ý ý Q 
U 
ý 
















































































U >. >. 3 C, ) 0) 
Figure 6.8d. Results of BioGold and SuperProtein slides against target anti-D polyclonal. 
Slide type detailed in figure, slide reps 1, pins 900 pm, probes detailed on x-axis, probe reps 
3, SPM E; blocker PBS-BSA, target/detection Table 6.8, incubation time 60min, mixing, 
scanning method C, data processing method B. 
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In conclusion, this experiment has given some encouraging S/N values with specific 
probes, but also some non-specific reactions. It shows that there is potential in this 
technique for use in antibody screening. Also, as expected the gold surface is more 
suited to the use of whole erythrocytes, whereas the SuperProtein surface is more 
suited to membrane proteins. The synthetic B antigen gave a specific reaction on the 
gold surface. 
6.7 Chapter Discussion and Conclusions 
6.7.1 Chapter Discussion 
The results obtained in this chapter demonstrate how challenging the area of 
microarray-based antibody screening development is. Earlier chapters have shown 
that blood typing can be adapted to a solid-phase microarray format. However, for 
blood typing microarrays the probes are mainly highly specific, purified antibodies at 
defined concentration. These successfully bind whole erythrocytes via blood group 
antigens in solid-phase microarrays. For antibody screening, a reverse format to 
blood typing must be used, where the antigen is immobilised to detect target 
antibody. 
Antibody screening probes pose a different problem to the immobilisation of probe 
antibodies for blood typing. The antigen probes are, themselves, attached in solid- 
phase to the erythrocyte membrane; therefore a suitable method of antigen 
immobilisation must be developed. The immobilisation of antigens for use in 
microarrays has been demonstrated in many publications, but the preparation of 
erythrocyte microarrays has not yet been published. 
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Immobilisation of erythrocytes on microplates has been discussed (Scott, 1991; 
Tamai and Mazda, 1999), but it is known that the lifespan of a complete whole 
erythrocyte is unlikely to give the desired stability. The lifespan of an erythrocyte is, 
on average, 120 days, and at any time a sample will contain cells of all stages of the 
life cycle. Other formats of the blood group antigens may be more suitable for the 
purpose. If blood group antigens are available from a source other than the 
erythrocyte, this may have benefits to the blood bank and blood transfusion services 
as the blood can be used for transfusion. Also, non-erythrocyte derived blood group 
antigens may offer a more consistent source of antigen and be more cost effective to 
manufacture. Existing methods for the immobilisation and use of blood group 
antigens in microplates have used erythrocyte membranes, or `ghosts'. If these were 
to be used in a microarray format, another advantage would be a reduction in the 
volume required. 
Immucor patented a method for the immobilisation and drying of cells onto solid 
supports (Sinor and Eatz, 1991) for use in solid-phase immunoassays. The method 
described involves the immobilisation of cells by electrostatic charge and the in situ 
lysis of the cells. Once immobilised, the cells are fixed or dried by the use of a drying 
solution, which draws moisture out of the cells. This method has been successfully 
used as part of an antibody screening method for many years, and could possibly be 
adapted for use in microarrays. 
Another significant point in the development of an antibody screening method is the 
non-specific binding introduced when using serum or plasma samples. In the 
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Immucor system, the target sample is diluted up to 1 in 4 prior to use. In other 
microarray system publications, the serum samples have been diluted prior to use. 
Haab et al. (2001) stated that using their system, a total protein concentration of less 
than 1 mg/ml should be used for optimal performance, otherwise NSB of the target 
protein was evident. In existing donor antibody screening methods using the 
Olympus system, the plasma is diluted 1 in 6 before testing (G. Glassford, personal 
communication). 
In contrast to the use of purified antibodies, the use of materials such as membrane 
fragments may result in higher background. It is likely that this is due to many more 
structures and molecules being exposed on the fragments, causing non-specific 
binding. Much non-specific binding was evident in these experiments, particularly 
when using polyclonal material of human source. In the experiment in section 6.3, 
the NSB may have been due to the presence of other alloantibodies (such as anti-I), 
which may be only detectable at room temperature. Group 0 individuals usually 
produce a mixture of IgM and IgG anti-A and anti-B, but only anti-human IgG was 
used as the detection molecule. It may have been more appropriate to use anti-human 
IgM, or a blend of anti-human IgM and IgG, which was not available at the time of 
the experiment. However, the unwanted reactions of the group 0 serum with all 
erythrocytes may be eliminated if the assay was performed at 37 °C. The facility to 
perform this for microarray slides was not available during the experiment. 
Prior to their patent covering cell immobilisation, Immucor patented (Sinor et al., 
1989) a method of solid-phase indicator cell preparation. These cells were described 
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as a means of detecting IgG antibody binding where the secondary binding and 
subsequent layer of the indicator cells meant a positive reaction. This overcomes the 
problems of non-specific interaction demonstrated by other detection methods. This 
method could, theoretically, be used for microarray, but in microarrays fluorescence 
is most commonly used for detection. If the cells were fluorescently labelled and 
sensitised with anti-IgG they would bind to the array if IgG antibody was present and 
give a detectable fluorescent signal. Care would be required to ensure interpretation 
of results only from the antibody screening probes. Other probes on the microarray 
could be IgG or anti-IgG and would therefore bind the indicator cells non- 
specifically. If using this method, the indicator cells could interfere with other tests 
on the microarray. If desired, this detection method may require the use of a separate 
chamber on the array. Immucor have used the indicator cell technology described 
above for the detection of antibodies to platelets, leucocytes, HBsAg, HTLV-III and 
CMV. For these tests, cells expressing the antigen of interest must be immobilised. 
The patent covers any solid-support, and therefore also covers microarrays. 
The use of solid-phase techniques for serological assays means that it is immune 
adherence of antibody rather than haemagglutination that is used for detection. 
Although haemagglutination as an end-point may be automated, it can be somewhat 
subjective if read manually as individuals may read tests by different techniques. 
Immune binding of a fluorescent antibody to determine interaction is a far more 
objective and quantitative end-point than detection of an erythrocyte monolayer or 
haemagglutination as the result would be interpreted only from a fluorescent value. 
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In this chapter, three different types of probe have been investigated; whole 
erythrocytes, erythrocyte membrane (protein) fragments and synthetic carbohydrate- 
BSA conjugated blood group antigens. These probes were examined for use on 
different slide surfaces. It is clear that the slide surfaces are suited to different probe 
immobilisation, likely due to suitable surface-probe interactions. As discussed, whole 
erythrocytes have a limited life-span, a problem that may be overcome by the use of 
erythrocyte membranes, cell fragments or synthetic antigens. Other options not 
explored in this project are the use of peptides or recombinant antigens. 
Gold slides were shown to be successful in the immobilisation of whole erythrocytes. 
This would be an ideal surface on which to develop an antibody screening 
microarray as blood typing has been demonstrated on this surface in this project. 
This would facilitate the optimisation and multiplexing of both types of assay, which 
would be compatible for one comprehensive microarray. The use of probes other 
than whole cells, were not as successful on gold slides. This is likely due to the 
properties of the gold surface and the surface plasmon waves that exist on this type 
of slide (see Campbell et al., Appendix 4). The gold causes quenching of fluorescent 
signals close to the surface, and detection of fluorescence is therefore distance 
dependent to the surface. This is one possible explanation for the results from whole 
cells on gold slides. 
However, the stability of whole cells attached to a solid-phase is unlikely to be 
suitable for such a test system where shelf life of product would ideally be months 
rather than weeks. Therefore other slide surface coatings were investigated for their 
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retention of erythrocyte membrane fragments. Slides that demonstrated highest 
binding of fragments tended to bind by hydrophobic interactions. The method for 
isolation of the membrane fragments would require standardisation to ensure that all 
material was at similar concentration. Orientation of the fragments is also random, 
but occur through hydrophobic interactions. Intrinsic membrane proteins consist of 
two hydrophilic and one hydrophobic domain (reviewed in Schenkel-Brunner, 2000). 
The hydrophobic domain is integrated in the lipid bilayer. When used for antibody 
screening purposes, the membrane fragments, in general, showed significant levels of 
binding to target antibody, which could be deemed mainly specific. Other methods 
for attachment of erythrocytes have been developed, (Sinor et al., 1989; Scott, 1991; 
Tamai and Mazda, 1999) and could be applied to microarrays. 
In section 6.3, the monoclonal anti-D used was an IgG molecule, whereas the anti-A 
and anti-B were IgM. This reflects the presence of these antibody specificities in 
nature, where circulating anti-A and anti-B antibodies are mostly IgM and alloanti-D 
is usually IgG. The potency of the polyclonal human group 0 serum against both 
group Al and B cells was 1/32, and the potency of the human anti-D serum was 
1/256. The latter had not been adsorbed to remove unwanted antibodies, such as anti- 
A and anti-B, therefore may have been expected to react with all the erythrocytes, 
perhaps to different degrees, but it did not react significantly with any. It may be that 
the dilution (1/10) may have diluted out the antibody to an undetectable level, and as 
discussed previously the dilution of plasma/serum samples requires further 
investigation. To ensure the system is capable of weak antibody detection, panels of 
weak antibodies of clinical significance should be prepared for validation purposes. 
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It is clear that the area of microarray erythrocyte antibody screening requires much 
development. Due to the huge potential in this area, Alba Bioscience was awarded 
funding from Scottish Enterprise for the development of this project area over the 
next two years. 
Apart from suitable surface and probes for antibody screening, other microarray 
options are applicable to this development. Microarray design options have been 
previously discussed (in Chapter 1) and applied (in Chapters 3 and 4). The main 
design options for antibody screening, which are not discussed here but would form 
the next step of this research and development area, would be as follows: 
Microarray fabrication. Are solid pins the best option or could other pin types or 
deposition methods be more suitable? 
Blocking. Different types of probes and surfaces require the optimisation of 
blocking steps to minimise NSB. The use of membrane fragments demonstrated the 
need for improved blocking to reduce non-specific interactions, perhaps caused by 
the presence of more antigens on the fragments. 
Reaction conditions. Conditions for the reaction to take place require 
optimisation of temperature, incubation time, plasma/serum dilutions and reaction 
volumes. 
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Washing procedures. Procedures have to be optimised to ensure delicate 
immobilised probes or targets are not removed from the surface, while ensuring the 
elimination of unbound materials. 
Detection methods. The most suitable detection method would detect all 
clinically significant antibodies bound to the microarray. This should be compatible 
with all probes on the array, and not give indication of a positive reaction by binding 
directly to a probe. Different coloured fluorophores could be an option. Ideally all 
detection molecules would be added at one time, for both the blood typing and 
alloantibody screening. Consideration must also be taken of the type of antibody 
target. The use of only anti-IgG for detection would fail to detect IgM antibodies. 
Attention should be paid to the selection of the optimal detection mixture so as not to 
miss clinically significant antibodies, yet not make the test too sensitive that it 
detects clinically insignificant antibodies or give false positives. Detection of such 
clinically insignificant antibodies would mean time consuming further testing in a 
routine situation. Although some success was seen in this work, the detection levels 
must be greatly increased, as currently they are not satisfactory for routine use in 
antibody screening or for reverse ABO typing. 
6.7.2 Chapter Conclusions 
The work of this chapter has demonstrated the following in response to the chapter 
aims: 
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" Investigation of different slide surface chemistries for the immobilisation of novel 
blood group antigens. 
Many different slide surfaces were used and those that showed most potential 
were investigated further. The surfaces selected were either gold surfaced or used 
hydrophobic interactions to immobilise antigen. 
" Evaluation of blood group antigens in a variety of forms for their use in antibody 
screening - whole erythrocytes, erythrocyte membrane (protein) fragments and 
synthetic antigens. 
All three types of antigen were investigated and each showed specific reactions 
or more suitable reactions on different slide surfaces, showing that both the 
antigen format and slide surface chemistry requires careful selection and much 
development work. Specific reaction patterns were obtained with whole cells and 
synthetic B antigen on a variety of surfaces, but especially BioGold. Probe 
membrane fragments gave some specific reactions when using slide surfaces 
such as P4VP, ZetaGrip and SuperProtein slides. Generally, higher S/N values 
were found when the targets were monoclonals, probably due to the purity and 
potency of these materials. 
To conclude this thesis, Chapter 7 reviews all the achievements of this work and 





7.1 Achievements of the Project 
This thesis has described a novel system to study multiple interactions of blood 
group antigens and antibodies in a microarray platform, and the exploitation of the 
results for potential diagnostic use of the system. Overall, this thesis provides a 
strong basis for further development of a comprehensive microarray based multi- 
parameter blood group serology diagnostic platform. 
Initial experiments focused on multiple parameters affecting the immobilisation and 
functionality of monoclonal and polyclonal antibodies and serum proteins on various 
microarray surfaces. Extensive evaluation of parameters important to the preparation 
and use of protein microarrays has been carried out. The microarray performance 
was improved during these evaluations, looking at blocking, reaction volume, mixing 
and time, and process improvements applied to establish an efficient and effective 
procedure. Selected microarray surfaces and optimised spotting and reaction 
conditions were then applied to interaction studies using erythrocytes and blood 
group antibodies. 
This thesis provides the first comprehensive study of non-agglutination blood group 
determination in an open-plan microarray format. Both direct and indirect labelling 
detection methods were investigated to find both a suitable method of detection for 
future use and a method that could be used for the development of the system. The 
optimisation of antibody immobilisation and interaction was further developed by 
adjustment of spotting buffers, the effect of pH clearly different for each antibody. 
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This demonstrated that each probe antibody must be optimised individually to give 
optimal performance. Using the developed microarray methods, both carbohydrate 
(ABO blood group system) and protein (Rhesus D, c, E and K) blood group antigenic 
determinants were successfully typed in a simultaneous multi-parameter microarray. 
The detection of erythrocytes sensitised with IgG was also successfully investigated 
simultaneously using the microarray approach. 
In order to verify performance of blood typing antibodies and quantitatively 
characterise interactions, the technology of surface plasmon resonance was used as 
an alternative solid-phase system. This work gave detailed information on the 
interactions between an antibody to blood group A and erythrocytes of different 
specificity. Also, the immobilisation of synthetic carbohydrate antigen to a Biacore 
chip permitted the quantitative determination of the reactivity of monoclonal 
antibodies in a reverse typing format. 
Preliminary work was carried out to extend the use of the microarray platform to 
include a reverse assay, an erythrocyte antibody screen. For erythrocyte antibody 
screening purposes, synthetic antigens, whole erythrocytes and erythrocyte 
membrane protein fragments were used in a microarray format. In this thesis, the 
different forms of the antigens were used for antibody screening using novel surfaces 
and subsequently defining the parameters for this purpose. Specific reaction patterns 
were obtained in many cases. However, the higher level of non-specific interaction 
and differences in data obtained on different slide surfaces does require substantial 
further development. 
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The work of this thesis lays the foundations for further development of microarray 
based blood group serology. Multi-parameter testing has been performed which helps 
foresee the potential of this test format for other diagnostic purposes, and also to 
extend this work to develop a comprehensive blood testing microarray chip. The 
considerations involved in a comprehensive and automated testing platform are 
discussed below. 
For the first time, blood grouping has been performed in a miniaturised multiplexed, 
open-plan format. Other blood testing systems differ in that they compartmentalise 
each probe-target interaction. In the microarray developed in this project, multiple 
probes could be used to probe a sample for multiple parameters, which are detected 
in simultaneous analysis. The open-plan microarray gave no apparent problems with 
cross-contamination of probes, which may be of concern to some when using such a 
format. Results were confirmed using the technology of surface plasmon resonance, 
which studied the interactions individually in real-time and gave precise comparisons 
between probe antibodies and interactions with different cell types. It also gave the 
basis for the use of synthetic antigens that were subsequently used in antibody 
screening. 
7.2 Potential Advantages of a Microarray Platform 
Multiplexing is a clear advantage that microarray technology possesses over other 
existing serological technologies. In the open-plan slide format, the number of probes 
may be limited only by their availability. The inclusion of new probes for new tests 
has only a small incremental cost on the preparation of the array, however reagent 
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costs must be considered for any probe. The microarrays used in this project 
contained 144 probe spots on average. Even including test replicates on the array, 
this may be enough to accommodate all current mandatory blood testing. Smaller 
pins are available and these would allow microarray fabrication to include hundreds 
of probes. The technology exists in DNA microarraying to fabricate microarrays with 
many thousands of probe spots. This multiplexing feature is also useful when new 
tests evolve or are required. Rather than requiring another testing system or machine 
in the testing laboratory, additional probes could be added to the pre-existing format 
and be interpreted simultaneously. 
When dealing with human blood and transfusion, new tests are currently being 
developed (e. g. Malarial tests, West Nile Virus), or may be required at any time in 
the future. The speed at which testing is introduced in a clinical environment can be 
critical to health authorities, who are under pressure to ensure best practice at all 
times. Although each new test would require extensive validation before it was 
routinely used, the technology to apply it to every blood sample is possible using 
microarrays. 
Miniaturisation has two main advantages. 1) A smaller test system such as a 
microarray can accommodate multiple tests, and 2) when used in an open-plan 
format it leads to reduced usage of both sample reagents and of human blood 
samples. This also means that the testing system itself can be made smaller and less 
space is required. 
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The amalgamation of all tests on one platform has many cost implications. As 
mentioned above, a smaller testing system means less space is required for multiple 
test platforms. This may also mean a reduced cost in running one system as opposed 
to multiple machines, where rental, reagent and maintenance costs are all to be 
considered. An obvious effect on costs will be staff requirement. If a fully automated 
system can run all mandatory and desired tests on one platform, then fewer staff are 
required to run and interpret the results. There is, of course, no substitute for human 
experience and expertise, but a well-designed system should minimise user input and 
may lead to a reduction in the specialist skills required in the workplace. 
Interpretation of traditional haemagglutination assays relies on the visible clumping 
of the cells as an end-point. This reaction can be read by programmed automation, 
which interprets a photograph of the reaction, or uses spectrophotometric-based 
analysis. The use of fluorescence (or other available detection methods) in 
microarrays gives a numerical value, which allows for ease of interpretation, and a 
clear positive or negative reaction can be obtained with well-developed and validated 
cut-off points for each reaction. 
If a fully automated microarray technology testing platform were to reach the market, 
it would therefore have some clear advantages over other testing systems involving 
antibody-antigen interactions. A comparison table is presented as Table 7.1. 
Although this project has demonstrated that microarray technology can be adapted 
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7.3 Challenges to the Future of Microarray Technology Testing 
Depending on the purpose, there are alternative platforms on which biological 
interactions can be studied and which may compete with the protein microarray 
platform. Some of these options are discussed below. 
The surface plasmon resonance (SPR) format offers useful information, and allows 
studies to be performed in real-time, which is something that microarrays currently 
do not offer. It also has the advantage that labelling of samples is not required due to 
the method of detection. But real-time studies are not a requirement of diagnostic 
systems. To use the definition of Ekins (1989), blood typing is an analytical assay, 
looking for structural specifics, as opposed to a comparative or functionally specific 
assay. A blood typing assay seeks a yes or no answer i. e. is an antigen or antibody 
present or not. To an extent a measure of quantity is not required, unless a level of 
antibody present in a sample is desired. The fact that a marker is present can be 
enough to diagnose and provide the desired care. 
SPR technology can use a variety of immobilisation methods to capture ligand on the 
sensor surface. Given the problems associated with RhD antigen isolation, especially 
their conformational requirement to be inserted into the cell membrane for support, 
then the technology of liposomes could be used to immobilise membrane proteins. 
Liposomes work by accommodating proteins and allowing them to take on their 
natural state in the membrane (Biacore. com). If isolated RhD proteins were available 
this may be one system that could be used to study the interactions with antibodies. 
Another advantage of the SPR format is the regeneration and re-use of the chips, 
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allowing for more economical analysis. The covalent attachment of probes means 
that it is possible to remove target particles and re-use the probe surface. The re-use 
of microarray chips is possible, although the costs involved would have to be lower 
than for disposable chips. 
NAT testing, or DNA genotyping can now be performed to determine many of the 
main blood groups, and can be performed to determine the pathogen status of 
individuals for some diseases. The most recent advances in blood group genotyping 
were discussed in Chapter 1, where it was also mentioned why, for the foreseeable 
future, antibody-antigen interactions would remain a critical part of testing. DNA 
genotyping cannot determine immune antibodies produced by an individual, and 
unless patients receive identical blood to their own it is likely that antibodies will still 
be made and require detection to provide compatible blood. It may at some time, 
however, be beneficial to include traditional antibody-antigen immunohaematology 
and DNA testing on one microarray. The use of a combined technology chip using 
microfluidics channels to separate samples was considered by Petrik (2001), and 
depending on whether antibodies and antigens to all desired targets are available, this 
type of chip may be the best option. Chiron and Roche have both recently launched 
new automated NAT systems, demonstrating that the technology to automate such 
testing is already available. 
The Ciphergen system (ciphergen. com) offers affinity capture of probes and can 
isolate target molecules directly from patient samples. This system allows the 
verification of sample identity from analysis of the bound molecules, which although 
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useful, is not necessary for blood testing, as it would be unable to distinguish IgG 
antibodies from each other, or erythrocytes. The technology also has cost 
implications and throughput is limited. 
The Luminex (TX, USA) 100TM system (luminex. com) uses a suspension array 
where probes are captured onto beads, which are manufactured with a distinctive 
proportion of red and orange fluorescent dyes (Carson and Vignali, 1999). A reporter 
dye is used for detection of bound target and results are read using flow cytometric 
analysis, which identifies each bead set using one red detection laser and the quantity 
of target bound using another green detection laser. Although this system has been 
shown useful in cytokine detection, it is yet to be proven compatible when using cell 
targets. Likewise, the Illumina BeadChip system (San Diego, USA) (illumina. com), 
which uses optic fibres bundles and beads to prepare interaction arrays, had not yet 
been shown capable of dealing with large cells such as erythrocytes. 
As many probes can be included on an array, it should be noted that even with 
around 144 spots per array as in this project, the data generation is large. With even 
more probes the data generation will increase and data interpretation and presentation 
would be more difficult. Failure to find adequate data analysis software could be a 
risk associated with this technology. Another consideration that a small error rate 
applied across a large data set can give a large number of inaccuracies. For example, 
if a typical system has 99.9 % accuracy, with 10,000 probes it would give 
approximately 10 false results. Therefore, the inclusion of replicate probes should 
reduce imprecision and increase accuracy. 
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When considering if any technology will challenge the potential of microarrays in 
the diagnostic field, the answer seems clearly that no other available format could 
offer the same advantages. As discussed, alternative systems can offer some 
individual advantages, but some may not be required and may make analysis over 
complicated. Disadvantages to microarray technology are limited, but it may be that 
the potential advantages are limited by their nature. These issues must be overcome 
during the development of a robust system. Issues such as cross reactivity and 
detection conflicts are further discussed, but it may be that detection is difficult due 
to cross-reactivity, which may arise with detection of multiple interactions. Any 
added sensitivity of microarrays may also increase detection of clinically 
insignificant antibodies. 
7.4 Is Microarray Technology the Future of Blood Testing? 
To achieve the second generation of microarray systems, automated flow-through 
systems to take samples from start to finish will be required, along with powerful 
data-processing software; fully integrated systems that combine all components into 
one single unit. Chapter 1 described how Blolnn and Guiseppe-Elie (2001) reported 
that at least five components are required for a successful microarray assay system. 
These are the chip/slide on which to build a `microarray', a device to fabricate the 
microarrays, a system or method for hybridisation (sensitisation/incubation), and a 
scanner to read the microarrays and software to process and analyse the results. 
Equipment for the preparation of samples would be in addition to this. For a new 
automated microarray test format, all of these components would be required to work 
as one integrated system. However, it is most likely that the microarrays would be 
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prepared and supplied ready-for-use by a manufacturer, and only the test performed 
in test laboratories. 
As well as factors such as sensitivity, specificity, costs, speed and the benefits of 
miniaturisation, the level of automation available for such a test system must be 
considered. The level of automation can indeed offer benefits to the aforementioned 
factors. While automation was not evaluated as part of this thesis, it is considered 
now as it impacts on blood testing microarrays reaching the market. 
An automated test system must be capable of positive sample identification, sample 
processing, sample-chip interaction, processing steps and data interpretation. Both 
high-throughput systems and point-of-care devices should be considered with a level 
of automation. Also relevant is the level of user input and level of training required 
to interpret results. It is possible that taking testing out of a central laboratory to the 
bedside may result in false interpretation when read by inadequately trained staff, 
and this would require risk analysis. The support software must offer sophisticated, 
robust computer programs and testing algorithms to deal with large data set 
generation. 
Along with the consideration of user-friendliness is the issue of controls and 
calibration. The highly regulated area of blood testing requires the use of valid 
controls and calibration testing. The subject of controls for such a system is complex, 
and is discussed in section 7.5. 
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It is likely that the combination of science and technology required to develop such a 
system would require the collaboration of many disciplines. SNBTS scientists are 
currently investigating all aspects of a future blood testing microarray. This thesis 
has demonstrated that blood typing by microarray is a realistic option, and work has 
begun on antibody screening. Pathogen antigen arrays have been performed (Ewart 
et al., 2001; Bacarese-Hamilton and Crisanti, 2002) and are being actively performed 
by our group. The preliminary results from our Proof of Concept group have shown 
that blood typing and pathogen testing can be combined in one microarray assay. It 
may be that pathogen detection will still require an amplification step to allow a 
suitable level of detection, and this is likely to involve target or signal amplification. 
The sensitivity of a blood-testing chip is critical. The test system must be of suitable 
sensitivity to detect clinically significant targets. To offer benefits over existing test 
systems, a new system must give equal or increased detection of pathogen targets. 
This may not be achievable without amplification methods. Reverse transcriptase 
polymerase chain reaction testing or rolling circle amplification are two options to 
increase the sensitivity of detection. This has implications with regards to the format 
of a comprehensive blood testing microarray chip. Ideally there would be one 
reaction chamber into which whole blood (with or without dilution) would be added. 
If the different probes are directed towards different type targets then there is a 
possibility that microfluidics could be employed to perform multiple reaction steps 
within one chip. 
Microarray technology could evolve into point of care testing, where testing is 
performed in the ward, clinic, or home or close to the patient bedside. The 
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miniaturisation aspect of microarrays would appear to lend itself to this area, where 
there has been talk of gross development increases over several years. 
While expansion of the number of probes is an advantageous factor, care should be 
taken not to include unnecessary probes, giving the laboratory more information than 
is required and overcomplicating the process. Clinical significance must be the 
primary parameter. One consideration, however, is the use of a single chip for all 
purposes, and only the software licensed to un-lock the results to only those tests 
required (similar to Randox, Ireland). This method of microarray preparation would 
aid manufacture and the subsequent quality control testing of batches of microarray 
slides. 
7.5 Development to Market Place 
To take the described technology from the development stage to the market will 
require much work. Some of the remaining development is discussed in section 7.6, 
but discussed here are some of the regulatory and practical issues, as well as 
marketing considerations, which must be considered before this new technology can 
reach the blood testing market. 
As discussed in Chapter 1, there are many quality system requirements that govern 
the area of blood testing diagnostics. In order to comply with the European Union in 
vitro Diagnostic Medical Devices Directive (IVD Directive (98/79/EC), the 
following stages of development must be performed: 
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" risk analysis of the product and its possible risks to the health of 
manufacturing staff, users and patients 
" performance evaluation of the product in compliance with recommended 
guidelines 
" validation/verification of all procedures involved in its manufacture and use 
" extensive stability testing of all components of the test system and especially 
biological components 
" full technical documentation detailing all materials used in the manufacture; 
and detailed accounts of all design stages. 
All stages of the development should comply with the appropriate regulations by 
adhering to standard operating procedures and product specifications. Voak (1999b) 
discusses six critical tests for the introduction of a new technology for red cell 
agglutination. The described tests include tests for sensitivity, replication, titration 
tests, clinical trials and detection of weak samples/antibodies. All of these things 
have to be considered within development stages before taking this product closer to 
the market place. During the development stages, logistics for manufacture scale-up 
must be reviewed. While the fabrication of microarrays is possible for the production 
of small numbers of slides, full production batches would most likely consist of 
thousands of slides. Quality control testing procedures must be put in place prior to 
manufacture to ensure post preparation batch verification. 
For a comprehensive testing system, the provision of suitable controls would be of 
concern to the manufacturer and the user. Currently there are regulations for all 
mandatory testing controls, where known positives and negatives are employed for 
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each single probe assay. Acceptable controls for a multi-parameter test would require 
careful consideration as there would be cost implications if many control microarrays 
were used with each sample batch. It is probable that controls would be supplied by 
an appropriate manufacturer as this may involve the preparation of multi-target 
control spiked samples. For gene expression data, there are guidelines for standard 
information formats. These guidelines are known as `minimum information about a 
microarray experiment' (MIAME) (Brazma et al., 2001). The use of MIAME 
guidelines means that users can share data and have comparable data between 
different locations. This may be beneficial in the future, so that all clinicians may 
have access to information about all available donor characteristics. Although an 
automated blood typing system should analyse and interpret results, MIAME could 
be used as a reference point from which to develop a data analysis system. 
For the remaining development work to take place and then to consider a movement 
from the research laboratory to the market place is likely to take several more years. 
During this time, it is likely that many companies will be investigating new methods 
for blood testing and there will be competition. Detailed development, marketing and 
commercialisation strategies will be required to take this promising technology from 
the development stage. 
7.6 Future Work Arising From This Thesis 
This thesis has provided a strong basis for the future development of microarray 
based multi-parameter blood group serology diagnostic platforms for routine, high- 
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throughput use. The following areas of development should be considered in more 
detail. 
The system should be validated with further erythrocyte samples to test the system 
and to ensure its capability of blood grouping. For example, further A,, cells and 
weak D cells should be evaluated, as well as cord blood samples with weak antigen 
expression. Panels of these cells should be collected for use and may be evaluated by 
use of lectin reagents. These should be evaluated to rigourously test the sensitivity 
and detection limits of the system. Minimum specifications are detailed in the 
Commission Decision on common technical specifications for in vitro diagnostic 
medical devices (2002/364/EC) (European Parliament website). The results must be 
highly reproducible and precise (Petricoin III et al., 2002). The panel of antibodies 
should be optimised to ensure detection of rare or weak cell types. For each antibody 
specificity tested, the Guidelines for the United Kingdom Blood Transfusion 
Services (U. K. Blood Transfusion Services, 2002) should be followed to ensure that 
clinically significant antigens are detectable. Once established, the microarray test 
platform would require validation to ensure compliance with the European Union in 
vitro Diagnostic Medical Devices Directive (ND Directive (98/79/EC), (European 
Parliament website) and the Food and Drug Administration (FDA) regulations if it 
were to be marketed worldwide. The FDA has already anticipated the expansion of 
microarray technology into all aspects of healthcare, and uses the guiding principle 
of benefit versus risk analysis (Petricoin III et al., 2002), and recommends the 
involvement of the relevant regulatory body early in the development process. 
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An initial stage of microarray erythrocyte antibody screening has been carried out in 
this project. This area could be further developed to increase specificity and 
sensitivity. Whole erythrocytes, fragments and synthetic antigens were used, but 
other forms of blood group antigen could also be spotted onto the microarray and 
their use explored for this purpose. Alternatives to native antigens were mentioned in 
Chapter 1 and include the use of peptides and aptamers. These areas are currently 
being actively researched by the SNBTS. These alternative forms of antigens may 
offer advantages in terms of manufacture and cost, concentration, specificity and 
stability. 
The stability of both probes and spotted microarrays is an area that requires critical 
examination and must be performed. An excellent probe in terms of performance on 
a microarray (sensitivity and specificity) could possibly be rendered useless in terms 
of stability. The purity of probes maybe a factor in the stability of protein probes and 
the formulation may be of paramount importance. The expense of purified antibodies 
may be limiting and it is unclear what level of purity is best for stability. The 
inclusion of stabilising proteins, glycerol (MacBeath and Schreiber, 2000), salts and 
sugars (Lee and Kim, 2002) may assist long-term stability and requires investigation. 
The method of storage may also affect stability. Both freezing and lyophilisation 
should be investigated for long-term storage. Extensive stability testing (European 
Union in vitro Diagnostic Medical Devices Directive (IVD Directive (98/79/EC)) 
should be carried out, which includes the stability of the probes both prior to spotting 
and following spotting by performing on-microarray stability. Both accelerated and 
real-time studies should be performed as well as transport studies of the microarrays, 
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performed to ensure the product is still functional and meets product specification 
once it reaches the customer. 
During this project, it was always considered that blood typing and antibody 
screening might be included as part of a comprehensive blood testing microarray. 
These considerations included the type of surface and that the detection of interaction 
between each probe and target set must be compatible with other sets on the array. 
This is relatively simple when considering only blood typing, or only antibody 
screening, but may be complicated if all mandatory tests were amalgamated on one 
microarray. For example, many of the probes used in this project were monoclonal 
anti-human IgG to human blood group antigens. This thesis looked at the use of 
directly labelled erythrocytes, and secondary (indirect) labelling via another 
molecule that bound to all cells. Both approaches were successful. However, if the 
reaction was negative i. e. no erythrocytes were bound to the human IgG probe, and 
this was on the same open-plan microarray as the antibody screening testing, then 
false positive reactions would be possible as probe human IgG would bind the 
detection antibody, anti-human IgG. It is most likely that the detection method for 
antibody screening will use anti-human IgG and perhaps anti-human IgM reagents. 
Compatibility may be even more complicated once other testing systems are included 
and multiple detection reagents are required. One possible method to avoid this 
problem would be the use of multiple fluorophores that use distinct excitation and 
emission wavelengths. Using this method, a signal of a certain wavelength would be 
expected from a certain probe spot when scanned using specific laser settings. 
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Although not a mandatory test, the Direct Antiglobulin Test (DAT) has been 
demonstrated in this thesis in the microarray format (Chapter 4). It may be 
advantageous to include this test on a comprehensive testing format, especially in 
patient testing scenarios. A positive DAT result can be indicative of many clinical 
situations including autoimmune disorders. It would be of interest to further 
investigate this test to determine the effect of cell sensitisation on blood typing, and 
to determine the sensitivity of the technique in this format. The use of multiple 
fluorophores could also benefit tests such as to perform differential Indirect 
Antiglobulin Testing. Some testing laboratories like to differentiate between immune 
antibody classes in serological testing. An anti-human IgGI reagent could be labelled 
with a fluorophore and an anti-human IgG3 with another enabling the serologist a 
differential reading. 
The scanning of unlabelled erythrocytes gave an indication that autofluorescence 
may be a possible form of detection of cell binding. This could be further 
investigated to develop optimal scanning settings to detect the fluorescence and 
ensure the desired level of sensitivity. As erythrocyte binding to a microarray is a 
visible phenomenon, the use some form of photography or reading through the slides 
may be an approach worthy of investigation, especially if using multiple detection 
antibodies for detection of other interactions. 
To reduce testing times for blood typing on microarrays, and to increase sensitivity, 
the use of low ionic strength solutions could be further investigated (this was touched 
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on in Chapter 4). A reduction in testing times may be an advantage, especially to 
produce a high-throughput system. 
Given the basis that the work presented in this thesis represents, and once these areas 
discussed are investigated successfully, it could be estimated, given appropriate time 
and resources, that a blood testing microarray may reach the market in the next five 
to ten years. 
In summary, this work has exploited microarray technology to develop a novel 
approach for potential use in blood testing. The platform developed clearly has the 
potential to compete with existing technology in terms of speed, sensitivity, 
throughput and costs. While there may now be a key focus in the area of commercial 
development of the test system, there is a great deal of optimisation work to be done, 
and the benefits of protein microarrays as research and investigative tools should also 
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Appendix 1. Manufacturers and Contact Details 
This appendix contains the contact details (or distributors) of manufacturers whose 
products were used in this thesis. 
COMPANY ADDRESS 
Actigen Ltd. Affitech AS, Gaustadalleen 21,0349 Oslo, Norway. 
Voyager, Mercury Park, Wycombe Lane, Wooburn 
. Affymetrix UK Ltd. Green, High Wycombe U. K. HP10 OHH 
Alba Bioscience 
21 Ellen's Glen Road, Edinburgh, UK, EH17 7QT 
(formerly Diagnostics Scotland) 
Amersham Place, Little Chalfont, Buckinghamshire, 
Amersham BioSciences UK Ltd. 
U. K. HP7 9NA 
Amersham Pharmacia As Amersham BioSciences U. K. Ltd. 
TeleChem International, Inc., Arraylt® Division 
Arrayit 
524 East Weddell Drive, Sunnyvale, CA 94089, USA 
Molecular Devices Corporation 
Axon Instruments 
1311 Orleans Drive, Sunnyvale, CA 94089. 
Baxter Healthcare Ltd. Thetford, Norfolk, U. K. 
McQuilkin & Co., 21 Polmadie Avenue, Glasgow, U. K. 
BDH 
G5 OBB 
21 Between Towns Road, Cowley, Oxford, U. K. 
Becton Dickinson 
OX4 3LY 
Biacore AB Rapsgatan 7, SE-574 50 Uppsala, Sweden 
Apogent Discoveries, Corporate Headquarters, 22 
BioRobotics 
Friars Drive Hudson, NH 03051 U. S. A. 
CalbioChem As Merck Biosciences, U. K. 
Cecil Instruments Ltd. Milton Technical Centre, Cambridge, U. K. CB4 4AZ 
Corning As BDH 
Science and Technology Centre, Earley Gate, Dextra Laboratories 
Whiteknights Road, Reading, U. K. RG6 6BZ 
DiaMed AG 1785 Cressier Sur Morat, Switzerland 
Eppendorf-Netheler-Hinz GmbH D-22331 Hamburg, Germany 
VWR International Ltd 
Erie Scientific, U. S. A. 
Merck House, Poole, U. K. BH15 1DT 
VWR International Ltd. 
Filtron (PALL Filtron) 
Merck House, Poole, U. K. BH15 1TD 
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A1-Biotech UK, Anachem House, Charles Street, 
Gene Machines 
Luton, Bedfordshire, U. K. LU2 OEB 
Genetix Ltd. Queensway, New Milton, Hampshire, U. K. BH25 5NN 
105 Schneider Road, Kanata, Ontario, Canada 
GSI Lumonics Inc. 
Parc E. S. T. E. R. Technopole, 6 Allee Skylab, B. P. 
ID Bio 
6806, F-87068 LIMOGES C6dex, France 
Invitrogen PO Box 2312,9704 CH Groningen, The Netherlands 
Box 5347,4700 Superior Street, Lincoln, 
ISCO Inc. . Nebraska, U. S. A. 65805 
Merlin Way, Quarry Hill Road, Ilkeston, Derbyshire, 
Jouan Ltd 
U. K. DE7 4RA 
Merck Biosciences Padge Road, Beeston, Nottingham U. K. NG9 2JR 
Microsoft Ltd, Microsoft Campus, Reading, U. K. 
Microsoft 
RG6 1 WG 
Units 3&5 The Courtyards, Hatters Lane, Watford, 
. Millipore UK Ltd U. K., WD18 BYH 
National Blood Service (Bristol) Southmead Road, Bristol, U. K. BS10 5ND. 
11040 Roselle Street, San Diego, California, U. S. A. 
Novex 
92121 
Life Technologies Ltd, 3 Fountain Drive, Inchinnan 
Nunc 
Business Park, Paisley, U. K. PA4 9RF 
PerkinElmer Life and Analytical Sciences 
Packard Bioscience 
Via Tiepolo, 24, -20052 Monza (Milano), Italy. 
Perbio Science UK Ltd. Century House, Tattenhall, 
Pierce 
Cheshire, U. K. CH3 9RJ 
PO Box 8, Moreton, Wirral, Merseyside, U. K. 
Premier Brands UK Ltd 
CH46 8XF 
VWR International Ltd. 
Schleicher & Schuell 
Merck House, Poole, U. K. BH15 1TD 
The University of Edinburgh, The Chancellor's Building 
Scottish Centre For Genomic 
College of Medicine, 49 Little France Crescent, 
Technology & Informatics 
Edinburgh, U. K. EH16 4SB 
Fleming Road, Kirkton Campus, Livingston, U. K., 
Serologicals (now Celliance) 
EH54 7BN 
Sigma-Aldrich Company Ltd. Fancy Road, Poole, Dorset, U. K. BH12 4QH 
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Sysmex House, Garamonde Drive, Wymbush 
Sysmex 
Milton Keynes, U. K. MK8 8DF 
Systat Software U. K. Limited, 23 Vista Centre, 50 
Systat Software 
Salisbury Road, Hounslow, London, U. K. TW4 6JQ 
The Binding Site PO Box 4073, Birmingham, U. K. B29 6AT 
V&P Scientific Inc. San Diego, CA, U. S. A. 
PerkinElmer Life and Analytical Sciences 
Wallas 
Via Tiepolo, 24, -20052 Monza (Milano), Italy 
Falmouth, Cornwall TR11 4RU, 
Watson-Marlow Ltd. . or via VWR International Ltd. 
APPENDIX 2. Concanavalin A calculations and testing 
To determine the optimal quantity of ConA to label an erythrocyte, the following 
calculations were performed. At pH 7.0 the molecular weight of ConA was estimated 
as 76,500 Da per molecule, therefore the number of molecules in one mg was 
calculated: 
1Da =1.657x1024g 
76,500 Da (one molecule of ConA) = 1.27 x 10"19 g 
1 mg of ConA = 1/1.27 x 10"16 = 0.8 x 1016 molecules 
Determination of the number of ConA molecules required to give a theoretical 
number per erythrocyte was calculated assuming the use of a2% suspension 
(estimated to contain 2x 108 erythrocytes/ml). The details for ConA required are 
given in Table Al. 
To add ConA to give a theoretical number of molecules/erythrocyte: 
ConA/erythrocyte = molecules required/molecules per mg 
So for 100 ConA/erythrocyte =2x 1010 / 0.8 x 1016 molecules 
= 0.025 pg required (so, if using ConA 0.1 mg/ml, 2.5 µl required/ml) 
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Table Al. Detail of the number of ConA molecules to be added to 1 ml of cells to give an 
amount per erythrocyte, if using cells at 2x 108/ml (estimated). 
No. of ConA per erythrocyte No. of ConA molecules required/I ml 
100 2x 1010 
1,000 2x 1011 
10,000 2x 1012 
100,000 2x 1013 
1,000,000 2x 1014 
Table A2. Results of FAGS analysis on erythrocytes labelled with fluorescent ConA. Number 
of events 'gated' describes the number of cells (from 10,000 counted) which fall within the 
allocated level of fluorescence. 
Label & quantity No. of events Gated % of total labelled 
Unlabelled 1 0.01 
FITC ConA, 100 per cell 5 0.05 
FITC ConA, 1K per cell 26 0.26 
FITC ConA, 1 OK per cell 110 1.1 
FITC ConA, 100K per cell 9882 98.82 
FITC ConA, 1 million per cell 9933 99.33 
Cy3 ConA, 100 per cell 5 0.05 
Cy3 ConA, 1K per cell 4 0.04 
Cy3 ConA, 10K per cell 2 0.02 
Cy3 ConA, 100K per cell 49 0.49 
Cy3 ConA, 1 million per cell 9442 94.42 
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APPENDIX 3. Optimisation of Epoxy Silane Coated Slide Blocking 
This is discussed here as it formed the basis of a change from non-fat milk blocking 
to BSA blocking for all blood typing microarrays. Epoxy silane slides were 
optimised using this blocking and subsequently this method was used to block all 
blood typing microarrays performed on gold-coated slides. This is an appendix as it 
was not directly related to the work presented in this thesis, but did have some 
impact on processing. 
Epoxy silane coated slides were prepared by the SCGTI. The probes printed were 
detailed in Table 4.9. Four replicates of each probe were printed and 700 fan pins 
were used. FITC group B cells were used and were suspended in the appropriate 
blocking solution. The blocking solutions investigated were as follows at varying 
concentrations; non-fat milk, bovine serum albumin (BSA), non-hydrolysed casein, 
hydrolysed casein and PBS. The concentrations are detailed on the result figures. 
The results are detailed in Figure Al. For the expected negative probes, only data 
from the highest concentration is presented for clarity. The results show higher SIN 
values than previously using poly-L-lysine slides and that the non-fat milk, BSA and 
PBS blocking give the highest specific values. Although the PBS has comparatively 
low S/N it still give sufficient specific reactions. Those blocked with casein all 
showed high background and therefore low S/N values. The casein appears to have a 
detrimental effect on the Ab-Ag interaction. For these reasons non-fat milk, BSA and 
PBS were selected for further evaluation. The results are presented in Figure A2. 
When using three replicate slides the results are calculated from the combined S/N 
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values for each spot from the three slides. The I% BSA was selected as the blocker 
for subsequent experiments using epoxy silane slides. This is a more convenient 
blocker to use than the non-fat milk. Although PBS gave good results it was decided 
that no blocking might cause NSB at some time. 
3.0 % non-fat milk 
1.0 % bovine serum albumin 
I. 1.0 % non-hydrolysed casein 
60 ý 
i 0.25 % non-hydrolysed casein I 
1.0 % hydrolysed casein 






LB2 DILl LB2 DIL2 LA2 DILl ES9 DILl ES15 DILl 
0 
Probe antibody 





LB2 DIL1 LB2 DIL2 LA2 DIL1 ES9 DIL1 ES15 DIL1 
Probe antibody 
Figure A2. Results of repeat blocking optimisation experiment on epoxy silane slides. 
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APPENDIX 4. Publications Arising from this Thesis 
Robb, J. S., Roy, D. J., Ghazal, P., Allan, J. and Petrik, J. Development of non- 
agglutination microarray blood grouping. Accepted for publication in Transfusion 
Medicine, 2005. 
Petrik, J. and Robb, J. S. Microarrays and Blood Diagnostics. In BioArrays: From 
Basics to Diagnostics. Accepted for publication. Human Press Inc. 2005. 
Campbell, C. J., O'Looney, N., Chong Kwan, M., Robb, J. S., Ross, A. J., Beattie, J. S., 
Petrik, J. and Ghazal, P. A cell interaction microarray for blood phenotyping. 
Accepted for publication in Analytical Chemistry, 2006. 
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SUMMARY. Microarray technology provides an 
opportunity to monitor multiple parameters simulta- 
neously. High-throughput applications such as blood 
donation screening could greatly benefit from per- 
forming various tests on a single testing platform. 
Blood grouping represents one part of the donation 
testing complementing the screening for blood-borne 
pathogens. Blood group serology traditionally 
exploited agglutination as the detection method. In 
this investigation, we have adapted blood grouping 
reactions to a solid-phase microarray substrate in a 
non-agglutination reaction format as an initial step in 
the development of a combined microarray testing 
platform. We have investigated immobilization of 
proprietary antibodies on multiple surfaces and 
monitored their performance under various reaction 
conditions. For the first time, highly specific blood 
grouping has been achieved on a planar microarray 
using directly labelled erythrocytes or a secondary 
labelled reagent using fluorescent signal end point 
readout. We have also complemented microarray 
data with a label-free, surface plasmon resonance- 
based Biacore platform data and used the real time 
quantitative measurement to rank anti-A antibodies 
according to the strength of reaction with the immo- 
bilized synthetic blood group antigen A. 
Key words: blood grouping, microarrays, protein 
arrays, solid phase. 
Haemagglutination in liquid phase has long been the 
method of choice for blood group serology. Tubes 
gradually replaced slide and tile reactions, but ever 
increasing test numbers have driven the development 
of new assay formats such as microplate. Solid-phase 
assays (Beck et al., 1984; Sinor el al., 1985) offered 
better storage of pre-dispensed dried reagents, higher 
standardization and easier automation, including 
operator-independent readout. A microplate format 
(Wegmann & Smithies, 1966) with immobilized spe- 
cific antibody became popular for ABO/11) grouping, 
taking advantage of instrumentation already in use 
for microbiology blood screening. Various para- 
meters affecting the assay, such as the purity and 
concentration of antibody, pH and ionic strength 
during the coating procedure and chemical composi- 
tion of coated surfaces have been investigated in 
Correspondence: Juraj Petrik, PhD, Scottish National Blood 
Transfusion Service. TTI Department, LCMV, Royal (Dick) 
Veterinary College. Summerhall, Edinburgh EH9 1Q11, UK. 
c-mail: janinc. robb(ualbabioscicncc. co. uk 
detail (Scott, 1991). The need for repeated microplate 
centrifugation prompted development of an alternate 
solid-phase assay the gel card system containing 
microtuhes with antibodies suspended within a gel 
(Lapierre ei al., 1990; marketed by 1)iaMed) or [] 
glass microheads (Reis el al., 1993; marketed by 
Ortho Clinical Diagnostics). This system requires 
only final centrifugation and no washes, but it is 
generally more expensive than microplates. 
Alternative solid-phase, nmentbrane-based dipstick 
assays (Plapp et al., 1986) are used mostly in bed- 
side blood grouping, as they are not designed for 
high-throughput applications. 
Agglutination techniques on solid phase have been 
exploited with lesser success in the reverse format to 
test for clinically relevant alloantihodies against 
blood group antigens. It proved more difficult to 
reproducibly immobilize and store erythrocytes or 
erythrocyte ghosts than immobilized antibodies 
(Scott, 1991; Knight & de Silva, 1996), and despite 
various systems being developed (Ramsey ei al., 
1977; Uthermann & Poschmann, 1990: Beck et al., 
1991; Rolih eI al., 1995), gel cards are still the most 
2005 Blackwell Publishing Ltd I 
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widely used format. Centrifugal forces may sometime 
break weak agglutinates leading to the failure to 
detect some weak antibodies (Phillips et al., 1997). 
Microplate format dominates the field of immuno- 
assays in general. Attempts to further miniaturize 
these assays started as far back as the late 80s, in 
relation to the development of multianalyte assays 
and based on a theoretical prediction that they may 
require much smaller amounts of antibodies than 
originally thought (F. kins, 1989,1998). This work 
has been facilitated by the initially unrelated devel- 
opment of DNA arrays. Aimed at detecting simulta- 
neous expression profiles of multiple genes and 
driven by large sequencing projects providing the 
content for expression profiling microarrays, these 
arrays are produced by contact printing of cDNAs 
(Schena et al., 1995) or in situ lithographic synthesis 
of oligonucleotides (Fodor et al., 1991). The transi- 
tion from porous membranes to non-adsorbent silica- 
based materials and new surface chemistries led to a 
significant reduction in reaction volumes, increasing 
the reaction kinetics. While genomic research was the 
main driver for the development of these techniques, 
it soon transpired that diagnostics could not only 
greatly benefit from them but may also become the 
main application in the future. In blood banking, 
microarrays may provide improved antibody screen- 
ing (Voak, 1999), as well as a desirable single plat- 
form for performing a variety of tests simultaneously 
(Petrik, 2001). 
The development of protein microarrays lagged 
behind DNA microarrays mainly due to the more 
complex patterns of protein interactions compared 
with those governing re-annealing of complementary 
nucleic acid strands. The first protein microarray 
experiments involved interactions of expression 
libraries immobilized on porous membranes 
(Bussow et al., 1998; de Wildt et al., 2000) but new, 
non-porous materials and printing techniques used 
for DNA microarrays were quickly adopted. 
MacBeath & Schrieber, 2000) described contact 
printing of nanolitre amounts of selected protein 
solutions on treated glass slides resulting in a 
covalent attachment allowing the analysis of protein 
protein and protein small molecule interactions. 
Multianalyte antibody antigen interactions were 
investigated by Haab ei al. (2001) on poly-L-lysine- 
coated slides. Other modifications included the use of 
polyacrylamide patches and subarrays within micro- 
plate wells (Mendoza et al., 1999; Arenkov el al., 
2000). Numerous other microarray systems were 
developed, bead-based or electronic flat arrays, in 
some cases utilizing microfluidics (Cheng et a!., 1998; 
Michael et al., 1998; Vignali, 2000). 
K 
Blood typing has been demonstrated in solid sur- 
face systems other than microplate. Quinn et al. 
(1997) described successful ABO grouping using the 
commercial Biacore platform, which provides useful 
information on interactions detected by surface plas- 
mon resonance. The Biacore platform in its current 
configuration is not, however, designed for it cost- 
effective mass screening with considerable sample 
throughput such as blood donation screening. Open 
plan microarrays offer a number of potential advan- 
tages for blood typing analysis. 
The aim of this study was to develop an array 
platform for the discrimination of the A130 blood 
group system antigens using it set of well-defined 
proprietary antibodies, which are routinely used in 
current agglutination-based assays. A number of'cri- 
tical factors were considered in the development of 
arrays. These were definition of microarray sub- 
strates and spotting conditions preserving the anti- 
body functionality; definition of reaction conditions 
and definition of methods for fluorescent detection of 
bound erythrocytes. In this paper, we show for the 
first time successful non-agglutination blood typing 
using an open plane microarray and a fluorescence 
readout. We have also complemented microarray 
data using an established analytical 13iacore platform 
based on the label-free surface plasmon resonance 
detection method. Biacore real time interaction ana- 
lysis provided further characterization of reagent 
antibodies on a solid phase and a method of ranking 
the antibodies using a reverse assay with the inuno- 
bilized synthetic blood group A antigen. 
MATERIALS AND MFTHO)I)S 
Anlihorlirs, a, ui, gen. c and scra 
The antibody probes consisted of a panel of estab- 
lished blood group antibody reagents, well character- 
ized using routine blood group serology 
agglutination assays. The majority of antibodies are 
proprietary Scottish National Blood Transfusion 
Service reagents extensively used in it wide range of 
tests. A list of antibodies and sera utilized in this 
study is given in 'T'able 1. Inimunoglobulin (Ig)M 
antibodies were purified either by gel filtration or 
by affinity chromatography. For gel filtration, a 
pre-filtered culture supernatant was loaded onto it 
500-nit, Sephacryl S-300 column connected to (IV 
detector. The biological activity of material in col- 
lected fractions was measured by haemagglutination 
assay. The eluted antibodies were concentrated using 
appropriate Amicon Ultra centrifugal filter devices 
(Millipore, UK). 
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Affinity chromatography was carried out on 2- 
mercaptopyridine (1-mL HiTrap IgM Purification 
HP Columns, Amersham Biosciences, UJK) according 
to the manufacturer's instructions. 
IgG antibodies were affinity purified on Prosep G 
or Prosep A (Millipore, UK) according to the manu- 
facturer's protocol. 
Antibody functionality was tested using standard 
serological haemagglutination assays, and antibodies 
were quantified by enzyme-linked immunosorbant 
assay (ELISA). 
fn 
Labelling of'err! lrrocv(es 
Erythrocyte labelling followed the method of 
Dr D. Pepper (personal communication). Whole 
blood was collected into 7-mL tubes containing ethyle- 
nediaminetetraacetic acid (EDTA). The pH of it 2% 
suspension of washed erythrocytes in phosphate buf- 
fered saline (PBS) pH 7.0 was adjusted to between 8.5 
and 9.0 using IM NaOH. Ten mililigram per millilitre 
of fluorescein isothiocyanate (FITC) in dimethyl sulph- 
oxide was added to a final concentration of 0" I mg mL 
1 of FITC. The pH was then re-adjusted to between 
8.5 and 9.0. The solution was incubated at 37 °C for 2 It 
then washed five times in PBS pH 7.0 and then sus- 
pended in PBS containing 2% bovine serum albumin 
(BSA). Fluorescence-activated cell sorter (FACTS) ana- 
lysis was performed on labelled erythrocytes using it 
Becton Dickinson FACScan. FITC labelled erythro- 
cytes were detected in the FLI (flow channel one) 
channel and demonstrated that using this FITC label- 
ling method erythrocytes were labelled to over 99% 
efficiency (data not shown). Erythrocytes to be used 
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Alba Bioscience 
buffer, as detailed in the processing of microarrays 
section below. 
I'reparalion o/'unlahel/cd eryihroc vies 
Whole blood was collected into 7-mL tubes contain- 
ing EI)TA. Erythrocytes were washed at least four 
times in PBS pH 7.0 and resuspended at the required 
concentration in PBS. Erythrocytes to be used in the 
Biacore system were suspended in HEPES huffered 
saline (HBS) IO mM HF, PES, 0.15M NaCl, 3.4 mM 
EI)TA and pH 7.4 buffer. 
Printing of inic"rourra}"e 
Antibody or serum proteins to he printed onto nitro- 
cellulose-coated slides (FAST " slides, Schleicher & 
Schnell, Germany) were prepared in Ix array butler 
(Schleicher & Schuell). Proteins to he printed onto 
other array substrates were prepared in PBS p11 7.0. 
Poly-L-lysine slides were prepared in-house, amino 
silane slides were purchased from Corning, and poly- 
acrylamide (Hydrogel) slides were purchased from 
Packard Biosciences. All antibody probes were at a 
x 
concentration of 50 µg mL ', except LA2. which was 
printed at 200 jig mL 1, and serum proteins at 
3 mg mL 1. All samples for deposition were dis- 
pensed into it 384-well source microplate. Slides 
were printed using a MicroGrid II Arrayer 
(BioRobotics) using a print head containing 16 solid ) 
pins, 700 pm in diameter. At least three replicates of' 
each sample were printed on each slide. Fach slide 
contained typically 144 spots. Following printing, the 
arrays were air-dried for I Ih. 
1 2005 ßlackwcll Publishing Lid, 7ransJusirm , bledit7ne, 011,1 11 
4 J. S. Robb et al. 
Processing of nricroarravs 
For the development of the antibody-red blood cell 
(RBC) antigen screening array, we have modified 
the method described by Haab ei al. (2001). All 
arrays, apart from nitrocellulose, were re-hydrated 
over PBS pH 7.0, then rinsed in PBS pH 7.0 
containing 3% non-fat milk or 1% BSA and 0-1% 
ween 20 (Signa). A blocking was carried out in 
blocking buffer (PBS pH 7.0 containing 3% non-fat 
milk or I% BSA for 1 h). A hybridization chamber 
(Schleicher & Schnell; 450 pL volume) or Lifter Slip 
M Erie Scientific; 25 tL volume) was placed over each 
array. Slides were then incubated with erythrocytes 
suspended in blocking buffer for 2 h. One percent 
erythrocyte suspension was used throughout, unless 
specified otherwise. Slides with hybridization cham- 
bers were gently mixed throughout to allow move- 
ment of the erythrocytes. Slides were submerged 
into PBS pH 7.0, then transferred to PBS pH 7.0 
containing 0.1% Tween 20 for a 20-min washing 
step with constant mixing. This was followed by 
two additional washes in PBS pH 7.0 for 10 min. 
After the final wash, the slides were dried by brief 
entrifugation at 1000 r. p. m. Nitrocellulose slides 
were processed by Schleicher & Schuell recom- 
mended methods. 
Imaging and data analysis 
All slides were scanned in an Affymetrix 428 Array 
Scanner set to the Cy3 channel for the detection of 
FITC. Numerical data was extracted from the micro- 
arrays using QUANIARRAY MICROARRAY ANALYSIS 
13 Software (GSI Lumonics, Canada). This gave a 
fluorescence intensity value from the centre of each 
spot and a background value from the area surround- 
ing each spot. For each spot, the background fluor- 
escence value was subtracted from the fluorescence 
intensity value. Each slide was scanned with at least 
three different photo-multiplier tube settings. A scat- 
ter plot was prepared for each slide using the signal 
intensity values from each scan setting set against 
each other. The shape of the resulting data cloud 
gave an indication of the scan qualities. The R2 
value was applied to each graph, and the scan giving 
the most highly optimized data was selected. A nega- 
tive control population was derived from human 
monoclonal IgM and IgG (LDM3 and ESDI anti- 
bodies as described in Table I). A median of replicate 
spots signal/noise (S/N) ratio was then calculated and 
used in presented data. Use of S/N ratios meant 
normalization was not required between comparative 
slides. 
Biacore afla/)'SiS 
The method used was adapted from that detailed in 
Quinn et of. (1997), with modifications: The Biacore 
X, Biacore CM5 chip, BIACORE X CONTROL Software 
and BIALVALUn nON Software were used. Data pre- 
sented in this work are reference subtracted (data 
from a reference flow cell subtracted from data 
from active flow cell). Briefly, ligands were dialysed 
against 10 mM sodium acetate pH 5.0 and applied at 
a flow rate of 5 µL per minute. The concentration of 
ligand was 50 µg mL 1. The surface of the chip was 
activated for 10 min. The coupling of ligand was 
performed using contact time of 10 min. The surface 
of the chip was deactivated for 7 min using IM 
ethanolamine-HCI pH 8.5. The analyte was prepared 
in HBS buffer, and interaction analysis was per- 
formed for 10 min. Response is measured in response 
units (RU) and is proportional to the mass on the 
sensor surface (one RU represents a change of 00001 
in the angle of reflective light). NaOH (I mM) was 
used for the chip regeneration. 
RESULTS 
Slicte Sill-/ace selection and optimization of reaction 
conditions 
Initial development involved a selection of slide sur- 
faces suitable for antibody immobilization and at the 
same time for specific erythrocyte binding, optimal 
erythrocyte concentration and effect of reaction con- 
ditions such as volume and mixing (Fig. IA I)). 
Additional experimental variables investigated 
included various blocking agents, detergents and 
incubation and washing times (data not shown). 
Figure IA shows the specific binding of ('y3 labelled 
anti-human IgG to human IgG antibody and human 
serum while the cross-reactivity with heterologous 
sera and antibodies was generally low. In this type 
of assay, S/N ratio on the polyacrylamide slide was 
superior to other substrates, exhibiting around five 
times higher S/N than other substrates. Indeed, poly- 
acrylamide pore size is unlikely to permit the pene- 
tration of erythrocytes used in blood typing 
reactions. Amino silane-, poly-L-lysine- and nitrocel- 
lulose-coated slides showed substantial but lower S/N 
(between 10 and 40). The lowest values of signal on 
heterologous probes were on poly-L-lysine slides, 
with nitrocellulose slides showing slightly higher 
cross-reactivity for certain probes. 
Poly-L-lysine and polyacrylamide slides were 
chosen for evaluation of blood typing reactions, the 
polyacrylamide slides for their generally high S/N 
values (see below) and poly-L-lysine slides for easy 
4 2005 Blackwell Publishing Lid, Trans/union t! edirine, 1111,1 11 
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Fig. I. Optimization of parameters for microarray blood grouping assay. Antibody and serum probes were printed, slides 
processed, scanned and data analysed as described in MATERIALS and AIL-17100S. Signal noise (S/N) ratios are the 
median of at least three replicates. (A) Specificity of reaction of C'y3-labelled anti-human Ig( reaction with human 
immunoglobulin (Ig)G and mammalian sera on four di! l'erent microarray surfaces. (13) Binding of Iluoresccin isothiocyanate 
(FITC)-labelled group Al erythrocytes to blood group antibodies on poly-L-lysine- and polyacrylamide-coaled slides. ((') 
Effect of erythrocyte concentration (haematocrit). Different concentrations of I11('-labelled group I3 er Ihrocytcs were 
incubated with anti-B (LB2) immobilized on poly-L-lysine slides. (I)) Nffect of reaction volume and mixing. III ('-labelled 
group Al erythrocytes were incubated with anti-A (LA2) antibodies innnobilized on poly-I. -lysine, using different volumes 
and mixing conditions. 
and reproducible in-house preparation and relatively 
low background values. As shown in Fig. I B, this 
test permitted specific detection of blood group anti- 
gen A-specific RBC with both substrates. The group 
A erythrocytes reacted with antibodies of anti-A and 
anti-A(B) specificities but not those with anti-B spe- 
cificity. Of note is that the poly-L-lysine slides gener- 
ated a higher S/N ratio than polyacrylamide slides, 
contrary to antibody antigen interactions (Fig. IA), 
presumably due to the RBC-probe ligand reaction 
being limited to the polyacrylamide patch surface. 
A parameter that may vary depending on the 







erythrocytes of the corresponding specificity is the 
optimal RBC concentration. We have investigated 
erythrocyte preparations of different hacmatocrits 
and found that for microarray-based A1«) grouping 
the optimal RB C concentration was I as shown in 
Fig. I('. 
Other parameters to consider for the reaction of' 
itmnobilized antibody probes with an antigen on it 
corpuscular carrier (erythrocyte) were the reaction 
volume and the effect of mixing. We have compared 
it static incubation in it minimal volume of 25 µL 
under Lifter Slips' NI with gentle mixing in it larger 
reaction volume of 45(1 pL using reaction chanihers. 
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Figure ID shows the latter providing better S/N 
ratios, most probably by increasing the interaction 
probability by keeping the erythrocytes in suspension. 
Biacore analysis - erythrocyte hinding and anlihody 
activity 
During the development of new assay, a possibility to 
compare the data with data obtained using analogical 
system may prove extremely beneficial. We have cho- 
sen the Biacore system for following reasons: 
I It is a long-established analytical platform for pro- 
tein interactions; 
2 Uses for detection, plasmon surface resonance, 
which does not require labelling allowing the eva- 
luation of the potential effect of erythrocyte label- 
ling in microarray assay: 
3 Use of different chip surfaces which may indicate 
the importance of particular surface or way of 
immobilization for antibody performance, if using 
identical antibody preparations; 
4 Reverse arrangement with immobilized synthetic 
blood group antigen can provide quantitative char- 
acterization of antibodies used; 
5 Successful use of Biacore for blood typing has been 
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A mouse monoclonal antibody against blood group 
A antigen (cell line LA2) was immobilized onto a 
13iacore CM5 chip under optimized conditions. 
Erythrocytes of different groups were passed over the 
surface and binding reactions recorded as sensorgram 
profiles and as tabulated binding data. Figure 2 shows 
sensorgrams revealing clearly the best interaction with 
Al-specific cells, followed by A2-specific cells. 
Reactivity of A, cells is usually higher due to the higher 
number of antigenic sites (see DISCUSSION). Lower 
values for RBC A, B and A7B specificity corresponds to 
LA2 reactivity in haemagglutination assay, with no 
reactivity detected for B- and O-specific erythrocytes. 
Biacore antibody ranking using synthetic blood group 
1 antigen 
In a series of preliminary experiments on the Biacore 
platform, we have demonstrated the specific interac- 
tion of immobilized synthetic blood group A antigen 
conjugated to BSA, with an anti-A antibody LA? 
(data not shown). Therefore, we attempted to com- 
pare or rank several blood typing antibodies in terms 
of binding to the particular antigen. This could pro- 
vide a useful, additional, more detailed characteriza- 
tion of' antibody behaviour on a solid phase. Given 
that some of the IgM antibodies had been purified by 
RBC group / potency Al / 1024 
. -ý 
A2/ 512 
320 360 460 530 
A, B/512 






Fig. 2. Surface plasmon resonance sensorgrarn of the interactions of immobilized blood group antibody anti-A ( LA2) with 
erythrocytes of various ABO groups (AI, A, Ai B, A, B, B and 0) as determined by Biacore analysis. Potency of the 
anti-A (LA2) against each erythrocyte as measured by haemagglulination is shown next to the corresponding curve. 
, 2005 Blackwell Publishing Ltd, 77uns/umun tlrdimue, 110,1 11 
Development of non-agglutination microarrar blood grouping 7 
two different methods, it could also serve as a compar- 
ison of functionality when the antibodies have been 
processed differently. Synthetic blood group A antigen 
14 Jconjugated to BSA (Dextra Laboratories) was coupled 
to a CM5 chip. Selected blood group antibodies were 
sequentially injected over the sensor chip surface. 
Table 2 lists the response and mean response from 
two runs in RU. All anti-A antibodies (ES9, LA2 and 
DAM1) showed the strongest reactivity, almost two 
times (three times in the case of ES9) of that for anti 
A(B) antibody ES 15. Anti-B antibody, LB2 showed no 
reactivity. It can also be seen from Table 2 that anti- 
bodies purified with two different methods gave similar 
results, although affinity-purified antibodies exhibited 
slightly increased values. Biacore chips can be used 
repeatedly, and the data presented show the means of 
two runs which were highly reproducible, showing a 
difference of no more than 7%. Quantitative measure- 
ments provided by Biacore represent useful character- 
ization of reagents to be immobilized on a solid phase. 
Microarray-baser/ blood t tieing 
A panel of antibodies specific for the ABO blood group 
system were arrayed onto poly-L-lysine slides at a range 
of concentrations. The optimal detection method used in 
the development stage of the assay was direct labelling of 
erythrocytes with FITC. FACS analysis was used to 
determine the degree of labelling. High labelling effi- 
ciency of around 99% was normally achieved (data not 
shown). To establish the principle of specific erythrocyte 
detection on a microarray, we used FITC-labelled ery- 
15 throcytes of different specificities to probe the array dis- 
criminatory for the ABO blood group system. 
Additional experiments were conducted on a micro- 
array containing an extended panel of anti-A, -B 
and -A(B) blood group antibodies to further increase 
range and specificity of erythrocyte-type detection. 
Figure 3 shows data from a typical experimental run 
demonstrating the specific detection of the four main 
ABO group erythrocytes on a poly-L-lysine-based 
array format. Antibodies were reacted with directly 
fluorescently labelled RBC preparations of each of 
the four main blood group specificities. Group 0 
cells have neither A or B antigen present and they 
effectively serve as a negative control. Anti-A, -B and 
-A(B) antibodies exhibit specific reactivities with S/N 
between 38 and 96. Somewhat surprisingly, anti-A(B) 
antibody ES15 outperforms the single specificity anti- 
A (LA2) and anti-B (LB2) antibodies in reactivity 
against A- and AB-specific RBC, although reactivity 
with B-specific erythrocytes was minimal. The cell line 
ES15 is known to react only very weakly with group B 
RBC (Moore et al., 1984). Although giving similar 
results to the other probe antibodies, the concentra- 
tion of anti-A (LA2) is far higher (about four times 
more concentrated). Further technological improve- 
ments using an extended range of anti-blood group 
antibodies have been investigated in a parallel study. 
The labelling of each individual crythrocyte pre- 
paration is, however, impractical for high-throughput 
screening. We have therefore investigated various sec- 
ondary FITC-labelled reagents [anti-Rh29 antibody 
and wheat germ agglutinin (W(; A) lectin]. Figure 4 
shows the detection of hound Al-specific erythrocytes 
with FITC-labelled WGA and anti-Rh29. The 
achieved S/N ratio (3 5) was lower, in some cases 
considerably lower, than that of directly labelled ery- 
throcytes, albeit still sufficient for specific typing, with 
the specificity retained. We are currently investigating 
ways to improve the S/N ratios using this method. 
DISCUSSION 
The microscope slide has made a full circle as a 
matrix for blood grouping applications, supporting 
"fable 2. Antibody ranking using Biacore chip-immobilized synthetic blood group antigen A 









*Gel filtration purified. 
tAffinity chromatography purified. 
Response units Response units Mean response units 
(first run) (repeat run) (mean of two runs) Rank 
9267.8 8431.1 8849.45 I 
8114"3 7573"9 7844"1 4 
12393"5 12503.1 12448"3 I 
8112.7 7816"3 7964"5 3 
4605"1 4158"6 4381"85 5 
4369"0 3795"6 4082"3 6 
83"1 39"7 61.4 7 
-103"5 -177"8 -140"65 8 
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Fig. 3. Microarray blood grouping with directly labelled 
erythrocytes. Fluorescein isothiocyanate (FITC)-labelled 
erythrocytes carrying antigens of different specificities (A, 
B, 0 and AB) were incubated with blood group specific 
antibodies printed onto poly-L-lysine slides. Signal/noise 
(S/N) ratios as Fig. 1. 
a single antibody-single blood sample assay a few 
decades ago and a multiple antibodies-one blood 
sample (one chip-one donation format) assay today. 
Miniaturization reduces consumption of the probes 
and samples and decreases reaction times. These 
assay parameters are primarily important in mass 
screening application such as blood typing in a 
blood bank setting. In this study, we have investi- 
gated if the benefits of miniaturization as seen in a 
whole genome analysis could be applied to this pro- 
tein-based diagnostic technique. 
Antibodies immobilized on a solid phase have been 
used in blood typing either in a microplate format or 
in gel cards, although in the latter case the antibodies 
are suspended rather than attached. In both cases, 
the interaction with red cells leads to agglutination, 
automated readout of which may sometime be pro- 
blematic (Scott, 1991). An individual well of a micro- 
plate or a microtube within the gel card both contain 
single specificity antibody. Planar (or open plan) 
microarrays prepared by contact or ink-jet printing 
are more suitable for multiplexing, as the number of 
probes is highly flexible. We have investigated param- 
eters such as the antibody concentration, various 
spotting surfaces and blockers, sample dilution, etc. 
Although polyacrylamide-coated (Hydrogel) slides 
were superior in a classical antibody antigen type 
reaction, mainly due to high capacity, this advantage 
was lost in a blood typing reaction. Hydrogel pores 
are impenetrable to very large molecules such as IgM 
and also to erythrocytes and other cells. It is likely 
that with polyacrylamide, interactions are limited to 
ý FITC WGA (300µgmL-1) 
I FITC WGA (30µgmL-1) I 
FITC Anti-Rh29 (300µgmL-') 





Anti-B (LB2) Anti-A (LA2) Anti-A(B) (ES15) 
Antibody specificity (cell line) 
Fig. 4. Microarray blood grouping determined by indirect 
labelling of bound erythrocytes. Group A, erythrocytes 
were incubated with blood group antibodies immobilized 
on poly- L-lysi ne-coated slides and then with fluorescein 
isothiocyanate (FITC)-labelled wheat germ agglutinin 
(WGA) or FITC-labelled anti-Rh29 monoclonal antibody. 
Signal/noise (S/N) ratios as Fig. 1. 
the polyacrylamide patch surface, perhaps slightly 
bigger than normal two-dimensional spot due to its 
shape but still not sufficient to compensate for it loss 
of internal patch capacity. Poly-L-lysine slides pro- 
vided it satisfactory and cost efficient matrix for 
ABO typing. We have opted for rather large printing 
pins, 700 µm in diameter, to ensure sufficient numbers 
of erythrocytes can bind to immobilized antibodies. 
Sensitivity does not seem to he it critical parameter in 
basic ABO typing as a 700-µm spot can theoretically 
accommodate 45x 10' erythrocytes (7-8 X-3 pin in 
diameter) with 2.5 x 105-1 x 106 antigenic sites per 
erythrocyte (Daniels, 2002). However, it could he 
more important for antigens like Ax with around 
1400 antigenic sites or weak D with only 200 sites 
per erythrocyte. We have investigated additional sur- 
faces and an extended range of blood group antigens 
in a parallel study. The reaction between an inunobi- 
lized antibody and antigens carried on the cell surface 
is different from the reaction with a soluble antigen. 
The role of antibody affinity is perhaps more impor- 
tant for retention of specifically attached red cell 
through the antigens on its surface, especially during 
the washing procedure. Protein cell interaction stu- 
dies using microarrays are still uncommon, and we 
believe this is the first comprehensive study showing 
the feasibility of blood group typing in this format. An 
analogical study using antibody arrays for leucocyte 
immunophenotyping has been described by Belov 
el at. (2001), although in a slightly different set up, 
using nitrocellulose slides and a non-conventional 
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dark-Field microscopy as a detection method for 
bound leucocytes. Protein array cell interactions 
were described also for rat neuronal stern cell analysis 
(Ko et al., 2005). 
Non-agglutination blood typing on a solid phase 
has been reported previously by Quinn el al. (1997). 
The authors used the Biacore platform which pro- 
vides sensitive surface plasmon resonance, label-free 
detection of the interacting molecules. Biacore analy- 
sis generates informative real time quantitative meas- 
urements. In its current configuration, however, it is 
an analytical rather than a high-throughput platform. 
We have initially quantified the interactions of an 
immobilized anti-A blood group antigen antibody 
(LA2) with erythrocytes of various specificities and 
obtained a pattern of reactivity matching that of 
soluble haemagglutination with the same antibody. 
Indeed, several antibodies (e. g. LA2, ES9 and ESI5) 
have been used in three parallel assays: haemaggluti- 
nation, Biacore and microarray. We have also used 
the Biacore chip in a reverse assay with immobilized 
BSA-conjugated synthetic blood group A antigen 
for ranking various ABO typing antibodies. 
Interestingly, we observed differences in reactivity 
patterns of certain probe antibodies in different 
assay formats. While anti-A antibodies such as LA2 
or ES9 are used at same potency as anti-A(B) ESI5 in 
haemagglutination assays, ES15 reacted less well with 
a synthetic blood group A antigen immobilized on a 
Biacore chip. However, ES 15 usually outperformed 
ES9 and LA2, when immobilized on a microarray. 
This type of comparative data will be useful for 
defining choice of surface, immobilization technique 
and antibody probes for microarray-based blood 
group serology. Where IgM antibody preparations 
Table 3. Parameters of different blood grouping techniques 
Ah* probe volume (pL) 
Method per data point 
Manual/tube 40 per test 
Microplate 25 per well 
Column 25 per tube 
agglutination 
Biacore chip 70 per chip 
Planar protein 0.02 per spot$ 
microarray 
purified with two different methods (affinity chroma- 
tography and gel filtration) were used, the affinity 
chromatography-purified antibodies gave slightly 
better signal. 
The new assays are generally expected to provide 
an advantage over the current assays, be it higher 
sensitivity/specificity, better cost efficiency, higher 
throughput, etc. When considering parameters of 
different serological testing methods (Table 3), 
microarray blood typing could easily outperform 
other currently used assays in terms of reagent con- 
sumption and there is a significant potential advan- 
tage in throughput, although this needs to be 
confirmed on an automated system once available. 
Even the 20 nL of antibody probe used per spot in 
this study can be greatly reduced with smaller dia- 
meter printing pins. Compared with the other meth- 
ods, the antibodies used in microarrays were purified, 
and it remains to be seen how important the purifica- 
tion step really is for microarray blood grouping and 
by how much it would affect the savings made on 
reagent consumption. Multiplexing power, however, 
is what sets the microarray format apart from the 
other systems. 
We describe in this paper microarray-based A13O 
blood grouping, as the first step in the development 
of it comprehensive microarray platform for blood 
donation screening. This work is being extended to 
other blood group antigens and antibody screening 
work, as well as assays that would combine at least 
some aspects of'blood group serology with microbiol- 
ogy testing. One chip one donation concept of' 
screening would greatly simplify the testing algo- 
rithms. This concept could be extended to it more 
logistically demanding one chip multiple donations 
Sample volume (µl. ) 
per number of probes Readout method 
40 per I Ilaemagglutination 
25 per I Ilacmagglutination 
50 per I Ilacmagglutination 
70 per I Surface plasmon resonance 
25 450 per nx 10 Fluorescence 
ton x 100 
'I liroughput: number of' 
samples (data points) 
per run in 6 Ii 
SU (350)1- 300 (2100)t 
240 (2980) 1440(I7290) 
70 (420) 420 (2520) 
1 (1) 24(24) 
it x 10 nx 101) 
(n x I000)§ (n x IO(H)0)§ 
*All antibodies arc used at similar titre (between I: 256 and I: 5121. Purified antibodies were used for ßiacore and microarray analysis. 
tEstimatc. 
$Por 700-µm solid pin. The volume can be reduced significantly using smaller pins or ink-jet printing. 
¶Estimate. 
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algorithm, technically achievable in a microarray for- 
mat. More immediate extension of blood typing 
arrays is, however, likely to be a combination with 
antibody screen probes and/or with probes relevant 
for blood-borne pathogens screening, both approaches 
being actively pursued by this group. 
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Summary 
Microarray technology has a potential to alter many diagnostic applications, especially high throughput 
multiparameter assays. In this paper we discuss potential impact of microarrays on blood donation screening 
algorithms by providing a single testing platform for microbiology and blood group markers. An Initial stage of such 
development is demonstrated on examples of successful blood grouping and antibody screen for some rare 
alloantibodies. 
1. Current blood testing methods 
Blood tests can reveal a variety of changes taking place during disease processes, as well as genotype 
and phenotype characteristics necessary for further medical Interventions. There are a huge number of tests and 
Instruments in use, reflecting the needs of specialised hospital laboratories as well as Individual point of care 
devices. Microarrays could play an Important role predominantly in high throughput applications. In this paper we 
focus on the potential role of microarrays In future blood donation screening techniques. 
1.1. Unique features of blood donation screening 
Blood transfusion occupies rather an unusual place among medical procedures In the level of expected 
safety of both the procedures and the outcome. Risk assessments for very few other medical procedures would be 
comparable to figures for residual risk of transfusion-transmitted viruses, currently In the range of one In several 
million of donations (1). Combination of donor selection methods, testing procedures and, in some cases 
inactivation techniques guarantees an extremely safe blood supply (2). 
Blood donation screening is a unique process for several reasons: 
a) the vast majority of donations will produce a negative result for blood borne pathogen because blood donors 
represent a self-selected healthy population; 
b) each sample positive for blood borne pathogens must, however, be detected because blood, blood products and 
components are destined for recipients. The sensitivity of the screening test needs to be extremely high, even at the 
expense of slightly lower specificity. Repeat testing is a routine component of testing algorithms; 
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c) for the same reasons, clinically relevant blood groups and the presence of blood group alloantibodles have to be 
reliably determined; 
d) screening procedures have to be able to satisfy throughput needs between several hundreds and a few 
thousand donations per day (for an average size blood centre); 
e) turnaround time has to be short due to the shelf life of some of the components (e. g. five day shelf life for 
platelets) and flexibility of stock management. 
1.2. Testing targets 
Each donation has to undergo testing for a set of markers for selected blood borne pathogens and to 
determine blood group compatibility. Table I lists the testing targets and parameters of currently used testing 
procedures. 
1.2.1. Testing for blood borne pathogens 
Highly sensitive immunoassays form the basis for the majority of microbiology assays. They usually 
represent various modifications of sandwich ELISAs. Ideally, the screening would be based on direct antigen 
detection, confirming the presence of an infectious agent. In many cases, however, the antigen concentration or titre 
of the infectious agent in circulating blood is too low to be detected in this way. One exception Is hepatitis B surface 
antigen (HBsAg) produced at quantities sufficient for robust antigen detection. The best HBsAg assays can detect 
around one pg /ml which Is approximately 8.35 x 106 molecules for 24 kDa protein. 
In most cases we are measuring antibodies developed as a response to Infection. The appearance of 
measurable antibodies may take a significant amount of time creating a potentially long window period. 
For immunoassays, the antibodies (polyconal or monoclonal) or antigens (recombinant proteins; 
peptides) are attached to a solid phase, most frequently represented by the surface of a bead (microsphere) or a 
microplate well. One or two step sandwich detection is usually used, with conjugated enzymes converting substrate 
into colour or (chemi) luminiscent signal. 
Due to the sensitivity Issue with many antigen-detecting immunoassays, much hope was placed In the 
application of nucleic acid amplification technologies (NAT). most frequently represented by the polymerase chain 
reaction (PCR). This technology Indeed has an exquisite sensitivity (Table 1) and detects the component of the 
infectious agent rather than antibodies. The window period for viruses for which PCR was introduced as a routine 
screening method, has been shortened significantly and residual risk of transfusion transmitted events are 
extremely low. It would seem to be an Ideal screening procedure. However, the cost efficiency of this type of testing 
is being increasingly questioned, especially as the number of NAT only positive donations Is lower than originally 
expected (see 1.3. ). 
1.2.2. Blood typing and detection of alloantibodies 
The traditional method of monitoring blood group serology reactions Is haemagglutinatlon. It Is an 
Inexpensive technique with easily Identifiable end point detection. There are two basic types of assays both Included 
In routine testing procedures. In "forward blood typing" the red blood cell (RBC) antigens of clinically relevant blood 
group systems are determined using specific polyclonal (minority) or monoclonal antibodies (MAb). IgM MAb are 
preferred to IgGs as they cause haemagglutination In one step thanks to their structure - providing 10 antigen 
binding sites per molecule compared to two per IgG molecule. Microplate assay format Is most frequently used for 
donation blood typing (Table 1). "Reverse typing" is designed to detect antibodies against blood group antigens. 
The reason for development of alloantibodies (or isoantibodies) Is usually Ab pregnancy, blood transfusion or some 
Immunisations. Clinically relevant antibodies need to be detected in donors and, especially In recipients as they 
could cause life-threatening reactions. The microplate haemagglutination is the most frequently used detection 
method for donation testing, while lower throughput patient testing Is most often done using gel cards. 
1.3. Advantages and disadvantages of current testing methods 
As mentioned earlier, current preventative screening and testing procedures used in developed countries 
provide an extremely safe blood supply. Introduction of a conceptually different method In the form of PCR Into a 
routine testing algorithm for certain blood borne pathogens ended an era completely dominated by immunoassays. 
It makes it easier for blood centres to accommodate Improved and new technologies as they emerge. 
PCR would be a very attractive general testing platform due to its sensitivity and precision. PCR and other 
target amplification techniques have been used not only to detect pathogens but also for determination of RBC and 
platelet antigens (3-6). Unfortunately, there is a high cost attached to PCR screening, both direct (contamination 
prevention measures, reagents, Instrumentation. specialist staff) and indirect (significant license fees etc. ). The only 
viable way to achieve satisfactory cost efficiency would be extensive multiplexing. While some multiplex assays 
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were successfully developed, the number of targets Is generally low. This is mostly due to an interference of primers 
and probes, difficult to predict even with the help of oligonuceotide design software. Future improvements may, 
however Increase the multiplexing potential of target amplification methods. At the same time there Is a continuous 
Improvement In the performance of immunoassays and some antigen or combi (antigen and antibody) assays are 
getting closer to NAT assays in respect of closing the window period (7). It does not seem probable at present that 
one type of assays (nucleic acid based or immunoassays) would be able to replace the other type entirely. It 
remains to be seen how successfully they can be co-developed in the future. 
It is fair to say we have an extremely safe but also a complex testing algorithm in place. Microarray 
technology could address this complexity by providing a single donation testing Instrumental platform for a complete 
set of required markers (8; see below). 
2. Microarrays as the potential next generation testing platform 
First experiments to further miniaturise the existing immunoassays date back to late eighties- early 
nineties (9). In parallel, several groups were developing techniques for simultaneous monitoring of large groups of 
genes. These techniques required high probe density facilitated by the use of new, non- porous materials such as 
glass, silicon or plastic, allowing for the reduction in the quantities of deposited probes and reaction volumes. 
Robotic spotting techniques (10,11) and in-situ oligonucleotide synthesis (12) speeded up gene expression studies 
with information content provided by large sequencing projects. Significant efforts were dedicated to developing new 
surface chemistries as well as alternative microarray formats including encoded beads and exploiting microfluidics 
and additional features such as electronic probe and sample addressing (13-15). While driven mainly by genomic 
research, the potential of microarrays for diagnostics has been quickly identified. In fact, diagnostics may well 
become the main microarray application In the future. 
It soon became clear that some of the techniques used for preparation of DNA arrays could be adapted to 
protein microarrays (16,17) despite the more complex character of protein Interactions compared to rules for 
complementary nucleic acid strands re-annealing. Alternative systems describing the use of polyacrylamide patches 
and subarrays within microplate wells were also reported (18,19). 
For mass screening applications such as blood donation testing the cost efficiency Is one of the main 
parameters to consider, together with high sensitivity and specificity, robustness and a high level of automation, 
limiting or eliminating the operator-introduced errors. This will Inevitably affect the complexity of future microarray 
based testing platforms. An open plan blood typing microarray, with no physical barriers between the probes, has 
the potential to develop Into a highly cost-effective high throughput system for blood screening If It can sustain the 
specificity of reactions and achieve the required sensitivity. 
Most protein arrays described to date Investigate the Interaction of free protein molecules with the defined 
partner (probe) Immobilised on the solid surface. Probes are represented predominantly by antibodies (18-21), is 
some cases by antigens (22,23). Blood group serology adds another dimension to these interactions as the 
Interaction Involves blood group antigens on the surface of red blood cells (RBC). Antibody - cell Interaction on 
planar microarrays have been described for applications such as leucocyte typing (24) but still are rather rare. Quinn 
et al. (25) described solid phase blood grouping using the Blacore platform but this Is an analytical rather than high 
throughput application platform. 
2.1. Potential benefits of microarray testing 
In the currently used testing algorithms, several aliquots of donated blood are taken to be used on 
between three and six Instrumental platforms to test for a complete set of required markers (see 1.2.1. and 1.2.2. ). 
Time required for testing on different Instruments varies and sets of results become available at different times, the 
slowest holding up the release of blood and blood components which cannot be Issued without final data 
reconciliation. A proportion of samples will undergo repeat testing as the sensitive tests necessary for Initial 
screening produce some false positive samples in addition to true positives. Table 2 provides a comparison of 
current algorithms with potential changes, which might be possible, for future microarray based testing platform. 
The most significant change would be transition from testing many samples in parallel for one or few markers on 
multiple instrumental platforms, to simultaneous testing of each sample for the required set of markers on 1 -2 chips. 
The IT side of the operations would be simplified by data provided simultaneously. One platform would not require 
multiple sets of reagents for various Instruments or staff dedicated to Individual platforms, as Is the case at present. 
Inclusion of multiple probes per target Is easier in microarrays as the incremental cost of additional probes Is low. 
This could perhaps eliminate the need for repeat testing, as the reactivity pattern on multiple probes should provide 
a Gear answer on sample reactivity. 
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2.2. Options to Increase microarray sensitivity 
Sensitivity Is probably the major problem for wider use of microarrays for some diagnostic purposes. This 
problem is often being addressed by combining target amplification (e. g. PCR) using degenerate primers or non- 
specific amplification, with subsequent microarray analysis (26-28). Such combination would add another extra step 
to existing blood donation testing algorithms, Increasing the complexity of testing as well as costs. Fortunately, there 
are multiple alternative approaches currently being developed to Increase the detection limits. 
Ideally, the screening assays would approach the PCR sensitivity at lower cost, effectively through the 
higher multiplexing power, and perhaps the true multianalyte character of the procedures. Current PCR techniques 
allow detection of less than 10 genome equivalents per reaction, amplifying the target around billion times. The best 
ELISA based assays can detect 10° -101 molecules per ml. How can this gap of around six orders of magnitude be 
closed in the absence of target amplification methods for proteins? Certain advantage is offered by the presence of 
hundreds to thousands of copies of the viral antigens compared to 1-2 copies of genomic RNA or DNA per virion. In 
addition, there are some alternative methods of signal enhancement as listed in Table 3. Signal amplification 
methods seem to provide the biggest gain In sensitivity In comparison to usual methods using few fluorophore 
molecules conjugated to primary or secondary reagents In sandwich assays. In order to apply any amplification 
method simultaneously to all sites on a planar microarray, the amplified signal needs to be localised, not diffuse. 
One primer variant of rolling circle amplification (RCA: 29) produces a long product physically attached to the site 
and can provide signal amplification exceeding 8x 103 (30). Another amplification method is tyramide signal 
amplification (TSA) based on the catalytic activity of horseradish peroxidase (HRP) generating high-density labelling 
of a target claiming sub pg/ml sensitivity. Elimination of the need for physical separation of Individual sites 
necessary for target amplification methods makes these techniques less expensive. Other advantages include use 
of RCA and TSA for both, DNA and protein arrays (31,32) and Isothermal reaction. 
A smaller, but significant Increase In sensitivity is provided by new detection techniques. Resonance light 
scattering (RLS) uses a white-light source scanner to detect monochromatic, scattered light signals of metal (gold, 
silver eta) particles. The material, size and shape of the particles determine the signal. When RLS was directly 
compared to fluorescent detection of bacterial pathogens, the authors observed even 50-times more Intense signal 
(33). 
Planar waveguide technology developed by Zeptosens utilises a special coating of T305 or TiO 2 to Induce 
evanescence field for efficient fluorescence detection (34), at least 10 times more sensitive than the conventional 
fluorescence if using the companys chips and a reader. 
New materials such as quantum dots (or semiconductor nanoparticles) provide brighter fluorescence, 
narrower emission spectra and higher resistance to photobleaching compared to the conventional small molecule 
dyes. Signal can be Increased, however also using small molecule dyes enclosing thousands of dye molecules 
within a derivatised nanoparticle and enhancing the signal many times (35). 
Instead of using a linear probe, usually labelled with a single fluorophore, dendrimers or multiply branched 
molecules provide the opportunity to introduce many dye molecules and to Increase generated signal. When used 
for DNA microarray human herpes virus diagnosis, the signal has been enhanced at least 30 times (36). 
Some of the described approaches can be further combined leading to very sensitive assays, potentially 
approaching the sensitivity of nucleic acid amplification techniques. Combined with easier multiplexing such assays 
could be well suited for high throughput blood screening of the future. 
3. Development of microarray blood testing format 
As outlined In Table 2, a microarray-based blood screening platform could provide advantages over 
existing testing algorithms. An ultimate testing platform would combine pathogen testing with blood group serology. 
As the first step in this development we have investigated the applicability of blood grouping In a microarray format. 
3.1. Blood group serology 
The vast majority of blood serological methods are based on the ability of erythrocytes to agglutinate. Reactions In 
the liquid phase using tubes was replaced by slide and ble reactions and later by microplate format. Solid phase 
assays (37,38) were more suitable for pre-dispensed dried reagents and automation, Including operator- 
Independent readout. An alternative solid phase assay is the gel card system containing microtubes with antibodies 
suspended within a gel or glass microbeads (39,40). 
Agglutination techniques on solid phase have been exploited with lesser success In the reverse format to 
test for clinically relevant alloantibodies against blood group antigens. It proved more difficult to reproducibly 
Appendix 4 
immobilise and store erythrocytes or erythrocyte ghosts than immobilised antibodies (41.42). and despite various 
systems being developed gel cards are still the most widely used format. 
The experiments described below aimed at developing an array platform for the determination of the 
antigens of main blood group systems using a set of well-defined proprietary antibodies routinely used In current 
agglutination-based assays. 
3.2.1. Blood grouping 
Microarray blood grouping could replace an agglutination reaction with fluorescent or other quantifiable 
readout signals. Affinity of Immobilised antibodies needs to be sufficiently high to keep specifically bound RBC 
attached during the incubation and washing steps. In addition, the reaction conditions must guarantee preserving 
the integrity of the RBC necessary for binding of the labelled RBC or fluorophore-conjugated secondary reagent. 
We have Investigated multiple parameters of these Interactions on a variety of slide surfaces under various printing 
regimes, reaction conditions etc. An extensive set of well functionally characterised proprietary antibodies, used In a 
variety of current blood grouping assays, has been exploited in these studies to be published elsewhere (Robb et 
al., submitted; Campbell et al., In preparation). We have shown that a reproducible ABO grouping can be achieved 
and successful typing can be extended to Rhesus (D, C, c, E, e), Kell and other clinically relevant blood group 
systems. Table 4 lists the most clinically relevant of the 25 blood group systems and shows the basis of their 
characteristics. Even a selection of most Important of blood group systems reveals the structural variability of blood 
group antigens as well as large differences in their abundance. When adding the functional heterogeneity and 
various modes of attachment to RBC membrane affecting the access to antigens, the character of various 
interactions Involving antigens of blood group systems could be studied by microarrays, apart from purely diagnostic 
application. 
Figure 1 depicts a typical blood grouping experiment conducted on gold slides. Monoclonal antibodies 
specific for A, B, A(B), Rhesus D and K blood group antigens were immobilised on gold slides and their reactivity 
Investigated separately with RBC of different phenotypes in respect of the above mentioned blood group antigens. 
In Fig 1A RBC carrying blood group A antigen bound to both anti-A and anti A(B) antibodies and RBC carrying both, 
blood group A and B antigens bound in addition to anti-B antibody, as expected. RBC carrying blood group antigen 
B bound to anti-13 antibody. They could be expected to react as well with anti A(B) antibody, but reaction with this 
unique, single available antibody of this specificity Is known to be weak even In normal heamagglutinatlon assays 
(46). RBC of blood group 0 specificity do not, of course, react with any of the antibodies as they do not carry A or B 
antigens and serve at the same time as a negative control. Various levels of reactivity can be seen in Fig 1B with 
RBC carrying two (DD) one (Dd) or no (dd) copy of the RhD antigen. Again RBC of dd phenotype serve at the same 
time as a negative control In this assay. Fig. 1C shows a dose dependent signal produced by binding homozygous 
(KK) and heterozygous (Kk) cells to the immobilised K specific antibody. All other four RBC preparations are K 
negative (kk) and show no or minimal reactivity. As pointed out earlier, we were assaying two different types of 
blood group antigens in this experiment - carbohydrate A and B blood group antigens and protein Rhesus D and K 
antigens (Table 4). 
3.2.2. Antibody screen 
Another part of blood group serology is the determination of alloantibodies against blood group antigens, 
which may cause significant, sometime life-threatening situations if undetected In donors and especially recipients. 
These assays are more difficult to adapt to a solid phase, as they require immobilisation of red cells, although 
alternative systems can be developed. 
During the Initial stage of microarray antibody screen development we have Immobilised RBC of various 
specificities on planar microarray slides modified with different surface treatments. Fig. 2A shows that signals 
produced by specific binding of monoclonal anti-A and anti-13 antibodies to gold slides-immobilised RBC carrying 
corresponding antigens are several times higher than those caused by non-specific binding and/or cross-reactivity 
and can be clearly distinguished. Fig. 2 shows an Initial series experiment under conditions not fully optimised yet. 
The reaction parameters are being continuously Improved to reduce non-specific signal. However the background 
will always be higher with Immobilised whole cells than Isolated antigens. It can be documented by using the 
synthetic blood group B antigen (last column), producing lower signal to noise ratio for specific (anti-B) reaction but 
no cross reactivity or non-specific signal. Much lower S/N values were obtained for anti-D monoclonal antibody 
binding to immobilised RhD+ RBC (Fig 2B). Again, the signal on RhD- cells Is detectable but significantly lower than 
on RhD+ cells. As In Fig 1, In this case we were also measuring the reactivity of two compositionally and structurally 
different blood group antigens. It Is known that carbohydrate A and B antigens protrude from the surface of RBC 
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and easily accessible, while access to protein Rhesus D antigen with epitopes close to the membrane surface is 
more difficult As in other types of blood group assay this could explain the differences In the obtained S/N values. 
Another important factor is, of course the number of antigenic sites per RBC (Table 4). 
In addition to higher background on immobilised whole cells, the stability of such reagents is a cause for 
concern. As an alternative, recombinant blood group antigens could be used and this approach Is a subject of 
intense development. However, some of the antigens are multi-pass transmembrane proteins making it difficult to 
adopt proper configuration preserving the conformational epitopes. Linear epitopes, on the other hand can often be 
mimicked by synthetic peptides. Immobilisation of these probes Instead of red cells provides an alternative way for 
antibody screening In the future. 
4. Future developments 
A complete set of currently used reagent panels for blood grouping and antibody screening needs to be 
evaluated on real samples to confirm applicability of a planar microarray to this type of assay. With colleagues from 
the Centre for Genomic Technology and Informatics (GTI), University of Edinburgh we are working on adapting 
mandatory blood borne pathogen tests to microarray platform. While blood group serology usually does not suffer 
from sensitivity problem, it can be an issue with some antigens present in low numbers on the surface of RBCs. As 
mentioned earlier, it Is a much more pronounced problem for pathogen detection and we envisage exploiting signal 
enhancing methods to overcome insufficient sensitivity in some cases. Signal amplification methods could be used 
for both weak blood grouping and pathogen detection. In addition, these techniques could be applied to both DNA 
and protein arrays, should both types be necessary for complete blood donation screening. Although we have 
focused on protein microarrays in this paper, there is an extensive development work going on for blood group 
genotyping. It is quite possible that no single type of assay. DNA based or protein based will be able to completely 
replace the other type. This Is due to some genotype - phenotype discrepancies as well as existence of certain 
protein only agents such as prions. Microarray technology has, however potential to accommodate all required 
assay formats on one testing platform. 
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Figure Legends. 
Figure 1. Microarray red cell grouping. Monoclonal antibodies specific for blood group antigens A and B (1A), Rhesus 
D (IB) or K antigen (1C) were printed using MicroGrid II Arrayer (BioRobotics) on gold slides (Eire Scientific), 
blocked and incubated for 1 hr at room temperature with I% suspension of fluorescently labeled erythrocytes of six 
different phenotypes: ABO: cells carrying A, B. both (AB) or none (0) antigen. DD cells carry two copies of D 
antigen, Dd one and dd none. Similarly, KK cells carry two copies of K antigen, Kk one and kk none. Slides were 
washed twice with PBS briefly spun and scanned on Packard Bioscience ScanArray 5000 using QuantArray® 
Microarray Analysis Software (GSI Lumonics). Reactivity is expressed as signal to noise ratio (S/N), with signal from 
PBS spots providing noise values. Values represent median of at least 3 replicates. 
Figure 2. Microarray blood group antibody detection. Group A, B or 0 red blood cells, positive (RhD+) or negative 
(RhD-) for Rhesus D antigen were spotted on gold slides (Erle Scientific Company), alongside the synthetic blood 
group B antigen (Dextra Laboratories) using manual spotter (V&P Scientific) with solid pins. Slides were Incubated 
for 1 hr at room temperature with monoclonal antibodies for blood group antigens A and B (Fig 2A) or Rhesus D 
antigen (Fig 2B). After repeated washing the slides were Incubated with FITC anti-mouse IgM (Sigma) at 33.3 µg/ml 
(Fig 2A) or Cy3 conjugated anti human IgG (Sigma) at same concentration (Fig 2B), repeatedly washed , briefly spun 
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Table 4: Characteristics of most important blood group antigens (compiled from 43-45). 
Antigen Blood Antigen Determinants Size Number of Clinical 
Group antigenic sites Significance' 
System per Erythrocyte 
H ABO A, B Precursor carried Fucose determinant Variable 1.5-2 million 
(groupO) on glycoshingolipid or (branched). Up to H 
glycoprotein 60 carbohydrate 
residues 
A ABO Sugar attached to H N- Variable Al: 8.1x10 -1.17 
precursor Acetylgalactosamine (branched). Up to x 106 H 
oligosaccharide chain determinant (GaINAc) 60 carbohydrate A2: 1.8.4.4 x 10 
residues 
B ABO Sugar attached to H Galactose Variable 6.1 -8.3 x 10 
precursor determinant (Gal) (branched). Up to H 
oligosaccharlde chain 60 carbohydrate 
residues 
D Rhesus" Multi-pass membrane 8 substitutions on 30-32kDa Common: 1-3 x10 
protein Protein/lipid extracellular loops 417 Aa Weak: 2x10'-104 H 
aggregates. High: 7.5x 104 - 
-2x10' 
C. C Rhesus" Multi-pass membrane Differences at 30-32kDa -4 x 10' 
protein Protein/lipid positions 60,68,103,16 417 Aa M to H 
aggregates. of RhCE polypeptide. 
E, e Rhesus" Multi-pass membrane Difference at pos. 226 30-32kDa -2 x 10' 
protein Protein/lipid of RhCE polypeptide 417 As M to H 
aggregates. 
Cw Rhesus** Multi-pass membrane Difference at pos. 41 30-32kDa 2.15-4 x 10 
protein Protein/lipid of RhCE polypeptide 417 Aa L to M 
aggregates. 
K, k Kell Single-pass membrane 93kDa 3.5 x 10'- 1.8 x 
glycoprotein. Difference at pos. 193 732 Aa 10' M to H 
Fya, Fyb Duffy Multi-pass membrane Difference at pos. 42 35-43kDa 1.35 x 10 M to H (Fya) 
I co roteln 336 As LFb 
Jka, Jkb Kidd Multi-pass membrane Difference at pos. 280 45kDa 1.4 x 10 
protein 391 As M to H 
S. s MNS Single pass membrane Difference at pos. 29 24kDa 2x 10' 
protein GPB 72 Aa M 
M, N MNS Difference at pos. 1,5 37kDa 8x 10' 
GPA (0-glycans at 131 Aa 
s. 2,3&4 L 
P1 P Globotetraosylceramide Terminal a-Galactose Variable 5x 10 
L 
Le" Le Lewis 40-100 carbohydrate Fucose (Le ) or 2 300 kDa incl. Variable (attached 
chains per 300 kDa Fucose (Leattached carrier(average); by passive L 
carrier molecule to precursor Heterodisperse adsorption) 
"H high; M moderate; L low 
RhCE and RhD proteins are 92% Identical with only 35 amino acid substitutions variance; 
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Abstract 
Microarrays promise to revolutionise diagnostic testing since multiple assays can be performed in parallel leading to 
improved reliability of diagnosis. In the short term, protein microarrays have the greatest potential to Impact 
diagnostics due to their potential for non-invasive direct sample measurements. Here, we report a protein 
microarray technique for selectively recognising glycan and peptide motifs on the surface of red blood cells. We 
present results demonstrating the efficacy of the biochip approach as a rapid, highly sensitive and specific 
microscale multiplex assay for blood typing. We also show that the blood chip can be used to screen erythrocyte 
surface antigens using whole-blood in a label-free detection mode. Finally, our results Indicate this method has 
potential for broader applications in biochip medicine. 
Introduction 
The development of DNA microarray technology in conjunction with the completion of the Human Genome 
Sequence has led to great advances In the field of biomedical research. ' Microarray technology has enabled the 
screening of gene activity across the entire genome of several organisms and the quality and quantity of Information 
gained has given insights into the pathways and interactions responsible for both health and disease. " Microarrays 
function on the basis of molecular recognition, either between complementary DNA strands or complementary 
protein complexes. The fact that this recognition Is specific and has high affinity means that several different 
molecules can be Immobilised on a solid surface (probes) In order to identify and quantify their binding partners 
(targets) from complex mixtures in solution. The microscaling afforded by the microarray platform can also offer a 
number of key advantages relating to improvements In binding kinetics and increased sensitivityY 
More recently microarrays are gaining Increasing Interest In being used as a potential diagnostic tool for e. g. 
Infectious disease, 8.12 markers for Rheumatoid Arthritis, 73 differentially expressed proteins In breast cancer tissue,, 4 
antibodies against tumor antigens, 75"8 and sets of common allergens. " 
Protein microarrays suffer from significant complications and challenges compared to DNA microarrays. In particular, 
in the generation and production of protein based reagents and their Inherent physico-chemical heterogeneity. While 
nucleic acid recognition Is achieved primarily by primary sequence determinants, proteins necessitate molecular 
recognition through a combination of primary, secondary and tertiary structures. In addition, non-productive surface 
interactions can results in unfolding or disorientation preventing target binding. 
The focus of this study Is the development a low density protein microarray for performing the battery of tests 
required of all blood donations before being passed safe for transfusion. Blood type Is determined by the expression 
of sugar (glycols) and peptide moieties on the red blood cell (erythrocyte) surface and determining the blood-type of 
the donation Is important since transfusion of Incompatible blood can be fatal. 10 
Current methods of blood donation and pre-transfusion patient testing Involve haemagglutination, enzyme-linked 
immunosorbent assays and nucleic acid testing, which are performed on several different test platforms with varying 
degrees of automation. An Improved system would Involve robust but more rapid testing using less blood sample 
and reagents, perform multi-parameter tests on one miniaturised but comprehensive platform, and allow a more 
cost-effective test whilst ensuring compliance within the highly regulated area of blood testing diagnostics. 
Two of the most commonly used blood typing techniques are microplate and column agglutination technology. 
Microplates of 96 stepped wells are used In which the antibody and erythrocytes are allowed to mix and Incubate 
prior to centrifugation. Formation of an aggregated film of erythrocytes at the bottom of the plate shows a positive 
reaction with the antibody. 19 
The column agglutination technology method (two examples of which are the Ortho BioVue® System from Ortho 
Clinical Diagnostics, 20 and the DiaMed-ID Micro Typing System2t) is currently popular for lower throughput 
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requirements. A gel card usually consists of six microwells each containing a 'gel' consisting either of glass beads or 
Sephadex. The antigen antibody reaction is allowed to take place above the gel during an Incubation period before 
the card is centrifuged. A positive reaction product, which Is demonstrated by haemagglutination, cannot pass 
through the spaces In the gel and therefore forms a line at the top of the gel. A negative reaction can easily pass 
through the spaces in the gel and this Is demonstrated by the collection of erythrocytes at the bottom of the gel. 
In this paper we report a robust protein microarray method for simultaneously detecting and accurately determining 
the type and sub-types of erythrocytes In blood. We have used this method to screen erythrocytes with complex 
mixtures of surface antigens and distinguish peptide from sugar antigens and also distinguished between types of 
peptide and sugar antigen. Remarkably, we show that microarray technique enables whole blood screening and Is 
amenable for exploiting the intrinsic fluorescence properties of erythrocytes obviating the need for either direct or 
Indirect labelling of samples. These results open new opportunities for the clinical use of biochips. 
Materials and Methods 
DMEM was obtained from Hyclone, UK. and hybridomas were proprietary cell lines (SNBTS). BRAD 3 was 
purchased from the International Blood Group Reference Laboratory. Southmead Road, Bristol. All buffers, 
detergents and Bovine Serum Albumin (BSA) were purchased from Sigma Aldrich. Erie Array slides were 
purchased from VWR, UK; Ssens Gold slides were purchased from Ssens By, The Netherlands; Full Moon 
Hydrogel slides were purchased from Eurogentec, Belgium and Schott Hydrogel Slides were purchased directly 
from Schott UK Ltd. Poly-I-lysine slides were prepared in accordance with a previously published method n Blood 
samples were obtained from SNBTS, Edinburgh, UK and were labelled as described using fluorescence 
procedure 22 
Blood samples were obtained and used with the donors' prior consent and ethical clearance obtained from the 
SNBTS Human Ethics Committee. 
Microarray Experiments 
Arrays were prepared by printing onto microarray substrates (26 x 76 mm2) using a Blorobotics MG II printer with 
700 pm solid pins also from Biorobotics. Printed arrays were checked by microscopy to ensure that all probes had 
been printed. Arrays were stored under N2 at < 5°C when not In use. Prior to use, the arrays were blocked In BSA. 
To block, the arrays were rinsed briefly in Phosphate Buffered Saline (PBS) pH 7.0 containing 1% BSA and 0.05 % 
Tween 20 (submerged 10 times), then placed into a fresh container of PBS pH 7.0 containing I% BSA for one hour 
at room temperature, with constant mixing before being rinsed briefly In PBS pH 7.0 (submerged 10 times). The 
arrays were then centrifuged to dryness in an Eppendorf 5810R centrifuge at 1000 rpm for one minute. 
Data Acquisition and Processing 
Blood samples were contained on the array using hybridization chambers from Schleicher and Schuell (approximate 
capacity: 450 p1). Blood samples were Incubated on arrays for 1 hour at room temperature with constant shaking. 
After incubation, the hybridisation chambers were removed and the slides washed In a mixture of PBS and Tween 
20 (0.05 %) by vigorously submerging them ten times. The slides were then rinsed twice In PBS and centrifuged to 
dryness In an Eppendorf 581 OR centrifuge at 1000 rpm for one minute. 
Scanning was carried out using a Scanarray 5000 confocal microarray scanner from Packard Biochip Technologies 
(maximum laser power at slide 3 mW, excitation bandwidth 10 nm). For each array, five scans were taken using 
consistent pmt setting and incrementally increasing laser power settings. Microarray Images were analysed with 
Quantarray software using the fixed circle method, and subtracting the background fluorescence from the spot value. 
From the five scans of each slide, the optimal scan In terms of linear range was selected on the basis of 
comparative scatter plot analysis? ' 
A signal to noise ratio (S/N) was calculated for each antibody spot. The noise level was determined for each slide by 
taking the average fluorescent intensity plus two standard deviations of the PBS spots (negative controls since no 
cells should be specifically bound). The signal to noise ratio was then calculated by dividing the fluorescence 
intensity for each spot by the noise. For each group of replicate spots, a median value was obtained. Negative 




Hybridomas were grown in a fermenter in DMEM/F12 media containing foetal calf serum under controlled conditions 
(02, CO2, pH, temperature) specific for individual cell lines. After expansion of cell cultures and reaching the desired 
volume the antibodies were harvested using the Pellicon tangential flow filtration system (Millipore). 
IgM antibodies were purified either by gel filtration or affinity chromatography. For gel filtration approximately 5 ml of 
culture supernatant was first filtered through a 100 kDa cut off filter to reduce its albumin content and then loaded 
onto a 500 ml Sephacryl S-300 column connected to a UV detector. Collected peaks were assayed for IgM activity 
by hemagglutination. The eluate (usually around 70 ml) was concentrated using 30 kDa centrifugation concentrators. 
Affinity chromatography was carried out on 2-mercaptopyridine (1 ml HiTrap IgM Purification HP Columns, 
Amersham Biosciences, UK) according to the manufacturer's instructions. Briefly, the column was equilibrated with 
5 volumes of binding buffer (0.02 M sodium phosphate, pH 7.5; 0.8 M ammonium sulphate). Culture supernatants 
were adjusted to 0.8 M ammonium sulphate and subsequently filtered through a 0.45 micron filter. IgM was bound 
to the column by passing the sample through the column at 1 ml/min. Unbound material was washed away with 15 
volumes of binding buffer and the IgM eluted with 12 volumes of elution buffer (0.02 M sodium phosphate, pH 7.5). 
IgG antibodies were affinity purified on Prosep G or Prosep A (Millipore) according to the manufacturer's protocol. 
Antibody profiles after purification were obtained by SDS-PAGE. Aliquots of antibody preparations were analysed on 
pre-cast 4-12 % NuPAGE Bis-Tris gels (Invitrogen) under reducing conditions. The gels were stained using colloidal 
Coomassie stain (Invitrogen) or Silver Stain Plus kit (BioRad) according to the manufacturers' Instructions. 
The antibody potency was measured using hemagglutination in two-fold dilutions of antibodies added to the 
suspension of erythrocytes. IgM agglutination is visible directly after a5 minute Incubation; IgG agglutination 
requires addition of anti-human globulin after an initial 20 minute sensitisation period. 
Results and Discussion 
Choice of microarray surface 
Protein probe arrays are particularly sensitive to surface chemistry for attachment and retention of structural Integrity 
and molecular recognition properties. We undertook a systematic optimisation process to identify optimal surface 
chemistries and tested a variety of substrates. The results of these investigations Indicated that gold-coated glass 
slides were the preferred option with epoxysilane coated glass being the second best choice (See supplementary 
material, Figure S1). Since we found it interesting that gold slides gave the best SIN ratios we further investigated 
the difference between gold slides and epoxy silane slides. When comparing these two surfaces, there are two 
factors that could explain the marked difference in performance. The first is the chemistry of attachment of the 
antibodies to the slide and the second is the effect that the microarray surface has on the fluorophores positioned 
close to It. It is well established and has been extensively studied, that proximity to a noble metal surface will lead to 
alteration of the output of a fluorophore. 24 Although this is most pronounced for nanoparticles, It also applies to 
planar surfaces. To investigate this effect, we have printed fluorescently labelled blomolecules onto epoxy silane 
coated glass slides and gold coated glass slides. Fluorescein-labelled 25mer oligonucleotides and fluorescein- 
labelled red blood-cells were printed onto both epoxysilane and gold coated slides. For each combination, 200 
Identical spots of the fluorescently labelled biomolecule were printed on the slide. All the slides were scanned using 
a commercial scanner at a laser power of 75% and gain setting chosen at which a minimum of spots were saturated 
In order to enable comparison of Intensities at a given scanner setting: for oligonucleotides 50% and for red blood 
cells 75%. 
From Figure 1 it can be seen that while fluorescent ollgonucleotides spotted on gold slides have lower fluorescence 
than on epoxy silane slides (median Intensities 4487 and 27030 Relative fluorescent units (RFU) respectively), the 
intensity of spots of labelled red blood cells Is comparatively higher on gold than on epoxy slides (median Intensities 
12126 and 4332 RFU respectively). This can be explained in terms of the enhanced electromagnetic field created 
by a surface plasmon wave (SPW) propagating along the gold interface. Within ca. 7 nm of the gold surface, non- 
radiative energy transfer occurs between the excited fluorophore and the surface. 
2520, fl This results In quenching of 
the emitted light and a concomitant decrease in the fluorescent signal associated with a spot as seen In Figure 1a, 
this property has, for example, been used to good effect in the design of molecular beacons' 20 While fluorescent 
oiigonucleotides are nanometres in size and experience a significant quenching, red blood-cells are roughly 6-8 pm 
in diameter and 1 pm in depth meaning that 98% of the cell volume is outside this area and the fluorescence Is not 
significantly quenched. However, when we compare the fluorescence of red blood cells spotted on gold slides with 
red blood cells on epoxy silane slides (Figure 1 b), the fluorescence on the gold slides Is higher. At length scales 
greater than 7 nm and less than 100 nm, the SPW enhances the emission of fluorophores. 2 ' While the power of 
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the SPW Is dependant on the angle at which the laser strikes the gold surface, there appears to be some 
enhancement even when using a non-optimized scanner, a similar effect has been shown using slides printed with a 
grating pattem. 90 The enhanced fluorescence caused by the excitation of red blood-cells by a surface-confined 
wave causes the signal from spots of blood on gold to emit a higher Intensity of light than on the epoxy-silane 
coated films. This is a significant advantage of the use of gold as a microarray surface. Since the difference 
between fluorescence quenching and enhancement of signal Is caused by a distance dependence, gold Is an Ideal 
surface to work with for a range of assays? ' Gold can be easily functionalised using well established techniques for 
self assembled monolayer formation" meaning that the distance between a fluorophore and the gold surface can 
be tuned by (for example) the length of an alkyl chain26.32 and the surface chemistry for attachment can be easily 
controlled by the choice of end group. This approach means that any fluorescent labels used in an assay could 
potentially be positioned to take advantage of the enhancement and avoid quenching. To take full advantage of this 
process the surface roughness of the gold may need to be optimized since this will affect the local field 
enhancement and the configuration of the microarray scanner should be matched to the surface plasmon resonance 
angle. 
Detection of cell surface glycolic groups : Typing blood group A, 13 and 0. 
Having optimised several factors of array fabrication and assay protocol, we used this system to differentiate 
between several different phenotypes of erythrocyte. Blood group antigens are composed from a family of 
glycolipids or glycoproteins expressed at the surface of erythocytes. The ABO system is defined by polymorphisms 
of complex carbohydrate structures of glycoproteins and glycolipids expressed on the cell surface of erythrocytes. 
The basic unit of the ABO system is the 0 antigen which is a pentasaccharide terminated In a fucose. The A and B 
antigens are derivatives of this unit, varying by a single sugar residue branched from the penultimate galactose of 
the 0 antigen. In the case of A the sugar is N-acetyl galactose and In the case of B It Is galactose. ' The antibodies 
that characterise ABO blood types therefore differentiate on the basis of single sugar changes on the basic 
pentameric motif. 
Using reagents that have been shown to accurately type erythrocytes In solution phase assays, " we printed a 
microarray (including a negative control antibody which we know to have no solid-phase reactivity with red blood cell 
antigens and buffer spots to which no red blood cells should bind) for determining blood type (the antibody details 
are shown in table 1). We used both gold coated and epoxy-silane coated slides In order to further establish the 
difference in these surfaces for this assay. It can be seen from Figure 2a that type A, cells have a strong Interaction 
with anti-A antibodies printed on gold slides: ES IS (S/N 232), LA2 (S/N 125) and DAM1 (S/N 177): there Is very little 
cross reactivity with other antibodies, the strongest being LB2 (S/N 2.5). For type B cells, as can be seen In Figure 
2b, there Is a strong reaction with LB2 (S/N 223) and a weaker reactivity with ES15 (SIN 21) as would be expected. 
The cross reactivity is low across the rest of the array, the strongest reaction being with LA2 (SIN 2). Type A2 cells 
(Figure 2c) have fewer surface antigens (approximately 250,000 compared to approximately 1 million for A, ) but the 
antibody reactivities of ESI5 (S/N 291), LA2 (S/N 30) and DAMI (S/N 179) are of a similar magnitude, there Is also 
low cross-reactivity with LB2 (S/N 1.7). The similarity of the signal reflects that the assay Is not optimized to 
differentiate surface antigen concentrations of this order. However from figure 3f, It can be seen that type A. which 
has approximately 1000 surface antigens per cell has a significantly lower reactivity with the same group of 
antibodies on gold: ES15 (S/N 125), LA2 (SIN 3.4) and DAM1 (S/N 3.6): and maintains low cross reactivity with LB2 
(S/N 2). Type 0 blood (Figure 2d) which has neither A or B antigens shows very low reactivity with all of the 
antibodies in the array, never having a S/N higher than 2 when using a gold surface, and not higher than 2.4 when 
using epoxy silane coated slides. In summary we have shown that erythrocytes expressing A and B antigens react 
specifically with their respective antisera In an array for at, and express low cross reactivity with other non-specific 
antibodies. 
For cells which have mixtures of antigens seen In Figure 3, our arrays have successfully identified both antigens 
simultaneously in those blood groups which have both A and B surface antigens. Type A1BRhD (Figure 3a) reacts 
with all antibodies with S/N over 100 In all cases except our negative control (JLDM3 SIN 1). Type A2BRhD (Figure 
3b) also reacts with all antibodies except JLDM3 (SIN 6) with S/N over over 100 In all cases. This shows that our 
array can Identify complex mixtures of sugar and peptide antigens on cell surfaces. 
Detection of peptide moieties, RhD, C and E antigens 
Appendix 4 
In addition to sugar antigens, red blood cells contain Important peptide antigens. The rhesus antigen which can be 
so important in antenatal testing is among this group of antigens., e. as The most common Rhesus antigens are D, C 
or c and E or e which are encoded on two structurally homologous genes on the Rh locus. Both antigens are 417 
amino acid multi-pass integral membrane proteins with 6 exposed peptide loops on the erythrocyte surface which 
present discrete antigenic epitopes. The two proteins differ by 36 amino acids and the antigenic regions differ by as 
little as one amino acid between RhD and RhCE. ° 
From figure 3 it is clear that we can detect peptide antigens both in the presence and absence of sugar antigens. 
The detection of the D antigen can be seen from figure 3e since ORhD positive blood carries D antigens and neither 
A nor B antigens. In this case, we see a specific reaction with BRADS (SIN 136) with very low cross reactivity across 
the rest of the array. In cases where we have a mixture of sugar and peptide antigens both can be detected. For 
example in the case of BRhD positive cells (Figure 3c), the cells react with LB2 (S/N 363) and BRADS (S/N 275) 
while the highest non-specific cross reactivity Is seen with DAMI (S/N 4.6). Similarly type A1RhD positive (Figure 
3d) reacts with the same antibodies and to a similar degree as type A,: ES15 (SIN 236), LA2 (SIN 55) and DAMI 
(S/N 182), as well as reacting with BRAD3 (S/N 152). As mentioned above, type A, RhD positive blood can be 
detected even though the number of sugar antigens is very low in comparison to other blood types. Types A1BRhD 
positive and A2BRhD positive (Figures 4a and b respectively) have the most complex mixture of antigens and in 
both cases the Rhesus antigen is reliably detected by BRAD3 (S/N 120 and 137 respectively). In all cases Gold 
coated slides proved to be superior to epoxy coated slides, confirming the result of the initial surface scoping 
exercise. 
Although figure 3 shows the possibility of detecting a peptide antigen in the presence of a complex mixture of sugar 
antigens, it is not generally sufficient for all blood typing procedures, to only detect one type of peptide antigen. To 
ensure that we can detect peptide antigens and differentiate between types of peptide antigens, we have screened 
a panel of antibodies against rhesus antigens and used two types of red blood cell to measure the reactivity of these 
antibodies against different peptide surface antigens. The two blood types are: R, R, which has only the D antigen 
and r"r" which has c and E antigens but no D antigen. By measuring the reactivity of these different mixtures of 
surface antigen against our panel of antibodies we see from Figure 4 that the D antigen Is particularly reactive with 
LHM59/19 (S/N 165), LHM169/80 (SIN 206) and BRADS (SIN 103) as well as being more weakly reactive with 
LHM76/58 (SIN 15), LHM76/59 (S/N 17), ESD1 (S/N 41) and LHM76/55 (S/N 15). Noticeably, there Is no cross 
reactivity with the Anti-c (H48) or Anti E (DEMI) antibodies in the array (S/N <I in both cases). In comparison, 
blood cells from group r"r" which has c and E antigens but no D antigens shows a distinctly different pattern of 
reactivity. The antibodies which reacted strongly with the D antigens in RR, blood have negligible fluorescent 
signals: LHM59/19 (SIN 1.0), LHM169/80 (S/N 1.4), BRAD3 (S/N 0.9); some of those which reacted less strongly 
also have a low signal for the r"r" le. ESD1 (SIN 1.1) and LHM76155 (S/N 0.7) and two of those which reacted 
weakly with R, R, also reacted weakly with r"r" LHM76/58 (S/N 4.4), LHM76/59 (S/N 2.5), suggesting a non-specific 
cross reactivity. So from this panel we can select at least three strong candidates for reliable detection of the D 
antigen: LHM59/19, LHM169/80 and BRAD3. Given that r"r" has c and E antigens on Its surface, we expect 
reactions with Anti-c and Anti-E antibodies as seen in figure 4 (H48 S/N 13 and DEM1 S/N 4.3) which compare 
favourably with the their R, R, reactivity (S/N 0.5 and 0.4 respectively). This shows three antibodies from the panel 
screened emerge as candidates for detection of the D antigen. The Anti-c and Anti-E antibodies, while providing a 
good negative control in this case, also show the potential to differentiate between common peptide antigens. 
Differential detection sensitivity between attachment and solution phase antibody reagents 
We have screened a panel of antibodies for their blood grouping performance and found large differences In solid- 
phase microarray performance between antibodies of similar solution phase heamagglutination activity. For 
example, In table 1, it can be seen that NLA2, NLB2 and NES15 are very similar In their solution phase potency (i. e. 
they cause agglutination of cells at the same dilution), all are of the same antibody subclass and have similar purity 
profiles by SDS PAGE, but have widely varying reactivity when used on a microarray. Similarly, LHM76/59 and LHM 
169/80 (both anti-D) have the same potency In an agglutination assay but the microarray S/N of the latter Is nearly 
14 times greater than that of the former. Whether these differences are due to the structural stability or the 
orientation of the antibody on the surface, we have not Investigated, however It Is clear that there are differences In 
antibody performance between solution and solid phase that cannot be accounted for in terms of antibody class or 
purity. 
Screening whole blood 
Appendix 4 
Using purified and labelled cells to type blood on a microarray requires several sample preparation and 
derivatisation steps that are all potential sources of variation for experimental output In order to simplify this 
procedure, we attempted to type whole blood and thus dispose of some blood pre-treatment steps. To this end, we 
attempted to label whole blood using fluorescein Isothiocyanate (FITC) and then Incubate this on an array In the 
expectation that the fluorescently labelled red cells would be quantifiable where they had bound to antibody spots. 
Although red cells were clearly bound to the spots and were visible by phase contrast microscopy, when scanned 
using FITC settings the fluorescence from the background between the spots was so strong that It overpowered the 
specific signal from the spots. 
This can probably be explained by considering the make up of the blood proteome. About 40% of the human serum 
proteome Is Human Serum Albumin which will have been fluorescently labelled at the same time as the red cells. 
This occurs since FITC non-specifically labels all proteins. HSA Is known to bind non-specifically to several 
proteins 31 and In high concentrations such a relatively weak Interaction can be responsible for the high background 
between the antibody spots. In order to circumvent this problem In whole blood typing, we examined whether the 
intrinsic fluorescence from erythrocytes Is sufficient to quantify the binding reaction. 
Label-free cell phenotyping 
Figure 5 Is a graph showing the reactivity of an array of antibodies with labelled red cells, whole blood, whole blood 
diluted 1: 5 with PBS and whole blood diluted 1: 10 with PBS. It can be seen from this graph that the pattern of 
reactivity is the same for labelled cells as for whole blood but that the signal intensity is lesser without labelling. 
However, it is clear from the data that in all cases, the signal to noise ratios are high enough to allow discrimination 
between type A, B and 0 blood. For type A cells, 1: 5 diluted blood appears to have the highest S/N ratio but for B, 
neat whole blood has the highest S/N. 
Red blood cells have an absorbance spectrum as shown In figure 6 inset. This absorbance spectrum Is typical of 
oxy-haemoglobin, as would be expected with native red blood cells. Since we originally thought that haemoglobin 
species were responsible for the fluorescence of erythrocytes, we tried to maximise the fluorescent signal by tuning 
the excitation wavelength to the absorbance spectrum shown In figure 6 Inset. Since unlabelled red blood cells 
absorb strongly at 420,540 and 580 nm, we would expect one of these wavelengths to give the strongest 
fluorescence when excited. The peak at 420 nm has the strongest absorbance but since commercial microarray 
scanners do not have lasers which can excite at this wavelength, the lowest excitation available was 488 nm. We 
compared the signal to noise ratio for this setting with three other settings which excite at the 543 nm (close to the 
absorbance peak) as detailed in table 2. The signal to noise ratios obtained using these settings are shown In figure 
6. After scanning, the 488/1 scan was repeated to ensure that deleterious bleaching of fluorescence could be 
controlled for. From this figure, we show that the optimal scanner setting is 488/1, the setting commonly used to 
detect fluorescein. Since this does not correlate with the absorbance spectrum of haemoglobin, we suggest that the 
majority of autofluorescence from the erythrocytes is caused by other cellular components such as lipids and 
proteins. 
Conclusion 
We have shown that we can use protein microarray technology to phenotype erythrocytes by detecting complex 
mixtures of antigens on cell surfaces. The antigens are both sugar antigens which tend to be well presented and 
easily accessible and peptide antigens which are epitopes of transmembrane proteins and therefore buried and held 
more closely to the cell surface. We also show that we can differentiate different types of surface antigen, both 
sugar and peptide, using the correct choice of antibodies. The choice of antibodies is not Immediately obvious and 
we see that some antibodies which have very similar solution reactivity do not perform comparably on a microarray 
surface. Until the structural and surface characteristics that control these differences are fully understood, the best 
way of constructing such a protein microarray for such a purpose will be by screening a library of antibodies in the 
way we have described. We have found that an array consisting of LA2, LB2, ES15, DAMI, LHM169/80, LHM59115, 
DEM1 and H48 Is sufficient to phenotype several classes of erythrocyte. In addition we have demonstrated the 
particular utility of gold coated array slides for the screening of cells and attribute this in part to the Interaction 
between the fluorophore and excited plasmons on the microarray slide surface. By maximising S/N through the 
correct choice of antibody and microarray surface we have created an array which can not only phenotype labelled 
erythrocytes, but also screen whole blood for surface antigens. This obviates both labelling and sample purification 
steps, significantly simplifying the blood typing procedure. 
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